

Financial news for MRK dated on 2020-06-11: Shares of several healthcare companies are trading lower in sympathy with the overall market following an increase in coronavirus cases in some US states that have reopened, leading to concerns of a second wave of the virus.

Financial news for MRK dated on 2020-06-11: Johnson & Johnson To Start Coronavirus Vaccine Human Trials Ahead Of Schedule In July

Financial news for MRK dated on 2020-06-10: The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset

Financial news for MRK dated on 2020-06-09: Merck Announces That The Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA As Monotherapy And In Combination With Chemotherapy In Patients With Advanced Or Metastatic Urothelial Carcinoma

Financial news for MRK dated on 2020-06-07: The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage

Financial news for MRK dated on 2020-06-05: The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets \$400M Bid

Financial news for MRK dated on 2020-06-05: Merck Reports FDA Approved RECARBIO For Treatment Of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

Financial news for MRK dated on 2020-06-04: Ex-FDA Chief On White House's Coronavirus Vaccine Shortlist: 'They Chose Very Novel Platforms'

Financial news for MRK dated on 2020-06-04: The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic

Financial news for MRK dated on 2020-06-03: Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In Clinics

Financial news for MRK dated on 2020-06-03: Traders Share Their Health Care Picks

Financial news for MRK dated on 2020-06-03: UPDATE: Five Companies Chosen For 'Vaccine Finalist' Are Moderna, Johnson & Johnson, Merck, Pfizer And AstraZeneca

Financial news for MRK dated on 2020-06-02: Pharma Large And Mid-Caps Race Against COVID-19

Financial news for MRK dated on 2020-06-01: Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

Financial news for MRK dated on 2020-06-01: 'New Ebola epidemic' in northwest DR Congo: health ministry' -AFP

Financial news for MRK dated on 2020-06-01: Merck and AstraZeneca's LYNPARZA Receives a Positive Opinion from the European Medicines Agency

Financial news for MRK dated on 2020-06-01: AstraZeneca Announces Lynparza Recommended for Approval in EU by CHMP for BRCA-mutated Metastatic Pancreatic Cancer

Financial news for MRK dated on 2020-05-30: The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight

Financial news for MRK dated on 2020-05-29: Merck Yesterday Announced KEYTRUDA plus LENVIMA Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma

Financial news for MRK dated on 2020-05-29: The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immuteq Gets R&D Grant

Financial news for MRK dated on 2020-05-29: Cramer Shares His Thoughts On Teva, Oxford Industries And More

Financial news for MRK dated on 2020-05-28: Merck's Keytruda (Pembrolizumab) Superior To Standard Of Care Chemotherapy In Patients With MSI-H Colorectal Cancer

Financial news for MRK dated on 2020-05-26: Merck CEO Can't Give A Timeline Or Date For COVID-19 Approval

Financial news for MRK dated on 2020-05-26: Merck CEO Ken Frazier To Appear On CNBC

Financial news for MRK dated on 2020-05-26: 'Merck chief casts doubt on coronavirus vaccine timeframe' -Financial Times

Financial news for MRK dated on 2020-05-26: Merck's Coronavirus Plan Of Attack: 2 Partnerships, M&A Deal Aimed At Treatment, Vaccine Development

Financial news for MRK dated on 2020-05-26: Benzinga Pro's Top 5 Stocks To Watch For Tues., May 26, 2020: NVAX, EWJ, SNY, SOXX, MRK

Financial news for MRK dated on 2020-05-26: Merck To Acquire Vaccine Company Themis Bioscience; Also Announces Collaboration With IAVI For Coronavirus Vaccine And Collaboration With Ridgeback Bio For Coronavirus Antiviral Candidate

Financial news for MRK dated on 2020-05-24: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for MRK dated on 2020-05-22: US Health Official Says Vaccines From J&J, Sanofi, Merck May Be Added This Summer As They Complete Phase 1 Safety Studies

Financial news for MRK dated on 2020-05-22: US Says Will Test Experimental Coronavirus Vaccines In 100,000+ People, Health Official Says Oxford Vaccine May Be Tested "Side By Side" With Moderna's Starting In July

Financial news for MRK dated on 2020-05-22: 64 Biggest Movers From Yesterday

Financial news for MRK dated on 2020-05-21: Mid-Afternoon Market Update: Dow Falls 50 Points; L Brands Shares Spike Higher

Financial news for MRK dated on 2020-05-21: 51 Stocks Moving In Thursday's Mid-Day Session

Financial news for MRK dated on 2020-05-21: Mid-Day Market Update: Crude Oil Rises Over 1%; Aurora Cannabis Shares Jump

Financial news for MRK dated on 2020-05-21: Mid-Morning Market Update: Markets Mixed; Best Buy Tops Q1 Expectations

Financial news for MRK dated on 2020-05-21: The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive

Financial news for MRK dated on 2020-05-20: Mid-Afternoon Market Update: Crude Oil Up 5%; Surface Oncology Shares Spike Higher

Financial news for MRK dated on 2020-05-20: Why Surface Oncology's Stock Is Surging Higher

Financial news for MRK dated on 2020-05-20: Checkpoint Therapeutics CEO On Tapping Into A \$25 Billion Cancer Treatment Market

Financial news for MRK dated on 2020-05-20: The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test

Financial news for MRK dated on 2020-05-20: AstraZeneca And Merck Announce LYNPARZA Approved By FDA For Treatment Of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment With Enzalutamide Or Abiraterone

Financial news for MRK dated on 2020-05-20: AstraZeneca Says Lynparza Approved in the U.S. for Prostate Cancer

Financial news for MRK dated on 2020-05-19: Telemedicine A COVID-19 Winner

Financial news for MRK dated on 2020-05-19: Merck And UPMC Announces Infectious Disease Connect Has Combined Merck's ILUM Health Solutions To 'Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship '

Financial news for MRK dated on 2020-05-13: Merck Reports KEYTRUDA Plus Chemo Showed Statistically Significant Improvement In Progression-Free Survival vs Chemo In Certain Patients With Metastatic Triple-Negative Breast Cancer

Financial news for MRK dated on 2020-05-13: Merck Reports KEYTRUDA Superior To Brentuximab Vedotin In Patients With Classical Hodgkin Lymphoma In Head-To-Head Phase 3 Trial

Financial news for MRK dated on 2020-05-13: Merck Reports New Combo Data For KEYTRUDA Showed Benefit In Stage 3 Non-Small Cell Lung Cancer

Financial news for MRK dated on 2020-05-13: Merck Reports Novel HIF-2a Inhibitor Showed Objective Response Rate Of Nearly 30% In Patients With von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma

Financial news for MRK dated on 2020-05-13: AbbVie's Potential Is 'Underappreciated, '

Says Morgan Stanley Analyst

Financial news for MRK dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for MRK dated on 2020-05-13: Merck Animal Health to Acquire U.S. Rights to SENTINEL Brand of Combination Parasitocides for Companion Animals for ~\$400M in Cash

Financial news for MRK dated on 2020-05-11: UPDATE: Cococrystal Says Collaboration With Merck For Discovery, Development Of Certain Proprietary Flu A/B Antiviral Agents Ongoing

Financial news for MRK dated on 2020-05-11: AstraZeneca And Merck Announce LYNPARZA Approved In US As 1st-line Maintenance Treatment With bevacizumab For HRD-Positive Advanced Ovarian Cancer

Financial news for MRK dated on 2020-05-11: AstraZeneca Announces Lynparza Approved in the U.S, as 1st-line Maintenance Treatment With Bevacizumab for HED-positive Advanced Ovarian Cancer

Financial news for MRK dated on 2020-05-08: 5 Biopharmas Where BofA Would Put Its Money To Work

Financial news for MRK dated on 2020-05-06: Merck Announces RECARBRIO Demonstrated Noninferiority Compared To Piperacillin And Tazobactam In Primary And Key Secondary Endpoints

Financial news for MRK dated on 2020-05-05: Why Shares Of Gene Therapy Company Genprex Are Surging Higher

Financial news for MRK dated on 2020-05-03: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

Financial news for MRK dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for MRK dated on 2020-04-30: ServiceNow CEO Bill McDermott Says Company 'Hungry And Humble,' With \$10B Ambitions

Financial news for MRK dated on 2020-04-29: Guggenheim Maintains Buy on Merck & Co, Lowers Price Target to \$93

Financial news for MRK dated on 2020-04-29: Barclays Maintains Overweight on Merck & Co, Lowers Price Target to \$90

Financial news for MRK dated on 2020-04-29: Merck Analysts Focus On Fundamentals, Keytruda Strength Following Guidance Cut

Financial news for MRK dated on 2020-04-29: The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda

Financial news for MRK dated on 2020-04-29: SVB Leerink Maintains Outperform on Merck & Co, Lowers Price Target to \$95

Financial news for MRK dated on 2020-04-28: FDA Approves Merck's KEYTRUDA For Use At An Additional Recommended Dose Of 400 mg Every Six Weeks For All Approved Adult Indications

Financial news for MRK dated on 2020-04-28: A CURE For The Common Earnings Play

Financial news for MRK dated on 2020-04-28: Morning Market Stats in 5 Minutes

Financial news for MRK dated on 2020-04-28: Earnings Feast: Bring a Plate With Healthcare and Caterpillar in Morning, GOOGL And AMD Later

Financial news for MRK dated on 2020-04-28: Merck shares are trading lower after the company issued FY20 guidance below consensus estimates.

Financial news for MRK dated on 2020-04-28: The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

Financial news for MRK dated on 2020-04-28: Merck Sees FY20 EPS \$5.17-\$5.37 vs \$5.56 Est., Sales \$46.1B-\$48.1B vs \$48.72B Est.

Financial news for MRK dated on 2020-04-28: Merck & Co Q1 Adj. EPS \$1.500 Beats \$1.340 Estimate, Sales \$12.100B Beat \$11.460B Estimate

Financial news for MRK dated on 2020-04-28: Earnings Scheduled For April 28, 2020

Financial news for MRK dated on 2020-04-27: Apple And Amazon Earnings, Fed Meeting Among Highlights In Busy Week Ahead

Financial news for MRK dated on 2020-04-27: Merck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers for Coronavirus

Financial news for MRK dated on 2020-04-27: Lynparza Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-mutated Metastatic Castration-resistant Prostate Cancer

Financial news for MRK dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for MRK dated on 2020-04-24: AstraZeneca, Merck Announce Lynparza Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-mutated Metastatic Castration-resistant Prostate Cancer

Financial news for MRK dated on 2020-04-23: Shares of several healthcare companies are trading higher. Movement appears market-related as equities gain amid a rebound in oil prices.

Financial news for MRK dated on 2020-04-23: Merck Reports Resubmission Of Supplemental Biologics License Applications For KEYTRUDA 6-Week Dosing Schedule

Financial news for MRK dated on 2020-04-21: Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.

Financial news for MRK dated on 2020-04-21: Merck Broadens Patient Support And Assistance Programs As Part Of Overall COVID-19 Relief Efforts

Financial news for MRK dated on 2020-04-20: Cue Biopharma Announces Clinical Trial Collaboration Agreement With Merck To Evaluate CUE-101 In Combination With KEYTRUDA As First-line Treatment For HPV+ Recurrent/Metastatic Head And Neck Cancer

Financial news for MRK dated on 2020-04-19: Barron's Picks And Pans: Dropbox, Ford, Johnson & Johnson, Teladoc And More

Financial news for MRK dated on 2020-04-16: Gilead's Encouraging Remdesivir Data: Rapid Reaction On The Stock

Financial news for MRK dated on 2020-04-16: S&P 500 Futures Up 3.2% After Hours; Many Other Stocks Moving Higher With Futures; Investors Reacting Favorably To White Phase Guidelines On Reopening Economy

Financial news for MRK dated on 2020-04-16: Next 45 Days Will Be 'Most Critical Period' For US, Says Alan Lancz Who Predicted 1987 and 2008 Crises

Financial news for MRK dated on 2020-04-15: Every Member Of Trump's 'Great American Economic Revival' Industry Groups

Financial news for MRK dated on 2020-04-15: The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US

Financial news for MRK dated on 2020-04-15: Merck Announces US Launch Of ONTRUZANT (trastuzumab-dttb), A Biosimilar Of Herceptin (trastuzumab)

Financial news for MRK dated on 2020-04-13: UBS Maintains Buy on Merck & Co, Lowers Price Target to \$92

Financial news for MRK dated on 2020-04-13: AstraZeneca and Merck Announce Approval of KOSELUGO for Pediatric Patients Two Years and Older With Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas

Financial news for MRK dated on 2020-04-08: FDA Approves Generic Version Of Merck's Proventil HFA Metered-Dose Inhaler

Financial news for MRK dated on 2020-04-07: Merck Receives Priority Review From FDA For Second Application For KEYTRUDA Based On Biomarker, Regardless Of Tumor Type

Financial news for MRK dated on 2020-04-06: Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.

Financial news for MRK dated on 2020-04-02: Cannabis Opportunity In The Time Of The Coronavirus

Financial news for MRK dated on 2020-04-02: Morgan Stanley Maintains Overweight on Merck & Co, Lowers Price Target to \$89

Financial news for MRK dated on 2020-04-02: Merck Reports KEYTRUDA Significantly Improved Progression-Free Survival As First-Line Treatment For MSI-H, dMMR Colorectal Cancer

Financial news for MRK dated on 2020-04-01: RBC Capital Maintains Sector Perform on Merck & Co, Lowers Price Target to \$89

Financial news for MRK dated on 2020-04-01: Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.

Financial news for MRK dated on 2020-03-30: Shares of several healthcare companies are trading higher as the market rebounds on extended measures to help curb the coronavirus. NOTE: The sector could also be trading higher due to increased demand for medical products amid the coronavirus outbreak.

Financial news for MRK dated on 2020-03-29: Barron's Picks And Pans: Tech Picks, SoftBank, REITs, Tesla And More

Financial news for MRK dated on 2020-03-27: Cramer Reveals Stock Favorites, Says Intuitive Surgical A 'Winner'

Financial news for MRK dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus legislation has boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for MRK dated on 2020-03-26: Shares of several healthcare companies are trading higher following Senate passage of a \$2 trillion economic stimulus package, which has lifted stocks across sectors.

Financial news for MRK dated on 2020-03-25: UPS Seeks To Accelerate Growth Of Drone-Delivery

Financial news for MRK dated on 2020-03-24: 10 Biggest Price Target Changes For Tuesday

Financial news for MRK dated on 2020-03-24: Argus Research Maintains Buy on Merck & Co, Lowers Price Target to \$95

Financial news for MRK dated on 2020-03-24: The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test

Financial news for MRK dated on 2020-03-23: Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.

Financial news for MRK dated on 2020-03-22: Merck Donates a Half a Million Masks to Support COVID-19 Emergency Response in New York City

Financial news for MRK dated on 2020-03-17: Shares of several healthcare companies are trading higher, rebounding from Monday's crash. Stocks may also potentially be getting a boost from expectations of further stimulus proposals.

Financial news for MRK dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for MRK dated on 2020-03-17: Merck Announces Top-Line Results From Phase 3 Trials Evaluating Gefapixant For Refractory Of Unexplained Chronic Cough; Gefapixant Demonstrated Statistically Significant Decrease In 24-Hour Coughs Per Hour Compared To Placebo At Week 12 And 24

Financial news for MRK dated on 2020-03-16: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for MRK dated on 2020-03-14: Barron's Picks And Pans: Roundtable Picks, Airline And Oil Stocks, And More

Financial news for MRK dated on 2020-03-13: Intec Pharma Posts Q4 Net Loss Of \$6.6M,

Down By Nearly Half Year-Over-Year

Financial news for MRK dated on 2020-03-13: Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.

Financial news for MRK dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for MRK dated on 2020-03-12: Merck & Co shares are trading lower after the company announced its Phase 3 GY004 trial for Cediranib and LYNPARZA did not meet its primary endpoint.

Financial news for MRK dated on 2020-03-12: WebMD Acquires Merck Subsidiary Staywell

Financial news for MRK dated on 2020-03-12: AstraZeneca and Merck Announce Phase 3 GY004 for Cediranib and LYNPARZA in Platinum-Sensitive Relapsed Ovarian Cancer Did Not Meet the Primary Endpoint of Progression-Free Survival vs. Platinum-Based Chemotherapy

Financial news for MRK dated on 2020-03-11: Shares of several healthcare companies are trading lower. Movement appears market related amid selloff in equities. The global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors.

Financial news for MRK dated on 2020-03-10: CDC's Redfield Says Will Know By April If Ebola-Tied Drug Helps Coronavirus

Financial news for MRK dated on 2020-03-09: 52 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for MRK dated on 2020-03-07: Barron's Picks And Pans: Coronavirus Picks, Bonds, Safe Havens And More

Financial news for MRK dated on 2020-03-04: FDA Issues Warning On Merck's Singulair, Warns Of Mental Health Side Effects

Financial news for MRK dated on 2020-03-04: Shares of several healthcare-related companies are trading higher after Joe Biden secured several key wins in Super Tuesday. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.

Financial news for MRK dated on 2020-03-02: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Financial news for MRK dated on 2020-03-02: Merck shares are trading higher after the company's KEYNOTE-204 of KEYTRUDA met one of its primary endpoints of progression-free survival.

Financial news for MRK dated on 2020-03-02: Merck Announces New Data from Broad HIV Program at CROI 2020

Financial news for MRK dated on 2020-03-02: A Peek Into The Markets: US Stock Futures Down Ahead Of Manufacturing Reports

Financial news for MRK dated on 2020-03-02: Merck's Phase 3 KEYNOTE-204 Trial of KEYTRUDA Met One of its Primary Endpoints

Financial news for MRK dated on 2020-02-28: Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.

Financial news for MRK dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for MRK dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for MRK dated on 2020-02-24: What Drove Merck's Keytruda Shortfall In Q4

Financial news for MRK dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for MRK dated on 2020-02-22: Benzinga's Bulls And Bears Of The Week: Merck, Nike, Target And More

Financial news for MRK dated on 2020-02-20: Why Merck Has Had Underwhelming Start To 2020

Financial news for MRK dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for MRK dated on 2020-02-19: Elanco Signs Agreement with Merck Animal Health to Divest Worldwide Rights for Vecoxan

Financial news for MRK dated on 2020-02-19: The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA

Financial news for MRK dated on 2020-02-19: Merck Receives CRL from FDA for sBLAs for KEYTRUDA Six-Week Dosing Schedule

Financial news for MRK dated on 2020-02-16: The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions

Financial news for MRK dated on 2020-02-14: Ervebo Now Registered In Four African Countries, Within 90 Days Of Reference Country Approval And WHO Prequalification

Financial news for MRK dated on 2020-02-12: Merck Says Keytruda In Combination With Chemotherapy Met Primary Endpoint Of Progression-Free Survival As First-Line Treatment For Metastatic Triple-Negative Breast Cancer

Financial news for MRK dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for MRK dated on 2020-02-10: KalVista Pharma Reports Option Deal Between Co., Merck Related To Intravitreal Diabetic Macular Edema Candidate KVD001, Future Oral DME Molecules Has Expired

Financial news for MRK dated on 2020-02-09: The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight

Financial news for MRK dated on 2020-02-08: Barron's Picks And Pans: GM, Kraft Heinz, Tesla, Under Armour And More

Financial news for MRK dated on 2020-02-07: The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

Financial news for MRK dated on 2020-02-06: Twitter Up, Tesla Down: Strong User Numbers Help TWTR, But TSLA Selling Continues

Financial news for MRK dated on 2020-02-06: UBS Maintains Buy on Merck & Co, Lowers Price Target to \$96

Financial news for MRK dated on 2020-02-05: Merck To Spin Off Slow-Growing Women's Health, Legacy, Biosimilars Businesses: What You Need To Know

Financial news for MRK dated on 2020-02-05: Earnings Bonanza: Results Keep Pouring In, With Investors Looking Over Merck, Disney

Financial news for MRK dated on 2020-02-05: Merck & Co shares are trading lower after the company reported worse-than-expected Q4 sales results.

Financial news for MRK dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for MRK dated on 2020-02-05: Merck Reports Mixed Q4 Earnings

Financial news for MRK dated on 2020-02-05: Merck Sees FY20 Adj. EPS \$5.62-\$5.77 vs \$5.61 Est., Sales \$48.8B-\$50.3B vs \$49.53B Est.

Financial news for MRK dated on 2020-02-05: Merck & Co Q4 Adj. EPS \$1.16 Beats \$1.15 Estimate, Sales \$11.87B Miss \$11.98B Estimate

Financial news for MRK dated on 2020-02-05: Merck To Spin Off Products From Its Women's Health, Trusted Legacy Brands And Biosimilars Business Into New Independent Publicly-Traded Co.; Co. Says Transaction Enables It To Achieve \$2.4B n Operating Efficiencies By 2024

Financial news for MRK dated on 2020-02-05: 10 Stocks To Watch For February 5, 2020

Financial news for MRK dated on 2020-02-05: Earnings Scheduled For February 5, 2020

Financial news for MRK dated on 2020-02-03: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

Financial news for MRK dated on 2020-02-03: Merck & Co shares are trading higher after the company's RECARBRIO supplemental new drug application was accepted for FDA review.

Financial news for MRK dated on 2020-02-03: Surprise, Surprise: Stocks Wearing Their Rally Hats Despite China Market Tanking

Financial news for MRK dated on 2020-02-03: Merck's RECARBRIO Supplemental New Drug Application Accepted for FDA Review

Financial news for MRK dated on 2020-02-02: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Financial news for MRK dated on 2020-01-31: Position Scrimmage: Coronavirus, End-Of-Month Profit Taking Influencing Markets

Financial news for MRK dated on 2020-01-29: February Market Outlook: Coronavirus, D.C. Proceedings, Earnings Season Could Mean Volatility

Financial news for MRK dated on 2020-01-28: Turnaround Tuesday? Stocks Look To Bounce Back As Apple Earnings Loom Later

Financial news for MRK dated on 2020-01-27: A Peek Into The Markets: US Stock Futures Down; Dow Futures Tumble Over 400 Points

Financial news for MRK dated on 2020-01-27: Merck's DIFICID Receives FDA Approval to Treat Clostridioides in Children Aged Six Months and Older

Financial news for MRK dated on 2020-01-24: Shares of several companies in the healthcare and pharmaceutical space are trading lower, not currently seeing sector-specific news. NOTE: The global spread of the Wuhan coronavirus has caused equities across to sell off.

Financial news for MRK dated on 2020-01-24: The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study

Financial news for MRK dated on 2020-01-23: UBS Maintains Buy on Merck & Co, Raises Price Target to \$99

Financial news for MRK dated on 2020-01-21: FDA Accepts Regulatory Submission Of Supplemental New Drug Application For Merck's LYNPARZA In HRR-Mutated Metastatic Castration-Resistant Prostate Cancer And Grants Priority Review

Financial news for MRK dated on 2020-01-20: The Week Ahead In Biotech: Focus On Epizyme, Merck Ahead Of PDUFA Dates, J&J To Kickstart Big Pharma Earnings

Financial news for MRK dated on 2020-01-17: Cannabis Media Company The Fresh Toast Expands Again, Announces It's Now Cash Positive

Financial news for MRK dated on 2020-01-13: AstraZeneca and Merck's Supplemental New Drug Application for LYNPARZA Granted Priority Review by the FDA

Financial news for MRK dated on 2020-01-10: 'California Gov. Gavin Newsom wants the state to become the first to create its own generic drug label, an attempt to create more competition and bring down prices.' -Axios, From Earlier

Financial news for MRK dated on 2020-01-09: The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results

Financial news for MRK dated on 2020-01-08: Merck Reports FDA Approval Of KEYTRUDA For Patients BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Ineligible for or Have Elected Not to Undergo Cystectomy

Financial news for MRK dated on 2020-01-08: Merck Announces FDA Approves Pembrolizumab For BCG-Unresponsive, High-risk Non-muscle Invasive Bladder Cancer

Financial news for MRK dated on 2020-01-07: The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering

Financial news for MRK dated on 2020-01-06: Merck's Announces Phase 3 Of KEYNOTE-604 Study Did Not Meet Other Dual Primary Endpoint of Overall Survival; Results to be Presented at Upcoming Medical Meeting

Financial news for MRK dated on 2020-01-06: Merck Buys Exclusive Global License from

Taiho and Astex for its Small Molecule Inhibitor Candidates for \$50M Upfront and Milestone Payments

Financial news for MRK dated on 2020-01-02: Speaker Of The House Nancy Pelosi Says "Enough is enough. @HouseDemocrats passed the bipartisan #LowerDrugCosts Now Act last year to stop Big Pharma from charging Americans more for our medicines than what they charge for the same drugs overseas."

Financial news for MRK dated on 2020-01-01: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Financial news for MRK dated on 2019-12-30: Merck-AstraZeneca's Lynparza Snags FDA Nod For Pancreatic Cancer

Financial news for MRK dated on 2019-12-30: Merck's LYNPARZA Approved By FDA As First-Line Maintenance Treatment Of Germline BRCA-Mutated Metastatic Pancreatic Cancer

Financial news for MRK dated on 2019-12-30: AstraZeneca Says FDA Approved Lynparza for Pancreatic Cancer

Financial news for MRK dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for MRK dated on 2019-12-27: Merck & Co Option Alert: Jun 19 \$92.5 Calls Sweep (49) above Ask!: 4764 @ \$4.107 vs 5293 OI; Earnings 1/31 Before Open [est] Ref=\$91.46

Financial news for MRK dated on 2019-12-23: A Perspective On Biopharma's Record M&A Run In 2019

Financial news for MRK dated on 2019-12-22: How The Dow Jones Industrial Average Changed Over The Past Decade

Financial news for MRK dated on 2019-12-20: Stocks That Hit 52-Week Highs On Friday

Financial news for MRK dated on 2019-12-20: NewLink Genetics Announces FDA Approval Of Ebola Vaccine V920

Financial news for MRK dated on 2019-12-20: The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering

Financial news for MRK dated on 2019-12-20: Merck Reports FDA Approval For ERVEBO

Financial news for MRK dated on 2019-12-20: Merck Reports KEYTRUDA Approved In Japan For 3 New First-Line Indications Across Advanced Renal Cell Carcinoma, Recurrent or Distant Metastatic Head and Neck Cancer

Financial news for MRK dated on 2019-12-20: FDA Approves First Ebola Vaccine

Financial news for MRK dated on 2019-12-19: Stocks That Hit 52-Week Highs On Thursday

Financial news for MRK dated on 2019-12-19: The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic

Financial news for MRK dated on 2019-12-18: The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data

Financial news for MRK dated on 2019-12-17: Merck Reports FDA's Oncologic Drugs AdCom Recommends KEYTRUDA For Treatment Of Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer

Financial news for MRK dated on 2019-12-17: The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

Financial news for MRK dated on 2019-12-15: The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week

Financial news for MRK dated on 2019-12-13: OncoSec Reports Interim Data From KEYNOTE-890 Study Evaluation TAVO In Combination With KEYTRUDA

Financial news for MRK dated on 2019-12-13: The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer

Financial news for MRK dated on 2019-12-13: EMA Reports Positive Opinion For Merck's Recarbrio By CHMP For Treatment Of Infections From Aerobic Gram-Negative Organisms In

Adults

Financial news for MRK dated on 2019-12-12: Traders Circulating Materials From Merck's Keytruda Presentation At ESMO

Financial news for MRK dated on 2019-12-12: Stocks That Hit 52-Week Highs On Thursday

Financial news for MRK dated on 2019-12-12: Merck Highlights Exploratory Analysis Of KEYTRUDA Which Showed Improved Overall Survival As Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KRAS Mutational Status

Financial news for MRK dated on 2019-12-11: Cantor Fitzgerald Says Thinks ArQule May See Other Bidders But Thinks Merck Makes A 'Great Strategic Fit,' Says Thinks Merck's Proposed Acquisition Is 'Fair'

Financial news for MRK dated on 2019-12-11: The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

Financial news for MRK dated on 2019-12-10: Stocks That Hit 52-Week Highs On Tuesday

Financial news for MRK dated on 2019-12-10: The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy \$3M In ContraFect Shares

Financial news for MRK dated on 2019-12-10: 80 Biggest Movers From Yesterday

Financial news for MRK dated on 2019-12-09: Mid-Afternoon Market Update: Dow Falls 90 Points; XBiotech Shares Spike Higher

Financial news for MRK dated on 2019-12-09: PreMarket Prep Recap: Small Biotech Firms Looking Healthy, Street Fades Macy's Downgrade

Financial news for MRK dated on 2019-12-09: 48 Stocks Moving In Monday's Mid-Day Session

Financial news for MRK dated on 2019-12-09: Mid-Day Market Update: Synthorx Jumps Following Acquisition News; Biocept Shares Plunge

Financial news for MRK dated on 2019-12-09: Mid-Morning Market Update: Markets Mixed; Merck To Acquire ArQule For \$20/Share

Financial news for MRK dated on 2019-12-09: KalVista Shares Sink On Failed Mid-Stage Study Of Diabetic Macular Edema Drug

Financial news for MRK dated on 2019-12-09: Benzinga Pro's Top 5 Stocks To Watch For Mon., Dec. 9, 2019: MRK, PCG, M, DPLO, CHWY

Financial news for MRK dated on 2019-12-09: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for MRK dated on 2019-12-09: ArQule To Be Acquired By Merck For \$2.7B

Financial news for MRK dated on 2019-12-09: A Peek Into The Markets: US Stock Futures Down; Crude Oil Falls 1%

Financial news for MRK dated on 2019-12-09: ArQule to be Acquired by Merck for \$20/Share Cash

Financial news for MRK dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for MRK dated on 2019-12-06: Stocks That Hit 52-Week Highs On Friday

Financial news for MRK dated on 2019-12-06: The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

Financial news for MRK dated on 2019-12-05: Stocks That Hit 52-Week Highs On Thursday

Financial news for MRK dated on 2019-12-05: The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

Financial news for MRK dated on 2019-12-05: AstraZeneca, Merck Announce Lynparza Approved in China as a 1st-line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer

Financial news for MRK dated on 2019-12-04: Stocks That Hit 52-Week Highs On Wednesday

Financial news for MRK dated on 2019-12-03: The Daily Biotech Pulse: Astellas To Buy

Audentes For \$3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial

Financial news for MRK dated on 2019-12-02: Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.

Financial news for MRK dated on 2019-12-02: Stocks That Hit 52-Week Highs On Monday

Financial news for MRK dated on 2019-12-02: Seattle Genetics Announces Collaboration with Merck to Evaluate its Enfortumab in Combination with KEYTRUDA

Financial news for MRK dated on 2019-12-02: Merck's KEYTRUDA Granted Priority Review by the FDA for Patients with High-Risk, Non-Muscle Invasive Bladder Cancer

Financial news for MRK dated on 2019-11-29: National Business Daily Reports Drugmakers including Johnson & Johnson, Roche, Novartis and Merck have Agreed to Massively Cut the Prices of Some Drugs to Get Included in China's Medical Reimbursement List

Financial news for MRK dated on 2019-11-27: Stocks That Hit 52-Week Highs On Wednesday

Financial news for MRK dated on 2019-11-27: The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen

Financial news for MRK dated on 2019-11-26: Merck Reports KEYTRUDA Now Approved In China For First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in Combination with Chemotherapy

Financial news for MRK dated on 2019-11-22: AstraZeneca CEO: Closing In On A Cancer Cure

Financial news for MRK dated on 2019-11-22: Trump Says he Will Release a Plan to Let States Import Prescription Drugs Which are "MUCH CHEAPER"

Financial news for MRK dated on 2019-11-20: European Commission Approves Two New Regimens Of Merck's KEYTRUDA As First-Line Treatment For Metastatic Or Unresectable Recurrent Head And Neck Squamous Cell Carcinoma

Financial news for MRK dated on 2019-11-19: Merck Raises Quarterly Dividend From \$0.55 To \$0.61/Share

Financial news for MRK dated on 2019-11-18: Merck and Bayer's Investigational Drug Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure

Financial news for MRK dated on 2019-11-15: Merck Reports Its Animal Health Unit Announced US Approval Of BRAVECTO PLUS

Financial news for MRK dated on 2019-11-14: AstraZeneca, Merck Report FDA Acceptance Of Regulatory Submission For New Drug Application For Selumetinib In Neurofibromatosis Type 1, Priority Review Granted

Financial news for MRK dated on 2019-11-14: AstraZeneca Announces FDA Accepts NDA for Selumetinib

Financial news for MRK dated on 2019-11-13: Morgan Stanley Maintains Overweight on Merck & Co, Raises Price Target to \$95

Financial news for MRK dated on 2019-11-13: The Daily Biotech Pulse: Merck Goes Shopping, Nuvecra Files For Bankruptcy Protection, Opiant Rips Higher

Financial news for MRK dated on 2019-11-11: Merck Reports Its ERVEBO Granted Conditional Approval In EU

Financial news for MRK dated on 2019-11-11: NextCure Shares Give Back Some Gains After Data Readout

Financial news for MRK dated on 2019-11-08: The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

Financial news for MRK dated on 2019-11-07: Biotech Stock On The Radar: Alkermes At A Crossroads

Financial news for MRK dated on 2019-11-06: AstraZeneca Named The Most Innovative Global Pharma Company

Financial news for MRK dated on 2019-11-05: BioLineRx Announces Data Showing BL-8040

In Combination With KEYTRUDA Shows Clinical Activity In Heavily Pretreated Metastatic Pancreatic Cancer Patients

Financial news for MRK dated on 2019-11-03: The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

Financial news for MRK dated on 2019-11-01: WeTrader Competition: Round Four Wrap-up

Financial news for MRK dated on 2019-10-30: US Appeals Court Upholds Lower Court Ruling That Tossed \$2.54B Jury Verdict For Merck In Patent Case Against Gilead

Financial news for MRK dated on 2019-10-30: Decision Day: Fed On Tap Later, Followed by Apple, Facebook After Close

Financial news for MRK dated on 2019-10-29: Alphabet Misses On Earnings, But Drugmakers, Mastercard Beat Expectations

Financial news for MRK dated on 2019-10-29: 28 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for MRK dated on 2019-10-29: Merck & Co Inc Sees Increased Pricing Pressure In 2020; Says Demand For Gardasil Continues To Outpace Supply

Financial news for MRK dated on 2019-10-29: Pharma Earnings: Merck, Pfizer Trade Higher On Q3 Beats

Financial news for MRK dated on 2019-10-29: The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study

Financial news for MRK dated on 2019-10-29: Merck & Co shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. The company also issued FY19 EPS and sales guidance above analyst estimates.

Financial news for MRK dated on 2019-10-29: Merck Sees FY19 Adj. EPS \$5.12-\$5.17 vs \$4.92 Est., Sales \$46.5B-\$47.0B vs \$45.98B Est.

Financial news for MRK dated on 2019-10-29: Merck & Co Q3 Adj. EPS \$1.51 Beats \$1.24 Estimate, Sales \$12.4B Beat \$11.63B Estimate

Financial news for MRK dated on 2019-10-29: 12 Stocks To Watch For October 29, 2019

Financial news for MRK dated on 2019-10-29: Earnings Scheduled For October 29, 2019

Financial news for MRK dated on 2019-10-28: More Earnings And A Fed Decision In Week Four Of The WeTrader Competition

Financial news for MRK dated on 2019-10-28: Merck Shares Fall 2% Following Report AstraZeneca Trial Of Imfinzi, Imfinzi Plus Tremelimumab Delayed Disease Progression In Phase 3 Trial

Financial news for MRK dated on 2019-10-27: The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

Financial news for MRK dated on 2019-10-22: Jim Cramer Gives His Take On AMD, Merck And More

Financial news for MRK dated on 2019-10-22: Merck & Co shares are trading lower on seemingly no company-specific news. The stock touched the \$85 resistance level and traded lower.

Financial news for MRK dated on 2019-10-22: The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug

Financial news for MRK dated on 2019-10-22: 8 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for MRK dated on 2019-10-21: NewLink Genetics Announces EU Regulatory Committee Recommendation For Conditional Marketing Authorization For Ebola Vaccine V920

Financial news for MRK dated on 2019-10-21: Exclusive: Plus Products Hires The Wonderful Company's Mackler As Chief Scientific Officer

Financial news for MRK dated on 2019-10-18: WHO Says Ebola Concentrated In Congo Mining Area, Still An Emergency

Financial news for MRK dated on 2019-10-18: Merck Reports Positive EU CHMP Opinion For 2 New Regimens Of KEYTRUDA As First-Line Treatment For Metastatic Or Unresectable

Recurrent Head, Neck Squamous Cell Carcinoma

Financial news for MRK dated on 2019-10-18: Merck Reports Received EU CHMP Positive Opinion For Investigational V920 Ebola Vaccine For Protection Against Ebola Virus

Financial news for MRK dated on 2019-10-17: Bank of America Reinstates Neutral on Merck & Co, Announces \$90 Price Target

Financial news for MRK dated on 2019-10-16: Biotech Stock On The Radar: Assessing Mirati's Oncology Franchise With An Eye On Multiple Readouts

Financial news for MRK dated on 2019-10-15: The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings

Financial news for MRK dated on 2019-10-13: The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings

Financial news for MRK dated on 2019-10-11: Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.

Financial news for MRK dated on 2019-10-08: Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks

Financial news for MRK dated on 2019-10-08: Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on \$250 billion worth of goods from 25% to 30% on Oct 15.

Financial news for MRK dated on 2019-10-03: Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar

Financial news for MRK dated on 2019-10-03: What's Behind PDS Biotech's Rally?

Financial news for MRK dated on 2019-10-03: PDS Biotech Reports Clinical Collaboration With Merck For Evaluation Of Combo Of PDS0101, Merck's KEYTRUDA

Financial news for MRK dated on 2019-10-02: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.

Financial news for MRK dated on 2019-10-02: Merck's KEYTRUDA Now Approved as Monotherapy In China For First-Line Treatment Of Certain Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

Financial news for MRK dated on 2019-10-02: FDA Accepts Two Applications For Merck's DIFICID To Treat Children Aged Six Months Up To 18 years With Clostridium difficile Infections

Financial news for MRK dated on 2019-10-01: The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines

Financial news for MRK dated on 2019-09-30: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

Financial news for MRK dated on 2019-09-30: Merck shares trading higher over the \$82 level. The company announced its RESTORE-IMI study of RECARBRIO met its primary endpoint. Separately, the company and AstraZeneca highlighted new LYNPARZA data.

Financial news for MRK dated on 2019-09-30: Movers And Shakers At ESMO 2019: Immunomedics, GI Therapeutics, Seattle Genetics And More

Financial news for MRK dated on 2019-09-30: Merck, AstraZeneca Highlight Data LYNPARZA More Than Doubled Median Radiographic Progression-Free Survival In BRCA1/2, ATM Metastatic Castration-Resistant Prostate Cancer

Financial news for MRK dated on 2019-09-30: Merck's Pivotal RESTORE-IMI 2 Phase 3 Study of RECARBRIO Met its Primary Endpoint

Financial news for MRK dated on 2019-09-29: The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear

Financial news for MRK dated on 2019-09-28: AstraZeneca , Merck Announced LYNPARZA Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer at

ESMO 2019

Financial news for MRK dated on 2019-09-25: Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company

Financial news for MRK dated on 2019-09-22: The Week Ahead In Biotech: Spotlight On ESMO Conference

Financial news for MRK dated on 2019-09-20: Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.

Financial news for MRK dated on 2019-09-20: The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering

Financial news for MRK dated on 2019-09-20: Merck's PIFELTRO And DELSTRIGO Receive FDA Approval For Use In Appropriate Adults Living With HIV-1 Who Are Virologically Suppressed

Financial news for MRK dated on 2019-09-18: NewLink Genetics Rallies After Ebola Vaccine Granted Priority Review Status

Financial news for MRK dated on 2019-09-18: The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts

Financial news for MRK dated on 2019-09-18: FDA Approves LENVIMA Plus KEYTRUDA Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

Financial news for MRK dated on 2019-09-17: Merck Press Release Confirms FDA Approval Of KEYTRUDA Plus LENVIMA Combo Treatment For Patients With Certain Types Of Endometrial Carcinoma

Financial news for MRK dated on 2019-09-17: FDA Says Granted Accelerated Approval To Lenvima In Combo With Keytruda For Treatment Of Patients With Advanced Endometrial Carcinoma

Financial news for MRK dated on 2019-09-17: Merck Reports FDA Accepted Biologics License Application, Granted Priority Review For V920 For Ebola Zaire Virus

Financial news for MRK dated on 2019-09-15: The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck

Financial news for MRK dated on 2019-09-12: Oracle Reports Early In Surprise Move As Trump Surprises With Positive Trade Tweet

Financial news for MRK dated on 2019-09-10: Shares of several drugmakers are trading lower on news of a drug pricing bill being developed by House Democrats. The proposed bill would set US drug prices based on prices in other wealthy countries.

Financial news for MRK dated on 2019-09-09: Merck & Co shares are trading lower. Not seeing any news to justify the price action.

Financial news for MRK dated on 2019-09-09: Merck to Present Data From its Phase 3 Trial for KEYTRUDA as Neoadjuvant Therapy at the European Society for Medical Oncology

Financial news for MRK dated on 2019-09-04: Aduro Biotech Announces First Patient Dosed In Phase 2 Study Of ADU-S100 In Combination With KEYTRUDA For First-Line Treatment Of Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

Financial news for MRK dated on 2019-09-04: European Commission Approves Merck's KEYTRUDA In Combination With Inlyta As First-Line Treatment For Patients With Advanced Renal Cell Carcinoma

Financial news for MRK dated on 2019-08-30: Xynomic Pharma Reports Interim Data From Phase 1b Study Of Abexinostat Combined With Keytruda In Multiple Solid Tumors

Financial news for MRK dated on 2019-08-30: Deaths from E. Congo Ebola Outbreak Top 2,000; Cases Top 3,000

Financial news for MRK dated on 2019-08-29: Uganda Confirms Another Case Of Ebola - A 9-Year Old Girl Who Traveled Democratic Republic Of Congo

Financial news for MRK dated on 2019-08-29: Stocks That Hit 52-Week Highs On Thursday

Financial news for MRK dated on 2019-08-28: Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates

Financial news for MRK dated on 2019-08-24: 10 Biopharmaceutical Companies Trying To

Cure Cancer

Financial news for MRK dated on 2019-08-22: Jim Cramer Weighs In On Pfizer, Teva And More

Financial news for MRK dated on 2019-08-22: Analysts Share Stocks To Buy On Fed Uncertainty

Financial news for MRK dated on 2019-08-22: The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study

Financial news for MRK dated on 2019-08-21: The Daily Biotech Pulse: Ra Pharma Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform

Financial news for MRK dated on 2019-08-19: Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.

Financial news for MRK dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for MRK dated on 2019-08-16: Benzinga's Top Upgrades, Downgrades For August 16, 2019

Financial news for MRK dated on 2019-08-16: SVB Leerink Initiates Coverage On Merck & Co with Outperform Rating, Announces \$103 Price Target

Financial news for MRK dated on 2019-08-14: The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering

Financial news for MRK dated on 2019-08-14: AstraZeneca And Merck Announce LYNPARZA) Phase 3 PAOLA-1 Trial Met Primary Endpoint In Ovarian Cancer Patients

Financial news for MRK dated on 2019-08-14: Lynparza Phase Iii Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer

Financial news for MRK dated on 2019-08-14: AstraZeneca, Merck Announce Lynparza Phase III PAOLA-1 Trial Met Primary Endpoint

Financial news for MRK dated on 2019-08-13: Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.

Financial news for MRK dated on 2019-08-06: Merck 10-Q Out; Shows Co. Received Set Of Investigative Interrogatories From California Attorney General's Office On Apr. 15, 2019 Related To Conduct, Deal That Allegedly Affected, Delayed Competition To Lantus In Insulin Market

Financial news for MRK dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for MRK dated on 2019-08-05: Universal Display and Merck Announce Research and Development Collaboration for OLED

Financial news for MRK dated on 2019-08-03: Bulls And Bears Of The Week: Boeing, GM, Pfizer, Starbucks And More

Financial news for MRK dated on 2019-08-03: The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Financial news for MRK dated on 2019-07-31: SELLAS Advances Galinpepimut-S (GPS) In Combination With KEYTRUDA Program With Dosing Of First Patient In Phase 1/2 Basket Study

Financial news for MRK dated on 2019-07-31: Merck Reports FDA Approved New Monotherapy Indication For KEYTRUDA: 'Recurrent Locally Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus in Patients Whose Tumors Express PD-L1 (CPS ≥ 10) With Disease Progression After One or More Prior Lines'

Financial news for MRK dated on 2019-07-30: Apple On Today's Menu, With Starring Roles From China Talks, Fed Meeting

Financial news for MRK dated on 2019-07-30: 33 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for MRK dated on 2019-07-30: Merck & Co shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also issued FY19 guidance above analyst estimates.

Financial news for MRK dated on 2019-07-30: A Peek Into The Markets: US Stock Futures Down Ahead of Fed Meeting, Apple Earnings

Financial news for MRK dated on 2019-07-30: Merck Reports Q2 Earnings Beat

Financial news for MRK dated on 2019-07-30: The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings

Financial news for MRK dated on 2019-07-30: Merck & Co. Sees FY19 Adj. EPS \$4.84-\$4.94 vs \$4.75 Est., Sees Sales \$45.2B-\$46.2B vs \$44.74B Est.

Financial news for MRK dated on 2019-07-30: Merck & Co Q2 Adj. EPS \$1.3 Beats \$1.16 Estimate, Sales \$11.76B Beat \$10.96B Estimate

Financial news for MRK dated on 2019-07-30: 15 Stocks To Watch For July 30, 2019

Financial news for MRK dated on 2019-07-30: Earnings Scheduled For July 30, 2019

Financial news for MRK dated on 2019-07-29: Merck Q2 Earnings Preview

Financial news for MRK dated on 2019-07-29: Merck's Keytruda Gets A Double Dose Of Positive News

Financial news for MRK dated on 2019-07-29: Merck's KEYTRUDA in Combination with Chemotherapy Met One of the Dual Primary Endpoints in Pivotal Phase 3 KEYNOTE-522

Financial news for MRK dated on 2019-07-29: Merck's KEYTRUDA in Combination with Inlyta as First-Line Treatment for Advanced Renal Cell Carcinoma Receives a Positive Opinion From the European Medicines Agency

Financial news for MRK dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for MRK dated on 2019-07-24: Merck Highlights Presentation Of Phase 2b Results For Investigational HIV-1 Therapy Islatravir (MK-8591) At IAS 2019

Financial news for MRK dated on 2019-07-24: The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index

Financial news for MRK dated on 2019-07-23: Merck Reports Results From Phase 1 Study Of Investigational Nucleoside Reverse Transcriptase Translocation Inhibitor Presented At International AIDS Society Conference on HIV Science

Financial news for MRK dated on 2019-07-23: Eisai's Cancer Drug Combo Gets Breakthrough Therapy Designation For Liver Cancer

Financial news for MRK dated on 2019-07-23: The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

Financial news for MRK dated on 2019-07-23: Merck And Eisai Receive Third Breakthrough Therapy Designation From FDA For KEYTRUDA Plus LENVIMA Combination Treatment

Financial news for MRK dated on 2019-07-20: The Week Ahead In Biotech: Pharma Earnings Pick Up Pace

Financial news for MRK dated on 2019-07-17: WHO Emergency Committee Says It Recognises Shortage Of Supply Of Merck's Ebola Vaccine, Says Who Should Work With Member States And Manufacturers To 'Take All Measures' To Increase Supply

Financial news for MRK dated on 2019-07-17: WHO Emergency Committee Chairman Says Ebola Is A Regional Emergency And In No Way A Global Threat

Financial news for MRK dated on 2019-07-17: World Health Organization's Emergency Committee Says Congo's Ebola Outbreak Constitutes A Public Health Emergency Of International Concern

Financial news for MRK dated on 2019-07-17: Merck's Novel Antibiotic For Abdominal, Urinary Tract Infections Receives FDA Nod

Financial news for MRK dated on 2019-07-17: FDA Approves Merck's RECARBRIO For the Treatment of Adults with Complicated Urinary Tract And Complicated Intra-Abdominal Bacterial Infections Where Limited Or No Alternative Treatment Options Are Available

Financial news for MRK dated on 2019-07-15: World Health Organization Chief Says Ebola Case In Congolese City Of Goma Could Be A Gamechanger

Financial news for MRK dated on 2019-07-13: The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings

Financial news for MRK dated on 2019-07-13: Bulls & Bears Of The Week: Costco, DuPont, IBM, Merck And More

Financial news for MRK dated on 2019-07-12: Washington Worries Trigger Bearish Merck Options Trades

Financial news for MRK dated on 2019-07-12: Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug

Financial news for MRK dated on 2019-07-12: Stock Market Eyes Records On Dovish Commentary From Federal Reserve

Financial news for MRK dated on 2019-07-12: Shares of several drug manufacturing companies are trading lower, potentially on continued weakness after the Trump Administration on Thursday rolled back a proposal to eliminate rebates from government drug plans.

Financial news for MRK dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for MRK dated on 2019-07-10: Merck To Present Results From Studies Evaluating Investigational Anti-HIV Agent MK-8591 At IAS 2019 On Jul. 21-24

Financial news for MRK dated on 2019-07-09: Judge Rules Against Trump Proposal Forcing Pharma Companies To Disclose Drug Prices In Commercials

Financial news for MRK dated on 2019-07-09: FDA Accepts Merck's Supplemental Biologics License Applications For KEYTRUDA Six-Week Dosing Schedule For Melanoma And Multiple Other Indications

Financial news for MRK dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for MRK dated on 2019-07-05: The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight

Financial news for MRK dated on 2019-07-03: Benzinga's Top Upgrades, Downgrades For July 3, 2019

Financial news for MRK dated on 2019-07-03: Mizuho Initiates Coverage On Merck & Co with Buy Rating, Announces \$97 Price Target

Financial news for MRK dated on 2019-07-02: Mizuho Initiates Coverage On Merck With Buy Rating, \$97 Price Target

Financial news for MRK dated on 2019-07-01: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Financial news for MRK dated on 2019-06-27: The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO

Financial news for MRK dated on 2019-06-25: Intensity Therapeutics Announces Clinical Collaboration With Merck For A Phase 1/2 Clinical Trial To Evaluate Co'S Int230-6 In Combination With Keytruda For Multiple Solid Tumor Types

Financial news for MRK dated on 2019-06-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Financial news for MRK dated on 2019-06-21: Morgan Stanley Maintains Overweight on Merck & Co, Raises Price Target to \$90

Financial news for MRK dated on 2019-06-21: The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy

Financial news for MRK dated on 2019-06-20: Merck CEO Frazier At Investor Day Says The Company Has Less Appetite For Big Deals Than Mid Or Small-Sized Deals; Says Most

Big Pharma Deals Have Not Created The Value They Said They Were Going To Create

Financial news for MRK dated on 2019-06-20: The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge

Financial news for MRK dated on 2019-06-20: Merck Highlights 2019 Investor Day Presentation

Financial news for MRK dated on 2019-06-19: Report: Merck Searching Internally For Next CEO

Financial news for MRK dated on 2019-06-19: Merck Prepping For CEO Departure, Has Begun Internal Successor Hunt

Financial news for MRK dated on 2019-06-19: The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut

Financial news for MRK dated on 2019-06-19: AstraZeneca, Merck Announce Lynparza Approved in Japan for 1st-line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer

Financial news for MRK dated on 2019-06-18: Merck Reports FDA Approved KEYTRUDA As Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy

Financial news for MRK dated on 2019-06-18: AstraZeneca, Merck Report LYNPARZA Approved In EU For Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer

Financial news for MRK dated on 2019-06-18: AstraZeneca, Merck Announce Lynparza Approved in the EU for 1st-line Maintenance Treatment Of BRCA-mutated Advanced Ovarian Cancer

Financial news for MRK dated on 2019-06-17: 'Measles cases in United States rise to 1,044- CNN

Financial news for MRK dated on 2019-06-15: The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

Financial news for MRK dated on 2019-06-14: From Earlier: 'Drug makers Amgen, Merck, Lilly and the Association of National Advertisers file suit to prevent the disclosure of drug prices in television ads.'

Financial news for MRK dated on 2019-06-14: JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to \$93

Financial news for MRK dated on 2019-06-13: IBM, Walmart, Merck Included In FDA Program To Test Blockchain Usage In US Drug Supply Chain

Financial news for MRK dated on 2019-06-13: IBM, KPMG, Merck, Walmart Report Have Been Selected By FDA To Be Included In Blockchain Program In Support Of US Drug Supply Chain Security Act To Address Requirement To Identify, Track, Trace Medicines, Vaccines Distributed In US

Financial news for MRK dated on 2019-06-12: WHO Emergency Committee Meeting To Decide If Ebola Outbreak Constitutes An Int'l. Emergency Will Begin Jun. 14, 2019

Financial news for MRK dated on 2019-06-12: The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana

Financial news for MRK dated on 2019-06-11: FDA Greenlights Merck's Blockbuster Drug Keytruda For First-Line Treatment Of Head, Neck Cancer

Financial news for MRK dated on 2019-06-11: FDA Approves Two New Indications For Merck's KEYTRUDA

Financial news for MRK dated on 2019-06-10: Merck Strikes \$773M Deal For Privately Held Tilos Therapeutics

Financial news for MRK dated on 2019-06-10: A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street

Financial news for MRK dated on 2019-06-10: Merck Reports Purchase Of Tilos Therapeutics For Total Potential Consideration OF \$773M

Financial news for MRK dated on 2019-06-08: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Financial news for MRK dated on 2019-06-07: Sanofi's Leadership Transition: What You Need To Know

Financial news for MRK dated on 2019-06-04: Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.

Financial news for MRK dated on 2019-06-04: 'I believe it is wrong to charge Americans astronomical prices for life-saving drugs developed with taxpayer dollars. You will not find me encouraging pharmaceutical companies to continue ripping off Americans like my Republican colleagues.' -Sen Sanders

Financial news for MRK dated on 2019-06-04: The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer

Financial news for MRK dated on 2019-06-03: Merck Reports LYNPARZA Phase 3 SOLO3 Trial Showed 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy

Financial news for MRK dated on 2019-06-03: FDA Grants Approval Of Zerbaxa To Merck & Co Inc

Financial news for MRK dated on 2019-06-03: Dynavax Highlights Presentation Of Results Showing 76% Overall Response Rate In Advanced Melanoma Patients With SD-101 In Combination With KEYTRUDA

Financial news for MRK dated on 2019-06-03: Merck Sat. Highlighted 5-Year Survival Data From KEYTRUDA In NSCLC As First Keynote Trial At ASCO

Financial news for MRK dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for MRK dated on 2019-06-01: Merck Announces Five-Year Survival Data for KEYTRUDA in Advanced Non-Small Cell Lung Cancer from First KEYNOTE Trial at #ASCO19

Financial news for MRK dated on 2019-05-31: Merck Reports KEYTRUDA Showed Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial

Financial news for MRK dated on 2019-05-28: Top 10 Most Overbought Stocks Via Benzinga Pro's Radar Tool For Tue., May 28, 2019

Financial news for MRK dated on 2019-05-28: Goldman Sachs Initiates Coverage On Merck & Co with Neutral Rating, Announces \$85 Price Target

Financial news for MRK dated on 2019-05-26: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for MRK dated on 2019-05-22: Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond

Financial news for MRK dated on 2019-05-21: Merck To Buy Clinical-Stage Biopharma Peloton Therapeutics For More Than \$1B

Financial news for MRK dated on 2019-05-21: The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

Financial news for MRK dated on 2019-05-21: Merck To Purchase Peloton Therapeutics For \$1.05B In Cash, Will Be Eligible To Receive Further \$1.15B Based On Regulatory, Sales Milestones

Financial news for MRK dated on 2019-05-20: UPDATE: Merck Says KEYTRUDA Trial Did Not Meet Primary Endpoint Of Superior Overall Survival

Financial news for MRK dated on 2019-05-20: Merck Offers Update On Phase 3 KEYNOTE-19 Study Of KEYTRUDA in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer

Financial news for MRK dated on 2019-05-20: Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To Sidelines

Financial news for MRK dated on 2019-05-16: 5 ASCO Abstracts That Moved Stocks

Financial news for MRK dated on 2019-05-16: Iovance Issues Cancer Trial Updates Ahead

Of ASCO Meeting, Sending Stock Skyward

Financial news for MRK dated on 2019-05-16: The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics

Financial news for MRK dated on 2019-05-16: Intec Pharma Announces Research Collaboration Agreement With Merck

Financial news for MRK dated on 2019-05-15: 13F From Loeb's Third Point Shows Liquidated Stake In Merck, Cut Stake In American Express

Financial news for MRK dated on 2019-05-15: The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGaA's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi

Financial news for MRK dated on 2019-05-10: Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%

Financial news for MRK dated on 2019-05-08: Merck Reports Results From Phase 2 Trial Of V114 In Infants: Met Primary Dndpoint

Financial news for MRK dated on 2019-05-07: Merck's BELSOMRA C-IV Meets Primary Efficacy Endpoint In Phase 3 Trial For Treatment Of Insomnia In People With Mild-To-Moderate Alzheimer's Disease Dementia

Financial news for MRK dated on 2019-05-07: Ebola Death Toll in Congo Rises to 979

Financial news for MRK dated on 2019-05-03: Canopy Growth, Lockheed Martin, Merck And More: 'Fast Money Halftime Report' Picks For May 3

Financial news for MRK dated on 2019-05-02: UBS Maintains Buy on Merck & Company, Inc. Common Stock (new), Raises Price Target to \$88

Financial news for MRK dated on 2019-05-01: BMO Capital Maintains Market Perform on Merck & Company, Inc. Common Stock (new), Raises Price Target to \$84

Financial news for MRK dated on 2019-05-01: Bank of America Maintains Buy on Merck & Company, Inc. Common Stock (new), Raises Price Target to \$91

Financial news for MRK dated on 2019-04-30: Alphabet Revenue Disappoints Ahead Of Apple Earnings After The Bell

Financial news for MRK dated on 2019-04-30: Merck & Co shares are trading higher after the company reported better-than-expected Q1 EPS and sales and issued strong FY19 guidance.

Financial news for MRK dated on 2019-04-30: The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering

Financial news for MRK dated on 2019-04-30: A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings, Fed Meeting

Financial news for MRK dated on 2019-04-30: Merck & Co. Sees FY19 Adj. EPS \$4.67-\$4.79 vs \$4.67 Est., Sales \$43.9B-\$45.1B vs \$44.42B Est.

Financial news for MRK dated on 2019-04-30: Merck & Co Q1 Adj. EPS \$1.22 Beats \$1.06 Estimate, Sales \$10.82B Beat \$10.48B Estimate

Financial news for MRK dated on 2019-04-30: 15 Stocks To Watch For April 30, 2019

Financial news for MRK dated on 2019-04-30: Earnings Scheduled For April 30, 2019

Financial news for MRK dated on 2019-04-29: This Week, Market Eyes China Talks, Fed Meeting As Earnings Continue

Financial news for MRK dated on 2019-04-29: AstraZeneca, Merck Announce Lynparza Receives Positive EU CHMP Opinion for 1st-line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer

Financial news for MRK dated on 2019-04-26: The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug

Financial news for MRK dated on 2019-04-25: Merck Offers Update On Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA(r) as Monotherapy, In Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Financial news for MRK dated on 2019-04-23: Shares of several healthcare stocks are

trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for MRK dated on 2019-04-23: OncoSec Announces Triple Combination Immunotherapy Clinical Trial Of TAVO, Epcadostat And KEYTRUDA In Squamous Cell Head And Neck (SCCHN) Cancer

Financial news for MRK dated on 2019-04-22: Merck's KEYTRUDA in Combination with Inlyta Approved by the FDA as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Financial news for MRK dated on 2019-04-18: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for MRK dated on 2019-04-17: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for MRK dated on 2019-04-16: Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.

Financial news for MRK dated on 2019-04-16: The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

Financial news for MRK dated on 2019-04-15: Measles Cases Worldwide Rose Nearly Four-Fold In First Quarter Of 2019 To 112,163 Against Same Period Last Year, Provisional Data Shows

Financial news for MRK dated on 2019-04-12: The Daily Biotech Pulse: Merck's Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug

Financial news for MRK dated on 2019-04-11: Merck Reports FDA Approval For Expanded Monotherapy Label For KEYTRUDA

Financial news for MRK dated on 2019-04-11: NYC Mandates Measles Vaccinations; Merck Is The Exclusive Manufacturer

Financial news for MRK dated on 2019-04-11: The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug

Financial news for MRK dated on 2019-04-10: AstraZeneca, Merck Announce Lynparza Approved in EU for the treatment of Germline BRCA-mutated HER2-negative Advanced Breast Cancer

Financial news for MRK dated on 2019-04-07: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Financial news for MRK dated on 2019-04-04: Myriad Genetics, AstraZeneca, Merck Report Expansion Of Companion Diagnostic Partnership

Financial news for MRK dated on 2019-04-02: The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

Financial news for MRK dated on 2019-04-01: Biotech Winners, Losers In Q1

Financial news for MRK dated on 2019-04-01: Advaxis Shares Surge After Positive Clinical Trial Updates

Financial news for MRK dated on 2019-04-01: AstraZeneca's Rare Pediatric Genetic Disorder Drug Granted Breakthrough Therapy Designation

Financial news for MRK dated on 2019-04-01: Syndax Pharmaceuticals Highlights Presentation Of Updated Phase 2 Data From ENCORE 601 Trial Of Entinostat In Combination With KEYTRUDA At American Association For Cancer Research 2019 Annual Meeting

Financial news for MRK dated on 2019-04-01: Advaxis Says its Phase 1/2 KEYNOTE-046 Study Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer

Financial news for MRK dated on 2019-04-01: Alkermes, Merck, Sage Therapeutics and Takeda Pharma Announce a Partnership to Qualify Biomarkers for Schizophrenia Drug Development

Financial news for MRK dated on 2019-04-01: Merck's KEYTRUDA Approved in China for

First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in Combination with Chemotherapy

Financial news for MRK dated on 2019-04-01: Merck and AstraZeneca's Selumetinib is Granted Breakthrough Therapy Designation in Neurofibromatosis Type 1

Financial news for MRK dated on 2019-04-01: AstraZeneca, Merck Announce Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1

Financial news for MRK dated on 2019-03-29: Congo Health Ministry Says Has Recorded 15 New Confirmed Cases Of Ebola

Financial news for MRK dated on 2019-03-29: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for MRK dated on 2019-03-27: The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO

Financial news for MRK dated on 2019-03-26: Merck Shares Unaffected As Traders Circulate Business Insider Interview From Mon. Highlighting CEO Hinted He Could Step Down

Financial news for MRK dated on 2019-03-25: These Are Some Of The Best-Performing Leveraged ETFs Of The Year

Financial news for MRK dated on 2019-03-23: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for MRK dated on 2019-03-22: The Daily Biotech Pulse: Immute Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback

Financial news for MRK dated on 2019-03-21: FedEx's Struggles May Be Less About Global Demand And More About 'NotPetya'

Financial news for MRK dated on 2019-03-21: Watching Stocks With Alzheimer's Treatment Candidates: Merck, Roche, AbbVie, Neurotrope, AC Immune, Denali, INmune Bio, BioXcel Therapeutics, Intra-Cellular, Anavex, Pain Therapeutics, Grifols

Financial news for MRK dated on 2019-03-20: Merck and NGM Bio Announce Extension Of Strategic Collaboration To 2022

Financial news for MRK dated on 2019-03-18: Morgan Stanley Drops Bearish Exelixis Stance, Sees 'Limited Downside Risk'

Financial news for MRK dated on 2019-03-15: Enigma Biomedical Reports Exclusive License Deal With Merck For Global Development, Commercialization Of MK-6884, An Alzheimer's Treatment

Financial news for MRK dated on 2019-03-14: Merck Reports EC Approved KEYTRUDA In Combo With Chemo For First-Line Treatment Of Adults With Metastatic Squamous Non-Small Cell Lung Cancer

Financial news for MRK dated on 2019-03-07: Merck & Co Option Alert: Jun, 2020 \$85 Calls at the Ask: 1000 @ \$4.901 vs 113 OI; Earnings 4/30 Before Open [est] Ref=\$80.62

Financial news for MRK dated on 2019-03-06: The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split

Financial news for MRK dated on 2019-03-05: Merck Begins Tender Offer To Acquire Immune Design

Financial news for MRK dated on 2019-03-04: BioXcel Therapeutics Announces Merck and Pfizer Join its Clinical Collaboration with Nektar Therapeutics to Evaluate a Triple Therapy for Pancreatic Cancer

Financial news for MRK dated on 2019-03-04: Merck Says the European Medicines Agency Adopts Positive Opinion for Merck's KEYTRUDA for Six-Week Dosing Schedule Across All Current Monotherapy Indications

Financial news for MRK dated on 2019-03-01: Merck Reports Positive CHMP Opinion For Use In Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

Financial news for MRK dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for MRK dated on 2019-02-27: The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings

Financial news for MRK dated on 2019-02-26: Sellas Reviews Strategic Options To Fund Clinical Development Programs

Financial news for MRK dated on 2019-02-26: It Could Be Time For This Pharma ETF

Financial news for MRK dated on 2019-02-26: The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Financial news for MRK dated on 2019-02-26: UPDATE: Merck, AstraZeneca Report Phase III POLO Trial Met Primary Endpoint

Financial news for MRK dated on 2019-02-26: Merck, AstraZeneca Report LYNPARZA Reduced the Risk of Disease Progression or Death as 1st-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer

Financial news for MRK dated on 2019-02-26: AstraZeneca, Merck Announce Phase III POLO Trial Met its Primary Endpoint of Progression-free Survival

Financial news for MRK dated on 2019-02-25: Pharma M&A Wave: Spark Therapeutics, Clementia Pharma Among The Rare Disease Biotechs Acquired

Financial news for MRK dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for MRK dated on 2019-02-22: Cantor Fitzgerald Initiates Coverage On Merck & Co with Overweight Rating, Announces \$95 Price Target

Financial news for MRK dated on 2019-02-22: The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data

Financial news for MRK dated on 2019-02-22: 65 Biggest Movers From Yesterday

Financial news for MRK dated on 2019-02-21: Mid-Afternoon Market Update: Dow Falls 150 Points; Delphi Technologies Shares Spike Higher

Financial news for MRK dated on 2019-02-21: 50 Stocks Moving In Thursday's Mid-Day Session

Financial news for MRK dated on 2019-02-21: Mid-Day Market Update: Immune Design Jumps Following Acquisition News; Carbon Black Shares Slide

Financial news for MRK dated on 2019-02-21: Mid-Morning Market Update: Markets Open Lower; Domino's Pizza Misses Q4 Views

Financial news for MRK dated on 2019-02-21: Merck To Buy Immune Design For \$300M

Financial news for MRK dated on 2019-02-21: 31 Stocks Moving In Thursday's Pre-Market Session

Financial news for MRK dated on 2019-02-21: Merck To Acquire Immune Design At \$5.85/Share In Cash, Or ~\$300M

Financial news for MRK dated on 2019-02-20: The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering

Financial news for MRK dated on 2019-02-20: FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA Monotherapy For Third-Line Treatment of Patients with Advanced Small Cell Lung Cancer

Financial news for MRK dated on 2019-02-19: Merck Reports Phase 3 KEYNOTE-240 Trial Evaluating KEYTRUDA Did Not Meet Co-Primary Endpoints

Financial news for MRK dated on 2019-02-19: Merck Says US Patent & Trademark Office Issued Formal Notice Allowing Co.'s Patent Application Directed To Its Proxy-CRISPR Technology

Financial news for MRK dated on 2019-02-19: FDA Approves Merck's KEYTRUDA For Adjuvant Treatment Of Patients With Melanoma With Involvement Of Lymph Nodes Following Complete Resection

Financial news for MRK dated on 2019-02-17: Merck Announces KEYTRUDA in Combination with Inlyta Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced RCC at ASCO GU 2019

Financial news for MRK dated on 2019-02-15: Merck Reports FDA Granted Priority Review For Co.'s Supplemental Biologics License Application for KEYTRUDA Combo With Inlyta For First-Line Treatment for Advanced Renal Cell Carcinoma

Financial news for MRK dated on 2019-02-14: Merck Highlights 3 New Phase 3 Trials

Financial news for MRK dated on 2019-02-11: Hemispherx Biopharma Announces Commencement Of A New 45 Subject Clinical Trial Combining Ampligen And Merck's Keytruda In The Treatment Of Recurrent Ovarian Cancer

Financial news for MRK dated on 2019-02-11: Merck Granted FDA Priority Review for its Supplemental Biologics License Application for KEYTRUDA for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Financial news for MRK dated on 2019-02-10: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for MRK dated on 2019-02-09: Third Point Dissolves Stakes in Netflix, Microsoft; Cuts Stake in PayPal, Merck, Visa, American Express, Baxter; Raises Stakes in Campbell Soup, Salesforce

Financial news for MRK dated on 2019-02-07: Bank Of America Reiterates Buy And \$84 Target On Merck Due To 'Keytruda driven upside, undemanding valuation + optionality (animal health spin + OM expansion)'

Financial news for MRK dated on 2019-02-06: Drugmakers Offered C\$9.6B in Price Cuts; Freeze of Drug Prices in Response to Proposed Crackdown by Canada Regulator

Financial news for MRK dated on 2019-02-05: Merck Says CEO Frazier Plans To Testify At Feb 26 Senate Drug Pricing Hearing

Financial news for MRK dated on 2019-02-05: Codexis shares are trading higher after the company reported a multi-year agreement with Merck to perform technology upgrades.

Financial news for MRK dated on 2019-02-05: The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

Financial news for MRK dated on 2019-02-05: FDA Accepts For Review New Drug Application For Merck's Investigational Combination Of Imipenem/Cilastatin And Relebactam; Accepts Supplemental NDA For ZERBAXA

Financial news for MRK dated on 2019-02-04: UPDATE: Financial Terms Of Codexis/Merck Deal Were Not Disclosed

Financial news for MRK dated on 2019-02-04: Codexis Reports Secured Multi-Year Technology Upgrade Package For CodeEvolver Protein Engineering Platform License With Merck

Financial news for MRK dated on 2019-02-04: Merck Announces the European Medicines Agency Gave a Positive Opinion on KEYTRUDA in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer

Financial news for MRK dated on 2019-02-02: Barron's Picks And Pans: Corning, Merck, Microsoft And More

Financial news for MRK dated on 2019-02-01: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

Financial news for MRK dated on 2019-02-01: Merck & Co shares are trading higher after the company reported inline Q4 EPS figures and beat sales estimates.

Financial news for MRK dated on 2019-02-01: The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of Titan's Opioid Disorder Treatment Implant

Financial news for MRK dated on 2019-02-01: Merck Sees FY19 Adj. EPS \$4.57-\$4.72 vs \$4.69 Estimate, Sales \$43.2B-\$44.7B vs \$44.54B Est.

Financial news for MRK dated on 2019-02-01: Merck Q4 EPS \$1.04, Inline, Sales \$10.998B Beat \$10.96B Estimate

Financial news for MRK dated on 2019-02-01: 12 Stocks To Watch For February 1, 2019

Financial news for MRK dated on 2019-02-01: Earnings Scheduled For February 1, 2019

Financial news for MRK dated on 2019-01-31: Merck's Q4 Earnings Preview

Financial news for MRK dated on 2019-01-29: How To Approach Q4 Earnings: The Technical Perspective

Financial news for MRK dated on 2019-01-28: Evelo Biosciences Announces First Patient Does in Investigator-Sponsored Phase 2a Clinical Trial of EDP1503 in Combination with KEYTRUDA(r) in Patients with Metastatic Melanoma

Financial news for MRK dated on 2019-01-27: Barron's On: The Cost Of Climate Change

Financial news for MRK dated on 2019-01-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for MRK dated on 2019-01-24: Bristol-Myers Squibb Withdraws Regulatory Application For Lung Cancer Combo Drug

Financial news for MRK dated on 2019-01-23: Benzinga's Top Upgrades, Downgrades For January 23, 2019

Financial news for MRK dated on 2019-01-23: BMO Capital Downgrades Merck & Co to Market Perform, Announces \$80 Price Target

Financial news for MRK dated on 2019-01-15: Bank Of America, JPMorgan, Merck, Stratays: 'Fast Money' Picks For January 15

Financial news for MRK dated on 2019-01-14: Merck Reports KEYTRUDA Reduced Risk Of Death By 31% Vs Chemotherapy In Previously-Treated Patients With Advanced Esophageal, Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1

Financial news for MRK dated on 2019-01-09: How 7 New Laws Affected Stocks In The Last Week

Financial news for MRK dated on 2019-01-07: 5 Top-Selling Drugs With Growth Potential In 2019

Financial news for MRK dated on 2019-01-03: Amunix Reports Licensing Deal With Merck For ProTIA Immune Activator Platform, No Terms Disclosed

Financial news for MRK dated on 2019-01-03: Cococrystal Pharma Announces Exclusive Worldwide License And Collaboration Agreement With Merck To Develop Influenza A/B Agents; Cococrystal Will Receive Upfront Payment On An Undisclosed Amount, Is Eligible For Up To \$156M In Milestones Plus Royalties

Financial news for MRK dated on 2019-01-03: The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen

Financial news for MRK dated on 2019-01-03: Merck Reports KEYTRUDA Received 5 New Approvals In Japan, Including Advanced Non-Small Cell Lung Cancer, As Adjuvant Therapy for Melanoma, In Advanced Microsatellite Instability-High Tumors

Financial news for MRK dated on 2019-01-03: Merck Reports Exercise Of Its Option For NGM Bio's NGM313 For Treatment Of NASH, Type 2 Diabetes

Financial news for MRK dated on 2019-01-03: Merck Exercises Option for NGM Bio's Investigational Insulin Sensitizer NGM313 for Treatment of NASH and Type 2 Diabetes

Financial news for MRK dated on 2018-12-31: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Financial news for MRK dated on 2018-12-30: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for MRK dated on 2018-12-23: The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results

Financial news for MRK dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for MRK dated on 2018-12-20: Merck Extends PDUFA Date For Supplemental Biologics Licence For Keytruda By Three Months To April 11, 2019

Financial news for MRK dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for MRK dated on 2018-12-20: AstraZeneca, Merck Report LYNPARZA Met Primary Endpoint In Phase 3 SOLO-3 Trial For Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer

Financial news for MRK dated on 2018-12-19: FDA Approves Merck's KEYTRUDA For Treatment Of Recurrent Locally Advanced Or Metastatic Merkel Cell Carcinoma

Financial news for MRK dated on 2018-12-19: AstraZeneca, Merck Report FDA Approval For LYNPARZA For First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer

Financial news for MRK dated on 2018-12-19: Merck Announces FDA Approval Of LYNPARZA

For Ovarian Cancer

Financial news for MRK dated on 2018-12-19: Merck Receives FDA Approval For Pembrolizumab In Merkel Cell Carcinoma

Financial news for MRK dated on 2018-12-17: Merck's KEYTRUDA as Adjuvant Therapy for Adults with Resected Stage III Melanoma Approved by the European Commission

Financial news for MRK dated on 2018-12-14: Stocks Trading Ex Dividend For Fri., Dec. 14 2018

Financial news for MRK dated on 2018-12-14: A Peek Into The Markets: US Stock Futures Tumble Ahead Of Economic Reports

Financial news for MRK dated on 2018-12-14: Merck Reports Purchase Of Antelliq Group For EUR2.1B In Cash, Assume EUR1.15B In Co. Debt

Financial news for MRK dated on 2018-12-12: Merck and Instituto Butantan Announce Collaboration Agreement To Develop Dengue Infections Vaccine; Instituto Butantan To Receive \$26M Upfront And Is Eligible For Up To \$75M In Milestones

Financial news for MRK dated on 2018-12-11: Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate

Financial news for MRK dated on 2018-12-11: Merck And Roche Enter Into Collaboration Agreement To Develop Companion Diagnostic Test To Identify Patients Eligible For PD-1 Therapy Based On The Status Of A Biomarker In Advanced Solid Tumors

Financial news for MRK dated on 2018-12-11: The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

Financial news for MRK dated on 2018-12-10: Merck Names Frank Clyburn Chief Commercial Officer, Michael Nally Chief Marketing Officer; BZ NOTE: These Positions Are Both New Roles For Merck

Financial news for MRK dated on 2018-12-10: Merck Reports FDA Orphan Drug Designation For M7824 In Biliary Tract Cancer

Financial news for MRK dated on 2018-12-06: The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering

Financial news for MRK dated on 2018-12-06: Ra Pharma Reports Received Development Milestone Payment Under Deal With Merck; Says Is Eligible To Earn Up To \$59M In Added Milestone Payments

Financial news for MRK dated on 2018-12-04: Ahead Of Mid-Week Pause, Investors Fret Over Trade Pact Details

Financial news for MRK dated on 2018-12-04: Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018

Financial news for MRK dated on 2018-12-04: The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Financial news for MRK dated on 2018-11-30: Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Financial news for MRK dated on 2018-11-30: Stocks Which Set New 52-Week High Yesterday, Thurs., Nov. 29, 2018

Financial news for MRK dated on 2018-11-30: The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings

Financial news for MRK dated on 2018-11-29: Merck Is Up 40% In 2018: What's Driving The Rally?

Financial news for MRK dated on 2018-11-29: Ebola Outbreak In Eastern Congo Now World's Second Largest Ever With 426 Cases

Financial news for MRK dated on 2018-11-29: Merck shares rise after the European Commission approved Co's HIV treatments in Europe.

Financial news for MRK dated on 2018-11-29: Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 28, 2018

Financial news for MRK dated on 2018-11-29: The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved

Financial news for MRK dated on 2018-11-28: Merck Receives European Commission

Approval For DELSTRIGO As Part OF An HIV-1 Treatment Regimen

Financial news for MRK dated on 2018-11-27: The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

Financial news for MRK dated on 2018-11-26: Data Dive, Trade Talks And Powell: Busy Post-Holiday Week On The Way

Financial news for MRK dated on 2018-11-25: The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings

Financial news for MRK dated on 2018-11-25: 9 Policy Catalysts For Health Care Investors To Watch Before Year's End

Financial news for MRK dated on 2018-11-21: Stocks Of Vaccination Providers Do Not React Following Update From Health Ministry Suggesting 13 New Cases Of Ebola Were Reported In Eastern Congo Wed.

Financial news for MRK dated on 2018-11-21: October's Biggest Losers And Most Surprising Winners

Financial news for MRK dated on 2018-11-20: Stocks Which Set New 52-Week High Yesterday, Mon., Nov. 19, 2018

Financial news for MRK dated on 2018-11-20: The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings

Financial news for MRK dated on 2018-11-19: Merck and Pfizer's Avelumab in Platinum-Resistant/Refractory Ovarian Cancer Did Not Meet Primary Endpoints

Financial news for MRK dated on 2018-11-15: NewLink Genetics Announces Merck Has Begun Rolling Submission Of Licensure Application For Ebola vaccine V920 To U.S. FDA; In 2014, Co. Entered Ito License Agreement With Merck To Develop, Manufacture And Commercialize Ebola Vaccine

Financial news for MRK dated on 2018-11-14: The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut

Financial news for MRK dated on 2018-11-14: Merck Reports KEYTRUDA Significantly Improved Overall Survival Compared To Chemotherapy In Patients With Advanced Esophageal Or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1

Financial news for MRK dated on 2018-11-13: Merck Reports Commencement Of Rolling Submission Of Licensure Application For V920 To FDA

Financial news for MRK dated on 2018-11-13: World Health Organization's Emergency Response Chief Says We Expect Democratic Republic Of Congo's Ebola Outbreak To Last At Least Another Six Months

Financial news for MRK dated on 2018-11-12: October's biggest Losers And Most Surprising Winners

Financial news for MRK dated on 2018-11-12: Merck Announces the FDA Has Accepted a Supplemental New Drug Application for LYNPARZA

Financial news for MRK dated on 2018-11-12: AstraZeneca, Merck Announce FDA Accepts Regulatory Submission for Lynparza Maintenance Therapy in Newly-diagnosed, BRCA-mutated Advanced Ovarian Cancer and Grants Priority Review

Financial news for MRK dated on 2018-11-09: FDA Approves Merck's KEYTRUDA For Patients With Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated With Sorafenib

Financial news for MRK dated on 2018-11-09: Stocks Which Set New 52-Week High Yesterday, Thurs., Nov. 8, 2018

Financial news for MRK dated on 2018-11-09: The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

Financial news for MRK dated on 2018-11-08: Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 7, 2018

Financial news for MRK dated on 2018-11-08: The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering

Financial news for MRK dated on 2018-11-07: Merck Reports Early Phase 1 Data From MK-4280, MK-7684 Trial To Be Presented At SITC Meeting Nov. 9, 2018

Financial news for MRK dated on 2018-11-04: The Week Ahead In Biotech: Earnings,

Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for MRK dated on 2018-11-01: Stocks Which Set New 52-Week High Yesterday, October 31st

Financial news for MRK dated on 2018-11-01: Citigroup Maintains Buy on Merck & Co, Raises Price Target to \$84

Financial news for MRK dated on 2018-11-01: Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates

Financial news for MRK dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for MRK dated on 2018-10-31: Citigroup Maintains Buy on Merck & Co, Raises Price Target to \$84

Financial news for MRK dated on 2018-10-31: The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut

Financial news for MRK dated on 2018-10-30: Merck Reports FDA Approved KEYTRUDA In Combo With Carboplatin, Either Paclitaxel Or Nab-Paclitaxel For First-Line Treatment Of Patients With Metastatic Squamous Non-Small Cell Lung Cancer

Financial news for MRK dated on 2018-10-30: Wild Times: Market Seems To Seek Solid Ground After Monday's Manic

Financial news for MRK dated on 2018-10-30: The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio

Financial news for MRK dated on 2018-10-30: REMINDER: Merck Has PDUFA Date for KEYTRUDA+carboplatin-paclitaxel sBLA Today

Financial news for MRK dated on 2018-10-29: Benzinga's Week Ahead: Can Facebook, Apple Earnings Rescue The Stock Market?

Financial news for MRK dated on 2018-10-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for MRK dated on 2018-10-26: BMO Capital Maintains Outperform on Merck & Co, Lowers Price Target to \$80

Financial news for MRK dated on 2018-10-25: Snapping Back, But Can Rally Attempt Last? Strong Earnings Might Power Market

Financial news for MRK dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for MRK dated on 2018-10-25: A Peek Into The Markets: US Stock Futures Rise Ahead Of Earnings, Economic Reports

Financial news for MRK dated on 2018-10-25: Merck Raises Qtr. Dividend From \$0.48 To \$0.55/Share; Adds \$10B To Buyback

Financial news for MRK dated on 2018-10-25: UPDATE: Merck Raises FY18 Adj. EPS Guidance From \$4.22-\$4.30 As Of Jul. 27, 2018 To \$4.30-\$4.36 vs \$4.29 Estimate

Financial news for MRK dated on 2018-10-25: Merck Raises Guidance

Financial news for MRK dated on 2018-10-25: Merck & Co Q3 EPS \$1.19 Beats \$1.14 Estimate, Sales \$10.794B Miss \$10.88B Estimate

Financial news for MRK dated on 2018-10-24: Merck's Q3 Earnings Preview

Financial news for MRK dated on 2018-10-23: Stocks Which Set New 52-Week High Yesterday, October 22nd

Financial news for MRK dated on 2018-10-23: The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

Financial news for MRK dated on 2018-10-22: 11 Stocks That Moved From ESMO 2018

Financial news for MRK dated on 2018-10-22: Benzinga's Week Ahead: Can Tech Earnings Restore The Rally? Amazon, Google To Report

Financial news for MRK dated on 2018-10-22: BMO Capital Maintains Outperform on Merck & Co, Raises Price Target to \$82

Financial news for MRK dated on 2018-10-22: Merck Reports Presentation Of KEYTRUDA

Showing Improved Overall Survival In Patients With Recurrent Or Metastatic Head And Neck Cancer; Results Being Presented At ESMO 2018 Congress

Financial news for MRK dated on 2018-10-22: European Medicines Agency Adopts Positive Opinion for Merck's KEYTRUDA as Adjuvant Therapy in Melanoma

Financial news for MRK dated on 2018-10-22: REMINDER: ESMO 2018 Event Continues Today, Clinical Updates Presented Today Include: CytomX Therapeutics, Mirati Therapeutics, Merck, NuCana, Protagonist Therapeutics, SELLAS Life Sciences, Epizyme, Kura Oncology, Intra-Cellular Therapies, and AVEO Pharma

Financial news for MRK dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for MRK dated on 2018-10-21: AstraZeneca, Merck Announce Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70% in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer at ESMO

Financial news for MRK dated on 2018-10-21: Leap Therapeutics Presents Promising Esophagogastric Cancer Data at ESMO 2018

Financial news for MRK dated on 2018-10-20: Merck Announces KEYTRUDA Showed a Complete Response Rate of Nearly 40% in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Standard of Care at ESMO 2018

Financial news for MRK dated on 2018-10-20: ImmunoGen Presents Encouraging Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018

Financial news for MRK dated on 2018-10-20: Dynavax Announces SD-101 in Combination with Merck's KEYTRUDA Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at ESMO 2018

Financial news for MRK dated on 2018-10-20: Merck Announces First Presentation of Early Data for Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018

Financial news for MRK dated on 2018-10-19: The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut

Financial news for MRK dated on 2018-10-18: Merck Says 'Pivotal Phase 3 KEYNOTE-426 Trial Met Both Primary Endpoints; Data to be Filed with Global Regulatory Authorities'

Financial news for MRK dated on 2018-10-18: Merck Reports KEYTRUDA In Combo With Pfizer's Inlyta Improved Overall Survival, Progression-Free Survival As First-Line Therapy For Advanced, Metastatic Renal Cell Carcinoma

Financial news for MRK dated on 2018-10-17: World Health Organization's Emergency Committee Has Said The Ebola Outbreak In Congo Is Not Yet A Health Emergency Of Int'l. Concern, Warns Situation Likely To Deteriorate Significantly Unless Response Is Intensified

Financial news for MRK dated on 2018-10-16: Citigroup Maintains Buy on Merck & Co, Raises Price Target to \$79

Financial news for MRK dated on 2018-10-16: U.S. FDA Grants Merck And AstraZeneca's LYNPARZA Orphan Drug Designation For Pancreatic Cancer

Financial news for MRK dated on 2018-10-16: AstraZeneca, Merck Receive FDA Orphan Drug for Lynparza in Pancreatic Cancer

Financial news for MRK dated on 2018-10-15: OncoSec Initiates KEYNOTE-890 Phase 2 Clinical Trial Of TAVO In Combination With Merck's KEYTRUDA For Treatment Of Late-Stage Triple Negative Breast Cancer

Financial news for MRK dated on 2018-10-14: 4 Major Market Opportunities For The Cannabis Industry

Financial news for MRK dated on 2018-10-12: Barclays Maintains Overweight on Merck & Co, Raises Price Target to \$78

Financial news for MRK dated on 2018-10-12: The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Financial news for MRK dated on 2018-10-11: Credit Suisse Maintains Outperform on Merck & Co, Raises Price Target to \$81

Financial news for MRK dated on 2018-10-11: Stocks Which Set New 52-Week High Yesterday, October 10th

Financial news for MRK dated on 2018-10-11: The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares

Financial news for MRK dated on 2018-10-10: Stocks That Made New 52-Week Highs So Far Today Include: NextEra Energy, WEC Energy, Verizon, CMS Energy, Ameren, FirstEnergy, McCormick, AES, Merck, Public Service Enterprise, Express Scripts, and Public Service Enterprise

Financial news for MRK dated on 2018-10-10: Stocks Which Set New 52-Week High Yesterday, October 9th

Financial news for MRK dated on 2018-10-10: The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares

Financial news for MRK dated on 2018-10-05: REMINDER: Merck Has FDA PDUFA Date Tomorrow October 6th For GARDASIL sBLA

Financial news for MRK dated on 2018-10-04: Stocks Which Set New 52-Week High Yesterday, October 3rd

Financial news for MRK dated on 2018-10-04: The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut

Financial news for MRK dated on 2018-10-04: A Peek Into The Markets: US Stock Futures Drop Ahead Of Jobless Claims, Factory Orders Data

Financial news for MRK dated on 2018-10-04: Merck Reports DELSTRIGO Phase 3 DRIVE-SHIFT Trial Met Primary Efficacy Endpoint

Financial news for MRK dated on 2018-10-03: Stocks Which Set New 52-Week High Yesterday, October 2nd

Financial news for MRK dated on 2018-10-03: The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares

Financial news for MRK dated on 2018-10-02: Stocks Which Set New 52-Week High Yesterday, October 1st

Financial news for MRK dated on 2018-10-02: The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares

Financial news for MRK dated on 2018-09-26: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

Financial news for MRK dated on 2018-09-26: Merck Board Rescinds Mandatory CEO Retirement Policy; Current CEO Kenneth Frazier To Continue In Role Beyond December 2019

Financial news for MRK dated on 2018-09-24: Stocks Which Set New 52-Week High Friday, September 21

Financial news for MRK dated on 2018-09-24: OpGen Reports Partnership With New York State Dept. Of Health, Merck's ILUM Health Solutions To Detect Antimicrobial-Resistant Infections

Financial news for MRK dated on 2018-09-21: Democratic Republic Of Congo Confirms Ebola Case In Ituri Province Almost 200 KM Away From Closest Other Case And 50 KM From The Ugandan Border

Financial news for MRK dated on 2018-09-21: The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding

Financial news for MRK dated on 2018-09-21: XOMA Reports Purchase Of Royalty Interest Position From Agenus On 7 Assets Being Developed By Merck, Incyte For \$15M

Financial news for MRK dated on 2018-09-20: Merck Reports Received Positive CHMP Opinion For ELSTRIGO, PIFELTRO In EU For Treatment Of HIV-1 Infection

Financial news for MRK dated on 2018-09-20: Merck Or Pfizer: Which Is The Better Large-Cap Pharma Stock?

Financial news for MRK dated on 2018-09-17: Accenture and Merck Collaborate with Amazon Web Services to Launch a Research Platform to Drive Innovation in Drug Discovery and Scientific Research

Financial news for MRK dated on 2018-09-16: The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for MRK dated on 2018-09-14: Stocks Which Set New 52-Week High Yesterday, September 13th

Financial news for MRK dated on 2018-09-14: The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut

Financial news for MRK dated on 2018-09-13: Stocks That Will Be Trading Ex Dividend For Fri., Sep. 14, 2018

Financial news for MRK dated on 2018-09-12: FDA Grants Priority Review to Merck's Application for KEYTRUDA Monotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Patients Whose Tumors Express PD-L1

Financial news for MRK dated on 2018-09-11: The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces \$175M Offering, Leadership Transition At Insulet

Financial news for MRK dated on 2018-09-11: A Peek Into The Markets: US Stock Futures Down Ahead Of Job Openings, Wholesale Inventories Data

Financial news for MRK dated on 2018-09-11: IMV Inc. Announces Phase 2 Basket Trial With Merck To Evaluate DPX-Survivac In Combination With KEYTRUDA Across Five Solid Tumor Indications

Financial news for MRK dated on 2018-09-11: Merck's ZERBAXA Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study, Co. To Submit Supplemental New Drug App. In U.S. And EU

Financial news for MRK dated on 2018-09-10: A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street

Financial news for MRK dated on 2018-09-10: Merck's KEYTRUDA in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC Approved by the European Commission

Financial news for MRK dated on 2018-09-10: European Commission Approves Merck's KEYTRUDA in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC

Financial news for MRK dated on 2018-09-09: The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs

Financial news for MRK dated on 2018-09-07: Health Care Has Been On Fire. Will The Uptrend Continue?

Financial news for MRK dated on 2018-09-07: Barclays Maintains Overweight on Merck & Co, Raises Price Target to \$75

Financial news for MRK dated on 2018-09-05: The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

Financial news for MRK dated on 2018-09-05: Ebola-Related Stocks Unaffected Amid Earlier Report Officials In Congo Announced The First Ebola Case In A Major Eastern City, Butembo

Financial news for MRK dated on 2018-09-05: Eisai And Merck Announce China National Medical Products Administration (NMPA) Approval Of LENVIMA For Treatment Of Unresectable Hepatocellular Carcinoma (HCC)

Financial news for MRK dated on 2018-09-05: Eisai, Merck Announce China NMPA Approval of First Approval for LENVIMA for Treatment of Unresectable HCC

Financial news for MRK dated on 2018-09-04: Benzinga Pro's 5 Stocks To Watch Today

Financial news for MRK dated on 2018-09-04: FDA Grants Priority Review to Merck's Supplemental Biologics License Application for KEYTRUDA, Application Based on Data from Phase 2 KEYNOTE-017 Trial

Financial news for MRK dated on 2018-09-02: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for MRK dated on 2018-08-31: The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage

Financial news for MRK dated on 2018-08-30: Merck Announces FDA Approval of DELSTRIGO

Financial news for MRK dated on 2018-08-30: The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration

Financial news for MRK dated on 2018-08-24: 30 Stocks Moving In Friday's Pre-Market Session

Financial news for MRK dated on 2018-08-23: Morgan Stanley Maintains Overweight on Merck & Co, Raises Price Target to \$74

Financial news for MRK dated on 2018-08-23: Eisai and Merck Announce European Commission Grants Marketing Authorization for LENVIMA

Financial news for MRK dated on 2018-08-22: Stocks Which Set New 52-Week High Yesterday, August 21st

Financial news for MRK dated on 2018-08-22: The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin

Financial news for MRK dated on 2018-08-21: Incyte Has Quietly Risen 13 Percent In The Last Two Weeks, And That Uptrend Looks Like It Will Continue

Financial news for MRK dated on 2018-08-21: Stocks Which Set New 52-Week High Tues., Aug. 21, 2018

Financial news for MRK dated on 2018-08-21: The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows

Financial news for MRK dated on 2018-08-21: Rexahn Reports Clinical Collaboration With Merck For Evaluation Of RX-5902 In Combo With KEYTRUDA For Triple-Negative Breast Cancer

Financial news for MRK dated on 2018-08-20: FDA Approves Expanded Label for Merck's KEYTRUDA in Combination with Pemetrexed and Platinum Chemotherapy for First-Line Treatment

Financial news for MRK dated on 2018-08-17: Stocks Which Set New 52-Week High Yesterday, August 16th

Financial news for MRK dated on 2018-08-17: The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns

Financial news for MRK dated on 2018-08-17: Eisai And Merck Announce FDA Approval Of LENVIMA

Financial news for MRK dated on 2018-08-16: Eisai And Merck Announce FDA Approval Of LENVIMA (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)

Financial news for MRK dated on 2018-08-16: Stocks Which Set New 52-Week High Yesterday, August 15th

Financial news for MRK dated on 2018-08-16: The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait

Financial news for MRK dated on 2018-08-15: Agenus Receives Milestone Payment From Merck Of \$4M For Initiation Of Phase 1 Clinical Trial Of An Undisclosed Antibody Candidate Discovered By Agenus

Financial news for MRK dated on 2018-08-09: CDC Says There's No Recommendation To Avoid Travel To Democratic Republic Of The Congo Following Ebola Outbreaks

Financial news for MRK dated on 2018-08-09: Perrigo Announces Rx-To-OTC Switch Licensing For Nasonex

Financial news for MRK dated on 2018-08-08: Stocks Which Set New 52-Week High Yesterday, August 7th

Financial news for MRK dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for MRK dated on 2018-08-07: Stocks That Made New 52-Week Highs Earlier Today Include: SL Green Realty, Verisk Analytics, Medtronic, Pfizer, Conoco Phillips, Archer-Daniels, Eli Lilly, Merck, Phillips 66, Costco, Advance Auto Parts, Norfolk Southern, CSX, Zoetis, Apple, and Disney

Financial news for MRK dated on 2018-08-07: Stocks Which Set New 52-Week High Yesterday, August 6th

Financial news for MRK dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For

Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

Financial news for MRK dated on 2018-08-05: Congo Health Ministry Says Ebola Outbreak Likely to have Killed 33; Merck Vaccine Being Deployed to Control Spread of Outbreak

Financial news for MRK dated on 2018-08-03: Merck Reports Co., AstraZeneca's Selumetinib Granted Orphan Designation In Europe For Nerve Fibromatosis Type 1

Financial news for MRK dated on 2018-08-02: Health Ministry Officials Say Ebola In Latest Congo Outbreak Is of the Zaire Strain Which Has Been Successfully Treated By A Vaccine In The Past

Financial news for MRK dated on 2018-08-02: UPDATE: W.H.O. Says Depending On The Strain Of Ebola In Congo Outbreak, Merck Vaccine May Be 'An Option'

Financial news for MRK dated on 2018-08-01: WHO Chief Says That It Has Started Moving Staff, Supplies To The Area Of Democratic Republic Of Congo's New Ebola Outbreak

Financial news for MRK dated on 2018-08-01: 4 Samples From Northeastern Democratic Rep. Of Congo Test Positive For Ebola Virus, 20 Deaths From Hemorrhagic Fever Recorded In Northeastern Congo

Financial news for MRK dated on 2018-07-31: Benzinga Pro's 5 Stocks To Watch Today

Financial news for MRK dated on 2018-07-31: A Peek Into The Markets: US Stock Futures Up Ahead Of Earnings, Economic Data

Financial news for MRK dated on 2018-07-31: Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation For LENVIMA In Combination With KEYTRUDA As Therapy For Previously Treated Patients With Advanced And/Or Metastatic Non-MSI-H/pMMR Endometrial Carcinoma

Financial news for MRK dated on 2018-07-31: Eisai, Merck Announce FDA Breakthrough Therapy Designation for LENVIMA

Financial news for MRK dated on 2018-07-30: Benzinga Pro's 5 Stocks To Watch Today

Financial news for MRK dated on 2018-07-30: BioLineRx Expands its Immuno-Oncology Collaboration in Pancreatic Cancer with Merck

Financial news for MRK dated on 2018-07-27: Benzinga Pro's 5 Stocks To Watch Today

Financial news for MRK dated on 2018-07-27: Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter

Financial news for MRK dated on 2018-07-27: Endo Int'l. Reports Par Pharma Has Begun Shipping Authorized Generic Version Of Merck's INVANZ

Financial news for MRK dated on 2018-07-27: Merck Narrows FY18 Sales Guidance From \$41.8B-\$43B To \$42B-\$42.8B vs \$42.07B Estimate

Financial news for MRK dated on 2018-07-27: Merck Raises FY18 Adj. EPS From \$4.16-\$4.28 To \$4.22-\$4.30 vs \$4.23 Estimate

Financial news for MRK dated on 2018-07-27: Merck & Co Q2 EPS \$1.06 Beats \$1.03 Estimate, Sales \$10.465B Beat \$10.29B Estimate

Financial news for MRK dated on 2018-07-27: 12 Stocks To Watch For July 27, 2018

Financial news for MRK dated on 2018-07-27: Earnings Scheduled For July 27, 2018

Financial news for MRK dated on 2018-07-26: Merck Q2 Earnings Preview

Financial news for MRK dated on 2018-07-26: Sutro Pharma Earlier Reported Merck Was Part Of \$85.4M Series E Funding Round

Financial news for MRK dated on 2018-07-26: Merck Reports KEYTRUDA Approved By China National Drug Admin.

Financial news for MRK dated on 2018-07-25: Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile

Financial news for MRK dated on 2018-07-25: Merck Reports Phase 3 KEYNOTE-048 Trial Investigating KEYTRUDA Met Primary Endpoint Of Improving Overall Survival In Head And Neck Squamous Cell Carcinoma Patients

Financial news for MRK dated on 2018-07-25: Merck Announces KEYTRUDA Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial, Significantly Improving OS as First-Line Therapy in Head and Neck Squamous Cell Carcinoma Patients Whose Tumors

Expressed PD-L1

Financial news for MRK dated on 2018-07-24: Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine

Financial news for MRK dated on 2018-07-23: Morgan Stanley: Newly Public Neon Therapeutics Has Outperformance Potential

Financial news for MRK dated on 2018-07-23: Leap Therapeutics Announces Collaboration with Merck and Pfizer to Evaluate Combination of TRX518, Avelumab, and Chemotherapy in Advanced Solid Tumors

Financial news for MRK dated on 2018-07-20: Merck Announces Plans To Cut Drug Prices

Financial news for MRK dated on 2018-07-19: UPDATE: Merck Says 'Going forward, we will continue to evaluate our portfolio of products to look for opportunities to further reduce costs for patients and the health care system'

Financial news for MRK dated on 2018-07-19: UPDATE: Merck, Responding To Responsibility On Drug Pricing, Says 'We are also lowering our price on ZEPATIER by 60 percent and several other medicines by 10 percent to reduce out-of-pocket costs for patients across the country'

Financial news for MRK dated on 2018-07-19: Merck Says 'We commit to not increase the average net price across our portfolio of products by more than inflation annually'

Financial news for MRK dated on 2018-07-16: PreMarket Prep Opening NYSE Imbalance Update: ExxonMobil 55k Shares To Sell; Pfizer 50k To Sell; Merck 26k To Sell; Coca-Cola 54k To Sell; Johnson & Johnson 54k To Sell; Ford 103k To Sell; Kroger 90k To Sell

Financial news for MRK dated on 2018-07-12: Cue Biopharma Produces Immuno-STAT Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck

Financial news for MRK dated on 2018-07-11: FDA Grants Merck Priority Review To Co.'s Supplemental Biologics License Application For Its KEYTRUDA Hepatocellular Carcinoma Therapy

Financial news for MRK dated on 2018-07-09: Health Care Sector Outlook: Checking In Ahead Of Q2 Earnings Reports

Financial news for MRK dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for MRK dated on 2018-07-02: Merck's Supplemental Biologics License for KEYTRUDA in Combination with Chemotherapy is Granted Priority Review by the FDA

Financial news for MRK dated on 2018-07-02: AstraZeneca, Merck Announce LYNPARZA Approved in Japan for BRCA-Mutated Metastatic Breast Cancer

Financial news for MRK dated on 2018-06-28: U.S. Supreme Court Agrees To Hear Merck Appeal Of Lower Court Ruling THAT Revived Fosamax Warning Label Suits

Financial news for MRK dated on 2018-06-27: UPDATE: Merck Says Non-Inferiority Was Not Demonstrated For Second Primary Outcome Of Blood Loss Of Greater Than Equal To 1,000 ml Of Blood Loss

Financial news for MRK dated on 2018-06-27: Merck Reports Study Results From Heat-Stable Formulation Of Carbetocin For Prevention Of Excessive Bleeding After Childbirth: Showed Clinical Non-Inferiority To Oxycontin For Primary Outcome Of Greater Than Equal To 500 ml Of Blood Loss

Financial news for MRK dated on 2018-06-27: AstraZeneca Reports LYNPARZA Phase III Trial First-Line SOLO-1 Trial For Ovarian Cancer Met Primary Endpoint

Financial news for MRK dated on 2018-06-27: Merck To Report Q2 Earnings On Fri., Jul. 27, 2018 Before Market Open

Financial news for MRK dated on 2018-06-27: AstraZeneca, Merck Announce LYNPARZA S Met Primary Endpoint of Progression-Free Survival in Women with BRCA-Mutated Advanced Ovarian Cancer and Showed a Safety Profile Consistent with Previous Trials

Financial news for MRK dated on 2018-06-26: Incyte Downgraded As RBC Analyst Awaits More Revenue Visibility

Financial news for MRK dated on 2018-06-25: Merck's Supplemental Biologics License Application for KEYTRUDA is Accepted by the FDA

Financial news for MRK dated on 2018-06-23: Merck Presents New Data from Comparative Trials with Sitagliptin Clinical Trial Program with JANUVIA at #ADA2018

Financial news for MRK dated on 2018-06-18: 40 Biggest Movers From Friday

Financial news for MRK dated on 2018-06-15: Mid-Afternoon Market Update: Crude Oil Down Over 3%; Canada Goose Shares Gain Following Strong Q4 Results

Financial news for MRK dated on 2018-06-15: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for MRK dated on 2018-06-15: Mid-Day Market Update: Dow Down Over 200 Points; Affirmed Shares Plummet

Financial news for MRK dated on 2018-06-15: Affirmed Shares Slide On Updated Hodgkin Lymphoma Drug Combo Data

Financial news for MRK dated on 2018-06-15: Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug

Financial news for MRK dated on 2018-06-14: Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi

Financial news for MRK dated on 2018-06-13: Merck's KEYTRUDA Receives FDA Approval For Treatment of Primary Mediastinal Large B-Cell Lymphoma

Financial news for MRK dated on 2018-06-13: FDA Grants Priority Review To Merck's Supplemental Biologics License Application (sBLA) For GARDASIL 9 In Women And Men Ages 27-45 For Prevention Of Certain HPV-Related Cancers And Diseases

Financial news for MRK dated on 2018-06-12: Merck Press Release Confirms FDA Approval Of KEYTRUDA For Cervical Cancer

Financial news for MRK dated on 2018-06-12: Merck Receives FDA Approval For KEYTRUDA in Advanced Cervical Cancer

Financial news for MRK dated on 2018-06-08: Pharma Stock Roundup: Merck, Eli Lilly, AbbVie And More

Financial news for MRK dated on 2018-06-05: Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index

Financial news for MRK dated on 2018-06-04: Merck and Astrazeneca Pres Release Announces LYNPARZA In Combo With Abiraterone Delayed Metastatic Prostate Cancer Disease Progression

Financial news for MRK dated on 2018-06-04: Merck Gives an Update on its Pivotal Trial of JAVELIN into ASCO

Financial news for MRK dated on 2018-06-04: Donald Trump Tweets: 'We had Repeal & Replace done (and the saving to our country of one trillion dollars) except for one person, but it is getting done anyway'...'less expensive plans will be announced this month. Drug prices coming down & Right to Try!'

Financial news for MRK dated on 2018-06-04: Merck Says 'KEYTRUDA Showed Promising Anti-Tumor Activity in Patients with Advanced Small Cell Lung Cancer (SCLC) in Phase 2 KEYNOTE-158 Study'

Financial news for MRK dated on 2018-06-04: Merck Announces New Analysis of Four-Year Data for KEYTRUDA from Phase 3 KEYNOTE-006 Study Showed 86 Percent of Patients Were Progression-Free 20 Months After Completing Two Years of KEYTRUDA

Financial news for MRK dated on 2018-06-04: Five Additional Ebola Cases Detected by Congo Health Officials

Financial news for MRK dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for MRK dated on 2018-06-03: Merck Announces KEYTRUDA Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy in Patients with Advanced Clear Cell RCC in Phase 2 KEYNOTE-427 Study at #ASCO2018

Financial news for MRK dated on 2018-06-03: Eisai, Merck Announce Data from Investigational Studies of LENVIMA and KEYTRUDA Combination Therapy in Four Different Tumor Types AT #asco2018

Financial news for MRK dated on 2018-06-03: Merck Announces KEYTRUDA Plus

Chemotherapy Significantly Improved Overall Survival in First-Line Treatment of Metastatic Squamous NSCLC in Phase 3 KEYNOTE-407 Study

Financial news for MRK dated on 2018-06-03: Merck Announces KEYTRUDA Monotherapy Significantly Improved Overall Survival in KEYNOTE-042 Study as First-Line Treatment for Locally Advanced or Metastatic NSCLC Patients Whose Tumors Expressed PD-L1 (TPS >=1%)

Financial news for MRK dated on 2018-06-01: Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

Financial news for MRK dated on 2018-06-01: EMA Says CHMP Has Recommended Restricting Use Of Merck's Keytruda, Tecentriq As First-Line Treatments For Urothelial Cancer

Financial news for MRK dated on 2018-05-31: Merck, Premier Inc. Report Expansion Of Preventative, Chronic Disease Care Collaboration To Include New Effort Designed To Help Reduce Recurrence Of C. Diff

Financial news for MRK dated on 2018-05-31: 41 Biggest Movers From Yesterday

Financial news for MRK dated on 2018-05-30: 30 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MRK dated on 2018-05-30: Mid-Morning Market Update: Markets Open Higher; Michael Kors Beats Q4 Estimates

Financial news for MRK dated on 2018-05-30: Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immuteq Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA

Financial news for MRK dated on 2018-05-25: Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended

Financial news for MRK dated on 2018-05-25: Eisai, Merck Provide Update on sNDA for Lenvatinib

Financial news for MRK dated on 2018-05-23: Merck's KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival And Progression-Free Survival As First-Line Treatment For Squamous Non-Small Cell Lung Cancer (NSCLC) In Pivotal Phase 3 KEYNOTE-407 Trial

Financial news for MRK dated on 2018-05-22: Hearing A Suspected Ebola Case Is Being Treated At A Main Hospital In Congo's Capital City Kinshasa

Financial news for MRK dated on 2018-05-20: 4,000 Doses Of Ebola Vaccine Sent to Congolese City of Mbandaka on Saturday; Vaccination Campaign to Start Monday

Financial news for MRK dated on 2018-05-19: 12 Dow 30 Companies With Above-Average Salaries

Financial news for MRK dated on 2018-05-18: Merck, Bristol Myers Shares Move On Alleged FDA Alert On Keytruda

Financial news for MRK dated on 2018-05-18: WHO Official Says WHO Is Considering Using Mapp Biopharma's ZMapp Treatment For Ebola In Congo

Financial news for MRK dated on 2018-05-18: Merck Shares Dip Lower, Bristol-Myers Squibb Shares Spike Higher Following FDA Alert On Issue Found In Trials Of Keytruda, Tecentriq

Financial news for MRK dated on 2018-05-18: WHO Emergency Committee Says Ebola Outbreak In Congo Doesn't Yet Constitute A Public Health Emergency Of Intl. Concern

Financial news for MRK dated on 2018-05-18: WHO Says Ebola Vaccinations In Congo Will Begin Sun.

Financial news for MRK dated on 2018-05-18: WHO Raises Risk Assessment of Congo's Ebola Outbreak to 'Very High'

Financial news for MRK dated on 2018-05-17: WHO Says Will Convene Emergency Meeting On Fri. To Determine If Ebola Outbreak In Congo Is A Public Emergency Of Int'l. Concern

Financial news for MRK dated on 2018-05-17: WHO Says Ebola Outbreak has Spread to DR Congo city

Financial news for MRK dated on 2018-05-16: First Batch of Experimental Ebola Vaccine Arrives in Congo; Vaccinations Could Begin this Weekend

Financial news for MRK dated on 2018-05-14: WHO Says 39 Cases Of Ebola Reported In

Congo Outbreak So Far, Including 19 Deaths

Financial news for MRK dated on 2018-05-09: Jim Cramer Gives His Opinion On Exxon Mobil, Pfizer And Cisco

Financial news for MRK dated on 2018-05-08: OncoSec Announces Clinical Collaboration with Merck to Evaluate Combination of ImmunoPulse IL-12 and KEYTRUDA for Triple Negative Breast Cancer

Financial news for MRK dated on 2018-05-08: Jim Cramer Advises His Viewers On Prestige Brands, CVS Health And More

Financial news for MRK dated on 2018-05-08: AstraZeneca and Merck Announce LYNPARZA Tablets Receive EU Approval for the Treatment of Platinum-Sensitive Relapsed Ovarian Cancer

Financial news for MRK dated on 2018-05-04: PreMarket Prep Opening NYSE Imbalance Update: Alibaba 91k Shares To Sell; Merck 51k To Sell; Twitter 129k To Sell

Financial news for MRK dated on 2018-05-03: Moderna Snd Merck Expand mRNA Cancer Vaccines Collaboration

Financial news for MRK dated on 2018-05-03: Merck Says Phase 3 KEYNOTE-407 Met A Pre-Specified Secondary Endpoint Related To Overall Response Rate In A Cohort Of Participants At An Interim Analysis

Financial news for MRK dated on 2018-05-01: Apple Results, Fed Decision, Jobs Report In Focus; Merck, Pfizer Reports Mixed

Financial news for MRK dated on 2018-05-01: Benzinga Pro's 5 Stocks To Watch Today

Financial news for MRK dated on 2018-05-01: Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings

Financial news for MRK dated on 2018-05-01: Merck Raises FY18 EPS Guidance From \$4.08-\$4.23 to \$4.16-\$4.28 vs \$4.19 Est., Raises Sales From \$41.2B-\$42.7B to \$41.8B-\$43.0B vs \$41.9B Est.

Financial news for MRK dated on 2018-05-01: Merck Reports Q1 Adj. EPS \$1.05 Beats \$1.00 Est., Sales \$10.04B Misses \$10.10B Est.

Financial news for MRK dated on 2018-05-01: 15 Stocks To Watch For May 1, 2018

Financial news for MRK dated on 2018-05-01: Earnings Scheduled For May 1, 2018

Financial news for MRK dated on 2018-04-30: The Week Ahead: Tesla And Apple Earnings, Dropbox Quiet Period Expires, Fed Rate Decision And More

Financial news for MRK dated on 2018-04-30: Upcoming Earnings: Tech Giant Apple Reports After Tuesday's Close

Financial news for MRK dated on 2018-04-30: Pharmaceutical Earnings: Pfizer And Merck Are Slated To Report Tuesday Morning

Financial news for MRK dated on 2018-04-30: Busy Week Begins With McDonald's Beating Estimates; Fed Meeting, Jobs Data Loom

Financial news for MRK dated on 2018-04-30: Merck is Granted Priority Review of its sBLA for KEYTRUDA in Combination with Pemetrexed and Platinum Chemotherapy

Financial news for MRK dated on 2018-04-29: The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

Financial news for MRK dated on 2018-04-27: Upcoming Earnings: McDonald's Reports On Monday As It Continues On New Growth Plan

Financial news for MRK dated on 2018-04-27: BMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral Position

Financial news for MRK dated on 2018-04-26: Earnings Preview: Oil Giants Chevron And ExxonMobil Report Friday Morning

Financial news for MRK dated on 2018-04-23: Merck Reports EMA Validated Type II Variation For Co.'s KEYTRUDA In Combo With Pemetrexed, Platinum Chemotherapy As First-Line Therapy In Metastatic Nonsquamous NSCLC

Financial news for MRK dated on 2018-04-23: Keytruda Is Key To The Merck Thesis, Goldman Sachs Says In Upgrade

Financial news for MRK dated on 2018-04-23: Benzinga's Top Upgrades, Downgrades For April 23, 2018

Financial news for MRK dated on 2018-04-23: Goldman Sachs Upgrades Merck & Co to Buy

Financial news for MRK dated on 2018-04-20: AstraZeneca Shares Are Looking Very Weak Right Now

Financial news for MRK dated on 2018-04-19: Stock Market Seems Directionless, Volatility Low As Investors Await News

Financial news for MRK dated on 2018-04-18: Benzinga's Top Analyst Calls From April 18, 2018

Financial news for MRK dated on 2018-04-17: One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings

Financial news for MRK dated on 2018-04-17: Stock Market Gets Lift From Earnings As Geopolitical Fears Wane

Financial news for MRK dated on 2018-04-17: Benzinga's Top Upgrades, Downgrades For April 17, 2018

Financial news for MRK dated on 2018-04-17: Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine

Financial news for MRK dated on 2018-04-17: Morgan Stanley Upgrades Merck & Co to Overweight

Financial news for MRK dated on 2018-04-17: Morgan Stanley Upgrades Merck to Overweight from Equal Weight; Raises PT to \$68 from \$63

Financial news for MRK dated on 2018-04-16: Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA, Results Showed 'Encouraging Response Rates'

Financial news for MRK dated on 2018-04-16: UPDATE: Merck Says KEYTRUDA Combination Improved Overall Survival in Patients Regardless of PD-L1 Expression, Including Patients Who Tested Negative for PD-L1

Financial news for MRK dated on 2018-04-16: Merck's KEYTRUDAPlus Pemetrexed and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study

Financial news for MRK dated on 2018-04-16: Merck Sunday Announced Updated Overall Survival Data for LYNPARZA(r) (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at #AACR18

Financial news for MRK dated on 2018-04-15: Merck Announces KEYTRUDA Reduced Risk of Disease Recurrence or Death by More than 40% vs Placebo as Adjuvant Therapy in Resected, High-Risk Stage III Melanoma

Financial news for MRK dated on 2018-04-13: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for MRK dated on 2018-04-13: Mylan Shares Quiet Premarket; Co. Looking For Deal For Merck's Consumer Products Unit

Financial news for MRK dated on 2018-04-11: PreMarket Prep Opening NYSE Imbalance Update: Pfizer 149k Shares To Buy: ExxonMobil 81k Shares To Buy; Merck 50k Shares To Buy; General Electric 114k Shares To Sell; Ford 42k Shares To Buy

Financial news for MRK dated on 2018-04-10: 40 Biggest Movers From Yesterday

Financial news for MRK dated on 2018-04-09: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for MRK dated on 2018-04-09: Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial

Financial news for MRK dated on 2018-04-09: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for MRK dated on 2018-04-09: A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street

Financial news for MRK dated on 2018-04-09: Merck Reports its KEYTRUDA Monotherapy Met its Primary Endpoint in the Phase 3 KEYNOTE-042 Study

Financial news for MRK dated on 2018-04-06: Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial

Financial news for MRK dated on 2018-04-06: UPDATE: Incyte Shares Down 20.5% After its Phase 3 ECGI-301/KEYNOT-252 Study With Merck Did Not Meet the Primary Endpoint

Financial news for MRK dated on 2018-04-06: 'The first real test of the cancer immunotherapy combination thesis fails. \$INCY \$MRK' -Adam Feuerstein Tweet

Financial news for MRK dated on 2018-04-06: Incyte and Merck Says Phase 3 ECHO-301/KEYNOTE-252 Study Did Not Meet The Primary Endpoint Of Improving Progression-Free Survival

Financial news for MRK dated on 2018-04-05: Merck Spokesperson Tells Benzinga FDA Postponed PDUFA Date On sBLA For Keytruda In Mediastinal B-Cell Lymphoma To July 3rd After Co. Submitted Add'l Data; PDUFA Decision Was Originally Scheduled For April 3rd

Financial news for MRK dated on 2018-04-05: Recro Pharma CEO Talks Non-Opioid Pain Management Opportunity, CDMO Business

Financial news for MRK dated on 2018-04-05: Benzinga's Top Upgrades, Downgrades For April 5, 2018

Financial news for MRK dated on 2018-04-05: Barclays Upgrades Merck & Co to Overweight

Financial news for MRK dated on 2018-04-03: Stocks That Made New 52-Wk Lows Today Include: Incyte, Merck, Mallinckrodt, Celgene, Cerner, Willams Cos., AMD, Albemarle, Kinder Morgan, Western Union, Walgreens, Kraft Heinz, Nielsen, and Alliance Data Systems

Financial news for MRK dated on 2018-04-03: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for MRK dated on 2018-04-03: REMINDER: Merck Has FDA PDUFA Date Today For Keytruda sBLA in Primary Mediastinal Large B-Cell Lymphoma

Financial news for MRK dated on 2018-04-03: AstraZeneca, Merck Announces EMA Accepts Regulatory Submission for LYNPARZA in BRCA-Mutated HER2-Negative Metastatic Breast Cancer

Financial news for MRK dated on 2018-04-02: The Week Ahead: Switch's Lockup Expires, Spotify Debuts, And More

Financial news for MRK dated on 2018-04-02: What's NeuVax? Wainwright Says Sellas' Cancer Vaccine Candidate Makes It A Buy

Financial news for MRK dated on 2018-03-30: The Week Ahead In Biotech: PDUFA Dates, Clinical Trials And Conferences

Financial news for MRK dated on 2018-03-27: Merck Reports Received Fast-Track Designation For Tepotinib In NSCLC In Japan

Financial news for MRK dated on 2018-03-26: Stocks That Made New 52-Wk Lows Today Include: Charter Comms., Vornado Realty, Colgate-Palmolive, Merck, Hasbro, Ventas, Dentsply Sirona, Johnson Controls, Goodyear Tire, Clorox, GE, Kinder Morgan, Comcast, DISH Network, Stericycle and Patterson Cos.

Financial news for MRK dated on 2018-03-26: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for MRK dated on 2018-03-23: Merck Announces Anticancer Agent Lenvima Approved for Additional Indication of Unresectable HCC in Japan,

Financial news for MRK dated on 2018-03-20: Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season

Financial news for MRK dated on 2018-03-15: Jim Cramer Shares His Thoughts On Merck, Five Below And More

Financial news for MRK dated on 2018-03-13: Merck's Supplemental Biologics License Application for KEYTRUDA Granted Priority Review by the FDA for Treatment of Advanced Cervical Cancer

Financial news for MRK dated on 2018-03-12: The Market In 5 Minutes: Coincheck, Gun Violence, Oil And More

Financial news for MRK dated on 2018-03-11: Immutech Announces Clinical Trial Collaboration and Supply Agreement With Merck to Evaluate Combination of IMP321 with

Keytruda

Financial news for MRK dated on 2018-03-09: 'Pharma Bro' Martin Shkreli Gets 7 Years In Prison For Securities Fraud

Financial news for MRK dated on 2018-03-07: Eisai, Merck Report Global Strategic Oncology Collaboration For LENVIMA, Will Jointly Develop, Commercialize

Financial news for MRK dated on 2018-03-07: Height Casts 65% Odds That Congress Rolls Back Pharma Discounts

Financial news for MRK dated on 2018-03-05: 7 Biotech Stocks With Clinical Trial Outcomes In March

Financial news for MRK dated on 2018-02-23: Pharma Stock Roundup: AstraZeneca, Merck, AbbVie And More

Financial news for MRK dated on 2018-02-23: Merck, AstraZeneca Reports LYNPARZA Received Positive EU CHMP Opinion In Platinum-Sensitive Relapsed Ovarian Cancer

Financial news for MRK dated on 2018-02-21: Merck to Acquire Viralytics for ~\$394M

Financial news for MRK dated on 2018-02-20: Gilead, Merck Quiet As Traders Circulate Reuters Article From Feb. 17th Titled 'Gilead wins reversal of \$2.54 billion hepatitis C drug patent verdict'

Financial news for MRK dated on 2018-02-15: Merck Reports Co., AstraZeneca Won Orphan Drug Designation By FDA For Selumetinib For Treatment Of NF1

Financial news for MRK dated on 2018-02-15: AstraZeneca Says Selumetinib Granted Orphan Drug Designation by FDA for Neurofibromatosis Type 1

Financial news for MRK dated on 2018-02-14: Cramer Looks At The Dow's Biggest Losers

Financial news for MRK dated on 2018-02-14: BMO Capital Maintains Outperform on Merck & Co, Lowers price target to \$65.00

Financial news for MRK dated on 2018-02-14: Credit Suisse Maintains Outperform on Merck & Co, Lowers price target to \$65.00

Financial news for MRK dated on 2018-02-13: Merck Discontinues Alzheimer's MK-8931 Study, Unlikely That Positive Benefit/Risk Could Be Established

Financial news for MRK dated on 2018-02-13: DZ Bank Upgrades Merck & Co to Buy

Financial news for MRK dated on 2018-02-08: The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease

Financial news for MRK dated on 2018-02-06: Leerink Swann Maintains Market Perform on Merck & Co, Lowers Price Target to \$67.00

Financial news for MRK dated on 2018-02-02: Merck Sees FY18 Adj. EPS \$4.08-\$4.23 vs \$4.11 Est., Sales \$41.2B-\$42.7B vs \$41.1B Est.

Financial news for MRK dated on 2018-02-02: Merck Reports Q4 Adj. EPS \$0.98 vs \$0.94 Est., Sales \$10.4B vs \$10.49B Est.

Financial news for MRK dated on 2018-02-02: 12 Stocks To Watch For February 2, 2018

Financial news for MRK dated on 2018-02-02: Earnings Scheduled For February 2, 2018

Financial news for MRK dated on 2018-01-30: Hang On: Rate Fears In Focus As Futures Point Lower After Monday's Big Losses

Financial news for MRK dated on 2018-01-29: The Week Ahead: Big Tech Earnings, Fed Rate Decision Likely To Dominate Headlines

Financial news for MRK dated on 2018-01-29: PFE, LLY, MRK Write Up 'Scripts For Q4

Financial news for MRK dated on 2018-01-29: Fed, Earnings Are Meaty Filling Between Slices Of Job, Price Data

Financial news for MRK dated on 2018-01-23: Biotech M&A Off To A Strong Start In 2018: More Deals To Follow?

Financial news for MRK dated on 2018-01-19: Will Johnson & Johnson's Pharma Segment Pull Up Its Q4 Earnings?

Financial news for MRK dated on 2018-01-19: Merck Reports First-Time Data For

KEYTRUDA In Patients With Previously-Treated Advanced HCC: 'showed an overall response rate (ORR) of 16.3 percent (95% CI, 9.8-24.9) (n=17/104) with KEYTRUDA as monotherapy'

Financial news for MRK dated on 2018-01-19: Merck Reports LYNPARZA For Treatment Of Advanced Ovarian Cancer Received Approval In Japan

Financial news for MRK dated on 2018-01-16: Watching Shares Of AstraZeneca and Merck As White House Doctor Says Pres. Trump Takes Crestor For Cholesterol and Propecia For Hair Loss

Financial news for MRK dated on 2018-01-16: Early Keytruda Results Win Merck An Upgrade

Financial news for MRK dated on 2018-01-16: Merck Shares Up 5.8% On Earlier News That Phase 3 KEYNOTE-189 Trial Met Dual Primary Endpoints Of Overall Survival And Progression-Free Survival

Financial news for MRK dated on 2018-01-16: SunTrust Robinson Humphrey Upgrades Merck & Co to Buy

Financial news for MRK dated on 2018-01-12: FDA Approves AstraZeneca and Merck's Lynparza, For Breast Cancer With A Certain Inherited Genetic Mutation

Financial news for MRK dated on 2018-01-11: A Strategy That Beat The S&P 500: Here Are Your 2018 'Dogs Of The Dow'

Financial news for MRK dated on 2018-01-11: Key Takeaways From The J.P. Morgan Healthcare Conference

Financial news for MRK dated on 2018-01-09: Merck Announces Breakthrough Designation from the FDA for LENVIMA and KEYTRUDA as Combination Therapy for Renal Cell Carcinoma

Financial news for MRK dated on 2018-01-08: Alzheimer's Takes Another Hit As Pfizer Ends Research In The Area

Financial news for MRK dated on 2018-01-08: Merck's KEYTRUDA Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma

Financial news for MRK dated on 2018-01-08: Merck Announces FDA Accepts NDA For Doravirine

Financial news for MRK dated on 2018-01-05: Lower Jobs Growth in December, But Some Positive Signs For Economy

Financial news for MRK dated on 2018-01-02: 4 Reasons To Consider Adding Celldex To Your Portfolio

Financial news for MRK dated on 2018-01-02: Merck's KEYTRUDA Approved in Japan for Use in the Treatment of Patients with Urothelial Carcinoma

Financial news for MRK dated on 2017-12-26: Merck Shares Down 0.12%, Pfizer Shares Up 0.11%; Earlier Companies Together Announced FDA Approvla For Their Collaboration Treatment STEGLATRO, STEGLUJAN and SEGLUROMET

Financial news for MRK dated on 2017-12-26: Merck's Diabetes Drugs Get FDA Nod As Adjunct Therapies

Financial news for MRK dated on 2017-12-22: FDA Approves Merck's SGLT2 Inhibitor STEGLATRO and Fixed-Dose Combination STEGLUJAN for Adults with Type 2 Diabetes

Financial news for MRK dated on 2017-12-21: Merck Reports FDA Granted Breakthrough Therapy Designation For Avelumab In Combo With INLYTA In Advanced Renal Cell Carcinoma

Financial news for MRK dated on 2017-12-20: 3 Biotech Pipeline Areas To Keep An Eye On In 2018

Financial news for MRK dated on 2017-12-15: Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More

Financial news for MRK dated on 2017-12-14: UPDATE: Merck Says Progression Free Survival Did Not Show Statistical Significance In PD-L1 Positive Population

Financial news for MRK dated on 2017-12-14: Merck Announces KEYTRUDA Did NOT Meet Primary Endpoint In Phase 3 KEYNOTE-061 Study

Financial news for MRK dated on 2017-12-14: Merck Says PREVYMIS Expected To Be

Available In Canada By Year-End

Financial news for MRK dated on 2017-12-13: Merck's Keytruda Gets FDA Priority Review For Rare Lymphoma

Financial news for MRK dated on 2017-12-13: PreMarket Opening NYSE Imbalance Update: AT&T 168k Shares To Sell; Nike 54k Shares To Sell; Square 33k To Buy; Disney 41k To Buy; US Steel 53k Shares To Sell; Pfizer 50k Shares To Sell; Merck 28k Shares To Buy;

Financial news for MRK dated on 2017-12-11: 3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise

Financial news for MRK dated on 2017-12-11: Merck Reports FDA Accepted sBLA, Assigned Priority Review For KEYTRUDA For Treatment Of Relapsed, Refractory PMBCL

Financial news for MRK dated on 2017-12-07: Loncar Investment's Brad Loncar Tweets: Roche is trading slightly down in Europe and \$MRK seems not to be doing anything in this early pre-market hour. IMpower150 basically in line with high expectations.

Financial news for MRK dated on 2017-12-06: Merck Announces Publication Of Phase 3 PREVYMIS Study Results In NE Journal Of Medicine

Financial news for MRK dated on 2017-12-01: FDA Decisions In November: The Month In Review

Financial news for MRK dated on 2017-11-28: Merck Raises Qtr. Dividend From \$0.47 To \$0.48/Share

Financial news for MRK dated on 2017-11-28: Merck Reports \$10B Buyback Plan

Financial news for MRK dated on 2017-11-28: Bank of America Reinstates Buy on Merck & Co, Announces \$64.00

Financial news for MRK dated on 2017-11-28: Peregrine Pharmaceuticals, Ronin Trading and SW Investment Management Announce Settlement Agreement; Peregrine Board Reconstituted with Four New Independent Directors

Financial news for MRK dated on 2017-11-28: UPDATE: Merck, Pfizer On JAVELIN Trial Of Avelumab, Say, 'Safety profile was consistent with that observed in previously reported studies of avelumab; no new safety signals were identified'

Financial news for MRK dated on 2017-11-28: UPDATE: Merck, Pfizer Says Phase III JAVELIN Study Investigating Avelumab 'did not meet its pre-specified primary endpoint of superior overall survival compared to chemotherapy'

Financial news for MRK dated on 2017-11-28: Merck, Pfizer Offer Update Related To Phase III JAVELIN Gastric 300 Study In Patients With Pre-Treated Advanced Gastric Cancer

Financial news for MRK dated on 2017-11-24: 5 Biggest Price Target Changes For Friday

Financial news for MRK dated on 2017-11-17: Merck Will Miss a Promised Deadline for Filing an Ebola Vaccine License with the FDA, According to STAT News

Financial news for MRK dated on 2017-11-16: Cue Biopharma Reports Strategic Research Collab, License Deal With Merck; Terms Not Disclosed, However cue Will Receive Up-Front Payment, Co. Eligible To Earn Up To \$374M Milestone Payments In Addition To Tiered Royalties

Financial news for MRK dated on 2017-11-15: 13G Filing Shows Merck Reporting 6.5% Stake In Spero Therapeutics

Financial news for MRK dated on 2017-11-15: Merck Revisits Low Of Move And Rebounds

Financial news for MRK dated on 2017-11-13: Merck Receives a Positive CHMP Opinion for PREVYMIS in the European Union

Financial news for MRK dated on 2017-11-09: Pharma ETFs Down Post Q3 Earnings

Financial news for MRK dated on 2017-11-09: Merck Reports Received FDA Approval For PREVYMIS For Prevention Of CMV Infection, Disease In Adult Allogeneic Stem Cell Transplant Patients

Financial news for MRK dated on 2017-11-06: Pharma Stock Roundup: Pfizer, Teva, Novartis, And More

Financial news for MRK dated on 2017-11-02: Pre-Market Imbalance Update: Alibaba 278K Shares To Buy, BofA 111K Shares To Sell, Merck 85K To Buy, GE 8.5K To Buy

Financial news for MRK dated on 2017-10-31: Benzinga's Top Upgrades, Downgrades For October 31, 2017

Financial news for MRK dated on 2017-10-31: The Market In 5 Minutes: A Halloween Scare For Under Armour, Qualcomm And Other Big Tech Names

Financial news for MRK dated on 2017-10-31: A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Mastercard, Kellogg Earnings

Financial news for MRK dated on 2017-10-31: Jefferies Upgrades Merck & Co to Hold

Financial news for MRK dated on 2017-10-31: 40 Biggest Movers From Yesterday

Financial news for MRK dated on 2017-10-30: 35 Stocks Moving In Monday's Mid-Day Session

Financial news for MRK dated on 2017-10-30: The Bull Thesis For Merck Is Evaporating

Financial news for MRK dated on 2017-10-30: Analyst Grows Cautious On Merck's Keytruda After Company Withdraws European Application

Financial news for MRK dated on 2017-10-30: 8 Technical Levels Highlighted On Monday's PreMarket Prep

Financial news for MRK dated on 2017-10-30: 5 Biggest Price Target Changes For Monday

Financial news for MRK dated on 2017-10-30: Benzinga's Top Upgrades, Downgrades For October 30, 2017

Financial news for MRK dated on 2017-10-30: Barclays Downgrades Merck & Co to Equal-Weight

Financial news for MRK dated on 2017-10-30: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for MRK dated on 2017-10-30: SunTrust Robinson Humphrey Downgrades Merck & Co to Hold

Financial news for MRK dated on 2017-10-30: Morgan Stanley Downgrades Merck & Co to Equal-Weight

Financial news for MRK dated on 2017-10-30: 8 Stocks To Watch For October 30, 2017

Financial news for MRK dated on 2017-10-27: Merck Announces It Has Withdrawn KEYTRUDA European Application

Financial news for MRK dated on 2017-10-27: A Peek Into The Markets: U.S. Stock Futures Climb After Amazon, Alphabet Results

Financial news for MRK dated on 2017-10-27: Merck Raises FY17 Sales Guidance From \$39.4B-\$40.4B As Of Jul. 28 To \$40B-\$40.5B vs \$40.3B Est.

Financial news for MRK dated on 2017-10-27: Merck Raises FY17 Adj. EPS Outlook From \$3.76-\$3.88 As Of Jul. 28 To \$3.91-\$3.97 vs \$3.87 Est.

Financial news for MRK dated on 2017-10-27: Merck Reports Q3 Adj. EPS \$1.11 vs \$1.03 Est., Sales \$10.3B vs \$10.55B Est.

Financial news for MRK dated on 2017-10-27: 12 Stocks To Watch For October 27, 2017

Financial news for MRK dated on 2017-10-27: Earnings Scheduled For October 27, 2017

Financial news for MRK dated on 2017-10-24: Healthcare ETFs Set To Soar As Q3 Earnings Unfold

Financial news for MRK dated on 2017-10-23: The Week Ahead: Earnings Season Starts In Earnest

Financial news for MRK dated on 2017-10-23: 8 Firms To Debut On The Markets This Week

Financial news for MRK dated on 2017-10-23: AstraZeneca, Merck Rapidly Advance LYNPARZA in Japan With a NDA To Japan's Pharmaceuticals and Medical Devices Agency

Financial news for MRK dated on 2017-10-22: A Preview Of Next Week's Blue-Chip Earnings

Financial news for MRK dated on 2017-10-20: Fierce Pharma Reports Merck Lays Off 1,800 U.S. Sales Reps To Overhaul Primary Care Marketing

Financial news for MRK dated on 2017-10-19: OncoSec Shares Spike 17% After New Data Defended

Financial news for MRK dated on 2017-10-19: White House 'Shenanigans' Represent A Buying Opportunity: Cramer

Financial news for MRK dated on 2017-10-18: Benzinga's Top Upgrades, Downgrades For October 18, 2017

Financial news for MRK dated on 2017-10-18: Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever

Financial news for MRK dated on 2017-10-18: Merck Reports FDA Accepted Regulatory Submission For LYNPARZA In Metastatic Breast Cancer, Grants Priority Review

Financial news for MRK dated on 2017-10-18: UPDATE: Merck Highlights KEYTRUDA Data 'Showed Median Overall Survival of 30.0 Months for KEYTRUDA Group Compared to 14.2 Months for Chemotherapy Group'

Financial news for MRK dated on 2017-10-18: Merck Reports KEYTRUDA More Than Doubled Median Overall Survival Compared to Chemotherapy After 2 Years of Follow Up in First-Line Treatment of Patients with Metastatic NSCLC with High Levels of PD-L1

Financial news for MRK dated on 2017-10-18: Citigroup Upgrades Merck & Co to Buy

Financial news for MRK dated on 2017-10-16: Merck Reports 9.9% Passive Stake in KalVista Pharmaceuticals -13G

Financial news for MRK dated on 2017-10-16: Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea's AEB1102 (pegzilarginase) with Merck's KEYTRUDA (pembrolizumab) for the Treatment of Small Cell Lung Cancer

Financial news for MRK dated on 2017-10-13: Pharma Stock Roundup: Pfizer Mulls Options For Consumer Healthcare, Eli Lilly's Pipeline Setback

Financial news for MRK dated on 2017-10-13: Bank Of America Sees NewLink Genetics As 'Undervalued'

Financial news for MRK dated on 2017-10-11: UPDATE: Merck Says Co. Will Not Submit Apps For Regulatory Approval For Anacetrapib

Financial news for MRK dated on 2017-10-11: Merck Offers Update On Anacetrapid Development Program

Financial news for MRK dated on 2017-10-10: 5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings

Financial news for MRK dated on 2017-10-09: Health Care Sector Back In Focus In Congress Ahead Of Q3 Earnings Result

Financial news for MRK dated on 2017-10-09: Pre-Market Imbalance Update: GE Shares 198K To Buy, Macy's 75K To Buy, Pfizer 71K To Sell, Merck 56K To Buy, Citi 50K To Buy, P&G 40K To Buy, ExxonMobil 38K To Sell, Barrick Gold 30K To Buy, BofA 28K To Buy, Chevron 25K To Sell, JP Morgan 10K To Buy

Financial news for MRK dated on 2017-10-06: Heaps Of Healthy Health Care ETFs

Financial news for MRK dated on 2017-10-02: Galena Biopharma Shares Up 10.6% Following Earlier SEC Filing Showing SELLAS Life Sciences Entered Collab., Supply Deal With Merck For Initiation Of Phase 1/2 Trial With Galinpepimut-S, KEYTRUDA

Financial news for MRK dated on 2017-09-29: Merck To Offer New, Updated Data On KEYTRUDA At World Conference On Lung Cancer, No Further Details Given

Financial news for MRK dated on 2017-09-29: Merck Reports Discontinuation Of MK-3682B, MK-3682C Development Programs

Financial news for MRK dated on 2017-09-23: Cramer's Guide To Profit From Market Rotations

Financial news for MRK dated on 2017-09-22: Agilent Technologies Receives FDA Approval For Use Of Dako PD-L1 For Treatment With Merck's KEYTRUDA In Gastric or Gastroesophageal Junction Cancer

Financial news for MRK dated on 2017-09-22: REMINDER: Merck's KEYTRUDA In Gastric Or Gastroesophageal Cancer Indication Has PDUFA Date Today

Financial news for MRK dated on 2017-09-21: Merck and Pfizer Get European Commission

Approval for Bavencio

Financial news for MRK dated on 2017-09-12: This Analyst Predicts Bullish Growth Outlook For Incyte

Financial news for MRK dated on 2017-09-11: Morgan Stanley Healthcare Conference Begins Today, Presenters Include: Veeva Systems, Quorum Health, Neurocrine Biosciences, Vertex Pharma, Merck, Ocular Therapeutix, Biogen, Gilead, and Bristol-Myers

Financial news for MRK dated on 2017-09-11: Merck Reports Findings From Phase 3 Study OF KEYTRUDA vs Standard Of Care In Patients With Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Financial news for MRK dated on 2017-09-09: What Pharmaceuticals Spend On Lobbying To Influence Trump

Financial news for MRK dated on 2017-09-09: Incyte, Merck Announce Positive Progression-Free Survival Data from ECHO-202 Trial of Epacadostat in Combination with KEYTRUDA in Patients with Advanced Melanoma at ESMO 2017

Financial news for MRK dated on 2017-09-08: Merck Reports KEYTRUDA Plus Pemetrexed, Carboplatin Showed Continued Benefit in Overall Response Rates and Progression-Free Survival Compared to Pem/Carbo Alone in Patients with First-Line Nonsquamous NSCLC

Financial news for MRK dated on 2017-09-08: European Society for Medical Oncology(ESMO) 2017 Congress Begins Today, Day 1 Of 5

Financial news for MRK dated on 2017-09-08: Merck Reports Updated Data For KEYTRUDA In Patients With Advanced Gastric Cancer Across Treatment Settings

Financial news for MRK dated on 2017-09-07: Wall Street's M&A Chatter From September 6: Cabelas, Merck-Rigontec, Altice-Charter, Amazon-Kohl's

Financial news for MRK dated on 2017-09-06: Merck Announces Acquisition of Rigontec for EUR 115M Cash, May Make up to EUR 349M of Additional Payments

Financial news for MRK dated on 2017-09-06: Eisai Signs Agreement with Merck to Expand Enrollment of Combination Study for Lenvima and Pembrolizumab in Endometrial Carcinoma

Financial news for MRK dated on 2017-09-05: Merck's KEYTRUDA Approved by the European Commission for a Type of Bladder Cancer

Financial news for MRK dated on 2017-08-31: Merck Shares Down 0.5% Over Last Few Mins., Remain Up ~0.1% For Session

Financial news for MRK dated on 2017-08-31: Merck Shares Move To Session Lows, Up 0.4% For Session, As Traders Circulating FDA.gov Alert 'FDA Alerts Healthcare Professionals and Oncology Clinical Investigators about Two Clinical Trials on Hold Evaluating KEYTRUDA(r) in Patients w/ MM'

Financial news for MRK dated on 2017-08-30: Born On The Battlefield: AcelRx Awaits FDA Ruling On Device That Delivers Potent Opioid To Wounded Soldiers

Financial news for MRK dated on 2017-08-29: Merck Announces Presentation of Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease

Financial news for MRK dated on 2017-08-25: Jon Najarian Sees Unusual Options Activity In Marathon Petroleum, Caesars And Merck

Financial news for MRK dated on 2017-08-24: Playing The US Pharma Space: Buy Portola, Hold Corvus, Sell Teva

Financial news for MRK dated on 2017-08-17: AstraZeneca, Merck Issue Release Confirming Added, Broad Approval Of LYNPARZA In US For Ovarian Cancer

Financial news for MRK dated on 2017-08-16: You Can't Quit, Because You're Fired! Trump Disbands Manufacturing Council, Policy Forum

Financial news for MRK dated on 2017-08-16: Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive'

Financial news for MRK dated on 2017-08-15: Martin Shkreli Calls Merck CEO Ken Frazier 'Self-Indulgent,' 'Pathetic'

Financial news for MRK dated on 2017-08-15: The Market In 5 Minutes

Financial news for MRK dated on 2017-08-14: Merck Higher Despite Trump Bashing

Financial news for MRK dated on 2017-08-14: Doug Kass Tweets: I am buying \$MRK just on principle. @maddow @MSNBC @carlquintanilla @jimcramer @tomkeene @andrewrsorkin @BeckyQuick

Financial news for MRK dated on 2017-08-14: Merck CEO Quits Manufacturing Council To Stand Against Violence; Trump Promptly Calls Him Out About Drug Pricing

Financial news for MRK dated on 2017-08-14: Donald Trump Tweets: Now that Ken Frazier of Merck Pharma has resigned from President's Manufacturing Council, he will have more time to LOWER RIPOFF DRUG PRICES!

Financial news for MRK dated on 2017-08-14: CNBC Now Tweets: JUST IN: Merck CEO resigns from Trump's manufacturing council amid fallout from the President's comments.

Financial news for MRK dated on 2017-08-08: Merck 10-Q Just Out

Financial news for MRK dated on 2017-08-08: Nice Recommends Erbitux In Combination With Platinum-Based Chemotherapy For The Treatment Of Recurrent And/Or Metastatic Head And Neck Cancer In The Oral Cavity

Financial news for MRK dated on 2017-08-07: Merck Animal Health to Acquire Austrian Manufacturing Facility, Terms Not Disclosed

Financial news for MRK dated on 2017-08-01: August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty

Financial news for MRK dated on 2017-07-31: Merck To Collaborate With Generex Biotech For KEYTRUDA In Combination With AE37 Study

Financial news for MRK dated on 2017-07-28: A Peek Into The Markets: U.S. Stock Futures Down; Amazon Earnings Miss Views

Financial news for MRK dated on 2017-07-28: Merck Raises FY17 Sales Outlook From Feb. 2 Indication Of \$38.6B-\$40.1B To \$39.4B-\$40.4B vs \$40.1B Est.

Financial news for MRK dated on 2017-07-28: UPDATE: Merck Raises FY17 Adj. EPS Outlook From \$3.72-\$3.87 To \$3.76-\$3.88 vs \$3.85 Est.

Financial news for MRK dated on 2017-07-28: Merck Raises FY17 Adj. EPS Outlook

Financial news for MRK dated on 2017-07-28: Merck Reports Q2 Adj. EPS \$1.01 vs \$0.87 Est., Sales \$9.93B vs \$9.75B Est.

Financial news for MRK dated on 2017-07-28: 10 Stocks To Watch For July 28, 2017

Financial news for MRK dated on 2017-07-28: Earnings Scheduled For July 28, 2017

Financial news for MRK dated on 2017-07-27: Merck Shares Up 3.3% After Announcing Oncology Collaboration With AstraZeneca

Financial news for MRK dated on 2017-07-27: Why Is AstraZeneca Sinking Today?

Financial news for MRK dated on 2017-07-27: Samsung, Amazon -- Everyone Is Getting Into Pharmaceuticals

Financial news for MRK dated on 2017-07-27: AstraZeneca, Merck Announce Strategic Oncology Collaboration; Merck to pay AstraZeneca up to \$8.5B in Total Consideration

Financial news for MRK dated on 2017-07-25: UPDATE: Merck Plans to Submit New Drug Applications with the U.S. FDA in Q4 2017 For Doravirine

Financial news for MRK dated on 2017-07-25: Merck's Doravirine Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection

Financial news for MRK dated on 2017-07-24: UPDATE: Merck Reports No Safety Signals Identified In Phase 3 KEYTRUDA Study

Financial news for MRK dated on 2017-07-24: Merck Reports Update On Phase 3 KEYTRUDA Study, Did Not Meet Primary Endpoint

Financial news for MRK dated on 2017-07-24: What You Need To Know About Dow Components Reporting This Week

Financial news for MRK dated on 2017-07-24: Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers

Financial news for MRK dated on 2017-07-24: Merck Gives Results from ONCEMRK, A Study of ISENTRESS HD

Financial news for MRK dated on 2017-07-21: Merck Reports EMA CHMP Recommended Approval For Co.'s KEYTRUDA For Treatment Of Certain Patients With Locally-Advanced Or Metastatic Urothelial Carcinoma

Financial news for MRK dated on 2017-07-21: Merck and Pfizer's Avelumab Recommended for Approval by the EU Medicines Agency

Financial news for MRK dated on 2017-07-20: Hearing Merck Has Said Corning Will Make Initial \$500M Investment Related To Modernization Of Pharmaceutical Glass Packaging

Financial news for MRK dated on 2017-07-20: Trump Says Merck, Pfizer And Corning Announce That Glass Packaging Will Be Made In America

Financial news for MRK dated on 2017-07-20: Merck Reports FDA Granted Tentative Approvaal For LUSDUNA Nexvue

Financial news for MRK dated on 2017-07-17: 5 Biggest Price Target Changes For Monday

Financial news for MRK dated on 2017-07-13: Shares of Eli Lilly, AstraZeneca, Merck, Gilead, Abbvie, Other Large Cap Biotech Spiking Higher

Financial news for MRK dated on 2017-07-12: J&J To Commence Pharma Q2 Earnings Season: What's Up?

Financial news for MRK dated on 2017-07-10: The Royalty-Amassing Strategy Of Royalty Pharma

Financial news for MRK dated on 2017-07-06: Merck Falls As FDA Puts Hold On 3 Keytruda Myeloma Studies

Financial news for MRK dated on 2017-07-06: Merck to Present New Data from Clinical Trials Evaluating ISENTRESS HD and Investigational HIV Therapies Doravirine and MK-8591 at IAS 2017

Financial news for MRK dated on 2017-07-05: Merck Announces FDA Placed Clinical Hold On KEYNOTE-183, KEYNOTE-185 and KEYNOTE-023 Following Review Of Data By Data Monitoring Committee; FDA Has Determined Risk Of KEYTRUDA In Compination With Pomalidomide Of Lenalidomide Outweigh Potential Benefits

Financial news for MRK dated on 2017-07-05: Healthcare Repeal Bad For GlaxoSmithKline, Other HIV Treatment Stocks

Financial news for MRK dated on 2017-07-03: Watch These 5 Huge Put Purchases In Monday Trade

Financial news for MRK dated on 2017-06-30: Benzinga's Option Alert Recap From June 30

Financial news for MRK dated on 2017-06-29: Aduro Biotech Initiates Phase 2 Clinical Trial Of CRS-207 In Combination With KEYTRUDA

Financial news for MRK dated on 2017-06-28: Russia In The Spotlight As Second Wave Of Ransomware Grips Globe

Financial news for MRK dated on 2017-06-27: Ransomware Rears Its Head Again As 150 Countries Hit By New Virus

Financial news for MRK dated on 2017-06-27: Hearing Merck Has Confirmed Co.'s Computer Network Was Compromised

Financial news for MRK dated on 2017-06-27: Merck Announces REVEAL Met its Primary Endpoint, Says Will Consult With External Experts and Consider Whether to File NDA

Financial news for MRK dated on 2017-06-27: Ablynx Achieves EUR2.5M Milestone Iin Immuno-oncology Collaboration With Merck

Financial news for MRK dated on 2017-06-26: A Surprisingly Clean, Straightforward Approval Gives Portola Pharma Shares A Shot Of Upside

Financial news for MRK dated on 2017-06-22: Merck, Premier Report Expanded Collaboration To Address Chronic Care, Vaccination Rates

Financial news for MRK dated on 2017-06-21: Leap Therapeutics Reports Collab With Merck For Evaluation Of KEYTRUDA In Combo With DKN-01 In Esophagogastric Cancer

Financial news for MRK dated on 2017-06-20: Merck Subsidiary Announces Collaboration With Serimmune

Financial news for MRK dated on 2017-06-18: Merck Receives FDA Orphan Designation for Keytruda in Treatment of Esophageal Carcinoma

Financial news for MRK dated on 2017-06-16: Cerveau Technologies Reports FDA Accepted IND For MK-6240; BZ NOTE: Merck Is A Development Partner For The Candidate

Financial news for MRK dated on 2017-06-15: Merck Reports Expansion Of Distribution Deal With Public Health England

Financial news for MRK dated on 2017-06-12: Merck Reports Update On Multiple Myeloma Studies KEYNOTE-183, 185 Of KEYTRUDA In Combo With Other Therapies: Has Accepted External Data Monitoring Committee Recommendation To Pause New Enrollment

Financial news for MRK dated on 2017-06-12: Pre-Market Imbalance Update: Pfizer 74K Shares To Sell, Citi 61K To Sell, JP Morgan 35K Shares To Buy, Merck 33K To Buy

Financial news for MRK dated on 2017-06-11: Merck, Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies at #2017ADA

Financial news for MRK dated on 2017-06-05: Dynavax +21% Premarket @\$7.15; Co on Friday Presented Updated Data for SD-101 in Combination with KEYTRUDA

Financial news for MRK dated on 2017-06-05: Merck Gives Update on Phase 2 I-SPY 2 Trial

Financial news for MRK dated on 2017-06-04: Merck Announces Presentation of New Monotherapy Data for KEYTRUDA in Heavily Pre-Treated Patients with Advanced Gastric Cancer#ASCO17

Financial news for MRK dated on 2017-06-04: Merck Announces KEYTRUDA Shows Continued Overall Survival Benefit Over Chemotherapy as Second-Line Treatment for Advanced Urothelial Carcinoma Patients Post-Platinum Failure #ASCO17

Financial news for MRK dated on 2017-06-03: Combination of Incyte's Epacadostat + Merck's KEYTRUDA Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer #ASCO17

Financial news for MRK dated on 2017-06-03: Merck Announces New Data Show Durability of Response for KEYTRUDA in Advanced Microsatellite Instability-High or Mismatch Repair Deficient Solid Tumors, Regardless of Tumor Type #ASCO17

Financial news for MRK dated on 2017-06-02: Merck Gives Update on KEYTRUDA Effectiveness with Over 2 Years of Follow Up

Financial news for MRK dated on 2017-05-30: Tracking The Busy June PDUFA Calendar

Financial news for MRK dated on 2017-05-30: A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Economic Data

Financial news for MRK dated on 2017-05-30: Merck Gets FDA Approval of ISENTRESS for the Treatment of HIV-1

Financial news for MRK dated on 2017-05-29: Congo Approves Use of Merck Ebola Vaccine -DJ

Financial news for MRK dated on 2017-05-26: Reminder: Merck Has Isentress sNDA PDUFA Date Tomorrow May 27

Financial news for MRK dated on 2017-05-25: Merck Reports Exclusive Global License Deal with Teijin Pharma for Investigational Antibody Candidate Targeting Tau

Financial news for MRK dated on 2017-05-23: FDA Approves Pembrolizumab for Pancreatic Cancers with Mismatch Repair Deficiency

Financial news for MRK dated on 2017-05-23: FDA Reports Approval for Merck's Solid Tumor with a Specific Genetic Feature Treatment

Financial news for MRK dated on 2017-05-23: Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst

Financial news for MRK dated on 2017-05-23: Pre-Market Imbalance Update: Ford 397K Shares to Buy, GE 200K to Buy, Nike 57K to Buy, GM 32K to Buy, Alibaba 30K to Buy, Merck 25K Shares to Sell

Financial news for MRK dated on 2017-05-23: Companies Holding Annual Meetings Today

Include Waste Connections, Eastman Kodak, Alarm.com, Amyris, Achillion Pharma, GNC, Amazon, Nokia, Merck, Nvidia, Pinnacle Foods, Wendy's, & Xerox

Financial news for MRK dated on 2017-05-23: Merck Gets Priority FDA Review for KEYTRUDA sBLA

Financial news for MRK dated on 2017-05-22: UPDATE: Merck Says Highest Dose of MK-7264 Evaluated Reduced Awake Cough Frequency by 37% from Baseline Relative to Placebo

Financial news for MRK dated on 2017-05-22: Merck Reports Presentation of Phase 2 Results for MK-7264 for Treatment of Chronic Cough

Financial news for MRK dated on 2017-05-19: The Most Notable Abstracts Released Ahead Of ASCO 2017

Financial news for MRK dated on 2017-05-19: Merck Reports Received CHMP Opinion Recommending Approval of ISENTRESS 600 mg in EU

Financial news for MRK dated on 2017-05-18: Merck Issues Release Confirming FDA Has Approved KEYTRUDA for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Financial news for MRK dated on 2017-05-18: FDA Has Granted Approval for Merck's Pembrolizumab for Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Financial news for MRK dated on 2017-05-18: WHO Says Congo Ebola Cases Present High National, Low Global Risk -Reuters

Financial news for MRK dated on 2017-05-17: Incyte Issues Release Highlighting Co.'s IDO1 Enzyme Inhibitor in Combo with Merck's Anti-PD-1 Therapy is 'well-tolerated and demonstrates durable clinical responses across multiple solid tumors'

Financial news for MRK dated on 2017-05-17: Merck's Glucophage SR Has Received Label Extension to Include Patients at High Risk of Type-2 Diabetes within UK

Financial news for MRK dated on 2017-05-17: Aduro Biotech Reports Clinical Collaboration with Merck for Evaluation of CRS-207, KEYTRUDA Combo for Treatment of Mesothelioma

Financial news for MRK dated on 2017-05-14: WHO Confirms Second Ebola Case in Congo -Reuters

Financial news for MRK dated on 2017-05-12: Sympathy Moves, Explained: Unsympathetic Earnings Season Continues As Nvidia, Advanced Micro Devices Diverge

Financial news for MRK dated on 2017-05-11: Here's What The FDA Approval Of Keytruda Means For Merck, And For Bristol-Myers

Financial news for MRK dated on 2017-05-10: Merck Press Release Confirms FDA Approval For KEYTRUDA

Financial news for MRK dated on 2017-05-10: Andy Biotech Tweets: '\$MRK FDA approves Keytruda chemo combo in 1L NSCLC'

Financial news for MRK dated on 2017-05-10: Reminder: Merck Has Keytruda PDUFA Date Today

Financial news for MRK dated on 2017-05-10: OncoSec Medical +21.5% Premarket @\$1.30 Following Announcement of Clinical Collaboration with Merck to Evaluate Combination of ImmunoPulse IL-12 and KEYTRUDA

Financial news for MRK dated on 2017-05-10: OncoSec Medical Reports Clinical Trial Collaboration, Supply Deal with Merck to Evaluate Combo of ImmunoPulse IL-12 and KEYTRUDA

Financial news for MRK dated on 2017-05-09: UPDATE: Merck 10-Q Filing Shows Co. Eliminated ~545 Positions in Q1'17 Under Restructuring Program Activities

Financial news for MRK dated on 2017-05-09: Merck 10-Q Just Out

Financial news for MRK dated on 2017-05-08: Array BioPharma Reports Strategic Partnership with Merck

Financial news for MRK dated on 2017-05-06: Near-Term Events Cast Shadow Of Uncertainty On Bristol-Myers

Financial news for MRK dated on 2017-05-05: Pre-Market Imbalance Update: IBM 110K Shares to Sell, Twitter 100K to Sell, Ford 63K Shares to Buy, Merck 62K to Sell,

Disney 38K to Sell, P&G 20K to Sell

Financial news for MRK dated on 2017-05-05: Merck Reports EC Approval of KEYTRUDA for Patients with Relapsed, Refractory Classical Hodgkin Lymphoma Who Who Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who are Transplant-Ineligible and Have Failed BV

Financial news for MRK dated on 2017-05-03: Ahead Of Merck's Keytruda PDUFA Date, Analyst Says Expect Approval

Financial news for MRK dated on 2017-05-02: Apple Earnings In Focus, But Fed Meeting, Auto Sales Also Could Grab Headlines

Financial news for MRK dated on 2017-05-02: A Peek Into The Markets: U.S. Stock Futures Mostly Lower; Apple Earnings In Focus

Financial news for MRK dated on 2017-05-02: Merck Raises FY 2017 Guidance , Sees FY 2017 EPS \$3.76 to \$3.88 vs \$3.81 Est, Sales \$39.1B to \$40.3B vs \$39.7B Est

Financial news for MRK dated on 2017-05-02: Merck Q1 EPS \$0.88 vs \$0.83 Est, Sales \$9.43B vs \$9.25B Est

Financial news for MRK dated on 2017-05-02: 12 Stocks To Watch For May 2, 2017

Financial news for MRK dated on 2017-05-02: Earnings Scheduled For May 2, 2017

Financial news for MRK dated on 2017-05-01: Earnings Preview: Q1 Results From Pfizer, Merck, And Gilead Sciences This Week

Financial news for MRK dated on 2017-05-01: Feuerstein On Neurotrope: The Study Failed And There Was Never 'A Lot Of Hope Here'

Financial news for MRK dated on 2017-05-01: Looking For Action? Week Ahead Brings Heavy Load With Earnings, Data, Fed Meeting

Financial news for MRK dated on 2017-04-25: Watching Volatility in Vaccine Names Here as Traders Circulating WSJ Article from Mon. Evening 'Vaunted Ebola Vaccine Faces Questions'

Financial news for MRK dated on 2017-04-25: Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates

Financial news for MRK dated on 2017-04-24: Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow

Financial news for MRK dated on 2017-04-21: Merck Reports Study in US Veterans Affairs System Evaluating Use of ZEPATIER Showed High Sustained Virologic Response Rates in Patients with Chronic Hep C

Financial news for MRK dated on 2017-04-21: Atara Bio Partners With Merck To Evaluate KEYTRUDA In Combination With ATA129 In NPC

Financial news for MRK dated on 2017-04-20: What Would A \$5.8 Billion NIH Cut Look Like? Devastation

Financial news for MRK dated on 2017-04-19: Exclusive: Leading Biosciences Execs Talk About How The Company Could Save Hospitals Millions Of Dollars Per Year

Financial news for MRK dated on 2017-04-12: Healthcare Sector Earnings: Making A Comeback In Q1 2017?

Financial news for MRK dated on 2017-04-10: Cardiovascular Players Could Be Eyeing Esperion

Financial news for MRK dated on 2017-04-08: Barron's Picks And Pans: Gold, Energy, Dividends And More

Financial news for MRK dated on 2017-04-07: Pre-Market Imbalance Update: AmEx 89K Shares to Sell, Ford 71K Shares to Buy, Merck 40K to Buy, BofA 29K to Sell, Morgan Stanley 22K to Sell, Nike, GE 20K to Sell

Financial news for MRK dated on 2017-04-07: Merck Reports Received CRL from FDA Related to TECOS Study with Sitagliptin

Financial news for MRK dated on 2017-04-05: There Is Value To Be Had With The Right Healthcare ETFs

Financial news for MRK dated on 2017-04-03: Benzinga Premarket Prep Host Dennis Dick Tweets: Notable opening imbalances: \$PFE -243K, \$MRK -93K, \$BABA +115K, \$KO +104K, \$T

+111K, \$CAT -55K, \$IBM -42K

Financial news for MRK dated on 2017-03-31: UPDATE: Incyte, Merck Announce Clinical Program for Epacadostat, KEYTRUDA Includes 7 Registrational Trials Across 5 Tumor Types

Financial news for MRK dated on 2017-03-31: Incyte, Merck Offer Added Details on Previously Announced Collab. Investigating Epacadostat, KEYTRUDA

Financial news for MRK dated on 2017-03-24: European Medicines Agency's CHMP Recommends Approval of Merck's KEYTRUDA

Financial news for MRK dated on 2017-03-20: Leerink Presents: Your 2017 Biopharma Catalyst Tracker

Financial news for MRK dated on 2017-03-15: Prima Biomed Completes Recruitment For Second Patient Cohort In Melanoma Trial

Financial news for MRK dated on 2017-03-14: Merck Says Submission Of Additional Data Is Considered Major Amendment to sBLA Under PDUFA; Thus, Extending Target Action Date By 3 Months To June 9th, 2017

Financial news for MRK dated on 2017-03-14: FDA Has Approved Merck's Keytruda For Intravenous Use In Hodgkin Lymphoma

Financial news for MRK dated on 2017-03-10: Adam Feuerstein Talks Vulnerable Pharmaceuticals, Drug Pricing Under Trump

Financial news for MRK dated on 2017-03-10: Feuerstein on Benzinga's PreMarket Prep Discussing Stocks Which Could Be Impacted by Drug Pricing Changes: Believes Worst Case Scenario Would Create Vulnerabilities for Drugs with High Levels of Competition

Financial news for MRK dated on 2017-03-08: Here's Your March PDUFA Date Preview

Financial news for MRK dated on 2017-03-08: Everything We Know About Merck's Keytruda

Financial news for MRK dated on 2017-03-08: REMINDER: Merck's PDUFA Date For Keytruda In Microsatellite Instability-High Cancer Today

Financial news for MRK dated on 2017-03-06: Merck, Pfizer Report U.S. FDA and EMA Filing Acceptances of 3 Marketing Applications for Ertugliflozin-Containing Medicines For Adult Type 2 Diabetes Patients

Financial news for MRK dated on 2017-03-02: Why Bermuda Could Be The Next Switzerland

Financial news for MRK dated on 2017-03-01: Merck's Odactra Approved For House Dust Mite Allergies

Financial news for MRK dated on 2017-02-26: Merck Says Letemovir for Prevention of CMV Infection in Bone Marrow Transplant Recipients is Highly Effective Through Week 24 Post-Transplant in Pivotal Phase 3 Study

Financial news for MRK dated on 2017-02-25: Big Business Delivers Christmas Wish List To Trump, 10 Months Early

Financial news for MRK dated on 2017-02-24: Merck Reports First Phase 3 Trial of V212 Reduced Incidence of Confirmed Herpes Zoster Cases by ~64% in Immunocompromised Subjects

Financial news for MRK dated on 2017-02-24: Merck Receives Positive CHMP Opinion For New Pergoveris Fertility Pen

Financial news for MRK dated on 2017-02-23: Merck Says Will Record Intangible Asset Impairment Charge Related To MK-3682 Program, Previously Reported Q4 And FY Non-GAAP EPS Remain Unchanged

Financial news for MRK dated on 2017-02-23: Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market'

Financial news for MRK dated on 2017-02-21: Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?

Financial news for MRK dated on 2017-02-21: Boeing, Pfizer And Others Band Together To Ask Congress For More Taxes

Financial news for MRK dated on 2017-02-17: The Market In 5 Minutes

Financial news for MRK dated on 2017-02-16: After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?

Financial news for MRK dated on 2017-02-15: Merck Still Sees Path Forward For Failed Alzheimer's Drug

Financial news for MRK dated on 2017-02-15: Merck, On Its Alzheimer's Drug Program, Tells Benzinga Too Early To Speculate What Verubecestat Trial Results Mean For Validity Of 'Amyloid Hypothesis', Hopes By Evaluating Drug In People W/Less Impairment Will Be Able To Slow Disease Progression

Financial news for MRK dated on 2017-02-15: Deutsche Bank Casts Doubt On Pfizer's Rumored Takeover Approach To Bristol-Myers

Financial news for MRK dated on 2017-02-14: Merck Says APECS Study in People with Prodromal Alzheimer's Disease to Continue

Financial news for MRK dated on 2017-02-14: Meg Tirrell Tweets: \$MRK stops study of BACE inhibitor in mild to moderate Alzheimer's for lack of efficacy, prodromal study continues

Financial news for MRK dated on 2017-02-14: Merck's Doravirine Meets Primary Efficacy Endpoint In Pivotal Phase 3 Trial

Financial news for MRK dated on 2017-02-03: FDA to Review Two of Merck's Supplemental Biologics License Applications

Financial news for MRK dated on 2017-02-02: Q4 2016 Real-Time Call Brief

Financial news for MRK dated on 2017-02-02: The Market In 5 Minutes: Facebook Beats, Trump Tweets

Financial news for MRK dated on 2017-02-02: Merck CEO Says Trump Focus On Patients Being Able To Afford Co-Pays Rather Than Overall Cost of Drugs

Financial news for MRK dated on 2017-02-02: Merck Sees FY17 Adj. EPS \$3.72-\$3.87 vs \$3.85 Est., Sales \$38.6B-\$40.1B vs \$40B Est.

Financial news for MRK dated on 2017-02-02: Merck Reports Q4 Adj. EPS \$0.89, Inline, Sales \$10.1B vs \$10.22B Est.

Financial news for MRK dated on 2017-02-01: Earnings: Facebook and Merck Scheduled to Open Their Books

Financial news for MRK dated on 2017-02-01: Ringing up the iPhones: Strong Apple Results Put A Charge Into Markets

Financial news for MRK dated on 2017-01-31: Merck Announces EU Approves KEYTRUDA For First-Line Pateitns

Financial news for MRK dated on 2017-01-30: Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail

Financial news for MRK dated on 2017-01-30: Mixing It Up: Markets Await Host Of Economic Data, Key Earnings, And Fed Meeting

Financial news for MRK dated on 2017-01-30: The Market In 5 Minutes: Walgreens-Rite Aid, Personal Income And Trump's Executive Order

Financial news for MRK dated on 2017-01-30: Can Merck And Pfizer Beat Low Expectations?

Financial news for MRK dated on 2017-01-27: A CEO Who's Who Of Trump's Manufacturing Council

Financial news for MRK dated on 2017-01-27: Andrew Left Furthers Comments Following ESRX Release Today, Points To Comment Made By Merck President Of U.S. Commercial To Highlight Thesis That Drug Co.'s Offer Incentives To PBM's To Stay On Preferred Drug Lists

Financial news for MRK dated on 2017-01-27: WSJ Reporting Merck Raised List Prices By 9.6% Last Year

Financial news for MRK dated on 2017-01-26: Merck Shares Falling As Ketruda Brain Tumor Trial Put On Hold Due To Adverse Event

Financial news for MRK dated on 2017-01-26: Merck's Keytruda Gains Momentum At The Expense Of Bristol-Myers

Financial news for MRK dated on 2017-01-25: Dow 10K's Hottest Stocks: Where Are They Now?

Financial news for MRK dated on 2017-01-25: Which Pharma Players Dominate The Lung Cancer Space?

Financial news for MRK dated on 2017-01-20: UPDATE: Merck's Payment To Bristol-Myers Will Be Recorded In Its Q4 And FY16 Results, Excluded From Non-GAAP Results

Financial news for MRK dated on 2017-01-20: Merck Announces Settlement With Bristol-Myers Resolving KEYTRUDA Patent Litigation, Will Pay \$625M And Provide Royalties On KEYTRUDA In Any Market In Which It's Approved

Financial news for MRK dated on 2017-01-20: Bristol-Myers Squibb Falls 10% After Opdivo Decision

Financial news for MRK dated on 2017-01-20: Wall Street's M&A Chatter From January 19

Financial news for MRK dated on 2017-01-12: Favorable News On Keytruda Drives Piper Jaffray's Upgrade Of Merck

Financial news for MRK dated on 2017-01-12: 8 Biggest Price Target Changes For Thursday

Financial news for MRK dated on 2017-01-12: Benzinga's Top Upgrades, Downgrades For January 12, 2017

Financial news for MRK dated on 2017-01-12: Merck's Leadership Position In Immuno Oncology Is Improving

Financial news for MRK dated on 2017-01-12: The Market In 5 Minutes: Jobless Claims Lower, Trump Conference Shakes Sectors

Financial news for MRK dated on 2017-01-12: Guggenheim Upgrades Merck & Co to Buy, Announces \$70.00 Target

Financial news for MRK dated on 2017-01-12: Morgan Stanley Upgrades Merck & Co to Overweight, Raises Target to \$71.00

Financial news for MRK dated on 2017-01-11: All The Markets Trump Moved During His Speech Today

Financial news for MRK dated on 2017-01-11: Here's What Merck's Keytruda News Means For Bristol-Myers

Financial news for MRK dated on 2017-01-11: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for MRK dated on 2017-01-11: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MRK dated on 2017-01-11: Lilly and Merck Expand Immuno-Oncology Collaboration, Financial Terms Not Disclosed

Financial news for MRK dated on 2017-01-10: Bristol-Myers Shares Down 2.2% After Hours as Merck Shares Trade Up ~2.5% Following News KEYTRUDA Accepted for Supplemental BLA

Financial news for MRK dated on 2017-01-10: Merck Reports KEYTRUDA Has FDA PDUFA Date Of May 10, 2017 Under Accelerated Approval

Financial news for MRK dated on 2017-01-10: Merck Receives FDA Acceptance Of Supplemental Biologics License Application for KEYTRUDA

Financial news for MRK dated on 2017-01-09: Option Alert: Merck Jan 61.5 Calls Sweep: 745 @ ASK \$0.64: 843 traded vs 562 OI: Earnings 2/2 Before Open \$61.29 Ref

Financial news for MRK dated on 2017-01-09: Exclusive: Ziopharm CEO Talks Partnerships, Balance Sheet And JPM Healthcare Conference Presentation

Financial news for MRK dated on 2017-01-09: Incyte, Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA

Financial news for MRK dated on 2017-01-09: The Year's Biggest Healthcare Conference Commences This Week; Here's What You Need To Know

Financial news for MRK dated on 2017-01-04: Merck Acquires Biocontrol

Financial news for MRK dated on 2016-12-30: UPDATE: Merck Says It Will Defend Itself Vigorously In Response To Government Notice; Given They Were Neither A Manufacturer Or A Marketer Of The Subject Drug

Financial news for MRK dated on 2016-12-30: Merck Says NPPA Alleges Overcharging Of Price Of Polybion Syrup Formulation From Jan. 2006-June 2009

Financial news for MRK dated on 2016-12-29: Prima BioMed Announces First Clinical Data from Combination of IMP321 With Keytruda Show No Safety Concerns

Financial news for MRK dated on 2016-12-28: Merck Gets A Strong Sell From Vetr Crowd

Financial news for MRK dated on 2016-12-28: Technical Alert: Merck Lower

Financial news for MRK dated on 2016-12-23: NewLink CFO: 'Ebola Vaccine Highly Unlikely To Drive Future Profit In Company'

Financial news for MRK dated on 2016-12-23: Where Does Merck's Ebola Vaccine Breakthrough Leave Competitors?

Financial news for MRK dated on 2016-12-23: Shares of NewLink Genetics Up 10%, Earlier Today, Traders Attributed Move To Partnership With Merck, Whose Ebola Vaccine Was Shown To Provide 100% Protection

Financial news for MRK dated on 2016-12-23: 6 Worst Biotech Stocks Of 2016

Financial news for MRK dated on 2016-12-22: Meet The New Dogs: 2017's Dogs Of The Dow Include Coca-Cola, Boeing

Financial news for MRK dated on 2016-12-20: What Does Biogen's New CEO Mean For The Buyout Argument?

Financial news for MRK dated on 2016-12-19: Jefferies' 2017 Global Pharma Outlook

Financial news for MRK dated on 2016-12-19: Jefferies' Huge Pharma Pair Trade: Bristol-Myers Upgraded To Buy, Merck Downgraded To Sell

Financial news for MRK dated on 2016-12-19: Benzinga's Top Upgrades, Downgrades For December 19, 2016

Financial news for MRK dated on 2016-12-19: A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Yellen Speech

Financial news for MRK dated on 2016-12-19: Merck Gets Approval for KEYTRUDA in Japan

Financial news for MRK dated on 2016-12-19: Jefferies Downgrades Merck & Co to Underperform, Lowers Target to \$48.00

Financial news for MRK dated on 2016-12-16: European Medicines Agency's CHMP Recommends Merck's KEYTRUDA For First-Line Treatment Of Patients With NSCLC

Financial news for MRK dated on 2016-12-15: Gilead To Pay Merck \$2.54B In Hep. C Royalties

Financial news for MRK dated on 2016-12-12: 10 Notable Stocks Trading Ex-Dividend Tuesday, December 13

Financial news for MRK dated on 2016-12-12: Merck Reports New KEYTRUDA Data In Combination With HALAVEN For Metastatic Triple-Negative Breast Cancer

Financial news for MRK dated on 2016-12-09: European Crohn's, Colitis Organisation Issues New Statement Support a Switch to Biosimilar from Reference Product in Inflammatory Bowel Disease

Financial news for MRK dated on 2016-12-07: Merck Canada Says Zostavax II Showed Vaccine Effectiveness Against Shingles In Observational Effectiveness Study

Financial news for MRK dated on 2016-12-07: What If Trump Keeps Badmouthing Drug Pricing?

Financial news for MRK dated on 2016-12-07: Technical Alert: Merck Lower

Financial news for MRK dated on 2016-12-07: Pfizer, J&J, Other Big Pharma Names Dip Lower Just After the Open

Financial news for MRK dated on 2016-12-07: Merck Announces KEYTRUDA Demonstrated Improved Health-Related Quality of Life vs Chemotherapy in First-Line Treatment of Patients with Metastatic NSCLC at WCLC 2016

Financial news for MRK dated on 2016-12-06: Merck KEYTRUDA Findings Show ORR Of 33.3% and 20% In Small Cell Lung Cancer and Malignant Pleural Mesothelioma Respectively In KEYNOTE-028

Financial news for MRK dated on 2016-12-05: Merck Announces KEYTRUDA Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHL) Presented at ASH 2016

Financial news for MRK dated on 2016-12-05: Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell

Financial news for MRK dated on 2016-12-05: Merck Says Will Present Updated KEYTRUDA Findings at ASH: Data Showed KEYNOTE-013 Overall Response Rate of 41%, with 86% of Responses Ongoing at the Time of Analysis

Financial news for MRK dated on 2016-12-05: Biothera, Merck Further Expand Research Collaboration to Include Phase 2 Clinical Trial in Head and Neck Cancer

Financial news for MRK dated on 2016-12-01: CNBC's Meg Tirrell Tweets: \$MRK CEO: We are now at the equivalent stage in immunotherapy where we were w first effective treatments for HIV #ForbesHealth

Financial news for MRK dated on 2016-12-01: Forbes Healthcare Summit Concludes Today; Presenters Include Express Scripts, Allergan, IBM, Bristol-Myers Squibb, Merck, Anthem, Eli Lilly, And Regeneron

Financial news for MRK dated on 2016-12-01: FDA Grants Priority Review to Supplemental Biologics License Application for Merck's KEYTRUDA in Relapsed or Refractory Classical Hodgkin Lymphoma

Financial news for MRK dated on 2016-11-28: FDA Grants Priority Review to Merck's Supplemental Biologics License Application (sBLA) Seeking Approval for KEYTRUDA for New Indication in Microsatellite Instability-High Cancer

Financial news for MRK dated on 2016-11-22: Merck Increases Qtr. Dividend From \$0.46 To \$0.47/Share

Financial news for MRK dated on 2016-11-22: QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to Generate Real World Insights On Usage of Anti-Cancer Therapies Across Europe

Financial news for MRK dated on 2016-11-16: Vetr Opts To Hold On Merck Despite Biotech Optimism

Financial news for MRK dated on 2016-11-14: Gilead Responds To CMS Blog Highlighting High Cost Of Harvoni: Most Payers Receive Substantial Discounts Off The List Price

Financial news for MRK dated on 2016-11-13: Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection

Financial news for MRK dated on 2016-11-12: Merck Announes KEYTRUDA Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder Cancer

Financial news for MRK dated on 2016-11-12: Merck Presents New Findings for ZEPATIER in Patients with Chronic Hepatitis C at The Liver Meeting

Financial news for MRK dated on 2016-11-11: Technical Alert - Merck Lower

Financial news for MRK dated on 2016-11-10: 2 Big Medical Marijuana Stocks Riding High Post-Election

Financial news for MRK dated on 2016-11-09: Technical Alert: Merck Reaches \$65 And Retreats

Financial news for MRK dated on 2016-11-09: Stocks Hitting 52-Week Highs

Financial news for MRK dated on 2016-11-09: Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%

Financial news for MRK dated on 2016-11-09: Biotech Is Getting A Big Boost Following Clinton's Loss

Financial news for MRK dated on 2016-11-03: BZ NOTE Related to Traders Passing Around CNBC Story on New Cancer Drugs Possibly Damaging the Heart: NBC News via AP Published the Same Story ~7 p.m. EDT Wed. Evening

Financial news for MRK dated on 2016-11-03: Traders Passing Around Recent CNBC Article on Cancer Treatments: 'New cancer drugs may damage the heart'

Financial news for MRK dated on 2016-11-02: Merck Reports Publishing of New Research on Early Development of Verubecestat, Says 'Results of First Phase 3 Trial Anticipated in Late 2017'

Financial news for MRK dated on 2016-11-01: The Election Can't Come Soon Enough For Biotechs

Financial news for MRK dated on 2016-10-25: Technical Alert: Merck Higher After Q3 Report

Financial news for MRK dated on 2016-10-25: 6 Big Pharma Companies Left To Report September Quarterly Figures

Financial news for MRK dated on 2016-10-25: Epic Earnings: Many US Companies Beating Expectations As Season Continues

Financial news for MRK dated on 2016-10-25: The Market In 5 Minutes: UA, GM, P&G Earnings On The Street's Mind

Financial news for MRK dated on 2016-10-25: A Peek Into The Markets: U.S. Stock Futures Rise; GM, Apple Earnings In Focus

Financial news for MRK dated on 2016-10-25: Merck's Q3 Results, Guidance Look Strong

Financial news for MRK dated on 2016-10-25: Merck Narrows and Raises Guidance; Sees FY EPS \$3.71 to \$3.78 vs \$3.75 est, Revenue \$39.7B to \$40.2B vs \$39.7B est

Financial news for MRK dated on 2016-10-25: Merck Q3 EPS \$1.07 vs \$0.99 est, Revenue \$10.54B vs \$10.18B est

Financial news for MRK dated on 2016-10-25: 12 Stocks You Should Be Watching Today

Financial news for MRK dated on 2016-10-25: Earnings Scheduled For October 25, 2016

Financial news for MRK dated on 2016-10-24: Merck Reports FDA Approval Of KEYTRUDA

Financial news for MRK dated on 2016-10-24: Big News Out Of Merck This Weekend

Financial news for MRK dated on 2016-10-21: Merck Has An Upcoming PDUFA Date For Bezlotoxumab

Financial news for MRK dated on 2016-10-21: Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments

Financial news for MRK dated on 2016-10-21: Merck Has An Oct 23rd Pdufa Date For Bezlotoxumab; Drug Won FDA Advisory Panel Backing In June

Financial news for MRK dated on 2016-10-21: Jim Cramer Gives His Opinion On Merck And Smith & Wesson

Financial news for MRK dated on 2016-10-21: Merck Reports KEYNOTE-045 Studying KEYTRUDA in Advanced Bladder Cancer Meets Primary Endpoint, Stops Early

Financial news for MRK dated on 2016-10-19: Fed Speakers And Beige Book, Bank Earnings, Rising Crude Take Center Stage

Financial news for MRK dated on 2016-10-19: Roche Group, Competitor To Bristol-Myers And Merck, Has PDUFA DateFor Tecentriq Drug

Financial news for MRK dated on 2016-10-19: Merck Announces Pivotal Phase 3 Study of Letemovir Met Primary Endpoint

Financial news for MRK dated on 2016-10-13: 7 Biggest Price Target Changes For Thursday

Financial news for MRK dated on 2016-10-13: Benzinga's Top Upgrades

Financial news for MRK dated on 2016-10-13: A Peek Into The Markets: U.S. Stock Futures Tumble Ahead Of Jobless Claims Report

Financial news for MRK dated on 2016-10-13: Bank of America Upgrades Merck & Company to Buy, Raises Price Target to \$70.00

Financial news for MRK dated on 2016-10-11: Technical Alert: Merck Surrenders Monday's Gains

Financial news for MRK dated on 2016-10-11: Aetna and Merck Sign a Unique Value-Based Contract for Januvia and Janumet

Financial news for MRK dated on 2016-10-10: The ESMO Conference Proves Its Ability To Move Stocks

Financial news for MRK dated on 2016-10-10: Technical Alert: Merck Reaches Highest Level Since December 2001

Financial news for MRK dated on 2016-10-10: Bristol-Myers' Opdivo Vs. Merck's Keytruda In Front-Line Lung Treatment

Financial news for MRK dated on 2016-10-10: SunTrust Cuts Target On Bristol-Myers As Opdivo Estimates Revised Lower

Financial news for MRK dated on 2016-10-09: New Data on the Combination of Lilly's ALIMTA and Merck's KEYTRUDA Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic NSCLC Presented at ESMO 2016

Financial news for MRK dated on 2016-10-09: Merck Announces Two Major Studies to Be Presented at ESMO 2016 Demonstrate Potential of KEYTRUDA for the First-Line Treatment of Metastatic NSCLC in a Broad Range of Patients

Financial news for MRK dated on 2016-10-09: Merck Announces KEYTRUDA Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic NSCLC in Data to Be Presented at ESMO 2016

Financial news for MRK dated on 2016-10-09: Merck Presents Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA in Patients with Advanced Melanoma from KEYNOTE-002 at ESMO 2016

Financial news for MRK dated on 2016-10-09: Merck Announces New KEYTRUDA Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients

Financial news for MRK dated on 2016-10-08: Exclusive: Interview With DelMar Pharmaceutical CEO Jeffrey Bacha

Financial news for MRK dated on 2016-10-07: Merck Animal Health Announces USDA Approval of Innovative Canine Flu Bivalent Vaccine

Financial news for MRK dated on 2016-09-28: Merck Shares Indicated Up 1+% Premarket; Shares Could Be Higher Amid Positive Trial News from Incyte; Incyte Shares Up ~5% in Pre-Open

Financial news for MRK dated on 2016-09-26: vTv Therapeutics Shares Initiated With Buy Rating, \$13 Target

Financial news for MRK dated on 2016-09-21: The Market In 5 Minutes: We're Waiting For You, Mrs. Yellen

Financial news for MRK dated on 2016-09-21: Clovis Upgraded At Credit Suisse Following Acquisition Rumor

Financial news for MRK dated on 2016-09-20: Some Traders Attributing After-Hours Upside in Clovis to Janney Capital Analyst Comment During Bloomberg Interview There Are 'Many Suitors' for Co, Including Lilly, Roche, Merck

Financial news for MRK dated on 2016-09-20: New 5-Year Contraceptive Coming To U.S. Adds To Long-Acting Reversible Contraceptives List

Financial news for MRK dated on 2016-09-20: Citi Research Reevaluates Bristol-Myers, Lowers Price Target

Financial news for MRK dated on 2016-09-15: Seattle Genetics No Longer On Goldman Sachs' Sell List

Financial news for MRK dated on 2016-09-15: UPDATE: Pfizer, Merck's VERTIS SITA2 Also Achieved 4 Secondary Endpoints

Financial news for MRK dated on 2016-09-15: Merck, Pfizer Reports Ertugliflozin Met Primary Endpoint of A1C Reduction

Financial news for MRK dated on 2016-09-13: Presidential Merck: 'Jimmy Carter' Oncology Drug Expected To Dominate, Hep C Drug Approved Across EU

Financial news for MRK dated on 2016-09-09: Barclays Raises Target On Merck, Lowers Target On Bristol-Myers

Financial news for MRK dated on 2016-09-08: Another Election Year View On Healthcare ETFs

Financial news for MRK dated on 2016-09-07: Technical Alert: Merck Range-Bound For Third Day In A Row

Financial news for MRK dated on 2016-09-07: UPDATE: Merck To Continue Distributing Product On Behalf of Aralez For 12 Months, Considerations Also Include Sales-Based Milestones And Graduated Royalties

Financial news for MRK dated on 2016-09-07: Merck Gets FDA Priority Review and Breakthrough Therapy Designation for KEYTRUDA

Financial news for MRK dated on 2016-09-02: Merck Remains Stable Following Discontinuation Of Odanacatib Development Program

Financial news for MRK dated on 2016-09-02: Merck Provides Update on Odanacatib Development Program, Will Discontinue Development and Not Seek Regulatory Approval For Its Use

Financial news for MRK dated on 2016-08-31: Shares Of Celgene Spiking Higher, Hearing Unconfirmed Rumors That Big Restructuring Under Way & Speculation Is That They Are Prepping Deal With Merck

Financial news for MRK dated on 2016-08-24: The 2015 Flash Crash Was One Year Ago Today. Why Did It Happen?

Financial news for MRK dated on 2016-08-24: Write A Prescription For More Pharma M&A With This ETF

Financial news for MRK dated on 2016-08-17: UPDATE: Reuters Says Merck, Sanofi, Pfizer, Gilead, Celgene Have Each Submitted Expressions of Interest for Medivation

Financial news for MRK dated on 2016-08-16: Mirror Image: Bristol-Myers Loss Is Merck's Potential Gain

Financial news for MRK dated on 2016-08-11: Biogen Cancels Out Of Citigroup Conference Following Weeks Of Rumors

Financial news for MRK dated on 2016-08-10: Argus: Bristol-Myers Selloff Is Overdone, Reiterating \$90 Target

Financial news for MRK dated on 2016-08-09: Bernstein Says Merck's Lung Cancer Drug Will Lead The Market Near-Term, But Long-Term Market Share Harder To Predict

Financial news for MRK dated on 2016-08-08: Results from Merck's Phase 3 Study Of Zepatier Hep C Treatment Published In Annals Of Internal Medicine

Financial news for MRK dated on 2016-08-08: Technical Alert: Merck Surrenders Some Of Friday's Huge Gain

Financial news for MRK dated on 2016-08-08: After Roaring To New Highs on Jobs Data, Market Faces Retail Sales, Job Openings

Financial news for MRK dated on 2016-08-08: CheckMate Miss Is A Game Changer; Credit Suisse Downgrades Bristol, Upgrades Merck

Financial news for MRK dated on 2016-08-08: 8 Biggest Price Target Changes For Monday

Financial news for MRK dated on 2016-08-08: The Market in 5 Minutes: Can The Momentum Continue?

Financial news for MRK dated on 2016-08-08: Benzinga's Top Upgrades

Financial news for MRK dated on 2016-08-08: Citi Doesn't See Merck's Lung Cancer Success Lasting Long

Financial news for MRK dated on 2016-08-08: FDA Approves Merck's KEYTRUDA(r) (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

Financial news for MRK dated on 2016-08-08: Credit Suisse Upgrades Merck & Co to Outperform, Raises PT to \$73.00

Financial news for MRK dated on 2016-08-08: Watch These 5 Huge Put Purchases In Monday Trade

Financial news for MRK dated on 2016-08-06: BMO Capital Upgrades Merck To Outperform, Bullish On Co

Financial news for MRK dated on 2016-08-05: BMO Capital Upgrades Merck & Co to Outperform, Raises PT to \$72.00

Financial news for MRK dated on 2016-08-05: 25 Biggest Mid-Day Gainers For Friday

Financial news for MRK dated on 2016-08-05: Benzinga's Volume Movers

Financial news for MRK dated on 2016-08-05: Stocks Hitting 52-Week Highs

Financial news for MRK dated on 2016-08-05: Option Alert: MRK Oct16 60.0 Puts Sweep: 594 @ ASK \$1.71: 605 traded vs 1589 OI: \$61.04 Ref

Financial news for MRK dated on 2016-08-05: Bristol's Opdivo Misses Endpoint In Late-Stage Trial; Merck Rallies Sharply Amid Keytruda Potential

Financial news for MRK dated on 2016-08-05: The Market In 5 Minutes: Blowout Jobs Report Pushes Markets Higher

Financial news for MRK dated on 2016-08-05: UPDATE: Merck's KEYTRUDA is Viewed as Strongest Competitor to Bristol's Opdivo

Financial news for MRK dated on 2016-08-05: Merck Spike in Price Likely Attributed to Negative Results on Bristol-Myers' Opdivo

Financial news for MRK dated on 2016-08-05: Merck Shares Spiking ~\$6 Over Last Min

Financial news for MRK dated on 2016-08-05: Merck Reports Acceptance of FDA Filing for NDA for MK-1293

Financial news for MRK dated on 2016-08-04: Celgene Shares Spiking, Traders Circulating Takeover Chatter By Merck

Financial news for MRK dated on 2016-08-03: Benzinga's M&A Chatter for Wednesday August 3, 2016

Financial news for MRK dated on 2016-08-03: Terms Of The Trade: Dogs Of The Dow Investing Strategy

Financial news for MRK dated on 2016-08-03: Biogen Shares Down \$3 Over Last Min Following Reuters Report Co. Not Soliciting Offers; Allergan, Merck Shares Relatively Quiet, Not Impacted

Financial news for MRK dated on 2016-08-03: The Market In 5 Minutes: Downtrend Continues

Financial news for MRK dated on 2016-08-03: Why Is Biogen Attractive? Credit Suisse Sees 12-24% Upside Takeout Potential

Financial news for MRK dated on 2016-08-02: Benzinga's M&A Chatter for Tuesday August 2, 2016

Financial news for MRK dated on 2016-08-02: 6 Stocks Moving In Tuesday's After-Hours Session

Financial news for MRK dated on 2016-08-02: Merck Reports KEYTRUDA Has Received EC Approval for Patients with NSCLC Whose Tumors Express PD-L1

Financial news for MRK dated on 2016-08-02: Wall Street Journal Reports Biogen Drawing Interest From Merck, Allergan On Possibility Of Huge Deal

Financial news for MRK dated on 2016-08-01: Merck's Q2 Good, But Not Good Enough, Says BMO

Financial news for MRK dated on 2016-07-29: Weak GDP Data, Plunging Oil Renew Questions About Strength Of Economy

Financial news for MRK dated on 2016-07-29: A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of GDP Report

Financial news for MRK dated on 2016-07-29: Investors Greet Merck Q2 Results As Key Launches Help Beat

Financial news for MRK dated on 2016-07-29: Merck Reports EC Granted Marketing Authorization for Co.'s ZEPATIER for Treatment of Chronic Hep C Infection

Financial news for MRK dated on 2016-07-29: Merck Narrows, Raises FY16 Adj. EPS Outlook from \$3.60-\$3.75 to \$3.67-\$3.77 vs \$3.72 Est., Sales from \$38.7B-\$40.2B to \$39.1B-\$40.1B vs \$39.5B Est.

Financial news for MRK dated on 2016-07-29: Merck Reports Q2 Adj. EPS \$0.93 vs \$0.91 Est., Sales \$9.844B vs \$9.78B Est.

Financial news for MRK dated on 2016-07-29: 12 Stocks You Should Be Watching Today

Financial news for MRK dated on 2016-07-29: Earnings Scheduled For July 29, 2016

Financial news for MRK dated on 2016-07-27: Can Keytruda Deliver Earnings Growth For Merck?

Financial news for MRK dated on 2016-07-25: Merck Gets Breakthrough Therapy Status From FDA And PRIME Status From EMA For Investigational Ebola Zaire Vaccine

Financial news for MRK dated on 2016-07-25: NewLink Genetics Announces Merck Receives Breakthrough Therapy Designation from FDA, PRIME Status from EMA for Investigational Ebola Zaire Vaccine

Financial news for MRK dated on 2016-07-25: Merck Reports Received Breakthrough Therapy Designation from FDA, PRIME Status from EMA for V920

Financial news for MRK dated on 2016-07-25: Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine

Financial news for MRK dated on 2016-07-22: Merck Presents Data On Its Investigational Once-Daily Formulation Of ISENTRESS

Financial news for MRK dated on 2016-07-22: Merck Reports Investigational Once-Daily Formulation of ISENTRESS Showed Non-Inferior Efficacy, Safety to Regimen Containing Approved Twice-Daily Formulation

Financial news for MRK dated on 2016-07-21: Merck Animal Health Receives FDA Approval of BRAVECTO For Cats And Dogs, Topical Treatment for Fleas and Ticks Effective for up to 12 Weeks

Financial news for MRK dated on 2016-07-21: Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab

Financial news for MRK dated on 2016-07-21: The Market In 5 Minutes: Jam-Packed Day Of Earnings And Economic Data

Financial news for MRK dated on 2016-07-20: Benzinga's M&A Chatter for Wednesday July 20, 2016

Financial news for MRK dated on 2016-07-18: BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations

Financial news for MRK dated on 2016-07-18: Benzinga's Top Downgrades

Financial news for MRK dated on 2016-07-18: BMO Capital Downgrades Merck & Co to Market Perform

Financial news for MRK dated on 2016-07-06: Merck, Pfizer Report Initiation of Phase III Trial to Evaluate Avelumab as First-Line Treatment for Ovarian Cancer

Financial news for MRK dated on 2016-07-01: Merck Animal Health Announces Agreement to Acquire Controlling Interest In Brazilian Animal Health Company Vallee S.A., Will Acquire 93% Of Shares For \$400M

Financial news for MRK dated on 2016-06-30: Merck And Premier Join Hands To Prevent Fractures For Osteoporosis Patients

Financial news for MRK dated on 2016-06-30: Merck, Premier Report Collaboration to Prevent Fractures for Osteoporosis Patients

Financial news for MRK dated on 2016-06-29: Merck, Moderna Therapeutics Report Strategic Collaboration Related to Advancement of Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA

Financial news for MRK dated on 2016-06-27: Merck Gets CHMP Positive Opinion For KEYTRUDA For Advanced Non-Small Cell Lung Cancer Treatment

Financial news for MRK dated on 2016-06-27: Merck Receives CHMP Positive Opinion for KEYTRUDA for the Treatment of Advanced Non-Small Cell Lung Cancer

Financial news for MRK dated on 2016-06-20: UPDATE: Merck Says Pivotal Phase 3 Studies for Relebactam Ongoing in Treatment of Serious Bacterial Infections

Financial news for MRK dated on 2016-06-20: Merck Offers Results of Phase 2 Study for Relebactam in Combo with Imipenem/Cilastatin

Financial news for MRK dated on 2016-06-16: Cramer Talks About Merck's 'Fabulous News' And Why The Market Can't Rally

Financial news for MRK dated on 2016-06-16: Merck Rallies Of Drug Trial Results

Financial news for MRK dated on 2016-06-16: Merck Announces Keytruda Met Primary and Secondary Endpoint

Financial news for MRK dated on 2016-06-14: Jefferies Shares Pharma Stock Catalyst Outlook

Financial news for MRK dated on 2016-06-13: Merck Reports MK-1293 Met Primary Endpoint in Two Phase 3 Studies

Financial news for MRK dated on 2016-06-13: Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators

Financial news for MRK dated on 2016-06-12: Merck, Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes at the American Diabetes Association's 76th Scientific Sessions

Financial news for MRK dated on 2016-06-09: UPDATE: Merck To Pay \$500M Cash Upfront, Afferent Holders Eligible For Addition \$750M Tied To 'clinical development and commercial milestones for multiple indications and candidates, including AF-219'

Financial news for MRK dated on 2016-06-09: Merck To Acquire Afferent Pharmaceuticals

Financial news for MRK dated on 2016-06-09: Hearing FDA Panel Has Said Merck Has Provided Substantial Evidence of Safety, Effectiveness of Bezlotoxumab

Financial news for MRK dated on 2016-06-09: BZ NOTE: Relypsa Shares Still Up \$0.20-\$0.40 from Where Stock Was Trading Prior to Apparent Rumor Manipulation Ahead of Negative StreetSweeper Report (See Body of This Headline for More)

Financial news for MRK dated on 2016-06-09: Hearing Merck May Be Interested In RLYP, Unconfirmed Takeover Chatter

Financial news for MRK dated on 2016-06-09: Agenus Reports Lead Product Candidate Selection in its Collab with Merck, Received First Milestone Payment of \$2M

Financial news for MRK dated on 2016-06-07: Merck Says Ruling Reversal in Gilead Case 'Doesn't Reflect the Facts,' Co. Will Appeal Ruling Overturn

Financial news for MRK dated on 2016-06-07: Goldman Confident In Merck's Keytruda

Financial news for MRK dated on 2016-06-07: FDA Staff Has Said Overall Clinical Results from Merck's Bezlotoxumab Trial Could Negatively Impact Cure Rate of Initial Episode of Infection with C. Difficile

Financial news for MRK dated on 2016-06-06: US Judge Rules Gilead Won't have to Pay \$200M Jury Verdict to Merck in Hepatitis C Patent Dispute -Reuters

Financial news for MRK dated on 2016-06-06: 4 Key Takeaways From ASCO

Financial news for MRK dated on 2016-06-06: Merck, Pfizer Offers Results from Pivotal Avelumab Study

Financial news for MRK dated on 2016-06-06: Merck Reports Response Rates from KEYNOTE-055 Show Nearly One in Five Patients Respond with KEYTRUDA

Financial news for MRK dated on 2016-06-05: Merck Announces New Data from Phase 2 Study Evaluating KEYTRUDA for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers at #ASCO16

Financial news for MRK dated on 2016-06-05: Lilly Announces Encouraging Data of Early-Phase Immuno-Oncology Studies of ALIMTA and CYRAMZA with Merck's KEYTRUDA in NSCLC Presented at #ASCO16

Financial news for MRK dated on 2016-06-05: Merck Announces New Data for KEYTRUDA in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at #ASCO16

Financial news for MRK dated on 2016-06-04: New Data Evaluating KEYTRUDA in Combination with Chemotherapy for First-Line Treatment of NSCLC Demonstrate Response Rates Ranging of 48%71%; Data to be Presented at #ASCO16

Financial news for MRK dated on 2016-06-04: New KEYTRUDA Data from KEYNOTE-010 and KEYNOTE-001 in Advanced NSCLC, Including Survival Data, to be Presented at #ASCO16

Financial news for MRK dated on 2016-06-03: Ouch! Jobs Report Miss Sends Rate Hike Odds Down, Raises Questions

Financial news for MRK dated on 2016-05-27: Merck Gets Favorable Opinion From CHMP For Its ZEPATIER

Financial news for MRK dated on 2016-05-27: Merck Receives Positive CHMP Opinion for ZEPATIER in the European Union

Financial news for MRK dated on 2016-05-26: Celgene Rallies Of Possible Interest From Merck

Financial news for MRK dated on 2016-05-26: Celgene Shares Spiking, Traders Passing Vague Comments Of Possible Interest From Merck

Financial news for MRK dated on 2016-05-23: Chardan Initiates Asterias Biotherapeutics At Buy On Potential Cell Therapy Competitiveness

Financial news for MRK dated on 2016-05-19: JPMorgan's Take On Big Pharma's New ASCO Abstracts

Financial news for MRK dated on 2016-05-16: Merck To Present New And Updated Data On KEYTRUDA

Financial news for MRK dated on 2016-05-12: Berenberg Unimpressed With Pfizer, Initiates Coverage At Hold

Financial news for MRK dated on 2016-05-12: Merck To Present Final Stage Data On Investigational Medicines Ertugliflozin And MK-1293

Financial news for MRK dated on 2016-05-06: What's M&A Like In The Biotech Sector Right Now?

Financial news for MRK dated on 2016-05-05: Mid-Afternoon Market Update: U.S. Stocks Turn Lower; Zynga Shares Rise Following Earnings Beat

Financial news for MRK dated on 2016-05-05: Merck Lower After Mixed Q1 Report

Financial news for MRK dated on 2016-05-05: Mid-Day Market Update: Fitbit Slides On Weak Outlook; Atlas Air Worldwide Shares Spike Higher

Financial news for MRK dated on 2016-05-05: Mid-Morning Market Update: Markets Edge Higher; Merck Profit Beats Views

Financial news for MRK dated on 2016-05-05: Merck Launch of Zepatier in EU May be Delayed Until Late 2016, Early 2017 as Regulator Inspects Record-Keeping of Third Party Manufacturer -Reuters

Financial news for MRK dated on 2016-05-05: Merck's Q1 Adjusted Profit beats, But Revenue Miss, Narrows Adjusted EPS FY16 Forecast

Financial news for MRK dated on 2016-05-05: Merck Sees FY 2016 EPS \$3.65 to \$3.77 vs \$3.71 est

Financial news for MRK dated on 2016-05-05: Merck Q1 EPS \$0.89 vs \$0.85 est, Revenue \$9.3B vs \$9.5B est

Financial news for MRK dated on 2016-05-05: 12 Stocks To Watch For May 5, 2016

Financial news for MRK dated on 2016-05-05: Earnings Scheduled For May 5, 2016

Financial news for MRK dated on 2016-05-03: TheStreet's Adam Feuerstein Tweets '\$MRK \$BMY are not working with \$NWBO on cancer immunotherapy combination clinical trials, per their respective spokespersons.'

Financial news for MRK dated on 2016-05-02: Earnings: Drug Makers Merck And Pfizer Report Q1 Results

Financial news for MRK dated on 2016-05-02: The Market In 5 Minutes: May, She Will Stay

Financial news for MRK dated on 2016-05-01: Merck And Pfizer Earnings: Will They Beat Expectations Again?

Financial news for MRK dated on 2016-04-25: Pharma Names Under Pressure Amid Perrigo Warning

Financial news for MRK dated on 2016-04-19: Merck Animal Health To Acquire Rights To

Whisper Veterinary Stethoscope System, Terms Not Disclosed

Financial news for MRK dated on 2016-04-19: Merck Gives Statement On Blueprint Project Findings AT AACR, Encouraged By Findings And Eager To Support Greater Biomarker Testing Use

Financial news for MRK dated on 2016-04-18: Merck Reports Received Breakthrough Therapy Designation from FDA for KEYTRUDA in cHL

Financial news for MRK dated on 2016-04-16: Merck Announces Results From Phase 3 Studies of ZEPATIER in Chronic Hep C Patient Populations at ILC

Financial news for MRK dated on 2016-04-15: Jefferies Maintains Hold on Merck & Co, Raises PT to \$54.00

Financial news for MRK dated on 2016-04-14: After-Hours Recap: Big Banks, Liquidity Services's DoD Deal, Haemonetics' CFO & More

Financial news for MRK dated on 2016-04-14: Merck Kgaa Says Filed Answer in Response to Trademark Right Violation Claims Made By Merck

Financial news for MRK dated on 2016-04-14: Merck's ZEPATIER Showed Superiority on Efficacy and Safety Endpoints vs Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial

Financial news for MRK dated on 2016-04-13: Merck Says FDA Accepts Its sBLA For Keytruda And Grants Priority Review

Financial news for MRK dated on 2016-04-13: FDA Accepts Supplemental Biologics License Application for Merck's KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer, and Grants Priority Review

Financial news for MRK dated on 2016-04-13: Merck Announces License Application for Investigational House Dust Mite SLIT-tablet Accepted for Review by FDA

Financial news for MRK dated on 2016-04-12: Baird: Gilead Set For Q1 EPS Miss, But Hep C Trends Still Good Long Term

Financial news for MRK dated on 2016-04-12: Notable Imbalances Before Tuesday's Open Led By Under Armour, Boeing, Caterpillar

Financial news for MRK dated on 2016-04-07: How One Analyst Is Playing The Biotech Rebound This Week

Financial news for MRK dated on 2016-04-07: BZ NOTE: Relypsa Has Been Mentioned In Rumors Over Past 7 Months In Possible M&A Talk With Sanofi, Merck, Astra Zeneca

Financial news for MRK dated on 2016-04-06: PPH May Be Home To Hedge Fund Hotels, But This ETF Can Endure

Financial news for MRK dated on 2016-04-06: SocGen Picks New Favorites In Big Pharma

Financial news for MRK dated on 2016-04-06: Societe Generale Initiates Coverage on Merck & Co at Buy

Financial news for MRK dated on 2016-04-06: Merck Will Present New KEYTRUDA Data At AACR Meeting Apr. 16-20th

Financial news for MRK dated on 2016-04-06: WHO Says Number of Adults with Diabetes has Quadrupled Since 1980 -AFP

Financial news for MRK dated on 2016-04-05: Advaxis, Merck Combination Trial Evaluating ADXS-PSA Launches Third Dose-Escalation Cohort

Financial news for MRK dated on 2016-04-04: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for MRK dated on 2016-04-04: This Data Signals The End For Merck's Anacetrapib

Financial news for MRK dated on 2016-04-04: Make A House Call With A Familiar Healthcare ETF

Financial news for MRK dated on 2016-03-28: Biopharma Names LLY, PFE, MRK, And More Popping Higher Following Reports China FDA To Investigate Improper Vaccine Trading

Financial news for MRK dated on 2016-03-28: Data Shows Gilead's HCV Franchise Is Surviving New Competition

Financial news for MRK dated on 2016-03-24: Patent Expert: It's Not Over For Gilead, Still Has Strong Defense Against Merck

Financial news for MRK dated on 2016-03-23: Jury Rules Merck Patents Valid...Bad For Gilead?

Financial news for MRK dated on 2016-03-23: Gilead -2.5% Premarket Following Verdict Tuesday Validating Merck's Hep C Patents

Financial news for MRK dated on 2016-03-17: Organovo Is A Company 3D Printing Human Tissue And Its CEO Is Excited About Creating Livers

Financial news for MRK dated on 2016-03-12: Agenus Shares Spike Higher Following Mid-Day Upgrade To Buy From Maxim

Financial news for MRK dated on 2016-03-10: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for MRK dated on 2016-03-08: Jimmy Carter Boosts Social Media Buzz For Merck's Blockbuster Drug

Financial news for MRK dated on 2016-03-08: Sanofi Pasteur, Merck Report Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies

Financial news for MRK dated on 2016-03-07: Gilead Vs. Merck: What To Know

Financial news for MRK dated on 2016-03-07: FDA Accepts Supplemental Biologics License Application For Keytruda

Financial news for MRK dated on 2016-03-03: UPDATE: Merck, Pfizer, and Verastem Combination Trial Of Avelumab and VS-6063 Expected To Begin In 2nd Half 2016

Financial news for MRK dated on 2016-03-03: Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Report Combination Trial of Avelumab and VS-6063 in Ovarian Cancer

Financial news for MRK dated on 2016-02-29: Watch Pharma Names Following FDA Issuance Of New Mandatory Clinical Study For Bayer's 'Essure', Requires Product Labeling, Including Box Warnings And Patient Decision Checklist

Financial news for MRK dated on 2016-02-29: 3 Mega Biotechs Leerink Loves

Financial news for MRK dated on 2016-02-24: AureoGen Announces Licensing Agreement with Merck

Financial news for MRK dated on 2016-02-23: Will Merck Encroach On Gilead's Harvoni Territory?

Financial news for MRK dated on 2016-02-23: 8,383 Patients Contacted to Arrange Blood Test Following Possible Exposure to ex-NHS Worker with Hepatitis C -Sky News

Financial news for MRK dated on 2016-02-22: Merck Reports Investigational One-Daily Formulation of ISENTRESS Met Primary, Secondary Endpoints in Pivotal Phase 3 Trial

Financial news for MRK dated on 2016-02-10: ALK Announces Merck Submits BLA to FDA for Investigational House Dust Mite SLIT-tablet

Financial news for MRK dated on 2016-02-08: How To Invest In An Aging World With The 'Live Long & Prosper' ETF

Financial news for MRK dated on 2016-02-05: A Checkup On A Big Healthcare ETF

Financial news for MRK dated on 2016-02-04: How To Build A Defensive Portfolio

Financial news for MRK dated on 2016-02-04: 25 Companies That Could Still Buy Back Mountains Of Stock

Financial news for MRK dated on 2016-02-04: ImmunoGen, Merck Partner For Clinical Evaluation Of Mirvetuximab Soravtansine With Keytruda Combination For Ovarian Cancer Treatment

Financial news for MRK dated on 2016-02-03: Merck & Co., Inc. Falters After Q4 Report

Financial news for MRK dated on 2016-02-03: Joe McCann: Here's How To Play Biotech Market In Earnings Season

Financial news for MRK dated on 2016-02-03: Shares Of Merck Dip Lower Following Q4 Print

Financial news for MRK dated on 2016-02-03: Merck Sees FY16 EPS \$3.60-\$3.75 vs. Est. \$3.72, Rev. \$38.7-\$40.2B vs. Est. \$40.25B

Financial news for MRK dated on 2016-02-03: Merck Reports Q4 EPS \$0.93 vs. Est. \$0.91, Rev. \$10.215B vs. Est. \$10.35B

Financial news for MRK dated on 2016-02-03: Merck Sees FY 2016 EPS \$3.60 to \$3.75 vs \$3.72 est

Financial news for MRK dated on 2016-02-03: Merck Sees FY 2016 Revenue \$38.7B vs \$40.2B est

Financial news for MRK dated on 2016-02-03: Merck Q4 EPS \$0.93 vs \$0.91 est, Revenue \$10.2B vs \$10.4B est

Financial news for MRK dated on 2016-02-03: Keep an Eye on These 10 Stocks for February 3, 2016

Financial news for MRK dated on 2016-02-03: Earnings Scheduled For February 3, 2016

Financial news for MRK dated on 2016-02-02: Merck, Sanofi Exploring Potential End To Joint Venture In Europe

Financial news for MRK dated on 2016-02-02: Sanofi, Merck Considering Ending JV to Sell Vaccines in Europe -Bloomberg

Financial news for MRK dated on 2016-02-01: Earnings: Pharma Tends to Top Street Estimate--Can PFE, MRK Repeat?

Financial news for MRK dated on 2016-02-01: Stock Marquee is Crowded in Week Ahead: Oil, Earnings, Labor Data

Financial news for MRK dated on 2016-01-31: Mixed Earnings Expectations For Merck And Pfizer

Financial news for MRK dated on 2016-01-29: Gilead Hits New 52-Week Low; Here Are Two Reasons Why

Financial news for MRK dated on 2016-01-29: Merck Confirms FDA Approval Of Hep C Drug At A Cost Of \$54,600 Per Patient

Financial news for MRK dated on 2016-01-29: From Conf Call: Abbvie Says Merck's New Hep C Drug Will Crimp Viekira Pak Sales

Financial news for MRK dated on 2016-01-28: Merck Receives FDA Approval of Hep C Drug ZEPATIER; To Cost \$54,600/Patient for 12-Week Course

Financial news for MRK dated on 2016-01-28: Adam Feurestein Reminds Twitter Followers 'Today Is Merck's HepC elbasvir/grazoprevir PDUFA'

Financial news for MRK dated on 2016-01-28: Adam Feuerstein @adamfeuerstein Tweet: Reminder: Today is \$MRK HepC elbasvir/grazoprevir PDUFA. Co. spox knows first and most important post-approval question is: What price?

Financial news for MRK dated on 2016-01-28: Fast Money Picks For January 28

Financial news for MRK dated on 2016-01-28: Abbott to Sell ALK's House Dust Mite Sublingual Allergy Immunotherapy Tablet in SE Asia

Financial news for MRK dated on 2016-01-27: Bank of America Downgrades Merck & Co to Neutral

Financial news for MRK dated on 2016-01-27: Merck Reports FDA Acceptance of Biologics License Application for Bezlotoxumab

Financial news for MRK dated on 2016-01-27: Merck Reports FDA Acceptance of BLA for Bezlotoxumab

Financial news for MRK dated on 2016-01-27: ACARIZAX Receives Marketing Authorization in France

Financial news for MRK dated on 2016-01-25: US Big Pharma: What To Watch For In Q4 Results

Financial news for MRK dated on 2016-01-25: Affirmed to Collaborate with Merck to Evaluate AFM13 in Combination with KEYTRUDA for Patients with Hodgkin Lymphoma

Financial news for MRK dated on 2016-01-20: Sierra Leone Confirms Second New Ebola Case in Less than a Week -Reuters

Financial news for MRK dated on 2016-01-20: Credit Suisse Sets Outperform Rating, \$125 Target On Gilead Story

Financial news for MRK dated on 2016-01-20: Global Vaccine's Alliance Signs \$5M Advance Order for Merck's Ebola Vaccine -Reuters

Financial news for MRK dated on 2016-01-15: Write A Prescription For This Healthcare ETF

Financial news for MRK dated on 2016-01-15: Merck Announces Resolution of Vioxx Class Action Lawsuit, Cash Payment ~\$680M

Financial news for MRK dated on 2016-01-15: UPDATE: Sierra Leone Ebola Victim Said to have Exposed 27 to Disease; Woman was Living in House With 22 People When She Became Ill -Reuters

Financial news for MRK dated on 2016-01-15: UPDATE: Sierra Leone Health Ministry Confirms Death from Ebola -Reuters

Financial news for MRK dated on 2016-01-14: Sierra Leone Health Ministry Investigating Suspected Death from Ebola -Reuters

Financial news for MRK dated on 2016-01-13: WHO to Announce End of Ebola Outbreak on Thursday -AFP

Financial news for MRK dated on 2016-01-12: Fast Money Traders Share Their Biotech Picks

Financial news for MRK dated on 2016-01-11: Merck Acquires IOmet Pharma, Terms Not Disclosed

Financial news for MRK dated on 2016-01-06: Why This Codexis Analyst Is Confident Stock Is Worth \$6

Financial news for MRK dated on 2016-01-06: Washington University Initiates Clinical Study of Verastem's VS-6063 in Combination with Merck's Pembrolizumab and Gemcitabine in Pancreatic Cancer

Financial news for MRK dated on 2016-01-05: Watch Stocks of Small-, Mid-Cap Cos. with Experimental Drugs as AP Reporting Merck CEO Frazier at Goldman Healthcare Conference Said Co. 'Raring to Go' on M&A Deals This Year

Financial news for MRK dated on 2016-01-05: ANI Pharma Reports Closing of Deal to Purchase Two NDAs from Merck for \$75M

Financial news for MRK dated on 2016-01-04: Pfizer, Merck KGaA Report Syndax to Collab to Investigate Safety, Tolerability, Prelim. Efficacy of Avelumab, Entinostat in Advanced Ovarian Cancer

Financial news for MRK dated on 2015-12-29: WHO Declares End of Ebola Virus Transmission in Republic of Guinea

Financial news for MRK dated on 2015-12-23: Peering Through The Fog To Find The Best Sectors Into Year End

Financial news for MRK dated on 2015-12-22: Merck KGaA, Pfizer Report Advancement of Clinical Development Program with Two Added Phase III Trials of Avelumab

Financial news for MRK dated on 2015-12-21: Merck CEO: Using Keytruda Could Extend Patient's Life By 13 Months On Average

Financial news for MRK dated on 2015-12-21: ALK Sells European Veterinary Business to Fidelio Capital; Terms Not Disclosed

Financial news for MRK dated on 2015-12-19: Credit Suisse Offers 2016 U.S. Large-Cap Pharma Outlook

Financial news for MRK dated on 2015-12-19: Merck's KEYTRUDA Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1

Financial news for MRK dated on 2015-12-18: Merck Reports FDA Approval of Expanded Indication for KEYTRUDA for Treatment of Patients with Advanced Melanoma

Financial news for MRK dated on 2015-12-18: Merck Reports EMA's CHMP Has Responded to MAA for elbasvir/grazoprevir (50mg/100mg), Application Will Now Be Reviewed on Standard Timetable

Financial news for MRK dated on 2015-12-18: Codexis +7.1% Premarket @\$4.50; , Co Announces Agreement Extension With Merck

Financial news for MRK dated on 2015-12-15: UPDATE: Merck Says Expanded Age Indication for GARDASIL 9 Includes 16-26 Age Range

Financial news for MRK dated on 2015-12-15: Merck Announces FDA Approval for Expanded Age Indication for GARDASIL 9 in Males

Financial news for MRK dated on 2015-12-15: FDA Approves Bridion To Reverse Effects Of Neuromuscular Blocking Drugs Used In Surgery

Financial news for MRK dated on 2015-12-15: Fast Money Picks For December 15

Financial news for MRK dated on 2015-12-14: Hearing FDA Panel Has Voted IMPROVE-IT Data for Merck's Zetia to Statin Therapy Does Not Support Claim of Reduced Risk of CV Events

Financial news for MRK dated on 2015-12-12: Major Pharma Group Outlook In 2016: Fundamentals To Outweigh Political Headwinds

Financial news for MRK dated on 2015-12-10: 9 Healthcare Picks For 2016

Financial news for MRK dated on 2015-12-10: UPDATE: Merck Says Biothera Research Shows Imprime PGG Activates Key Immune Responses

Financial news for MRK dated on 2015-12-10: Biothera Announces Clinical Study to Evaluate Combination Therapy of Imprime PGG

Financial news for MRK dated on 2015-12-10: Eli Lilly and Merck Announces Expansion of Immuno Oncology Collaboration

Financial news for MRK dated on 2015-12-07: Merck Reports Samsung Bioepis Receives Approval of RENFLEXIS, a Biosimilar of Remicade, in Korea

Financial news for MRK dated on 2015-12-07: Must Watch Stocks for Today

Financial news for MRK dated on 2015-12-06: Benzinga's Weekend M&A Chatter

Financial news for MRK dated on 2015-12-04: Merck Spokesperson Declines Comment on Speculation Related to Relypsa

Financial news for MRK dated on 2015-12-04: EXCLUSIVE: Relypsa Being Evaluated By 3-4 Potential Acquirers; Sanofi Seen As 'Natural Buyer'

Financial news for MRK dated on 2015-12-04: EXCLUSIVE: Wedbush's Liana Moussatos Tells Benzinga Sanofi 'is a natural buyer of Relypsa'

Financial news for MRK dated on 2015-12-04: EXCLUSIVE: Source Tells Benzinga Merck Is Not Involved With Relypsa Bid; Calls To Merck Were Not Immediately Returned

Financial news for MRK dated on 2015-12-04: Hearing Unconfirmed Market Chatter of Potential Merck Bid for Relypsa

Financial news for MRK dated on 2015-12-04: Amgen, Merck Report Cancer Immunotherapy Partnership For Patients With Non-Hodgkin Lymphoma

Financial news for MRK dated on 2015-12-01: Barclays' Biopharmaceuticals Blueprint For 2016

Financial news for MRK dated on 2015-12-01: Barclays On Merck: Too Much Underlying Value To Ignore

Financial news for MRK dated on 2015-12-01: Barclays Upgrades Merck & Co to Overweight, Raises PT to \$66.00

Financial news for MRK dated on 2015-11-30: Deere Announces Factory Workforce Adjustments, 220 Employees On Indefinite Leave Starting Feb 2016

Financial news for MRK dated on 2015-11-25: MITICURE for house Dust Mite Allergic Rhinitis Now Available in Japan

Financial news for MRK dated on 2015-11-24: Merck Increases Qtr. Dividend From \$0.45 To \$0.46/Share

Financial news for MRK dated on 2015-11-24: Benzinga's Top Initiations

Financial news for MRK dated on 2015-11-24: Berenberg Initiates Coverage on Merck & Co at Buy

Financial news for MRK dated on 2015-11-24: 15-Year Old Boy is First Ebola Fatality in Liberia Since Country was Declared Ebola Free in September -Reuters

Financial news for MRK dated on 2015-11-22: Three New Ebola Cases Reported in Liberia; 153 Persons Under Observation -Reuters

Financial news for MRK dated on 2015-11-21: Merck Announces Initial Results for KEYTRUDA with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress

Financial news for MRK dated on 2015-11-20: Hearing Merck Planning to Expand Presence in African, Wants to More Than Double Sales in Africa by '20

Financial news for MRK dated on 2015-11-19: US Stock Futures Edge Higher Ahead Of Jobless Claims Report

Financial news for MRK dated on 2015-11-19: Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial

Financial news for MRK dated on 2015-11-18: Shares of Sigma Aldrich Halted, is Being Taken Out by Merck KGaA

Financial news for MRK dated on 2015-11-18: Merck, Darmstadt, Pfizer Report FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma

Financial news for MRK dated on 2015-11-16: Cambodia Reports Outbreak Of Highly Pathogenic H5N1 Bird Flu -Reuters

Financial news for MRK dated on 2015-11-15: Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting

Financial news for MRK dated on 2015-11-15: Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy

Financial news for MRK dated on 2015-11-13: Hearing Unconfirmed Market Chatter of Potential Merck Bid for Celgene

Financial news for MRK dated on 2015-11-13: Merck Issues Update on REVEAL Outcomes Sutdy

Financial news for MRK dated on 2015-11-12: Merck Issues Statement Regarding CUBICIN Patent Litigation; Says Reviewing Decision, Considering Next Steps

Financial news for MRK dated on 2015-11-11: Patient in Brazil Being Tested for Ebola; 46 Year Old Man Came from Guniea -Reuters

Financial news for MRK dated on 2015-11-09: WHO Declares Sierra Leone Ebola-Free

Financial news for MRK dated on 2015-11-06: UPDATE: Merck Says 'We believe that BRIDION has the potential to offer anesthesia professionals an important new option to reverse neuromuscular blockade in the surgical setting'

Financial news for MRK dated on 2015-11-06: Merck Issues Statement on FDA Panel Meeting for BRIDION

Financial news for MRK dated on 2015-11-06: FDA Panel Votes 13-1 In Favor Of Merck Presenting Sufficient Data To Characterize Risk Of Hypersensitivity With Sugammadex -Reuters

Financial news for MRK dated on 2015-11-06: Are You Investing Like A Millennial Or A Baby Boomer?

Financial news for MRK dated on 2015-11-05: Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting

Financial news for MRK dated on 2015-11-04: Merck, Pfizer Report Initiation of Phase III First-Line Trial of Avelumab

Financial news for MRK dated on 2015-11-03: GSK, Merck to Study Immunotherapy Combination as Potential Cancer Treatment

Financial news for MRK dated on 2015-11-02: Merck Receives Breakthrough Therapy Designation from U.S.FDA for KEYTRUDA(R) (pembrolizumab) in Advanced Colorectal Cancer

Financial news for MRK dated on 2015-10-27: These Three Pharma Giants Just Crushed Earnings

Financial news for MRK dated on 2015-10-27: UPDATE: Merck Sees FY15 Sales \$39.2B-\$39.8B vs \$39.67B Est.

Financial news for MRK dated on 2015-10-27: Merck Sees FY EPS \$3.55 to \$3.60 vs \$3.51 est

Financial news for MRK dated on 2015-10-27: Merck Reports Q3 EPS \$0.96 vs. Est. \$0.92, Rev. \$10.073B vs. Est. \$10.08B

Financial news for MRK dated on 2015-10-27: Earnings Scheduled For October 27, 2015

Financial news for MRK dated on 2015-10-26: Earnings Boom This Week: Big Pharma, E-Commerce Giant BABA And More

Financial news for MRK dated on 2015-10-26: Fed Meeting A Mid-Week Bump In Flurry Of Earnings News

Financial news for MRK dated on 2015-10-26: Merck's KEYTRUDA Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1

Financial news for MRK dated on 2015-10-22: Merck Trading Higher Off Of Abbvie, Gilead FDA Comments, Up 3.62% On The Day At \$52.42/Share

Financial news for MRK dated on 2015-10-14: Biotech ETFs Get More Refined With Debut Of Cancer Immunotherapy Fund

Financial news for MRK dated on 2015-10-14: Nurse who Contracted Ebola in West Africa Now Critically Ill from Complications -BBC

Financial news for MRK dated on 2015-10-14: Tianjin CanSino Biotechnology to Mass Produce Ebola Vaccine -Xinhua

Financial news for MRK dated on 2015-10-13: Incyte, Merck Increase Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda as First-line Treatment for Advanced Melanoma

Financial news for MRK dated on 2015-10-13: Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda(r) (pembrolizumab) as First-line Treatment for Advanced Melanoma

Financial news for MRK dated on 2015-10-12: Watching Volatility In Other Big Pharma Names Amid Eli Lilly Halt

Financial news for MRK dated on 2015-10-09: WHO Says Nigerian Suspected of Dying from Ebola, Did Not have the Virus -Reuters

Financial news for MRK dated on 2015-10-09: KEYTRUDA(r) (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma

Financial news for MRK dated on 2015-10-08: Ten People Quarantined Due to Possible Ebola Cases in Nigeria's Calabar City

Financial news for MRK dated on 2015-10-08: Dynavax Reports Initiation of Immuno-Oncology Clinical Trial of SD-101 in Combo with Merck's KEYTRUDA

Financial news for MRK dated on 2015-10-07: Guinea, Liberia, Sierra Leone See No New Cases for Week to October 4 -Reuters

Financial news for MRK dated on 2015-10-07: Merck KGaA, Darmstadt, Germany, and Pfizer Announce Investigational Immunotherapy Avelumab Given FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma

Financial news for MRK dated on 2015-10-05: Agilent Company Dako, Announces FDA Approval of New Companion Diagnostic for Lung Cancer

Financial news for MRK dated on 2015-10-02: Merck PR Confirms FDA Approves KEYTRUDA for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy

Financial news for MRK dated on 2015-10-02: Bristol-Myers Spikes to High Following FDA Approval of Merck's Keytruda

Financial news for MRK dated on 2015-10-02: FDA Approves Merck's Keytruda For Advanced Non-Small Cell Lung Cancer

Financial news for MRK dated on 2015-10-01: Merck, DNATRIX Report Phase 2 Immuno-Oncology Partnership in Patients with Aggressive Form of Brain Cancer

Financial news for MRK dated on 2015-09-28: Roth Capital Upgrades ANI Pharmaceuticals To Buy On Valuation

Financial news for MRK dated on 2015-09-28: Merck, Syndax Pharma Announce First Patients Dosed in Phase 1b/2 Trial of Entinostat, KEYTRUDA

Financial news for MRK dated on 2015-09-28: Merck Reports Japan's PMDA Approved MARIZEV 25, 12.5mg Tablets

Financial news for MRK dated on 2015-09-27: Merck Announces New Data from KEYNOTE-028 Trial Evaluating KEYTRUDA Across Range of Cancer Types, Presented at 2015 ECC

Financial news for MRK dated on 2015-09-26: Merck Presents New Findings Showing Anti-Tumor Activity of KEYTRUDA in Patients with Advanced NPC

Financial news for MRK dated on 2015-09-25: Merck, Pfizer Reports FDA Orphan Drug Designation for Investigation Avelumab

Financial news for MRK dated on 2015-09-24: Merck and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab

Financial news for MRK dated on 2015-09-21: ANI Pharmaceuticals to Acquire Two NDAs from Merck for \$75M

Financial news for MRK dated on 2015-09-21: Data in Nine Difficult-to-Treat Cancers from Merck's KEYTRUDA Development Program to be Presented at European Cancer Congress 2015

Financial news for MRK dated on 2015-09-20: Merck's Bezlotoxumab Met Primary Endpoint in Phase 3 Studies

Financial news for MRK dated on 2015-09-18: UPDATE: Merck Phase 2 Primary Efficacy Endpoint Was Similar Across Both Relebactam Groups Along With Placebo Group, All 95% Or Higher

Financial news for MRK dated on 2015-09-18: Merck Offers Results from Phase 2 Study of Investigational Beta-Lactamase Inhibitor at ICAAC/ICC '15: Met Primary Endpoint

Financial news for MRK dated on 2015-09-18: Eli Lilly's 'Home Run' Is Jardiance, Says Morgan Stanley

Financial news for MRK dated on 2015-09-17: Merck To Submit Applications To U.S. For Approval Of Ertugliflozin By End Of 2016

Financial news for MRK dated on 2015-09-17: Merck Provides Diabetes Portfolio Update and Underscores Comprehensive, Long-Term Commitment to Patients with Diabetes

Financial news for MRK dated on 2015-09-16: Merck Offers Highlights for Commitment to Infectious Disease with 40 Presentations of Data at ICAAC/ICC '15

Financial news for MRK dated on 2015-09-14: Amgen And Biogen Lead Short Interest Surge In Biotechs

Financial news for MRK dated on 2015-09-08: Merck, Samsung Bioepis Report Approval of BRENZYS, a Biosimilar of Enbrel, in Korea

Financial news for MRK dated on 2015-09-08: MKM Partners Would Sell These Healthcare Stocks On Weaker Relative Trends

Financial news for MRK dated on 2015-09-02: Sierra Leone to Vaccinate 200 People Who Came in Contact With Latest Ebola Victim -Reuters

Financial news for MRK dated on 2015-09-02: FDA Approves Pediatric Indication for EMEND(r) (aprepitant) Capsules in Combination with Other Antiemetic Agents

Financial news for MRK dated on 2015-09-01: Organovo CEO Keith Murphy: 'People Are Missing The Forest For The Trees'

Financial news for MRK dated on 2015-09-01: It's Not Shopping, It's Market Research: Talking Investing Trends With TD Ameritrade's Nicole Sherrod

Financial news for MRK dated on 2015-09-01: Hearing Buyside Volume Coming Into Staples, Drug, And Chemical Names

Financial news for MRK dated on 2015-09-01: New Analyses from the IMPROVE-IT Study with VYTORIN (ezetimibe and simvastatin)

Financial news for MRK dated on 2015-08-30: Barron's Recap: What's Next?

Financial news for MRK dated on 2015-08-24: Sierra Leone Released its Last Confirmed Ebola Patient from Hospital on Monday -Reuters

Financial news for MRK dated on 2015-08-20: New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN and the TECOS Cardiovascular Safety Trial of JANUVIA Will Be Presented at the European Society of Cardiology Congress

Financial news for MRK dated on 2015-08-18: FDA Accepts Supplemental Biologics License Application for KEYTRUDA, Merck's Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review

Financial news for MRK dated on 2015-08-13: Calls Of Note: Wall Street Research Moving The Market On Thursday

Financial news for MRK dated on 2015-08-13: What Are Payors Saying About Managed Care Giants?

Financial news for MRK dated on 2015-08-13: Good Data May Be Coming For Merck (And This Analyst Is Bullish)

Financial news for MRK dated on 2015-08-13: Benzinga's Top Upgrades

Financial news for MRK dated on 2015-08-13: US Stock Futures Rise Ahead of Jobless Claims, Retail Sales Data

Financial news for MRK dated on 2015-08-13: BMO Capital Upgrades Merck & Co to Outperform, Raises PT to \$70.00

Financial news for MRK dated on 2015-08-11: Sigma-Aldrich, Merck, Darmstadt, Germany, Report Antitrust Approval in Brazil for Planned Purchase

Financial news for MRK dated on 2015-08-10: Here's Which IT Stocks Benefit From Healthcare M&A

Financial news for MRK dated on 2015-08-07: ALK's Partner, Torii Pharmaceutical, Reports Positive Phase II/III Trial Results for Japanese Cedar SLIT-tablet

Financial news for MRK dated on 2015-08-04: Guinea, Sierra Leone Each Recorded Single Cases of Ebola in Past Week; WHO Says Risks Remain -Reuters

Financial news for MRK dated on 2015-08-04: Morning Market Gainers

Financial news for MRK dated on 2015-08-03: Codexis Reports CodeEvolver Technology Transfer, License Deal with Merck; Will Receive Up to \$5M Upfront Payment, Eligible for Up to \$18M in Milestones

Financial news for MRK dated on 2015-07-31: Merck Announces Global Collaboration Enabled Vaccine for Ebola Will Move from First-in-Human to Initial Phase 3 Results Within One Year

Financial news for MRK dated on 2015-07-31: WHO Says Initial Results from Merck/Newlink VSV-EBOV Ebola Vaccine Look Promising -Reuters

Financial news for MRK dated on 2015-07-28: Merck Q2 Profit Beats Estimates

Financial news for MRK dated on 2015-07-28: UPDATE: Merck Sees FY15 Adj. EPS \$3.45-\$3.55 vs \$3.45 Est.

Financial news for MRK dated on 2015-07-28: Merck Narrows, Raises FY15 Adj. EPS Outlook

Financial news for MRK dated on 2015-07-28: Merck Reports Q2 Adj. EPS \$0.86 vs \$0.81 Est., Sales \$9.8B, Inline

Financial news for MRK dated on 2015-07-28: Merck Boosts Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics

Financial news for MRK dated on 2015-07-28: Merck Announces FDA Priority Review For NDA For Hepatitis C Treatment

Financial news for MRK dated on 2015-07-28: Earnings Scheduled For July 28, 2015

Financial news for MRK dated on 2015-07-28: 10 Stocks You Should Be Watching Today

Financial news for MRK dated on 2015-07-27: Dollar Plagues Pharma Earnings But Did Street Get It Right?

Financial news for MRK dated on 2015-07-27: Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA

Financial news for MRK dated on 2015-07-23: MSD Reports European Medicines Agency Acceptance of Marketing Authorisation Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Infection

Financial news for MRK dated on 2015-07-23: RaNA Therapeutics Announces \$55 Million in Oversubscribed Series B Financing Led by Merck

Financial news for MRK dated on 2015-07-22: What's Coming For Large-Cap Pharma Stocks This Earnings Season?

Financial news for MRK dated on 2015-07-22: European Commission Approves MSD's Anti-PD-1 Therapy, KEYTRUDA(r) (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma

Financial news for MRK dated on 2015-07-10: Strong Dollar? Not So Good For Johnson & Johnson Earnings

Financial news for MRK dated on 2015-07-09: Barclays Expects M&A In Specialty Pharma To Continue, Likes Valeant And Jazz

Financial news for MRK dated on 2015-07-07: Allergan, Merck Enter Licensing Agreement to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program

Financial news for MRK dated on 2015-07-06: 9 Top Sell Ideas From Oppenheimer's Technical Analysis Division

Financial news for MRK dated on 2015-06-29: Merck Announces Phase 3 Study of Single-Dose EMEND(r) (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint

Financial news for MRK dated on 2015-06-21: Barron's Recap: Airline Stocks Ready To Soar

Financial news for MRK dated on 2015-06-21: Barron's Says Merck Shares Could Rise More than 20% to \$70

Financial news for MRK dated on 2015-06-17: Hearing Dept. of Justice Has Said Merck's Inspire Pharma to Pay \$5.9M to Settle Civil Claims of Fraud

Financial news for MRK dated on 2015-06-17: The Note Moving Pharma Giants Today

Financial news for MRK dated on 2015-06-17: Organovo Has Upside To \$6/Share, Cantor Fitzgerald Says

Financial news for MRK dated on 2015-06-17: Piper Jaffray Initiates Coverage on Merck & Co at Neutral

Financial news for MRK dated on 2015-06-16: Benzinga's M&A Chatter for Tuesday June 16, 2015

Financial news for MRK dated on 2015-06-16: New Report: Abbvie Is Jefferies' Top Global Pharma Stock

Financial news for MRK dated on 2015-06-16: Alkermes Declines Comment on Rumored Potential Bid from Merck

Financial news for MRK dated on 2015-06-16: Alkermes Shares Off the Highs; Shares Moving Higher on Takeover Chatter, Upcoming Presentation of Data from Late-Stage CNS Portfolio

Financial news for MRK dated on 2015-06-16: Hearing Merck Approached Dublin Based Alkermes With \$12.4B Offer-Market Sources

Financial news for MRK dated on 2015-06-15: JMP Sees A 'Negative Market Tone' In Biotechnology

Financial news for MRK dated on 2015-06-10: Merck, Samsung Bioepis Report Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints

Financial news for MRK dated on 2015-06-10: US Stock Futures Signal Higher Start On Wall Street

Financial news for MRK dated on 2015-06-10: Merck Publishes ALK's Data On Phase II

House Dust Mite SLIT-Tablet In Leading Allergy Journal

Financial news for MRK dated on 2015-06-10: TECOS, Merck's Cardiovascular Safety Trial of JANUVIA, Met Primary Endpoint in Patients with Type 2 Diabetes

Financial news for MRK dated on 2015-06-08: Benzinga's M&A Chatter for Monday June 8, 2015

Financial news for MRK dated on 2015-06-08: TECOS, Merck's Cardiovascular Safety Trial of JANUVIA, Met Primary Endpoint in Patients with Type 2 Diabetes

Financial news for MRK dated on 2015-06-08: This Technology Could Disrupt U.S. Pharma Stocks, Credit Suisse Says

Financial news for MRK dated on 2015-06-08: UPDATE: Celgene Shares at High Following Early Rumored Bid from Merck

Financial news for MRK dated on 2015-06-08: Hearing Unconfirmed Market Chatter of Potential Merck Bid for Celgene

Financial news for MRK dated on 2015-06-08: Merck KGaA, Darmstadt, Germany, Illumina and Genea Create the Global Fertility Alliance for Excellence in Assisted Reproductive Treatment

Financial news for MRK dated on 2015-06-04: ALK Announces Merck's North American Phase III Trial of House Dust Mite SLIT-Tablet Meets Primary Endpoint

Financial news for MRK dated on 2015-06-03: Merck Announces Results from Investigational IMPROVE-IT Study of VYTORIN Published in NEJM

Financial news for MRK dated on 2015-06-01: Merck Reports Acceptance of sBAL for KEYTRUDA in Advanced Non-Small Cell Lung Cancer, Priority Review Granted

Financial news for MRK dated on 2015-06-01: Merck, Dynavax Partner On Investigating Combination Of Immuno-Oncology Therapies

Financial news for MRK dated on 2015-06-01: Merck Announces New Data on Breadth of KEYTRUDA at ASCO: Anti-Tumor Activity Now Shown in 13 Different Tumor Types

Financial news for MRK dated on 2015-05-30: TESARO, Merck to Collaborate on Combination Study of Niraparib, KEYTRUDA

Financial news for MRK dated on 2015-05-29: Merck Shares Spike Higher Following Report on Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with KEYTRUDA

Financial news for MRK dated on 2015-05-29: Merck Shares Spiking Higher on Durable Anti-Tumor Activity With KEYTRUDA

Financial news for MRK dated on 2015-05-29: Initial Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Merck's KEYTRUDA (pembrolizumab) Showcased at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine

Financial news for MRK dated on 2015-05-29: Amgen, Merck Report Expansion of Collaboration to Support Studies of Talimogene Laherparepvec in Combo with KEYTRUDA in Patients with Head and Neck Cancer

Financial news for MRK dated on 2015-05-28: Merck Announces Has Submitted NDA for Grazoprevir/Elbasvir in US

Financial news for MRK dated on 2015-05-22: Expert Explains How To Play Merck In 2 Charts

Financial news for MRK dated on 2015-05-22: Merck Release Confirms CHMP Positive Recommendation for KEYTRUDA

Financial news for MRK dated on 2015-05-22: EMA Gives Positive Opinion for Merck's Melanoma Drug Keytruda

Financial news for MRK dated on 2015-05-12: GSK, NewLink Vaccine Trials May Not Produce Useful Efficacy Data as Ebola Disappears in W. Africa -Reuters

Financial news for MRK dated on 2015-05-05: Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers

Financial news for MRK dated on 2015-05-01: Hearing Unconfirmed Market Chatter of Potential Merck Bid for Lilly

Financial news for MRK dated on 2015-05-01: Bank Of America Reviews Gilead Earnings

Financial news for MRK dated on 2015-04-29: What's Wall Street Been Saying About Gilead Lately?

Financial news for MRK dated on 2015-04-28: Morning Market Gainers

Financial news for MRK dated on 2015-04-28: Bank Of America On Merck: 'MAGNIF-TECOS!'

Financial news for MRK dated on 2015-04-28: Benzinga's Top #PreMarket Gainers

Financial news for MRK dated on 2015-04-28: Merck Beats Q1 Estimates, Shares Rise

Financial news for MRK dated on 2015-04-28: Merck Raises FY15 Adj. EPS Outlook from \$3.32-\$3.47 Previously to \$3.35-\$3.48 vs \$3.37 Est., Affirms Sales Outlook

Financial news for MRK dated on 2015-04-28: Merck Reports Q1 EPS \$0.85 vs. Est. \$0.74, Rev. \$9.4B vs. Est. \$8.99B

Financial news for MRK dated on 2015-04-28: Earning & Economic Calendar for Thursday April 28, 2015

Financial news for MRK dated on 2015-04-28: Earnings Scheduled For April 28, 2015

Financial news for MRK dated on 2015-04-27: Merck Offers Results of Trial Evaluating CV Outcomes with Sitagliptin: Says Met Primary Endpoint

Financial news for MRK dated on 2015-04-27: Merck Earnings: The Street And The Crowd Expect A Double-Digit Year-Over-Year Decline

Financial news for MRK dated on 2015-04-26: Does Apple Hide More Cash Abroad Than Anyone?

Financial news for MRK dated on 2015-04-26: U.S. Tech, Dollar & Health Care ETFs To Watch This Week

Financial news for MRK dated on 2015-04-26: Apple & Other Earnings Expected To Dominate The Week Of April 27

Financial news for MRK dated on 2015-04-24: Morgan Stanley Alert: Gilead Investors Don't Have The Whole Story

Financial news for MRK dated on 2015-04-24: Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni

Financial news for MRK dated on 2015-04-24: Merck's Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection

Financial news for MRK dated on 2015-04-23: FDA Sentinel Study Finds No Association Between Venous Thromboembolism, Gardasil Vaccination -Reuters

Financial news for MRK dated on 2015-04-23: Merck Announces 99% of Patients in Phase 2/3 Study of Grazoprevir/Elbasvir Achieved Sustained Virologic Response

Financial news for MRK dated on 2015-04-22: Goat Plague (PPR) Affecting Herds in Africa, Asia -Reuters

Financial news for MRK dated on 2015-04-22: UPDATE: Organovo Shares Rise 15% Following Announcement of Deal With Merck

Financial news for MRK dated on 2015-04-22: Organovo Announces Multi-Year Research Collaboration Agreement With Merck Sharp & Dohme Corp

Financial news for MRK dated on 2015-04-21: Morgan Stanley Awaits This Merck Data

Financial news for MRK dated on 2015-04-20: CAR-T Therapy Stocks Hit Hard Following AACR Data

Financial news for MRK dated on 2015-04-20: Merck Will File "Totality Of Data" Regarding Hep C Drugs To FDA; Won't Limit FDA Filing To Breakthrough Status According To Phonecall With VP, Infectious Diseases Eliav Barr

Financial news for MRK dated on 2015-04-20: Morning Market Gainers

Financial news for MRK dated on 2015-04-20: Tetralogic Announces Co., Merck Will Collaborate Related to Evaluation of Birinapant In Combo With KEYTRUDA in Solid Tumors

Financial news for MRK dated on 2015-04-19: Early Findings with Merck's Pembrolizumab in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting

Financial news for MRK dated on 2015-04-19: Merck Announces New Data on Treatment of Advanced NSCLC with Pembrolizumab Presented at AACR Annual Meeting, Published in NEJM

Financial news for MRK dated on 2015-04-19: Early Findings with KEYTRUDA in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting

Financial news for MRK dated on 2015-04-17: It's A Big Weekend For Biotech

Financial news for MRK dated on 2015-04-15: SunTrust's Latest Comments On Merck

Financial news for MRK dated on 2015-04-15: Canine Flu Outbreak Reported in Chicago Area -Wall Street Journal

Financial news for MRK dated on 2015-04-14: Morgan Stanley's Major Pharma Q1 Preview

Financial news for MRK dated on 2015-04-14: UPDATE: Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone

Financial news for MRK dated on 2015-04-14: Ebola vaccine trial begins in Sierra Leone

Financial news for MRK dated on 2015-04-10: Biotech Investors: Nomura Says To Watch These Dates

Financial news for MRK dated on 2015-04-09: The Biotech Stocks JMP Is Watching

Financial news for MRK dated on 2015-04-08: Advaxis, Merck Report Initiation of Enrollment in Phase 1/2 Study of ADXS-PSA in Combo with Anti-PD-1 Therapy

Financial news for MRK dated on 2015-04-08: Grazoprevir/Elbasvir, Merck's Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2, 3 Data in Multiple HCV Patient Types Will Be Presented At The International Liver Congress TM 2015

Financial news for MRK dated on 2015-04-07: Sector ETFs And Earnings

Financial news for MRK dated on 2015-04-07: Arvinas in Strategic R&D Collaboration With Merck to Study Novel Protein Degradation Technology

Financial news for MRK dated on 2015-04-06: Gilead Alert: What Deutsche Bank Is Saying

Financial news for MRK dated on 2015-04-06: Merck Shares Teetering On The Brink Of A Further Downside Correction

Financial news for MRK dated on 2015-04-06: Top 4 Large-Cap Stocks In The Drug Manufacturers Industry With The Highest ROE

Financial news for MRK dated on 2015-03-31: Syndax and Merck to Partner on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA (pembrolizumab) in Lung Cancer and Melanoma

Financial news for MRK dated on 2015-03-27: EMA Recommends Approval of Merck's Gardasil 9 Vaccine

Financial news for MRK dated on 2015-03-26: Merck Announces Deal with American Diabetes Association for Education of Adults with Diabetes

Financial news for MRK dated on 2015-03-25: Key Catalysts Are Coming For Merck, Analyst Predicts

Financial news for MRK dated on 2015-03-24: Merck Announces New \$10B Share Repurchase Program

Financial news for MRK dated on 2015-03-24: Merck's Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints, Will be Stopped Early

Financial news for MRK dated on 2015-03-23: SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms

Financial news for MRK dated on 2015-03-16: Merck Announced Results From Investigational IMPROVE-IT Study That Shows VYTORIN Reduced Total Cardiovascular Events By 9% Vs. SIMVASTATIN

Financial news for MRK dated on 2015-03-13: Merck Provides Regulatory Update On

Sugammadex Injection

Financial news for MRK dated on 2015-03-12: Measles Cases Could ~Double in W African Countries Due to Stain on Health Systems from Ebola Outbreak; Inability to Maintain Child Immunizations -Reuters

Financial news for MRK dated on 2015-03-11: US Stock Futures Signal Higher Start On Wall Street

Financial news for MRK dated on 2015-03-11: Merck Announces KEYTRUDA is First Medicine to be Made Available to Patients Through UK EAMS for Advanced Melanoma

Financial news for MRK dated on 2015-03-10: 8 Healthcare Names Cowen & Co Are Talking About

Financial news for MRK dated on 2015-03-04: Merck Announces Co. Eisai Enter Deal to Explore Novel Combo Regimens Anti-PD-1 Therapy with RTK Inhibitor, Microtubule Dynamics Inhibitor for Cancers

Financial news for MRK dated on 2015-03-01: Fast Money Picks For March 2

Financial news for MRK dated on 2015-02-26: Merck HPV Vaccine GARDASIL(r)9, Recommended by CDC's Advisory Committee on Immunization Practices for Females Aged 9-26 and Males Aged 9-21

Financial news for MRK dated on 2015-02-25: Heavy News Day For Several Biotech Stocks

Financial news for MRK dated on 2015-02-24: Merck Collaborates with Medicines Patent Pool to Expand Access to Pediatric Formulations of Raltegravir in Developing Countries

Financial news for MRK dated on 2015-02-23: Evercore ISI Technical Analysis: The 'Single Best Idea'

Financial news for MRK dated on 2015-02-23: UPDATE: Merck to Make Upfront Payment NGM of \$94M; Acquire 15% Stake in NGM for \$106M

Financial news for MRK dated on 2015-02-23: Merck, NGM Report Broad Strategic Deal to Discover, Develop, Commercialize Novel Biologic Therapeutics

Financial news for MRK dated on 2015-02-19: NewLink Genetics Announces \$20M Milestone Payment From MERCK

Financial news for MRK dated on 2015-02-06: After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?

Financial news for MRK dated on 2015-02-06: Fast Money Halftime Report Final Trade From February 5

Financial news for MRK dated on 2015-02-05: Merck Prices \$8B Debt Offering

Financial news for MRK dated on 2015-02-04: UPDATE: Merck Posts Upbeat Q4 Earnings, Sales Decline

Financial news for MRK dated on 2015-02-04: Merck Sees FY15 Adj. EPS \$3.32-\$3.47 Including Items, Sales \$38.3B-\$39.8B Including Items

Financial news for MRK dated on 2015-02-04: Merck & Co Reports Q4 Adj. EPS \$0.87 Vs Est \$0.86, Sales \$10.48B Vs Est \$10.50B

Financial news for MRK dated on 2015-02-04: Earning & Economic Calendar for Wednesday February 4, 2015

Financial news for MRK dated on 2015-02-04: Earnings Scheduled For February 4, 2015

Financial news for MRK dated on 2015-02-04: Keep an Eye on These 10 Stocks for February 4, 2015

Financial news for MRK dated on 2015-02-03: Merck's Insomnia Medicine BELSOMRA(r) (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States

Financial news for MRK dated on 2015-02-01: Earnings Expectations For The Week Of February 2: Disney, Exxon, GM And More

Financial news for MRK dated on 2015-01-30: What Investors Are Watching For In Regulus Therapeutics' Next Data Release

Financial news for MRK dated on 2015-01-29: #Premarket Prep Technical Update - Merck

Lower

Financial news for MRK dated on 2015-01-27: Fast Money Halftime Report Final Trade From January 27

Financial news for MRK dated on 2015-01-27: White House Budget To Support Biotech Rally

Financial news for MRK dated on 2015-01-26: Merck Reports CHMP Positive Opinion for Investigational Antibiotic SIVEXTRO

Financial news for MRK dated on 2015-01-23: EMA Recommends Merck's Combination of Lamivudine/Raltegravir for Approval -Reuters

Financial news for MRK dated on 2015-01-20: The 5 Best Dow Stocks So Far In 2015

Financial news for MRK dated on 2015-01-20: #Premarket Prep Technical Update - Merck Lower

Financial news for MRK dated on 2015-01-16: Barclays Issues 3 Upgrades, 1 Downgrade On Pharma Stocks

Financial news for MRK dated on 2015-01-16: 'Merck Acquires OncoEthix'

Financial news for MRK dated on 2015-01-16: Barclays Upgrades Merck to Equalweight

Financial news for MRK dated on 2015-01-15: #Premarket Prep Technical Update - Merck Lower

Financial news for MRK dated on 2015-01-15: Fast Money Halftime Report Final Trade From January 14

Financial news for MRK dated on 2015-01-14: Practice Fusion Announces Positive Results of Population Health Vaccine Initiative

Financial news for MRK dated on 2015-01-13: Notes From The Street: 'FLASHBACK....Oil Going To \$200/Barrel'

Financial news for MRK dated on 2015-01-13: Merck and Eli Lilly Announce Agreement For Collaboration on Cancer Clinical Trial

Financial news for MRK dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for MRK dated on 2015-01-12: Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014

Financial news for MRK dated on 2015-01-06: FDA Has Approved Merck's Request to Supplement Pneumovax BLA, Will Add 2D Barcode on Label

Financial news for MRK dated on 2015-01-05: Bernstein Upgrades Merck to Outperform

Financial news for MRK dated on 2014-12-31: What Investors Should Be Watching In The Antibiotic Space

Financial news for MRK dated on 2014-12-31: 19 Lesser-Known Biotech Stocks With Robust Drug Pipelines

Financial news for MRK dated on 2014-12-23: US Dept. of Health & Human Services Issues Release: 'HHS supports efforts to speed Ebola vaccine delivery'

Financial news for MRK dated on 2014-12-23: Health Care And Biotech Sector Looking Sick

Financial news for MRK dated on 2014-12-23: FTC Requests Public Comment on Merck & Co., Inc.'s Application to Approve Sale of Facilities

Financial news for MRK dated on 2014-12-22: #Premarket Prep Technical Update - Merck Lower

Financial news for MRK dated on 2014-12-22: NewLink Genetics Surges 3% Following Ebola Contract News

Financial news for MRK dated on 2014-12-22: NewLink Genetics Announces Collaboration with Merck for Manufacture of Ebola Vaccine, Deal Supported by \$30M Award

Financial news for MRK dated on 2014-12-19: Merck Begins Tender Offer To Acquire Cubist

Financial news for MRK dated on 2014-12-18: Merck Reports Acquisition of OncoEthix for \$110M Upfront Payment, Could Pay Added \$265M in Milestone Payment

Financial news for MRK dated on 2014-12-11: Market Mixed Amid Plan To Spend \$300 Million On Ebola Vaccines

Financial news for MRK dated on 2014-12-11: These 4 Charts Highlight Twitter Sentiment For Today's Movers

Financial news for MRK dated on 2014-12-11: Sky News Newsdesk Tweets: 'Reuters: Geneva University Hospital suspends trials of #Ebola vaccine one week early "as a measure of precaution"'

Financial news for MRK dated on 2014-12-11: Global Vaccines Alliance GAVI Said Thursday it was Committing up to \$300M to Buy Ebola Vaccines -Reuters

Financial news for MRK dated on 2014-12-10: FDA Approves Gardasil 9 for Prevention of Certain Cancers Caused by 5 Additional Types of HPV

Financial news for MRK dated on 2014-12-10: Data Investigating KEYTRUDA, Merck's Anti-PD-1 Therapy, In Patients With Advanced Triple-Negative Breast Cancer Presented At 2014 San Antonio Breast Cancer Symposium

Financial news for MRK dated on 2014-12-09: Zoetis Inc. Spikes Briefly On Remarks From Sanofi CEO

Financial news for MRK dated on 2014-12-09: Mizuho Securities Downgrades Cubist Pharmaceuticals Post Acquisition Announcement

Financial news for MRK dated on 2014-12-09: #Premarket Prep Technical Update - Merck Lower

Financial news for MRK dated on 2014-12-09: Hospira, Inc. Ticks Up On Favorable Patent Ruling vs. Cubist Pharmaceuticals Inc

Financial news for MRK dated on 2014-12-09: Merck & Co. Under Pressure Following Patent Ruling

Financial news for MRK dated on 2014-12-09: Cellceutix Corp Shares Rise On Two Catalysts

Financial news for MRK dated on 2014-12-09: Merck Issues Statement Regarding CUBICIN Patent Litigation; Reaffirms Transaction To Proceed As Planned

Financial news for MRK dated on 2014-12-08: Benzinga's M&A Chatter for Monday December 8, 2014

Financial news for MRK dated on 2014-12-08: 3 Biotech ETFs Rally On Merger News

Financial news for MRK dated on 2014-12-08: Cubist Shares Fall Almost 5% After-Hours

Financial news for MRK dated on 2014-12-08: Mid-Afternoon Market Update: Dow Slides Over 100 Points; Oil Futures Down 4%

Financial news for MRK dated on 2014-12-08: Fitch Says Cubist Acquisition Will Strengthen Merck's Growth Opportunities, Particularly in Non-U.S./European Markets

Financial news for MRK dated on 2014-12-08: Mid-Day Market Update: McDonald's Drops On Weak November Sales; Acceleron Pharma Shares Jump

Financial news for MRK dated on 2014-12-08: Merck's CEO Doesn't Think That Valuations In The Biotech Industry Are 'Rich'

Financial news for MRK dated on 2014-12-08: Mid-Morning Market Update: Markets Mixed; Merck To Buy Cubist Pharmaceuticals For \$102/Share

Financial news for MRK dated on 2014-12-08: Benzinga's Volume Movers

Financial news for MRK dated on 2014-12-08: Stocks Hitting 52-Week Highs

Financial news for MRK dated on 2014-12-08: Morning Market Movers

Financial news for MRK dated on 2014-12-08: Pharmaceutical Stocks In Play Following Merck/Cubist Deal

Financial news for MRK dated on 2014-12-08: Benzinga's Top #PreMarket Gainers

Financial news for MRK dated on 2014-12-08: Advaxis Announces FDA Acceptance of Investigational NDA to Begin Clinical Trials of ADXS-PSA in Combo with Merck's

KEYTRUDA(R)

Financial news for MRK dated on 2014-12-08: Merck to Acquire Cubist Pharmaceuticals for \$102/Share in Cash

Financial news for MRK dated on 2014-12-08: UPDATE: Merck Says Cubist Deal Includes \$1.1B In Net Debt

Financial news for MRK dated on 2014-12-08: US Stock Futures Point To Lower Open Monday

Financial news for MRK dated on 2014-12-08: Merck To Acquire Cubist Pharmaceuticals For \$102 Per Share In Cash

Financial news for MRK dated on 2014-12-08: Cubist Shares Bid 28% Higher Premarket on Rumor of Merck \$100/Share Bid

Financial news for MRK dated on 2014-12-08: Must Watch Stocks for December 8, 2014

Financial news for MRK dated on 2014-12-07: Benzinga's Weekend M&A Chatter

Financial news for MRK dated on 2014-12-06: Merck Announces Anti-PD-1 Therapy, KEYTRUDA, Achieves Overall Response Rate of 66% in Classical Hodgkin Lymphoma Study

Financial news for MRK dated on 2014-12-05: Merck in Talks to Acquire Cubist for ~\$100/Share

Financial news for MRK dated on 2014-12-05: Merck in Talks to Acquire Cubist Pharmaceuticals for More Than \$7B; Could be Announced as Early as Next Week -NYT Dealbook

Financial news for MRK dated on 2014-12-04: Markets Marginally Lower Ahead Of Friday's Jobs Report

Financial news for MRK dated on 2014-12-04: Jefferies Maintains Hold on Merck & Company, Inc., Raises PT to \$65.00

Financial news for MRK dated on 2014-12-02: No Serious Side Effects Reported in Early Test of Experimental Ebola Vaccine Being Developed by Merck, NewLink -Reuters

Financial news for MRK dated on 2014-12-01: 8-K from Gilead Sciences Shows UK Court Invalidated Idenix 489 Patent, Trials Will Be Held on Merck's Idenix Patents in Canada in Jan.

Financial news for MRK dated on 2014-11-25: Merck Announces Increased Quarterly Dividend From \$0.44 To \$0.45/share

Financial news for MRK dated on 2014-11-24: #Premarket Prep Technical Update - Merck Trading Lower

Financial news for MRK dated on 2014-11-24: Merck Reports Submission to Japanese Pharma, Medical Devices Agency for Omarigliptin

Financial news for MRK dated on 2014-11-24: Merck, NewLink Genetics Announce Licensing and Collaboration Agreement for Investigational Ebola Vaccine

Financial news for MRK dated on 2014-11-24: Merck, NewLink Genetics Report Entering of Licensing, Collaboration Deal for Investigational Ebola Vaccine

Financial news for MRK dated on 2014-11-21: EMA Recommends Merck's Blood Clot Preventer Vorapaxar

Financial news for MRK dated on 2014-11-20: Hearing Newlink, Merck Working on Producing Ebola Vaccine

Financial news for MRK dated on 2014-11-17: Merck Announces Its Vytorin Reduces Heart Disease Risk By 6.4% Over Statin Alone

Financial news for MRK dated on 2014-11-17: Merck Announces That IMPROVE-IT Achieved Primary Endpoint; Data To Be Presented At American Heart Association Scientific Sessions Today

Financial news for MRK dated on 2014-11-17: Pfizer Will Study Merck's PDL-1 in Combo with Pfizer Assets; to Start 20 Clinical Dev Programs with Merck, Six Registration Programs

Financial news for MRK dated on 2014-11-16: Merck Announces Positive Study Investigating Use of KEYTRUDA Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma

Financial news for MRK dated on 2014-11-11: Merck Announces Results From Phase 2 Study Of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir In Genotype 1 Infected Treatment-Naive And Difficult-To-Cure Patients

Financial news for MRK dated on 2014-11-11: Merck Offers Results of Phase 2 Study of Investigational Chronic Hep C Treatment Grazoprevir/Elbasvir; First Wave of Phase 3 Enrolled, Co. Will Submit NDA App in 2015

Financial news for MRK dated on 2014-11-10: Merck Shares May Have Hit A Ceiling For The Most Recent Upside Move

Financial news for MRK dated on 2014-11-10: Merck Has Said Taking No Impairment Charge Following Results of Cholesterol-Drug Study

Financial news for MRK dated on 2014-11-10: RBC Sees Weak Merck Data As Positive For Gilead

Financial news for MRK dated on 2014-11-09: Interim Data from C-SWIFT Study of Merck's Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor Presented at The Liver Meeting

Financial news for MRK dated on 2014-11-06: US Stock Futures Edge Lower Ahead Of Earnings, Jobless Claims

Financial news for MRK dated on 2014-11-06: BIND Therapeutics Announces Joint Research Agreement with Merck

Financial news for MRK dated on 2014-11-05: Merck Animal Health Provides Update on Zilmax Five-Step Plan; Announces Next Steps

Financial news for MRK dated on 2014-11-03: Merck Reports Data from 48-Week Phase 2B Study of Investigational HIV Therapy Doravirine in Treatment-Naive Patients; Phase 3 Clinical Trial Enrollment Scheduled to Begin by End of 2014

Financial news for MRK dated on 2014-10-28: #PreMarket Primer: Tuesday, October 28: CDC Warns That Involuntary Quarantines Could Discourage Progress On Ebola

Financial news for MRK dated on 2014-10-27: Fast Money Traders Discuss Merck, Garmin And Sarepta Therapeutics

Financial news for MRK dated on 2014-10-27: Markets Virtually Flat, Oil Continues To Decline Following Bearish Outlook

Financial news for MRK dated on 2014-10-27: Merck Conference Call Highlights

Financial news for MRK dated on 2014-10-27: Mid-Afternoon Market Update: NQ Mobile Climbs On SEC Filing; Huntsman Shares Slide

Financial news for MRK dated on 2014-10-27: #Premarket Prep Technical Update - Merck Trading Lower

Financial news for MRK dated on 2014-10-27: Mid-Day Market Update: Micron Gains On Buyback Announcement; Sarepta Shares Dip

Financial news for MRK dated on 2014-10-27: Mid-Morning Market Update: Markets Down; Merck Posts Upbeat Earnings

Financial news for MRK dated on 2014-10-27: #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line With Expectations

Financial news for MRK dated on 2014-10-27: US Stock Futures Down Ahead Of Economic Data

Financial news for MRK dated on 2014-10-27: UPDATE: Merck Q3 Earnings Top Street View

Financial news for MRK dated on 2014-10-27: Merck & Company, Inc. Narrows FY2014 EPS Guidance from \$3.43-3.53 to \$3.46-3.50 vs \$3.47 Est

Financial news for MRK dated on 2014-10-27: Merck & Company, Inc. Reports Q3 EPS of \$0.31 vs \$0.88 Est; Revenue of \$10.60B vs \$10.68B Est

Financial news for MRK dated on 2014-10-27: Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA in Advanced NSCLC

Financial news for MRK dated on 2014-10-27: Earnings Scheduled For October 27, 2014

Financial news for MRK dated on 2014-10-27: Keep an Eye on These 7 Stocks for October 27, 2014

Financial news for MRK dated on 2014-10-26: Earnings Expectations For The Week Of October 27: Facebook, Exxon, Pfizer And Much More

Financial news for MRK dated on 2014-10-24: Fast Money Halftime Report Final Trade From October 24

Financial news for MRK dated on 2014-10-23: Fast Money Picks For October 23

Financial news for MRK dated on 2014-10-22: Drug ETFs Attractive Buys On Pullback

Financial news for MRK dated on 2014-10-21: #Premarket Technical Update - Merck Trading Higher

Financial news for MRK dated on 2014-10-20: US FDA Accepts For Review A Biologics License Application For Merck And Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine

Financial news for MRK dated on 2014-10-16: Will Actavis Win Competition For Allergan's Affection?

Financial news for MRK dated on 2014-10-15: Merck Announces Final Results of Tender Offers for Eight Series of Notes

Financial news for MRK dated on 2014-10-13: Markets Debut Week On Negative Note; S&P 500 Falls Through Key Level

Financial news for MRK dated on 2014-10-13: #Premarket Prep Technical Update - Merck Trading Lower

Financial news for MRK dated on 2014-10-13: Jefferies Maintains Hold on Merck & Company, Inc., Lowers PT to \$60.00

Financial news for MRK dated on 2014-10-13: 5 Companies That Could Develop An Enterovirus Treatment

Financial news for MRK dated on 2014-10-08: #Premarket Prep Technical Update - Merck Trading Sharply Higher

Financial news for MRK dated on 2014-10-06: Merck Prices \$3.1B Debt Offering

Financial news for MRK dated on 2014-10-06: 2 Mutual Funds Holding Hospital Stocks

Financial news for MRK dated on 2014-10-06: Merck Commences Tender Offers for Eight Series of Notes

Financial news for MRK dated on 2014-10-06: Merck Commences Public Debt Offering

Financial news for MRK dated on 2014-10-03: #Premarket Prep Technical Update - Merck Trading Higher

Financial news for MRK dated on 2014-10-02: Markets Little Changed Ahead Of Friday's Jobs Report

Financial news for MRK dated on 2014-10-02: Guggenheim Securities Initiates Coverage on Merck & Company, Inc. at Neutral, Announces \$65.00 PT

Financial news for MRK dated on 2014-09-29: Merck & Co., Inc. Stock Still Holding Its Position As A Big-Pharma Leader

Financial news for MRK dated on 2014-09-29: Merck Presents Early Data on Investigational Use of KEYTRUDA in Patients with Advanced Bladder Cancer at ESMO 2014

Financial news for MRK dated on 2014-09-26: Fast Money Halftime Report Final Trade From September 26 - Merck & Co., Inc., NCR Corporation And BP plc

Financial news for MRK dated on 2014-09-22: Citigroup Inc, Hertz Global Holdings, Inc. Highlight Fast Money Halftime Report Final Trade From September 22

Financial news for MRK dated on 2014-09-17: Merck Reports Entered Into License Deal with Sun Pharma for Tildrakizumab

Financial news for MRK dated on 2014-09-17: Merck Presents First Phase 3 Data In Japanese Patients for Omarigliptin, An Investigational Once-Weekly DPP-4 Inhibitor For Type 2 Diabetes

Financial news for MRK dated on 2014-09-17: Sun Pharma and Merck Enter into Licensing Agreement for Tildrakizumab

Financial news for MRK dated on 2014-09-16: #Premarket Prep Technical Update - Merck Trading Higher

Financial news for MRK dated on 2014-09-15: Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib; Expects to Submit NDA to FDA in 2015

Financial news for MRK dated on 2014-09-12: #Premarket Prep Technical Update - Merck Trading Lower

Financial news for MRK dated on 2014-09-10: Is Merck & Co., Inc. A Leader In A Red Hot Market?

Financial news for MRK dated on 2014-09-10: Option Alert: Merck Jan 15 \$50 Call; 32,105 Traded vs 12,719 OI; Currently \$60.78

Financial news for MRK dated on 2014-09-09: Merck CEO Says Tax Inversion Deals Would Not Fit Corporate Strategy -Reuters

Financial news for MRK dated on 2014-09-05: Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. Over Skin Cancer Drug

Financial news for MRK dated on 2014-09-05: Shares of Bristol-Myers Edge Off Session Lows as Bloomberg Reporting Co. Has Filed Suit Against Merck Related to Patent for Immunotherapy Drugs

Financial news for MRK dated on 2014-09-04: Merck Wins FDA Approval For Pembrolizumab In Melanoma

Financial news for MRK dated on 2014-09-04: Merck & Co (MK-7655) Gets Fast Track Designation From FDA

Financial news for MRK dated on 2014-08-27: Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend

Financial news for MRK dated on 2014-08-27: Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)

Financial news for MRK dated on 2014-08-27: Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers at Hold

Financial news for MRK dated on 2014-08-27: UPDATE: Deutsche Bank Initiates Coverage On Merck

Financial news for MRK dated on 2014-08-27: Deutsche Bank Initiates Coverage on Merck & Company, Inc. at Hold, Announces \$63.00 PT

Financial news for MRK dated on 2014-08-26: S&P 500 Closes Above 2,000; Dow Hits New All-Time High As Markets Continue To Rally

Financial news for MRK dated on 2014-08-26: Fast Money Halftime Report Final Trade From August 26

Financial news for MRK dated on 2014-08-26: Pfizer, Merck Report Collaboration on Study Evaluating Novel Anti-Cancer Combo Regimen

Financial news for MRK dated on 2014-08-25: #Premarket Prep Technical Update - Merck Approaches \$60.00

Financial news for MRK dated on 2014-08-25: US Stock Futures Rise Ahead Of Economic Data

Financial news for MRK dated on 2014-08-25: US Regulators Have Approved Merck's Pembrolizumab Soon - Reuters

Financial news for MRK dated on 2014-08-25: Advaxis, Merck to Collaborate on Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer

Financial news for MRK dated on 2014-08-13: Merck Issues Statement Related to Role of PNEUMOVAX 23 in Updated ACIP Recommendations

Financial news for MRK dated on 2014-08-13: UPDATE: FDA Approves Belsomra Tablets for Use as Sleep Aid

Financial news for MRK dated on 2014-08-13: FDA Approves Belsomra Tablets for Use as Sleep Aid

Financial news for MRK dated on 2014-08-13: Medicare Spokesperson Tells CDC Vaccine Advisory Panel, Medicare Would Need to Change Current Policy to Cover Pfizer's

Pprevnar 13 for Elderly Previously Vaccinated With Merck's Pneumovax -Reuters

Financial news for MRK dated on 2014-08-11: Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments

Financial news for MRK dated on 2014-08-05: Ukraine Tension Prominent As Dow Suffers Triple Digit Loss; S&P 500 & NASDAQ Also Lower

Financial news for MRK dated on 2014-08-05: #Premarket Prep Technical Update - Merck Trading Sharply Lower

Financial news for MRK dated on 2014-08-05: Merck Says on July 30 Was Advised by British Columbia Medical Beneficiary and Pharmaceutical Services Division of Delisting of Sitagliptin Products

Financial news for MRK dated on 2014-08-05: Merck Successfully Completes Tender Offer to Acquire Idenix for \$24.50/Share

Financial news for MRK dated on 2014-08-04: Glaxo, Sanofi Trend Up On Potential Deal For Established Brands

Financial news for MRK dated on 2014-07-31: 3 Reasons To Buy Merck For The Long Term

Financial news for MRK dated on 2014-07-29: Stocks Lower As Earnings Season Takes Back Seat To Geopolitical Uncertainties

Financial news for MRK dated on 2014-07-29: Pharmaceutical ETFs Are Health Care Sector Standouts

Financial news for MRK dated on 2014-07-29: Indices Remain Mixed; Merck Beats Expectations

Financial news for MRK dated on 2014-07-29: Tuesday Morning Earnings Releases

Financial news for MRK dated on 2014-07-29: #Premarket Prep Technical Update - Merck Trading Higher

Financial news for MRK dated on 2014-07-29: Herbalife Falls On Downbeat Results; Windstream Shares Spike Higher

Financial news for MRK dated on 2014-07-29: Markets Open Higher; Merck Posts Upbeat Profit

Financial news for MRK dated on 2014-07-29: US Stock Futures Rise Ahead Of Earnings, Consumer Confidence Data

Financial news for MRK dated on 2014-07-29: UPDATE: Merck Q2 Profit Beats Street View, Shares Rise

Financial news for MRK dated on 2014-07-29: Merck & Company, Inc. Raises FY2014 EPS Guidance from \$3.35-3.53 to \$3.43-3.53 vs \$3.48 Est, Reaffirms Sales Outlook

Financial news for MRK dated on 2014-07-29: Merck & Company, Inc. Reports Q2 EPS of \$0.85 vs \$0.80 Est; Revenue of \$10.93B vs \$10.60B Est

Financial news for MRK dated on 2014-07-29: Earnings Scheduled For July 29, 2014

Financial news for MRK dated on 2014-07-29: Stocks To Watch For July 29, 2014

Financial news for MRK dated on 2014-07-28: Markets Little Changed Ahead Of The Federal Reserve's Policy Decision

Financial news for MRK dated on 2014-07-27: Earnings Expectations For The Week Of July 28: Exxon, Pfizer, Twitter And Much More

Financial news for MRK dated on 2014-07-26: Benzinga Weekly Preview: FOMC In Focus As Earnings Season Progresses

Financial news for MRK dated on 2014-07-24: Merck Announces Initiation of Phase 3 For Letermovir

Financial news for MRK dated on 2014-07-21: Idenix Pharma Shares Spiking Higher following SEC Filing Showing HSR Approval of Purchase by Merck

Financial news for MRK dated on 2014-07-07: Markets Marginally Lower Ahead Of Earnings Season

Financial news for MRK dated on 2014-07-07: #Premarket Prep Technical Update - Merck Trading Lower

Financial news for MRK dated on 2014-07-03: Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline

Financial news for MRK dated on 2014-07-02: Markets Little Changed Ahead Of 4th Of July Break

Financial news for MRK dated on 2014-07-02: Barclays Downgrades Pharmaceutical Sector

Financial news for MRK dated on 2014-07-01: Bayer Could Keep Scholl's, Coppertone Brands from Merck - Reuters

Financial news for MRK dated on 2014-06-30: Merck Announces Investigational Data From Phase 3 Emend

Financial news for MRK dated on 2014-06-30: US Stock Futures Fall Ahead Of Home Sales Report

Financial news for MRK dated on 2014-06-30: Merck's Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review by EMA for Treatment of Advanced Melanoma

Financial news for MRK dated on 2014-06-27: Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly

Financial news for MRK dated on 2014-06-26: #Premarket Prep Technical Update - Merck Trading Lower

Financial news for MRK dated on 2014-06-20: Market Wrap For June 20: Yet Again, Dow And S&P 500 Indices Hit New Highs

Financial news for MRK dated on 2014-06-18: 5-Star Biotech Stock Watch: Synta Pharmaceuticals

Financial news for MRK dated on 2014-06-12: UPDATE: Merck Research Head Says Company Aims to Capture Big Share of Hep C Market, Selling Best Drugs at Fair Cost

Financial news for MRK dated on 2014-06-12: Merck Research Head Says Company Open to Big Acquisition for Biotech Products -Reuters

Financial news for MRK dated on 2014-06-12: UPDATE: Bank Of America Reiterates On Merck & Co. On Higher Sales Estimates

Financial news for MRK dated on 2014-06-11: Takeover Whispers Add To Achillion Pharmaceuticals' Momentum

Financial news for MRK dated on 2014-06-10: ETF Outlook For Tuesday, June 10, 2014 (IAT, FXE, PBE, HYHG, IDIX, MRK)

Financial news for MRK dated on 2014-06-09: Benzinga's M&A Chatter for Monday June 9, 2014

Financial news for MRK dated on 2014-06-09: Market Wrap For June 9: Markets Higher On St. Louis Fed Comments, Low Volume

Financial news for MRK dated on 2014-06-09: Mid-Afternoon Market Update; Icahn's 9% Stake In Family Dollar, Tyson Foods Wins Bid For Hillshire Brands

Financial news for MRK dated on 2014-06-09: Are Gilead Shares Overreacting To Merck's Idenix Acquisition?

Financial news for MRK dated on 2014-06-09: Mid-Day Market Update: Idenix Pharma Surges On Merck Buyout; Pilgrim's Pride Shares Slide

Financial news for MRK dated on 2014-06-09: Benzinga's Volume Movers

Financial news for MRK dated on 2014-06-09: Stocks Hitting 52-Week Highs

Financial news for MRK dated on 2014-06-09: Mid-Morning Market Update: Markets Edge Higher; Tyson Wins Bidding Battle To Buy Hillshire Brands For \$63/Share

Financial news for MRK dated on 2014-06-09: Morning Market Movers

Financial news for MRK dated on 2014-06-09: UPDATE: Merck Says Dual Therapy of MK-5172, MK-8742 Cures High 90's% of Patients In 12 Weeks; Triple Therapy Could Be More Effective, Faster

Financial news for MRK dated on 2014-06-09: Hepatitis C Stocks Move After Idenix Rockets Up 235%

Financial news for MRK dated on 2014-06-09: Merck Research Head Says Combination of Idenix Nucleotide Inhibitor IDX21437, Plus Leading Two Experimental Merck Drugs Could Produce Cures In 4-6 Weeks

Financial news for MRK dated on 2014-06-09: Benzinga's Top #PreMarket Losers

Financial news for MRK dated on 2014-06-09: Benzinga's Top #PreMarket Gainers

Financial news for MRK dated on 2014-06-09: Achillion Pharmaceuticals Shares Rise 38% Premarket on News of Merck-Idenix Deal

Financial news for MRK dated on 2014-06-09: Shares of Idenix Pharma Now Up 200+% to ~\$22

Financial news for MRK dated on 2014-06-09: UPDATE: Merck Announces Will Purchase Idenix for \$3.85Bn

Financial news for MRK dated on 2014-06-09: Merck Announces Will Purchase Idenix for \$24.50/Share

Financial news for MRK dated on 2014-06-06: #Premarket Prep Technical Update - Merck Trading Lower

Financial news for MRK dated on 2014-06-06: Merck Announces Will Present New Clinical Data on JANUVIA at SSADA

Financial news for MRK dated on 2014-06-05: Merck Announces First Patient in Phase 3 Trial of ISENTRESS Enrolled

Financial news for MRK dated on 2014-06-05: #Premarket Prep Technical Update - Merck Trading Higher

Financial news for MRK dated on 2014-06-04: ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

Financial news for MRK dated on 2014-06-01: Merck Presents Early Data for Pembrolizumab in Patients with PD-L1 Positive, Advanced Head and Neck Cancer at ASCO

Financial news for MRK dated on 2014-05-30: Merck Announces Generic Name for MK-3475, Pembrolizumab

Financial news for MRK dated on 2014-05-29: #Premarket Prep Technical Update - Merck Trading Higher

Financial news for MRK dated on 2014-05-23: #Premarket Technical Update - Merck Trading Higher

Financial news for MRK dated on 2014-05-20: Merck Reports Animal Health Has Announced FDA Approval of BRAVECTO

Financial news for MRK dated on 2014-05-19: Merck, Endocyte Report Withdrawal of Conditional Marketing Authorization for Vintafolide, Companion Imaging from EMA

Financial news for MRK dated on 2014-05-16: Chimerix Announces Has Regained Worldwide Rights to CMX157 from Merck, Says Co. Will No Longer Pursue Development

Financial news for MRK dated on 2014-05-14: Merck VP Schechter Sells 10,527 Shares @\$55.91/Share -Form 4

Financial news for MRK dated on 2014-05-14: R&D Tax Credit Passed In The House, Faces Challenges Ahead

Financial news for MRK dated on 2014-05-14: The 5 Most Overvalued Dow Stocks

Financial news for MRK dated on 2014-05-14: New Data on Merck's Investigational Anti-PD1 Antibody, MK-3475 to be Presented at ASCO 2014

Financial news for MRK dated on 2014-05-13: US Stock Futures Up Ahead Of Retail Sales Report

Financial news for MRK dated on 2014-05-13: Merck to Sell Ophthalmology Products in Japan, Key Markets in Europe and Asia Pacific to Santen for \$600M Upfront Payment

Financial news for MRK dated on 2014-05-12: UPDATE: Merck Reports FDA Okay of Zontivity

Financial news for MRK dated on 2014-05-12: Merck Reports FDA Okay o f Zontivity

Financial news for MRK dated on 2014-05-08: #Premarket Prep Technical Update - Merck Trading Lower Again

Financial news for MRK dated on 2014-05-08: This Morning BMO Capital Downgraded Merck & Company to Market Perform, Lowered PT to \$60.00

Financial news for MRK dated on 2014-05-08: Merck Announces Results Show Letemovir In CMV-Seropositive Allogeneic Human Blood Precursor Cell Recipients Met Study's Two Primary Efficacy Endpoints

Financial news for MRK dated on 2014-05-07: Market Wrap For May 7: Dow Banks Triple-Digit Point Gain While Nasdaq Closes Lower

Financial news for MRK dated on 2014-05-07: #Premarket Technical Update - Merck Trading Lower

Financial news for MRK dated on 2014-05-07: Merck Shares Tumble 2+% Following Morgan Stanley Downgrade

Financial news for MRK dated on 2014-05-06: Market Wrap For May 6: Dow Suffers Triple-Digit Point Loss, Nasdaq Underperforms Once Again

Financial news for MRK dated on 2014-05-06: #Premarket Prep Technical Update - Merck Trading Sharply Lower

Financial news for MRK dated on 2014-05-06: Fitch Says Merck Consumer Business Sale Improves Its Core Focus

Financial news for MRK dated on 2014-05-06: Merck Says Global Cancer Sales Could Reach \$120B by 2020

Financial news for MRK dated on 2014-05-06: Merck CEO Says Would be Interested in Acquiring Animal Health Brands with the Right Products at the Right Price -Reuters

Financial news for MRK dated on 2014-05-06: Merck Says May Look to M&A For Biotech Expansion- Bloomberg

Financial news for MRK dated on 2014-05-06: UPDATE: Merck Highlights Strategic Initiative

Financial news for MRK dated on 2014-05-06: Merck Offers Details of Plans to File Olanotecic for Osteoporosis in 2H, Will Continue to Explore Ways to Augment Animal Health Unit

Financial news for MRK dated on 2014-05-06: Merck Announces FDA Acceptance for Review of MK-3475

Financial news for MRK dated on 2014-05-06: US Stock Futures Flat Ahead Of International Trade Data

Financial news for MRK dated on 2014-05-06: Merck Announces Sale of Consumer Care Business to Bayer for \$14.2B

Financial news for MRK dated on 2014-05-06: Bayer to Buy Merck Consumer Care Ops for \$14.2B

Financial news for MRK dated on 2014-05-05: ETF Outlook For The Week Of May 5, 2014 (NGE, XLU, USMV, JJN)

Financial news for MRK dated on 2014-05-02: Market Wrap For May 2: Markets Slip On Ukraine Tensions Despite Positive Jobs Data

Financial news for MRK dated on 2014-05-02: Sanofi, Merck Rumored to Each Weigh Sale of Mature-Drug Portfolios - Bloomberg

Financial news for MRK dated on 2014-05-02: #Premarket Preo Technical Update - Merck Trading Lower

Financial news for MRK dated on 2014-05-02: Endocyte to Resume Trading at 8:30 AM ET

Financial news for MRK dated on 2014-05-02: Merck Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial Be Stopped for Futility Following Interim Analysis

Financial news for MRK dated on 2014-05-02: Merck, Endocyte Report DSMB Has Recommended Vintafolide Trial Be Suspended, Cites Trial Not Showing Efficacy

Financial news for MRK dated on 2014-05-01: Benzinga's M&A Chatter for Thursday May 1, 2014

Financial news for MRK dated on 2014-05-01: Bayer Could Be Preparing ~\$14B Bid for Merck's Consumer Unit - Bloomberg

Financial news for MRK dated on 2014-04-30: #Premarket Prep Technical Update - Merck Trading Lower

Financial news for MRK dated on 2014-04-30: Reckitt Benckiser Confirms it is No Longer in Talks with Merck Regarding Bid for Consumer Health Business

Financial news for MRK dated on 2014-04-30: #PreMarket Primer: Wednesday, April 30: No BOJ Stimulus On The Horizon

Financial news for MRK dated on 2014-04-29: Market Wrap For April 29: Dow Approaches Record Highs Despite Ongoing Ukraine Tension and Upcoming Fed Meeting

Financial news for MRK dated on 2014-04-29: Mid-Afternoon Market Update: Markets Show Strength as Prothena Shares Plummet

Financial news for MRK dated on 2014-04-29: Bids for Merck Consumer-Health Unit Said to Be Over \$14B, Bayer Looking to Weigh JV with Merck as Part of Offer - Bloomberg

Financial news for MRK dated on 2014-04-29: #Premarket Technical Update -Merck Trading Higher

Financial news for MRK dated on 2014-04-29: Mid-Day Market Update: Coach Slips After Q3 Results; Orbital Shares Spike Higher

Financial news for MRK dated on 2014-04-29: Mid-Morning Market Update: Markets Rise; Merck Earnings Beat Street View

Financial news for MRK dated on 2014-04-29: UPDATE: Merck Posts Upbeat Q1 Profit

Financial news for MRK dated on 2014-04-29: #PreMarket Primer: Tuesday, April 29: US Steps Up Sanctions Against Russia

Financial news for MRK dated on 2014-04-29: Merck & Company, Inc. Reports Q1 EPS of \$0.88 vs \$0.79 Est; Revenue of \$10.30B vs \$10.44B Est; Reaffirms Outlook

Financial news for MRK dated on 2014-04-28: Market Wrap For April 28: Apple Hits New 52-Week Highs In a Volatile Start To the Trading Week

Financial news for MRK dated on 2014-04-28: Reckitt Benckiser Confirms Talks With Merck Regarding Bid for Consumer Health Business, Bayer Also Rumored Bidder

Financial news for MRK dated on 2014-04-28: Agenus Announces License Deal with Merck Related to Novel Checkpoint Antibody-Based Cancer Immunotherapies, Eligible for ~\$100M in Milestone Payments

Financial news for MRK dated on 2014-04-27: Benzinga's Weekend M&A Chatter

Financial news for MRK dated on 2014-04-27: Earnings Expectations For The Week Of April 28: Big Oil, Big Pharma And More

Financial news for MRK dated on 2014-04-26: Reuters Reports Merck in Talks to Sell Consumer Health Unit to Bayer, Reckitt Benckiser for Approximately \$14B, According to Sources

Financial news for MRK dated on 2014-04-25: Benzinga Weekly Preview: Earnings Season Continues As Biotech & Pharmaceutical Companies Report

Financial news for MRK dated on 2014-04-25: 3 Ways To Profit From Merger Activity In The Pharmaceutical Sector

Financial news for MRK dated on 2014-04-24: Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns

Financial news for MRK dated on 2014-04-24: Fitch Affirms Merck's LT IDR at A+; Outlook Negative

Financial news for MRK dated on 2014-04-24: Bank of America Maintains Buy on Merck & Company, Inc., Raises PT to \$62.00

Financial news for MRK dated on 2014-04-23: #Premarket Technical Update -Merck Trading Lower

Financial news for MRK dated on 2014-04-23: Bill Ackman Talks Partnership With Valeant For Allergan Deal

Financial news for MRK dated on 2014-04-21: The Top 21 African-American CEOs In Business

Financial news for MRK dated on 2014-04-17: FDA Clears Merck's Ragwitek

Financial news for MRK dated on 2014-04-14: Merck Announces FDA Has Approved Grastek Sublingual Tablet for Treatment of Grass Pollen-Induced Allergic Rhinitis

Financial news for MRK dated on 2014-04-14: Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings

Financial news for MRK dated on 2014-04-14: Markets Falling? Get Your Defense Ready

Financial news for MRK dated on 2014-04-14: No Legwork Mondays - Merck And Vioxx

Financial news for MRK dated on 2014-04-11: Top 40 Upcoming Earnings Releases

Financial news for MRK dated on 2014-04-11: Google Honors Chemist Percy Julian & His Contributions

Financial news for MRK dated on 2014-04-11: US Stock Futures Slip Ahead Of Consumer Sentiment Report

Financial news for MRK dated on 2014-04-11: Phase 2 Trial of Merck's Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity

Financial news for MRK dated on 2014-04-10: When It Comes To Drug Stocks, Do Not Always Buy The News

Financial news for MRK dated on 2014-04-10: US Stock Futures Edge Lower Ahead Of Jobless Claims Data

Financial news for MRK dated on 2014-04-10: Merck Announces Results from Studies Evaluating MK-5172 and MK-8742 Investigational Hepatitis C Treatments,

Financial news for MRK dated on 2014-04-08: Biotechs Struggling To Find A Bottom

Financial news for MRK dated on 2014-04-08: Express Scripts Reports Spending on Hepatitis C Medications in US to Rise 1,800% by 2016

Financial news for MRK dated on 2014-04-06: Merck Presents Early Findings from MK-3475 Treatment at AARC 2014

Financial news for MRK dated on 2014-04-04: Merck Shares Volatile This Afternoon; Reuters Earlier Reported Co. is Seeing Resistance from Beef Industry for Test of Zilmax on 200K+ Cattle

Financial news for MRK dated on 2014-03-27: Merck Announces Appointment of Robert M. Davis as Chief Financial Officer; Succeeds Peter N. Kellogg, Who Has Served in the Role Since 2007

Financial news for MRK dated on 2014-03-27: Merck Names Robert Davis as CFO, Succeeding Peter Kellogg

Financial news for MRK dated on 2014-03-26: Nanobio Announces Licensing Agreement With Unit of Merck for Use of its Nanoemulsion Adjuvant Technology

Financial news for MRK dated on 2014-03-26: Nanobio Announces Licensing Agreement With Unit of Merck for Use of its Nanoemulsion Adjuvant Technology

Financial news for MRK dated on 2014-03-24: Reckitt Benckiser a Frontrunner for Merck's OTC Segment, Sanofi Rumored to Join Bidders, Final Bids Are Due Next Week - Bloomberg

Financial news for MRK dated on 2014-03-24: Google Honors Activist Dorothy Height & Her Contributions

Financial news for MRK dated on 2014-03-21: Mid-Day Market Update: Nike Drops On Cautious Forecast; Endocyte Shares Spike Higher

Financial news for MRK dated on 2014-03-21: "Premarket Prep" Technical Update - Merck Trading Lower After Higher Open

Financial news for MRK dated on 2014-03-21: Mid-Morning Market Update: Markets Open Higher; Tiffany Posts Downbeat Earnings

Financial news for MRK dated on 2014-03-21: Benzinga's Volume Movers

Financial news for MRK dated on 2014-03-21: UPDATE: Endocyte Shares Rise 158%

Financial news for MRK dated on 2014-03-21: UPDATE: Endocyte Shares Rise 91% on European CHMP Positive Opinions for VYNFINIT

Financial news for MRK dated on 2014-03-21: PREVIEW: Endocyte to Resume Trading at 8:30AM ET

Financial news for MRK dated on 2014-03-21: Benzinga's Top #PreMarket Gainers

Financial news for MRK dated on 2014-03-21: Merck, Endocyte Announce European CHMP Positive Opinions for VYNFINIT, Companion Agents FOLCEPRI, NEOCEPRI

Financial news for MRK dated on 2014-03-17: Ligand Pharma Announces \$1M Milestone Payment Triggered Following FDA Approval of Merck's Noxafil

Financial news for MRK dated on 2014-03-14: UPDATE: FDA Approves Merck Noxafi Injection for IV Use

Financial news for MRK dated on 2014-03-14: FDA Approves Merck Noxafi Injection for Intravenous Use

Financial news for MRK dated on 2014-03-12: Merck Unchanged

Financial news for MRK dated on 2014-03-06: Merck Trading Higher

Financial news for MRK dated on 2014-03-05: Merck Announces MK-1439 Shows Antiviral Activity in Phase 2b Trial, Co. Planning to Initiate Phase 2 Development Program During 2H'14

Financial news for MRK dated on 2014-03-05: UPDATE: Merck Plans to Initiate Phase 3 Clinical Development Program In Second Half Of 2014

Financial news for MRK dated on 2014-03-05: Merck's Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Naive Adults

Financial news for MRK dated on 2014-03-04: Merck Issues Results from Phase 2b Study of MK-8237, Says Secondary Efficacy Endpoints Average TNSS, DU Made Significant Dose, Time Dependent Reduction

Financial news for MRK dated on 2014-03-04: Biotechs vs. Pharmaceuticals: What's the Difference?

Financial news for MRK dated on 2014-03-03: The Top Five Dow Stocks In February

Financial news for MRK dated on 2014-02-28: Overvaluing Liquidity: Invest For The Future, Not For Today

Financial news for MRK dated on 2014-02-28: CHMP Issues Positive Opinion For Tablet Formulation Of Merck's NOXAFIL

Financial news for MRK dated on 2014-02-20: HB Reporting (via Bloomberg) Merck is Still Interested in More Purchases in the Pharma Group

Financial news for MRK dated on 2014-02-20: Merck Testing Multi-Year Highs

Financial news for MRK dated on 2014-02-20: Merck Reports FDA Acceptance for Review of BLA for V503

Financial news for MRK dated on 2014-02-20: FDA Accepts for Review Merck's Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine

Financial news for MRK dated on 2014-02-12: Merck Finds Resistance

Financial news for MRK dated on 2014-02-10: Three ETFs To Buy On The Pullback (PJP, SKYY, SPY)

Financial news for MRK dated on 2014-02-10: Merck, Samsung Bioepis Announce Deal to Develop Insulin Glargine Candidate

Financial news for MRK dated on 2014-02-07: Market Wrap For February 7: Jobs Report Not Great, But Not Too Bad

Financial news for MRK dated on 2014-02-07: Bloomberg Reporting Merck Has Reached Agreement in Principle to Resolve Suits Related to NuvaRing

Financial news for MRK dated on 2014-02-06: Bloomberg Reporting Merck Said to Agree to Pay \$100M Related to NuvaRing Settlement

Financial news for MRK dated on 2014-02-06: #PreMarket Primer: Thursday, February 6: Markets Taking A Breather After Twitter Earnings

Financial news for MRK dated on 2014-02-05: Market Wrap For February 5: Markets Unsure Of Which Direction To Take

Financial news for MRK dated on 2014-02-05: Merck Retreats From Highs

Financial news for MRK dated on 2014-02-05: Top Trending Tickers On StockTwits For February 5

Financial news for MRK dated on 2014-02-05: Stocks Hitting 52-Week Highs

Financial news for MRK dated on 2014-02-05: Benzinga's Top #PreMarket Gainers

Financial news for MRK dated on 2014-02-05: UPDATE: Merck Posts Drop In Q4 Profit

Financial news for MRK dated on 2014-02-05: Merck & Company, Inc. Sees FY2014 EPS \$3.35-3.53 vs \$3.47 Est; Sees Sales \$42.40B-43.20B vs \$43.54B Est

Financial news for MRK dated on 2014-02-05: US Stock Futures Flat; All Eyes On ADP Report

Financial news for MRK dated on 2014-02-05: Merck & Company, Inc. Reports Q4 Adjusted EPS of \$0.88, Inline; Revenue of \$11.32B vs \$11.36B Est

Financial news for MRK dated on 2014-02-05: Pfizer Confirms Collaboration with Merck on Innovative Anti-Cancer Combination Studies

Financial news for MRK dated on 2014-02-05: Incyte Confirms Clinical Trial Collaboration with Merck to Evaluate Combination of Two Novel Immunotherapies

Financial news for MRK dated on 2014-02-05: Merck Confirms Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475

Financial news for MRK dated on 2014-02-05: Amgen, Merck Announce Collaboration to Evaluate Investigational Combination Treatment for Advanced Melanoma

Financial news for MRK dated on 2014-02-05: Earnings Scheduled For February 5, 2014

Financial news for MRK dated on 2014-02-05: Stocks To Watch For February 5, 2014

Financial news for MRK dated on 2014-02-04: Merck Rallies Back

Financial news for MRK dated on 2014-02-04: SunTrust Robinson Humphrey Upgrades Merck & Company, Inc. to Buy

Financial news for MRK dated on 2014-02-03: Merck Receives Canadian Approval of Grastek

Financial news for MRK dated on 2014-02-03: Earnings Expectations For The Week Of February 3: GM, Twitter, Disney And More

Financial news for MRK dated on 2014-01-31: Market Wrap For January 31: Markets End January On Sour Note

Financial news for MRK dated on 2014-01-31: Reuters Reporting Merck Consumer Health Unit Could Get \$8-10B in Sale

Financial news for MRK dated on 2014-01-27: Market Wrap For January 27: China Concerns, Declining Home Sales, Tomorrow's Fed Meeting and Obama's Speech Keep Markets Lower

Financial news for MRK dated on 2014-01-27: Winter's Stock Knockdown May Give Way To A Spring Thaw

Financial news for MRK dated on 2014-01-27: UPDATE: Merck Upgraded by Morgan Stanley on Oncology Optimism

Financial news for MRK dated on 2014-01-27: Stocks Hitting 52-Week Highs

Financial news for MRK dated on 2014-01-27: Benzinga's Top Upgrades

Financial news for MRK dated on 2014-01-27: US Stock Futures Gain Ahead Of Home-Sales Data

Financial news for MRK dated on 2014-01-27: Morgan Stanley Upgrades Merck & Company, Inc. to Overweight, Announces \$60.00 PT

Financial news for MRK dated on 2014-01-24: Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

Financial news for MRK dated on 2014-01-15: Merck Pleased with FDA Advisory Committee Recommendation for Approval of Vorapaxar

Financial news for MRK dated on 2014-01-15: Market Wrap For January 15: Bulls Take Over As Economic Growth Remains Healthy

Financial news for MRK dated on 2014-01-15: Bloomberg First Word Reporting Merck Has Won FDA Advisory Panel Support for Vorapaxar

Financial news for MRK dated on 2014-01-14: Merck Voluntarily Recalls All Lots of Liptruzet, Cites Packaging Defects

Financial news for MRK dated on 2014-01-13: Benzinga's M&A Chatter for Monday January 13, 2014

Financial news for MRK dated on 2014-01-13: Market Wrap For January 13: Markets Showing Weakness Ahead Of Major Earning Releases

Financial news for MRK dated on 2014-01-13: Mid-Afternoon Market Update: Markets Dip Despite Large Amount of M&A

Financial news for MRK dated on 2014-01-13: Mid-Day Market Update: SodaStream Drops After Weak Outlook; Beam Shares Spike Higher

Financial news for MRK dated on 2014-01-13: Mid-Morning Market Update: Markets Open Lower; Lululemon Lowers Q4 Outlook

Financial news for MRK dated on 2014-01-13: Morning Market Movers

Financial news for MRK dated on 2014-01-13: Merck Initiates Rolling Submission to FDA of US Biologics License Application for MK-3475

Financial news for MRK dated on 2014-01-13: Merck Begins Enrollment of BLA for MK-3475, Sees Completing Application in 1H'14

Financial news for MRK dated on 2014-01-13: Benzinga's Top #PreMarket Gainers

Financial news for MRK dated on 2014-01-08: UPDATE: Novartis Could Swap Its Animal-Health, Human Vaccines Units for Merck's OTC Health-Products Unit

Financial news for MRK dated on 2014-01-08: Bloomberg Reporting Novartis Said to Be in Talks with Merck on \$5B Unit Swap

Financial news for MRK dated on 2014-01-08: Merck Receives FDA Approval for Isentress for Pediatric

Financial news for MRK dated on 2013-12-27: WSJ Reporting Merck on 'Radically Reshaping R&D'

Financial news for MRK dated on 2013-12-26: ALK Reports FDA Panel Will Review Ragweed Tablet

Financial news for MRK dated on 2013-12-26: Merck Sues to Stop Generic NuvaRing

Financial news for MRK dated on 2013-12-18: Merck Spikes Higher on Positive Jim Cramer/Mad Money Comments

Financial news for MRK dated on 2013-12-18: Merck Collaborates with GlaxoSmithKline on MK-3475

Financial news for MRK dated on 2013-12-17: Merck Says Vintafolide Has Won Orphan Drug Designation for Ovarian Cancer

Financial news for MRK dated on 2013-12-17: EMA Says Will Discuss Extension of Indication for Merck's Noxafil, Isentress, Pfizer's Vfend, Amgen's Xgeva, Vertex Pharma's Kalydeco

Financial news for MRK dated on 2013-12-12: FDA Reviewing Merck's Bid for Grastek; Panel Recommends Approval of Grastek;

Financial news for MRK dated on 2013-12-12: #PreMarket Primer: Thursday, December 12: US Budget Deal Gaining Momentum

Financial news for MRK dated on 2013-12-10: Merck Says Data Monitoring Committee Recommending Continuation of Phase II/III EPOCH Study for MK-8931

Financial news for MRK dated on 2013-12-09: Merck Agrees to settle Litigation over Jaw Injuries Caused by Fosamax -Reuters

Financial news for MRK dated on 2013-12-03: Bloomberg Reporting Merck, Eli Lilly Rumored to Be Interested in Novartis' Veterinary Unit

Financial news for MRK dated on 2013-11-26: Merck Raises Quarterly Dividend to \$0.44 from \$0.43

Financial news for MRK dated on 2013-11-26: FDA Okays Merck's Noxafil DR Tablets

Financial news for MRK dated on 2013-11-22: Merck Announces Position Opinion from CHMP on Update for Erbitux Metastatic Colorectal Cancer Labeling

Financial news for MRK dated on 2013-11-18: Investing in Companies Developing Promising Immunotherapy Drugs for Melanoma

Financial news for MRK dated on 2013-11-18: Merck's NDA for Noxafil Wins FDA Priority Review

Financial news for MRK dated on 2013-11-09: Merck's MK-7243 Significantly Reduced Allergy Symptoms in Adults and Children in Pivotal Phase III Study

Financial news for MRK dated on 2013-11-06: Job Cuts Higher in October; Pharmaceutical & Financial Sectors Took Biggest Hits

Financial news for MRK dated on 2013-11-04: Analysts Comment on Merck's Hep C Regimen Advances

Financial news for MRK dated on 2013-11-04: Merck Says Investigational V503 Prevented 97% of Cervical, Vaginal, Vulvar Pre-Cancers Caused by Five Added HPV Types

Financial news for MRK dated on 2013-11-01: BMO Capital Upgrades Merck & Company, Inc. to Outperform

Financial news for MRK dated on 2013-10-31: Market Wrap for October 31: Fed Worries Pull Stocks Lower

Financial news for MRK dated on 2013-10-29: US Stock Futures Flat Ahead Of Fed

Financial news for MRK dated on 2013-10-29: #PreMarket Primer: Tuesday, October 29: Fed Meeting Likely Uneventful

Financial news for MRK dated on 2013-10-29: Merck Presents Interim Data from Phase 1B Study of MK-3475 at 15th World Conference on Lung Cancer

Financial news for MRK dated on 2013-10-28: Think Silver: Top Stocks Catering to Seniors

Financial news for MRK dated on 2013-10-28: Mid-Afternoon Market Update: Markets Mixed as JC Penney Rises

Financial news for MRK dated on 2013-10-28: Mid-Day Market Update: Burger King Surges On Upbeat Earnings; Sohu Shares Dip

Financial news for MRK dated on 2013-10-28: Mid-Morning Market Update: Markets Mixed; Merck Profit Beats Estimates

Financial news for MRK dated on 2013-10-28: Merck's Q3 Call Just Beginning

Financial news for MRK dated on 2013-10-28: UPDATE: Merck Posts Upbeat Q3 Profit

Financial news for MRK dated on 2013-10-28: Merck & Company, Inc. Narrows FY2013 EPS Guidance from \$3.45-3.55 to \$3.48-3.52 vs \$3.47 Est

Financial news for MRK dated on 2013-10-28: Merck & Company, Inc. Reports Q3 EPS of \$0.92 vs \$0.88 Est; Revenue of \$11.03B vs \$11.19B Est

Financial news for MRK dated on 2013-10-28: #PreMarket Primer: Monday, October 28: All Eyes On Apple

Financial news for MRK dated on 2013-10-28: Earnings Scheduled For October 28, 2013

Financial news for MRK dated on 2013-10-28: Stocks To Watch For October 28, 2013

Financial news for MRK dated on 2013-10-27: Earnings Expectations For The Week Of October 28: Apple, Facebook, GM and More

Financial news for MRK dated on 2013-10-25: Benzinga Weekly Preview: FOMC Meeting Closely Watched

Financial news for MRK dated on 2013-10-25: Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)

Financial news for MRK dated on 2013-10-24: Merck Says Primary Endpoints Met for Investigational 9-Valent HPV Vaccine, Expecting to Submit BLA for V503 in 2013

Financial news for MRK dated on 2013-10-24: Merck Says Primary Endpoints Met for Investigational 9-Valent HPV Vaccine, Expecting to Submit BLA for V503 in 2013

Financial news for MRK dated on 2013-10-23: How Investors Can Play the "Losers" in Blue Chips

Financial news for MRK dated on 2013-10-22: Merck's MK-5172/MK-8742 Receives Breakthrough Therapy Designation from FDA

Financial news for MRK dated on 2013-10-16: Merck Confirms Development of Investigational Dosing ISENTRESS, Will Begin Phase III Trial Early 2014

Financial news for MRK dated on 2013-10-14: Merck, Endocyte Report Vintafolide-PLD Generally Well Tolerated, Showed Median PFS of Five Months

Financial news for MRK dated on 2013-10-14: UPDATE: Bernstein Downgrades Merck & Co. on Negative Outlook

Financial news for MRK dated on 2013-10-14: Barclays Downgrades Merck & Company, Inc. to Equalweight

Financial news for MRK dated on 2013-10-14: Benzinga's Top Downgrades

Financial news for MRK dated on 2013-10-14: Bernstein Downgrades Merck & Company, Inc. to Market Perform, Lowers PT to \$50.00

Financial news for MRK dated on 2013-10-11: Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

Financial news for MRK dated on 2013-10-11: Jefferies Downgrades Merck & Company, Inc. to Hold, Lowers PT to \$50.00

Financial news for MRK dated on 2013-10-08: Credit Suisse Starts Pfizer, Bristol-Myers, AbbVie, Allergan at Outperform, Merck, Eli Lilly, Forest Labs at Neutral

Financial news for MRK dated on 2013-10-08: FDA Postpones Advisory Committee Meeting for Grass Ait Tablet Due to US Government Shutdown

Financial news for MRK dated on 2013-10-07: Merck Says Data Shows Cognigram as Sensitive Assessment

Financial news for MRK dated on 2013-10-02: Pharmaceutical Industry Expected To Collect Billions From Obamacare

Financial news for MRK dated on 2013-10-01: Merck Shares Soar After Announcing More Job Cuts

Financial news for MRK dated on 2013-10-01: Merck Says Interim Data for MK-3475 to be Presented at 15th World Conference on Lung Cancer

Financial news for MRK dated on 2013-10-01: PreMarket Info Recap for October 1, 2013: Government Shutdown Gives Markets A Boost

Financial news for MRK dated on 2013-10-01: Merck Says Will Close Summit Campus, Will Move Global HQ to Kenilworth

Financial news for MRK dated on 2013-10-01: UPDATE: Merck Announces Global Initiative to Sharpen Commercial and R&D Focus; Cutting 8500 Jobs; Affirms FY Target

Financial news for MRK dated on 2013-10-01: Merck Cutting 8,500 Jobs Related to Global Initiative to 'Sharpen Commercial, R&D Focus,' Sees Pretax Charge \$2.5-3B, Reaffirms FY13 Outlook

Financial news for MRK dated on 2013-09-23: Merck Receives CRL for Investigational Medicine Sugammadex Sodium Injection

Financial news for MRK dated on 2013-09-19: Write A Prescription For Health Care ETFs

Financial news for MRK dated on 2013-09-14: Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)

Financial news for MRK dated on 2013-09-12: Watch Shares of Caterpillar, Deere, Devon, Merck, and Oracle to the Downside on a Bearish Article from Jim Cramer Tweeted Out by Carl Icahn

Financial news for MRK dated on 2013-09-11: US Stock Futures Flat; Apple Shares Drop In Pre-Market Trading

Financial news for MRK dated on 2013-09-11: Merck, AstraZeneca Announce License Agreement for MK-1775

Financial news for MRK dated on 2013-09-09: USA TD Ameritrade's Investor Movement Index for Aug 5.16 vs 4.87 Prior

Financial news for MRK dated on 2013-09-09: Merck Reports FDA Acceptance of NDA for Investigational Fertility Treatment

Financial news for MRK dated on 2013-09-04: Merck's Durham Site Receives US FDA License for Varicella Bulk

Financial news for MRK dated on 2013-08-30: Plenty Of ETFs With Favorable Risk Traits

Financial news for MRK dated on 2013-08-27: Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)

Financial news for MRK dated on 2013-08-26: Chicago Tribune Running Story 'Cargill to stop buying cows fed with questionable growth drug,' Related to Merck's Zillmax

Financial news for MRK dated on 2013-08-16: Merck Shares Down ~0.75% Today, But Have Been Relatively Quiet/Rangebound All Day; Traders Seemed to Shrug at Earlier Report Co. to Temporarily Halt Zilmax Sales

Financial news for MRK dated on 2013-08-14: 13F from Leon Cooperman's Omega Advisors Shows New Stakes in Thermo-Fisher, McKesson, Liquidated Stakes in Freeport-McMoRan, Facebook, Covidien, Raised Stakes in DISH, Citi, Lowered Stakes in Merck, AIG, Polycom

Financial news for MRK dated on 2013-08-13: Mid-Afternoon Market Update: Apple Rises Sharply On Icahn Stake, NASDAQ Pulled Upward

Financial news for MRK dated on 2013-08-13: Mid-Day Market Update: US Stocks Edge Higher; Valspar Shares Decline On Downbeat Results

Financial news for MRK dated on 2013-08-13: Mid-Morning Market Update: Markets Drop, Yum China Same-Store Sales Down 13%

Financial news for MRK dated on 2013-08-13: Benzinga's Top Pre-Market Gainers

Financial news for MRK dated on 2013-08-12: Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck

Financial news for MRK dated on 2013-08-05: Hearing Unconfirmed Takeover Chatter in Inovio

Financial news for MRK dated on 2013-08-05: Apple, Wal-Mart And Other Companies With Monster Share Buyback (AAPL, WMT)

Financial news for MRK dated on 2013-08-02: S&P: Heaping Praise For Some Health Care ETFs

Financial news for MRK dated on 2013-08-02: Three Soaring, But Overlooked Health Care ETFs

Financial news for MRK dated on 2013-07-31: Bionomics Signs Option and License Agreement With Merck

Financial news for MRK dated on 2013-07-31: Benzinga Market Primer: Wednesday, July 31: Futures Higher Heading Into FOMC Decision

Financial news for MRK dated on 2013-07-30: SLIDESHOW: 8 Stocks to Benefit From a Repatriation Deal In Congress

Financial news for MRK dated on 2013-07-30: Benzinga's PreMarket Info Recap for July 30, 2013: Potash Smash!

Financial news for MRK dated on 2013-07-30: UPDATE: Merck Posts Drop In Q2 Profit

Financial news for MRK dated on 2013-07-30: Merck & Company, Inc. Reports Q2 EPS of \$0.84 vs \$0.83 Est; Revenue of \$11.0B vs \$11.22B Est

Financial news for MRK dated on 2013-07-30: Benzinga Market Primer: Wednesday, July 30: Futures Higher After Asia Turnaround

Financial news for MRK dated on 2013-07-28: Earnings Expectations for the Week of July 29

Financial news for MRK dated on 2013-07-26: Weekly Preview: Earnings Season Continues, Fed In Focus, Economic Maelstrom Expected

Financial news for MRK dated on 2013-07-26: Short Interest in Pharmacocyclics Plunges (AMGN, ONXX, PCYC)

Financial news for MRK dated on 2013-07-26: Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin

Financial news for MRK dated on 2013-07-24: UPDATE: Merck Announces FDA Acceptance of New Drug Application for Vorapaxar, Investigational Anti-Thrombotic Medicine

Financial news for MRK dated on 2013-07-24: Merck Announces FDA Acceptance of NDA for Vorapaxar

Financial news for MRK dated on 2013-07-18: BMO Capital Downgrades Merck & Company, Inc. to Market Perform

Financial news for MRK dated on 2013-07-16: Merck in Talks with FDA to Identify Steps Needed for Review of Sugammadex Sodium Injection

Financial news for MRK dated on 2013-07-16: Eli Lilly Tries Again with Alzheimer's Drug as the Race for a Cure Continues (LLY)

Financial news for MRK dated on 2013-07-16: Life Technologies to Collaborate with Merck Serono for Companion Diagnostics Development and Commercialization

Financial news for MRK dated on 2013-07-15: Health Care ETFs Looking Healthy Ahead of Earnings

Financial news for MRK dated on 2013-07-12: Sanofi Pasteur Vaccine Suspended as Precautionary Measure - WHO Citing Quality Problem

Financial news for MRK dated on 2013-07-12: UPDATE: Jefferies Lowers PT on Merck on Challenges Ahead

Financial news for MRK dated on 2013-07-12: Jefferies Maintains Buy on Merck & Company, Inc., Lowers PT to \$54.00

Financial news for MRK dated on 2013-07-11: Short Interest Rises in Gilead Sciences, Onyx Pharmaceuticals (BIIB, GILD, ONXX)

Financial news for MRK dated on 2013-07-04: Financial Times Reporting That China Is Investigating 33 Foreign Pharmaceutical Companies For Pricing Irregularities

Financial news for MRK dated on 2013-07-02: Pfizer and Novartis Could Be Eyeing Onyx (PFE, NVS, ONXX)

Financial news for MRK dated on 2013-07-01: FDA Approves New U.S. Labeling for ISENTRESS(r) (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients

Financial news for MRK dated on 2013-07-01: Merck Receives Complete Response Letter for Suvorexant, Merck's Investigational Medicine for Insomnia; FDA Says Data Does Not Support Approval of Suvorexant 30mg and 40mg

Financial news for MRK dated on 2013-07-01: Merck Receives CRL for Suvorexant

Financial news for MRK dated on 2013-06-27: Aspen Pharmacare to Acquire Netherlands Plant, Portfolio of 11 Drug Brands from Merck for \$1B -Reuters

Financial news for MRK dated on 2013-06-26: Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)

Financial news for MRK dated on 2013-06-24: UPDATE: BMO Capital Markets Lowers PT on Merck Following New SGLT2 Data

Financial news for MRK dated on 2013-06-24: BMO Capital Maintains Outperform on Merck & Company, Inc., Lowers PT to \$52.00

Financial news for MRK dated on 2013-06-18: Interesting Similarities Among 2013's Top-Performing ETFs

Financial news for MRK dated on 2013-06-17: Mylan Being Sued by Pfizer, Merck, Want Blockage of Proposed Copy of Azasite

Financial news for MRK dated on 2013-06-14: Dow Jones Reporting Merck to Cut Jobs, Change Organizational Structure of R&D Unit

Financial news for MRK dated on 2013-06-12: Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)

Financial news for MRK dated on 2013-06-12: FDA Says Considering New Study of Incretin Mimetic Diabetes Drug, Says May Need to Look for Cancer-Link Patterns

Financial news for MRK dated on 2013-06-10: Merck Loses US Appeal of Apotex Patent Win Over Nasonex

Financial news for MRK dated on 2013-06-07: UPDATE: Jefferies Raises PT on Merck & Co. Following Global Pharma Review

Financial news for MRK dated on 2013-06-07: Jefferies Maintains Buy on Merck & Company, Inc., Raises PT to \$56.00

Financial news for MRK dated on 2013-06-04: With Bond Yields So Low, Reluctant Investors Are Now Making the Move into These Stocks

Financial news for MRK dated on 2013-06-03: ISM Manufacturing Index Drops in May, Shows Contraction

Financial news for MRK dated on 2013-06-03: Benzinga's Top Pre-Market Gainers

Financial news for MRK dated on 2013-05-29: SunTrust Robinson Humphrey Initiates Coverage on Merck & Company, Inc. at Neutral, Announces \$47.00 PT

Financial news for MRK dated on 2013-05-29: Short Interest in Vertex Rises, in Biogen Idec Falls

Financial news for MRK dated on 2013-05-28: UPDATE: Jefferies Upgrades Merck to Buy, Raises PT Following SOTP Analysis

Financial news for MRK dated on 2013-05-28: PreMarket Info Recap for May 28, 2013

Financial news for MRK dated on 2013-05-28: Jefferies Upgrades Merck & Company, Inc. to Buy, Raises PT to \$54.00

Financial news for MRK dated on 2013-05-23: Merck Issues Update on Phase III Trial for Preladenant

Financial news for MRK dated on 2013-05-22: Merck Issues Statement on FDA Advisory Committee Meeting Results for Suvorexant

Financial news for MRK dated on 2013-05-22: FDA Panel Votes 8-7 Merck's Suvorexant Unsafe in Higher Doses

Financial news for MRK dated on 2013-05-22: FDA Panel Votes 13-3 Merck's Suvorexant is Safe in Low Doses

Financial news for MRK dated on 2013-05-22: FDA Panel Finds Merck Doesn't Need to Study 10mg Suvorexant

Financial news for MRK dated on 2013-05-22: FDA Says Merck Insomnia Drug Helps Patients Stay Asleep -Bloomberg

Financial news for MRK dated on 2013-05-22: FDA Panel Votes 12 Yes 4 No on Effectiveness of Merck Insomnia Drug

Financial news for MRK dated on 2013-05-22: PreMarket Info Recap for May 22, 2013

Financial news for MRK dated on 2013-05-22: Merck FDA Advisory Committee Meeting for Insomnia Drug Suvorexant Begins at 8 AM ET

Financial news for MRK dated on 2013-05-21: Merck to Take Initial Delivery of ~99.5M Shares

Financial news for MRK dated on 2013-05-21: Merck Announces \$5B Accelerated Buyback Plan

Financial news for MRK dated on 2013-05-20: ISI Suggesting the FDA Report on Merck Points to 'Some Risk' from Panel

Financial news for MRK dated on 2013-05-15: Merck Prices \$6.5B Debt Offering

Financial news for MRK dated on 2013-05-14: Moody's Downgrades Merck's Guaranteed Senior Unsecured Rating from Aa3 to A1

Financial news for MRK dated on 2013-05-11: Short Interest in Vertex Rises, in Celgene Falls

Financial news for MRK dated on 2013-05-09: Merck, Glaxo Reduce Prices 95% for HPV Vaccine in Poor Nations

Financial news for MRK dated on 2013-05-08: Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet

Financial news for MRK dated on 2013-05-06: Barron's Recap: Apple Tops the Barron's 500

Financial news for MRK dated on 2013-05-03: FDA Approves Merck's LIPTRUZET for Hyperlipidemia Treatment

Financial news for MRK dated on 2013-05-03: UPDATE: Fitch Affirms Ratings on Merck; Outlook Lowered from Positive to Negative

Financial news for MRK dated on 2013-05-03: Fitch Affirms ratings on Merck; Outlook Lowered from Positive to Negative

Financial news for MRK dated on 2013-05-01: Earnings Trigger Volume Spike in Pharma ETF

Financial news for MRK dated on 2013-05-01: May 1st Watchlist

Financial news for MRK dated on 2013-05-01: Merck (CC): R&D Chief Calls Erosion on Singulair Sales 'Faster Than Expected,' Says Victrelis Sales Harmed in US, France, Germany

Financial news for MRK dated on 2013-05-01: From Merck Conference Call: Q1 Results 'Not Indicative of the Future'

Financial news for MRK dated on 2013-05-01: UPDATE: Merck Posts 8.3% Drop In Q1 Profit, Lowers Forecast

Financial news for MRK dated on 2013-05-01: Merck Announces New \$15B Buyback Plan

Financial news for MRK dated on 2013-05-01: Merck & Company, Inc. Lowers FY2013 EPS Guidance from \$3.60-3.70 to \$3.45-3.55 vs \$3.63 Est

Financial news for MRK dated on 2013-05-01: Merck & Company, Inc. Reports Q1 EPS of \$0.85 vs \$0.79 Est; Revenue of \$10.70B vs \$11.09B Est

Financial news for MRK dated on 2013-05-01: Merck Announces New \$15B Share Repurchase Program

Financial news for MRK dated on 2013-04-30: Pfizer Tanks on Earnings, Unhealthy Guidance

Financial news for MRK dated on 2013-04-29: Merck Wins FOSAMAX Federal Bellwether Trial Involving Atypical Femur Fracture Claims

Financial news for MRK dated on 2013-04-29: Market Wrap for Monday, April 29: Stocks Start Week With a Rally

Financial news for MRK dated on 2013-04-29: Merck, Pfizer Announce Worldwide Collaboration Deal for Development, Commercialization of Ertugliflozin

Financial news for MRK dated on 2013-04-28: Earnings Expectations for the Week of April 29

Financial news for MRK dated on 2013-04-28: A Look Ahead: This Week's ETFs to Watch

Financial news for MRK dated on 2013-04-26: Weekly Preview: Focus Shifts from Earnings to Economy

Financial news for MRK dated on 2013-04-26: Short Sellers Move into Celgene, Regeneron

Financial news for MRK dated on 2013-04-25: Stocks to Watch for April 25, 2013

Financial news for MRK dated on 2013-04-22: Merck & Co. Currently up \$0.33 to \$47.82;

\$0.17 Away from 52-Week and Multi-Year High

Financial news for MRK dated on 2013-04-19: UPDATE: BMO Capital Markets Raises PT on Merck & Co. on 1Q13 Preview, Long-Term Outlook

Financial news for MRK dated on 2013-04-19: BMO Capital Maintains Outperform on Merck & Company, Inc., Raises PT to \$51.00

Financial news for MRK dated on 2013-04-12: Merck Sees Odanacatib US, EU Filing in 2014

Financial news for MRK dated on 2013-04-12: Benzinga Market Primer: Friday, April 12

Financial news for MRK dated on 2013-04-11: ETF Showdown: A Pharma Fight

Financial news for MRK dated on 2013-04-11: Court Says Merck Victory Upholding Vytorin Patents Will Stand, Says Mylan Can't Sell Copies of Vytorin, Zetia Before Apr. 2017

Financial news for MRK dated on 2013-04-10: Short Sellers Move Out of Amgen, Celgene, Pharmacyclics

Financial news for MRK dated on 2013-04-10: UPDATE: Jefferies Raises PT on Merck & Co. on Positive Outlook

Financial news for MRK dated on 2013-04-10: Merck Announces FDA Acceptance of NDA for NOXAFIL Investigational Tablet Formulation

Financial news for MRK dated on 2013-04-10: Jefferies Maintains Hold on Merck & Company, Inc., Raises PT to \$48.00

Financial news for MRK dated on 2013-04-09: Merck Receives Positive Mad Money/Jim Cramer Mention -CNBC

Financial news for MRK dated on 2013-04-08: Golden Crosses Over The Past Trading Week (50 SMA Cross Above 200 SMA) CMG, LO, MRK, PRGO, SO, WMT, YUM

Financial news for MRK dated on 2013-04-08: Cheap Does not Always Mean BUY

Financial news for MRK dated on 2013-04-04: 2 New Dividend ETFs to Consider

Financial news for MRK dated on 2013-03-27: Merck Announces FDA Acceptance of Biologics License App for Investigational Grass Pollen Allergy Immunotherapy Tablet

Financial news for MRK dated on 2013-03-26: The Supreme Court is About to Stick it to Big Pharma

Financial news for MRK dated on 2013-03-26: Risk On Rally? These ETFs Say No

Financial news for MRK dated on 2013-03-26: EMA Investigating Pancreatic Risks with GLP-1 Diabetes Drugs

Financial news for MRK dated on 2013-03-25: Bank of America Reiterates Buy Rating, \$47 PT on Merck & Co. Ahead of Potential Approvals

Financial news for MRK dated on 2013-03-15: Reuters Reporting Merck Saying FDA Extended Review of Sugammadex

Financial news for MRK dated on 2013-03-14: Embrace These New ETFs

Financial news for MRK dated on 2013-03-13: The Top 20 African-American CEOs in Business Today

Financial news for MRK dated on 2013-03-13: Bank of America Reiterates Buy Rating, \$47 PT on Merck & Co. Following IMPROVE-IT Trial Review

Financial news for MRK dated on 2013-03-12: Unusual Options Alert: Merck & Co. Continues To Do Extremely Heavy Volume

Financial news for MRK dated on 2013-03-12: Short Interest Swings in Biotech Stocks (AMGN, CELG, PCYC)

Financial news for MRK dated on 2013-03-12: Lawyer Tells Jury in Merck Case Over Fosamax Co. Hid Product's Bone-Weakening Risks

Financial news for MRK dated on 2013-03-12: Merck Issues Update on IMPROVE-IT Trial, Says DSMB Recommend Study to Continue

Financial news for MRK dated on 2013-03-08: Top 4 NYSE Stocks In The Drug

Manufacturers-Major Industry With The Highest Dividend Yield

Financial news for MRK dated on 2013-03-07: Merck Announces Appointment of Roger M. Perlmutter, M.D., Ph.D., As President of Merck Research Laboratories; Peter S. Kim, Ph.D., to Retire

Financial news for MRK dated on 2013-03-06: 3 Sector ETFs Outpacing Larger Rivals

Financial news for MRK dated on 2013-03-06: From Merck Presentation for Cowen Healthcare Conference: Sees V503 for Cancer Endpoint Driven Trial Filing This Year, V212 Filing for HCT, V419 Pediatric Combo Vaccine Filing Next Year

Financial news for MRK dated on 2013-03-06: Hedging The Dow At Its All-Time High

Financial news for MRK dated on 2013-03-04: An HIV Cure Is Great News For These Drug Manufacturers

Financial news for MRK dated on 2013-03-04: Cardiome Ends Line of Credit Merck, to Buy Added \$3M of Vernakalant IV Inventory

Financial news for MRK dated on 2013-03-04: UPDATE: Bank of America Upgrades Merck to Buy; Pullback Creates Meaningful Upside Potential

Financial news for MRK dated on 2013-03-04: Bank of America Upgrades Merck & Company, Inc. to Buy, Maintains \$47.00 PO

Financial news for MRK dated on 2013-02-28: If The Market Falls, Try These Low Beta ETFs

Financial news for MRK dated on 2013-02-27: Still No Herbalife in 13F ETFs

Financial news for MRK dated on 2013-02-25: UPDATE: Jefferies Reiterates Hold Rating, Lowers PT on Merck & Co. on IMPROVE-IT Overhang Removal

Financial news for MRK dated on 2013-02-25: Jefferies Maintains Hold on Merck & Company, Inc., Lowers PT to \$46.00

Financial news for MRK dated on 2013-02-15: BMO Capital Maintains Outperform on Merck & Company, Inc., Lowers PT to \$47.00

Financial news for MRK dated on 2013-02-14: Merck Resolves Securities Class-Action Suit Related to ENHANCE, to Record \$493M Charge

Financial news for MRK dated on 2013-02-13: Merck Shares Down 0.6% Premarket Following Outlook Update

Financial news for MRK dated on 2013-02-13: Merck Sees Q1 Adj.EPS \$0.76-0.78 vs \$0.86 Est

Financial news for MRK dated on 2013-02-13: Merck Reaffirms Outlook

Financial news for MRK dated on 2013-02-12: Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

Financial news for MRK dated on 2013-02-07: Mylan Loses Appeals Court Bid to Invalidate Zetia Patents

Financial news for MRK dated on 2013-02-05: Merck Serono, Opexa Therapeutics Enter Option, License Agreement for Development of Tcelna

Financial news for MRK dated on 2013-02-04: UPDATE: BMO Capital Markets Reiterates Outperform Rating, Lowers PT on Merck & Co.

Financial news for MRK dated on 2013-02-04: UPDATE: Morgan Stanley Downgrades Merck to Underweight Ahead of Key March Trial

Financial news for MRK dated on 2013-02-04: Leerink Swann Downgrades Merck & Company, Inc. to Market Perform

Financial news for MRK dated on 2013-02-04: Morgan Stanley Downgrades Merck & Company, Inc. to Underweight, Removes \$43.00 PT

Financial news for MRK dated on 2013-02-01: Hearing Merck Defded at Credit Suisse

Financial news for MRK dated on 2013-02-01: Merck & Company, Inc. Reports Q4 EPS of \$0.83 vs \$0.81 Est; Revenue of \$11.74B vs \$11.54B Est

Financial news for MRK dated on 2013-02-01: US Stock Futures Up; All Eyes On Payroll Data

Financial news for MRK dated on 2013-02-01: Earnings Scheduled For February 1, 2013

Financial news for MRK dated on 2013-02-01: Stocks To Watch For February 1, 2013

Financial news for MRK dated on 2013-01-30: Isis and Sanofi's Drug OK'd to Treat Inherited Cholesterol Disease

Financial news for MRK dated on 2013-01-25: FDA Approves OXYTROL for Women

Financial news for MRK dated on 2013-01-16: UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Merck & Co.

Financial news for MRK dated on 2013-01-16: Jefferies Maintains Hold on Merck & Company, Inc., Lowers PT to \$47.00

Financial news for MRK dated on 2013-01-11: Three Stocks to Buy for Flu Season

Financial news for MRK dated on 2013-01-11: Merck to Suspend Availability of TREDAPTIVE Worldwide

Financial news for MRK dated on 2013-01-09: Microbiotix, Merck Announce Licensing Pact for HCV NS5B

Financial news for MRK dated on 2013-01-07: 4 Health Care ETFs Your Broker Forgot to Mention

Financial news for MRK dated on 2013-01-07: Merck Receives FDA Acceptance of Resubmission of NDA for Sugammadex Sodium Injection

Financial news for MRK dated on 2013-01-03: Merck, Pfizer, Abbott, J&J, Sanofi Said to Show Interest in Bausch & Lomb Bid - Bloomberg

Financial news for MRK dated on 2013-01-02: Merck Says FDA Acknowledged Resubmission of NDA for Ezetimibe, Atorvastatin Tablets

Financial news for MRK dated on 2012-12-28: Merck Sends Dear Doctor Letter Related to Tredaptive's Failed Study, Says Side Effects Include Muscle, Skin, Blood Damage

Financial news for MRK dated on 2012-12-26: Option Alert: Merck January 45 Call; Block Trade: 7,000 Contracts @\$0.03; Currently \$41.31

Financial news for MRK dated on 2012-12-20: Goldman Sachs Maintains Neutral on Merck & Company, Inc., Lowers PT to \$47.00

Financial news for MRK dated on 2012-12-20: Mid-Morning Market Update: Rite Aid Rallies, New York Stock Exchange Acquired by ICE

Financial news for MRK dated on 2012-12-20: Merck Says HPS2-THRIVE Study of TREDAPTIVE Did Not Achieve Primary Endpoint

Financial news for MRK dated on 2012-12-18: Merck, GE Healthcare Announce Collaboration on Use of Imaging Biomarkers for Investigational BACE Inhibitor Program

Financial news for MRK dated on 2012-12-16: These 2 Dow Laggards Could Rebound in 2013

Financial news for MRK dated on 2012-12-11: Benzinga's Small Cap Movers for Tuesday December 11, 2012

Financial news for MRK dated on 2012-12-11: Benzinga's M&A Chatter for Tuesday December 11, 2012

Financial news for MRK dated on 2012-12-11: Warburg Pincus Said to Hire Goldman Sachs to Sell Bausch & Lomb, Seeking At Least \$10B; Abbott, Glaxo, Merck, Sanofi Said to Be Contacted - Bloomberg

Financial news for MRK dated on 2012-12-11: Cardiome Reaches Deal with Merck to Retire Debt/Close Line of Credit; Will Pay Merck \$20M

Financial news for MRK dated on 2012-12-10: Three More Defensive Stock Picks for 2013 (LLY, PFE, VTR)

Financial news for MRK dated on 2012-12-08: Barron's Recap (12/8/12): Ten Stock Picks for 2013

Financial news for MRK dated on 2012-12-03: Merck Files Debt Securities Shelf

Financial news for MRK dated on 2012-12-03: Merck Begins Phase II/III Study of

Investigational BACE Inhibitor, MK-8931

Financial news for MRK dated on 2012-11-30: Citigroup Initiates Coverage on Merck & Company, Inc. at Neutral, Announces \$44.00 PT

Financial news for MRK dated on 2012-11-27: Merck Increases Dividend to \$0.43 from \$0.42

Financial news for MRK dated on 2012-11-20: Merck Receives FDA Orphan Status for Melanoma Treatment

Financial news for MRK dated on 2012-11-20: MKM Partners Upgrades Merck & from Neutral to Buy, Raises PT from \$47 to \$51

Financial news for MRK dated on 2012-11-20: Benzinga's Top Upgrades

Financial news for MRK dated on 2012-11-16: S&P Reiterates Bullish View on Health Care ETFs

Financial news for MRK dated on 2012-11-14: These ETFs Offer Solid Yield in Uncertain Times

Financial news for MRK dated on 2012-11-12: Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

Financial news for MRK dated on 2012-11-12: UPDATE: BMO Capital Markets Upgrades Merck & Co. to Outperform, Reiterates \$50 PT

Financial news for MRK dated on 2012-11-12: BMO Capital Markets Upgrades Merck & from Market Perform to Outperform, Maintains PT at \$50

Financial news for MRK dated on 2012-11-12: Merck Presents Early-Stage Interim Data for MK-3475 Study for Treatment of Advanced Melanoma

Financial news for MRK dated on 2012-11-08: Futures Flat, Euro Falls Ahead of Central Banks

Financial news for MRK dated on 2012-11-03: Moves in Smaller Health Care Stocks (GMED, SEM, UAM, VRTX)

Financial news for MRK dated on 2012-10-30: More Equal-Weight ETFs Your Broker Forgot to Mention

Financial news for MRK dated on 2012-10-29: UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Raises PT on Merck & Co.

Financial news for MRK dated on 2012-10-29: BMO Capital Markets Maintains Merck & at Market Perform, Raises PT from \$46 to \$50

Financial news for MRK dated on 2012-10-26: Merck Begins Earnings Call

Financial news for MRK dated on 2012-10-26: S&P Bullish on Select Dividend ETFs

Financial news for MRK dated on 2012-10-26: Merck & Reports Q3 EPS \$0.92 vs \$0.92 Est; Revenues \$11.49B vs \$11.57B Est

Financial news for MRK dated on 2012-10-26: Benzinga Market Primer, Friday, October 26

Financial news for MRK dated on 2012-10-26: US Stock Futures Down After Apple Earnings

Financial news for MRK dated on 2012-10-26: Earnings Scheduled For October 26, 2012

Financial news for MRK dated on 2012-10-26: Stocks To Watch For October 26, 2012

Financial news for MRK dated on 2012-10-26: Stocks To Watch For October 26, 2012

Financial news for MRK dated on 2012-10-24: S&P Likes a Trio of Biotech ETFs

Financial news for MRK dated on 2012-10-22: Earnings Expectations for the Week of October 22

Financial news for MRK dated on 2012-10-15: Barclays Maintains Merck & at Overweight, Raises PT from \$46 to \$50

Financial news for MRK dated on 2012-10-15: A Peek Into The Market Before The Trading Starts

Financial news for MRK dated on 2012-10-15: AiCuris, Merck Enter Exclusive Worldwide License Agreement

Financial news for MRK dated on 2012-10-13: Merck BMD Data from a Phase II Study of Odanacatib Shows Significantly Increased Bone Mineral Density

Financial news for MRK dated on 2012-10-12: Jefferies & Company Maintains Merck & at Hold, Raises PT from \$44 to \$47

Financial news for MRK dated on 2012-10-09: Part I: Must Know ETFs For Q3 Earnings

Financial news for MRK dated on 2012-10-09: Merck to Move Global Headquarters Within New Jersey

Financial news for MRK dated on 2012-10-08: Delphi Genetics Grants Merck License for the Use of the StabyExpress System

Financial news for MRK dated on 2012-10-01: Deutsche Bank Suspends Coverage on Merck &

Financial news for MRK dated on 2012-10-01: Merck HPV Vaccine Shown to be Safe in a Kaiser Study

Financial news for MRK dated on 2012-09-26: Merck Returns Rights for Vernakalant to Cardiome

Financial news for MRK dated on 2012-09-25: S&P Highlights Election ETFs

Financial news for MRK dated on 2012-09-19: Pfizer, Merck Set Up Chinese Joint Ventures for Generic Drugs -WantChinaTimes

Financial news for MRK dated on 2012-09-13: Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer

Financial news for MRK dated on 2012-09-10: Merck Announces New Phase III Data for Suvorexant, Says Patients Normal Sleep Patterns Return After Stopping Use

Financial news for MRK dated on 2012-08-26: Merck Provides Update on Cardiovascular Development Programs

Financial news for MRK dated on 2012-08-24: UPDATE: Bank of America Merrill Lynch Downgrades Merck to Neutral, Reiterates \$45 PT

Financial news for MRK dated on 2012-08-24: Bank of America Downgrades Merck & from Buy to Neutral, Announces PO of \$45

Financial news for MRK dated on 2012-08-16: S&P Still Bullish on Health Care ETFs

Financial news for MRK dated on 2012-08-13: Jefferies & Company Maintains Merck & Co. at Hold, Raises PT from \$42 to \$44

Financial news for MRK dated on 2012-08-13: Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield

Financial news for MRK dated on 2012-08-09: Under The Hood: Tempting Technicals And a Dividend

Financial news for MRK dated on 2012-08-09: Credit Suisse Maintains Merck & at Outperform, Lowers PT from \$48 to \$47

Financial news for MRK dated on 2012-07-30: UBS Maintains Merck & at Buy, Raises PT from \$45 to \$50

Financial news for MRK dated on 2012-07-30: BMO Capital Markets Maintains Merck & at Market Perform, Raises PT from \$43 to \$46

Financial news for MRK dated on 2012-07-30: Benzinga Market Primer, Monday July 30

Financial news for MRK dated on 2012-07-27: Merck on Call Says Expecting Multiple Generic Singulair Entrants on Day One

Financial news for MRK dated on 2012-07-27: UPDATE: Merck Beats EPS Estimates by \$0.03 and Beats Revenues Estimates While Reaffirming FY2012 Guidance

Financial news for MRK dated on 2012-07-27: Merck Reports Q2 Vytorin Sales \$445M vs \$432.3M Est; Q2 Remicade Sales \$518M vs \$545M Est

Financial news for MRK dated on 2012-07-27: Benzinga Market Primer, Friday July 27

Financial news for MRK dated on 2012-07-27: Merck says Suvorexant, Odanacatib Filings on Track

Financial news for MRK dated on 2012-07-27: Merck & Reports Q2 EPS \$1.05 vs \$1.01 Est; Revenues \$12.2B vs \$12.15B Est

Financial news for MRK dated on 2012-07-27: US Stock Futures Up; GDP Data In Focus

Financial news for MRK dated on 2012-07-27: Earnings Scheduled For July 27

Financial news for MRK dated on 2012-07-27: Stocks To Watch For July 27

Financial news for MRK dated on 2012-07-23: From Earlier: Merck ISENTRESS in Combination Therapy Demonstrated Long-Term Efficacy, Safety and Tolerability in Previously Untreated Adult Patients with HIV-1 for up to 240 Weeks

Financial news for MRK dated on 2012-07-23: Earnings Expectations for the Week of July 23

Financial news for MRK dated on 2012-07-22: ISENTRESS in Combination Therapy Demonstrated Long-Term Efficacy, Safety and Tolerability in Previously Untreated Adult Patients with HIV-1

Financial news for MRK dated on 2012-07-19: Alnylam In Talks On Cholesterol Drug Partnership, CEO Says, Has Completed Phase I Clinical Trial Of Drug

Financial news for MRK dated on 2012-07-18: Kapito: 'We Like ATT, VZ, MRK, JNJ for Yields''

Financial news for MRK dated on 2012-07-18: Morgan Stanley Maintains Merck & Co. at Equal-weight, Raises PT from \$37 to \$43

Financial news for MRK dated on 2012-07-17: Merck Says Court Approves Proposed Erisa Settlement

Financial news for MRK dated on 2012-07-17: Popular Drug Manufacturing Stocks Among Hedge Funds

Financial news for MRK dated on 2012-07-13: Low Volume, High Returns for These ETFs (BIB, FHC, DRW)

Financial news for MRK dated on 2012-07-13: 5 Market-Based ETFs Your Broker Forgot to Mention (HDIV, OFF, PDP)

Financial news for MRK dated on 2012-07-13: Social Media Outlook, Friday July 13

Financial news for MRK dated on 2012-07-13: Jefferies & Company Maintains Merck & Co. at Hold, Raises PT from \$40 to \$42

Financial news for MRK dated on 2012-07-12: Merck Hits 4-Year High Thursday on Positive Phase 3 Osteoporosis Drug Data -IBD

Financial news for MRK dated on 2012-07-12: Thursday Market Movers

Financial news for MRK dated on 2012-07-12: UPDATE: Citigroup Upgrades Merck; Raises PT

Financial news for MRK dated on 2012-07-12: From Earlier: Update on Phase III Trial for Odanacatib, Merck's Investigational Cat-K Inhibitor for Osteoporosis

Financial news for MRK dated on 2012-07-12: Benzinga's Top Pre-Market Gainers

Financial news for MRK dated on 2012-07-12: Goldman Sachs Maintains Merck & Co. at Neutral, Raises PT from \$41 to \$45

Financial news for MRK dated on 2012-07-12: Benzinga's Top Upgrades

Financial news for MRK dated on 2012-07-12: Citigroup Upgrades Merck & from Neutral to Buy, Raises PT from \$34 to \$50

Financial news for MRK dated on 2012-07-11: Study for Merck's Investigational Cat-K Inhibitor for Osteoporosis Meets Outcomes and Is Concluded Early

Financial news for MRK dated on 2012-07-11: Merck Announces Collaboration to Improve Maternal Health through Expanded Access to Family Planning

Financial news for MRK dated on 2012-07-10: Deutsche Bank Maintains Merck & at Buy, Raises PT from \$43 to \$47.25

Financial news for MRK dated on 2012-07-10: Dendreon, Pharmacyclics and Other Biotech Takeover Targets

Financial news for MRK dated on 2012-06-29: ALPS Unveils Dogs of the Dow ETF

Financial news for MRK dated on 2012-06-28: Ultimate Stock Watch List for The Supreme Court's Health Care Ruling

Financial news for MRK dated on 2012-06-27: A Peek Into The Market Before The Trading Starts

Financial news for MRK dated on 2012-06-27: Merck and AstraZeneca Agree to Amend Partnership

Financial news for MRK dated on 2012-06-26: Leveraged ETFs for the Obamacare Ruling

Financial news for MRK dated on 2012-06-26: Benzinga's M&A Chatter for Tuesday June 26, 2012

Financial news for MRK dated on 2012-06-26: Spokesperson for Amylin Pharmaceuticals Won't Comment on Rumor of Bids from Pharma Companies

Financial news for MRK dated on 2012-06-26: Amylin Pharmaceuticals Spiking to Highs on Earlier Bid Reports

Financial news for MRK dated on 2012-06-26: Novartis, Sanofi, Merck, Bristol, AstraZeneca Weigh Amylin Final Bids; Amylin Expects Final Bids Starting End of the Week -Reuters

Financial news for MRK dated on 2012-06-25: Ahead of Obamacare Ruling, S&P Likes Health Care SPDR

Financial news for MRK dated on 2012-06-22: Merck Spikes to New 52-Week High on Heavy Volume; \$40.18

Financial news for MRK dated on 2012-06-20: Merck Statement on CDC Advisory Committee on Immunization Practices' Recommendation for Pneumococcal Vaccination in Immunocompromised Adults

Financial news for MRK dated on 2012-06-18: Geisinger and Merck to Collaborate on Multi-year Effort to Improve Patient Adherence, Engagement and Care Delivery

Financial news for MRK dated on 2012-06-18: From Earlier: U.S. District Court Rules Against Merck in NASONEX Patent Lawsuit

Financial news for MRK dated on 2012-06-15: US District Court Rules Against Merck in NASONEX Patent Lawsuit

Financial news for MRK dated on 2012-06-14: Believe In The Rally? Try These ETFs (HDV, IYZ, HYD)

Financial news for MRK dated on 2012-06-14: Johnson & Johnson to Complete Synthes Acquisition

Financial news for MRK dated on 2012-06-07: Pfizer Plans to IPO Part of its Animal Health Segment

Financial news for MRK dated on 2012-06-05: Merck Sues Sandoz, Accord Healthcare on Proposed Emend Copy, Claims Infringement of Patents Expiring in 2015 and 2019

Financial news for MRK dated on 2012-06-05: Merck Gets Response Letter for Ridaforolimus, Says Added Clinical Trials Would Need to be Conducted; In Talks with EU Health Authorities -Bloomberg

Financial news for MRK dated on 2012-06-04: The US Economy and the United Nations: Bold Strategies Needed - Tax Reform and Benefits Reform

Financial news for MRK dated on 2012-06-03: Benzinga's M&A Chatter for Friday June 1, 2012

Financial news for MRK dated on 2012-06-01: Amylin Pharmaceuticals Spokesperson Declines Comment on Renewed Takeover Chatter

Financial news for MRK dated on 2012-06-01: Hearing Renewed Takeover Chatter in Amylin Pharmaceuticals

Financial news for MRK dated on 2012-05-31: 15 Great Stocks with Great Yield

Financial news for MRK dated on 2012-05-31: Merck CEO Says He Isn't Interested in

Breaking Up the Company -Bloomberg

Financial news for MRK dated on 2012-05-30: Benzinga's M&A Chatter for Wednesday May 30, 2012

Financial news for MRK dated on 2012-05-29: 5 Healthcare Stocks With The Highest Cash

Financial news for MRK dated on 2012-05-28: Benzinga's M&A Chatter for Friday May 25, 2012

Financial news for MRK dated on 2012-05-25: Amylin Shares Jump as Sanofi, Merck Submit Bids

Financial news for MRK dated on 2012-05-25: Merck Spokesperson Would Not Comment on Reports of Bid for Amylin

Financial news for MRK dated on 2012-05-25: Amylin Spokesperson Would Not Comment on Bloomberg Report of Bids from Merck and Sanofi

Financial news for MRK dated on 2012-05-25: Amylin Said to Get First-Round Bids from Sanofi, Merck -Bloomberg

Financial news for MRK dated on 2012-05-25: Government of Rwanda Introduces Merck's ROTATEQ

Financial news for MRK dated on 2012-05-22: Health Care SPDR In Focus Ahead Of Obamacare Decision

Financial news for MRK dated on 2012-05-21: Merck: FDA Approves New Labeling for ISENTRESS to Include 156-Week Data Demonstrating Long-Term Efficacy, Safety and Tolerability

Financial news for MRK dated on 2012-05-18: BMO Capital Markets Initiates Coverage on Merck & at Market Perform, Announces PT of \$43

Financial news for MRK dated on 2012-05-15: S&P Bullish On Biotech ETFs (FBT, IBB, XBI)

Financial news for MRK dated on 2012-05-11: The Shorts Report: 10 Mega-Caps With Increased Short Selling

Financial news for MRK dated on 2012-05-07: J.P. Morgan Reiterates Overweight Rating for Merck

Financial news for MRK dated on 2012-05-07: Goldman Sachs Reiterates Neutral Rating for Merck

Financial news for MRK dated on 2012-05-04: Pfizer, Merck Pulled Into Expanded Congressional Investigation, Republicans Seeking Documents Over Obama Deal -Bloomberg

Financial news for MRK dated on 2012-04-30: New Kids: Do These New ETFs Have The Right Stuff?

Financial news for MRK dated on 2012-04-30: FDA Considering Letting Patients Purchase Drugs Without Prescriptions

Financial news for MRK dated on 2012-04-27: Merck & Reports Q1 EPS \$0.99 vs \$0.98 Est; Revenues \$11.7B vs \$11.82B Est

Financial news for MRK dated on 2012-04-27: US Stock Futures Flat; GDP Data In Focus

Financial news for MRK dated on 2012-04-27: Earnings Scheduled For April 27

Financial news for MRK dated on 2012-04-22: Earnings Expectations for the Week of April 23 (AAPL, XOM, UPS)

Financial news for MRK dated on 2012-04-19: S&P: Bullish On Pharma ETFs Long-Term

Financial news for MRK dated on 2012-04-19: Merck Reports Phase III Study Results Evaluating Anaemia Management Strategies Used With VICTRELIS(r) (boceprevir) Combination Therapy

Financial news for MRK dated on 2012-04-18: Merck Wins Another FOSAMAX State Court Trial

Financial news for MRK dated on 2012-04-17: Benzinga's Microcap Movers for Monday April 16, 2012

Financial news for MRK dated on 2012-04-17: Benzinga's Top Pre-Market Gainers

Financial news for MRK dated on 2012-04-16: Option Alert: Endocyte Call Volume at 818% of Average on Merck Deal

Financial news for MRK dated on 2012-04-16: Morning Market Movers

Financial news for MRK dated on 2012-04-16: Benzinga's Top Pre-Market Gainers

Financial news for MRK dated on 2012-04-16: Endocyte Rises 100% Pre-Market on Merck Deal

Financial news for MRK dated on 2012-04-16: Financial Breakfast: Morning News Summary for April 16, 2012

Financial news for MRK dated on 2012-04-16: Endocyte Resumes Trading

Financial news for MRK dated on 2012-04-16: PREVIEW: Endocyte to Resume Trading at 7:30am

Financial news for MRK dated on 2012-04-16: Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide

Financial news for MRK dated on 2012-04-04: Decoding Wall St.: Express Scripts and Medco Merger is No Joke

Financial news for MRK dated on 2012-04-03: Merck

Financial news for MRK dated on 2012-04-03: Codexis and Merck Develop Prototype Enzyme-Based Method for Production of Boceprevir

Financial news for MRK dated on 2012-03-27: Benzinga's M&A Chatter for Tuesday March 27, 2012

Financial news for MRK dated on 2012-03-27: Merck Spokesperson, Responding to Chatter of \$26 Offer for Amarin, Says Company Policy is Not to Respond to Rumors Regarding Business Development Deals

Financial news for MRK dated on 2012-03-27: Hearing Chatter Merck Making \$26/Share Bid for Amarin

Financial news for MRK dated on 2012-03-26: Victrelis Available for Eligible Patients in British Columbia

Financial news for MRK dated on 2012-03-26: Merck Reports C\$35M Investment and Start of Merck Lumira Fund

Financial news for MRK dated on 2012-03-24: Adding Merck's Vorapaxar to Standard of Care Significantly Reduced the Risk of Cardiovascular Events

Financial news for MRK dated on 2012-03-21: UPDATE: Merck and ARIAD Pharmaceuticals Provide Update on FDA Advisory Committee Vote; Voted 13 To 1 Against The Use of Ridaforolimus

Financial news for MRK dated on 2012-03-20: Ariad Pharmaceuticals Falls 5% on FDA Panel Vote

Financial news for MRK dated on 2012-03-20: FDA Panel Votes 13-1 Against Recommending Taltorvic As Maintenance Treatment For Soft-tissue And Bone Sarcoma -Reuters

Financial news for MRK dated on 2012-03-16: ETF Showdown: Dividend Dilemma (HDV, HDIV, JNJ)

Financial news for MRK dated on 2012-03-16: Briefing Information for the March 20, 2012 Meeting of the Oncologic Drugs Advisory Committee

Financial news for MRK dated on 2012-03-15: A Look At The New Russell High Yield ETF (HDIV, ABT, KFT)

Financial news for MRK dated on 2012-03-12: Benzinga's M&A Chatter for Monday March 12, 2012

Financial news for MRK dated on 2012-03-12: Merck Repeats 2012 Forecast in Presentation Slides -Bloomberg

Financial news for MRK dated on 2012-03-12: Merck Spokesperson Would Not Comment on Earlier Speculation of Idenix Pharmaceuticals Takeover Bid

Financial news for MRK dated on 2012-03-12: Hearing Renewed Takeover Chatter in

Idenix Pharmaceuticals, Merck Rumored Buyer

Financial news for MRK dated on 2012-03-12: Positive Rumors Circulate About Idenix Pharmaceuticals

Financial news for MRK dated on 2012-03-07: Merck Gives Weak Q1 Outlook

Financial news for MRK dated on 2012-03-07: From Earlier: Merck Announces Results from Investigational Studies with VICTRELIS Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1

Financial news for MRK dated on 2012-03-06: Oncothyreon Analyst: Stimulax Continuation Was Expected; as Likely Outcome for Trial to be Completed Rather Than Stop Early for Positive Efficacy or Futility

Financial news for MRK dated on 2012-03-06: Merck Down 2% After Reaffirming 2012 Guidance

Financial news for MRK dated on 2012-03-06: Abbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer Therapy

Financial news for MRK dated on 2012-03-06: Merck Issues Q1 Profit Forecast

Financial news for MRK dated on 2012-03-06: UPDATE: Merck Confirms 2012 Full-Year Guidance

Financial news for MRK dated on 2012-03-06: Merck Guides Q1 EPS \$0.95-0.98 vs \$1.01 Est; Confirms 2012 Guidance

Financial news for MRK dated on 2012-03-06: Oncothyreon Falls 47% Pre-Market on Stimuvax Report

Financial news for MRK dated on 2012-03-06: UPDATE: Merck Says Stimuvax Trial to Continue to Final Analysis; Says Final Result Expected in 2013

Financial news for MRK dated on 2012-03-05: Merck Says FDA Declines To Approve Its New Drug Application For Ezetimibe And Atorvastatin Tablets -Reuters

Financial news for MRK dated on 2012-03-05: Merck's Investigational Allergy Immunotherapy Tablet Significantly Reduced the Combination of Ragweed Allergy Symptoms

Financial news for MRK dated on 2012-03-05: Merck Says FDA Says Added Data Needed on Ezetimibe/Atorvastatin -Bloomberg

Financial news for MRK dated on 2012-02-28: The Rick Santorum ETF Portfolio (KOL, PBS, IYZ)

Financial news for MRK dated on 2012-02-28: FDA Approves Important Safety Label Changes For The Class Of Cholesterol-Lowering Drugs Known As Statins -Reuters

Financial news for MRK dated on 2012-02-23: Viva Vivus, But Not In ETFs (VVUS, IBB, PJP)

Financial news for MRK dated on 2012-02-15: Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil

Financial news for MRK dated on 2012-02-13: FDA Approves ZIOPTAN, Merck's Once-Daily, Preservative-Free Ophthalmic Medication

Financial news for MRK dated on 2012-02-13: UPDATE: Morgan Stanley Raises PT to \$37 on Merck

Financial news for MRK dated on 2012-02-10: Grandpa's 2012 ETF Portfolio

Financial news for MRK dated on 2012-02-07: Merck Analyst: Effectiveness of Vorapaxar Was Surprise; But Ability to Reach Market is Limited Due to Bleeding Risk

Financial news for MRK dated on 2012-02-07: Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar

Financial news for MRK dated on 2012-02-06: Benzinga's M&A Chatter for Monday February 6, 2012

Financial news for MRK dated on 2012-02-06: Idenix Pharmaceuticals Spokesperson Has No Comment on Renewed Merck Takeover Chatter

Financial news for MRK dated on 2012-02-06: UPDATE: Idenix Pharmaceuticals Spiking Higher on Renewed Takeover Chatter; Merck Rumored Buyer

Financial news for MRK dated on 2012-02-06: Merck Confirms Plans to File NDA for Suvorexant in 2012

Financial news for MRK dated on 2012-02-03: Candlesticks - Bears Appeared on Merck

Financial news for MRK dated on 2012-02-03: From Earlier: Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302

Financial news for MRK dated on 2012-02-02: FDA Approves JANUMET XR for Type 2 Diabetes

Financial news for MRK dated on 2012-02-02: UPDATE: Merck Swings To Q4 Profit

Financial news for MRK dated on 2012-02-02: Merck's Earnings Are Up, But a Huge Drop may be Coming

Financial news for MRK dated on 2012-02-02: Financial Breakfast: Morning News Summary for February 2, 2012

Financial news for MRK dated on 2012-02-02: Merck & Reports Q4 EPS \$0.97 vs \$0.95 Est; Revenues \$12.30B vs \$12.53B Est

Financial news for MRK dated on 2012-02-02: Earnings Scheduled For February 2

Financial news for MRK dated on 2012-01-31: Merck Wins Patent Ruling Over Sandoz Version of Cancidas -Bloomberg

Financial news for MRK dated on 2012-01-29: Earnings Expectations for the Week of January 30

Financial news for MRK dated on 2012-01-26: Benzinga's M&A Chatter for Thursday January 26, 2012

Financial news for MRK dated on 2012-01-26: Seattle Genetics Spokesperson Would Not Comment on Earlier Merck Takeover Rumor

Financial news for MRK dated on 2012-01-25: Benzinga's M&A Chatter for Wednesday January 25, 2012

Financial news for MRK dated on 2012-01-25: Merck Spokesperson Would Not Comment on Earlier Speculation of Idenix Pharmaceuticals Takeover

Financial news for MRK dated on 2012-01-25: Idenix Pharmaceuticals Spokesperson Has No Comment on Earlier Merck Takeover Chatter

Financial news for MRK dated on 2012-01-25: Idenix Pharmaceuticals Spiking Higher on Renewed Takeover Chatter; Merck Rumored Buyer

Financial news for MRK dated on 2012-01-25: UPDATE: Merck: FDA Did Not Approve New Indication For Vytorin Because of Study Design

Financial news for MRK dated on 2012-01-25: Merck Announces New FDA Approved Labeling For VYTORIN Includes Results From the Study of Heart and Renal Protection in Patients With Moderate to Severe Chronic Kidney Disease

Financial news for MRK dated on 2012-01-24: UPDATE: ISI Group Initiates Buy, \$45 on Merck

Financial news for MRK dated on 2012-01-23: Merck Receives Positive Mad Money/Jim Cramer Mention -CNBC

Financial news for MRK dated on 2012-01-20: Merck Announces Remicade Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients

Financial news for MRK dated on 2012-01-20: What's the Future Like For Health Care?

Financial news for MRK dated on 2012-01-19: Merck & Hits 52-Week High of \$39.01

Financial news for MRK dated on 2012-01-18: Benzinga's M&A Chatter for Wednesday January 18, 2012

Financial news for MRK dated on 2012-01-18: Positive Rumors Circulate About Vertex Pharmaceuticals

Financial news for MRK dated on 2012-01-18: Hearing Wedbush Says Idenix Pharmaceuticals Takeover Target of Merck, Johnson & Johnson, Abbott Labs; \$24/Share

Financial news for MRK dated on 2012-01-11: How to Trade Biotechs Based on the JP Morgan Health Care Conference

Financial news for MRK dated on 2012-01-10: Going Nuclear on Hepatitis C -- Is Idenix the Next Target?

Financial news for MRK dated on 2012-01-10: Feuerstein: Merck for Idenix Pharma was Just a Prediction, Not a Rumor

Financial news for MRK dated on 2012-01-09: Jefferies Downgrades Merck & Company to Hold

Financial news for MRK dated on 2012-01-06: Merck Says FDA Approves Isentress for Children in Ages 2 & Up -Bloomberg

Financial news for MRK dated on 2012-01-05: Merck & Hits 52-Week High of \$38.57

Financial news for MRK dated on 2012-01-04: Will Alnylam's Prospective Obesity Drug Change the World Forever?

Financial news for MRK dated on 2012-01-04: Bark At The Dow's Dogs With These ETFs

Financial news for MRK dated on 2012-01-03: Merck & Hits 52-Week High of \$37.98

Financial news for MRK dated on 2012-01-03: Can Germany's Employers Turn Europe Around?

Financial news for MRK dated on 2011-12-30: ETF Showdown: Fun With Pharma

Financial news for MRK dated on 2011-12-27: Inside: 2012's Best Value Investment

Financial news for MRK dated on 2011-12-23: Merck & Hits 52-Week High of \$37.76

Financial news for MRK dated on 2011-12-22: Merck & Hits 52-Week High of \$37.66

Financial news for MRK dated on 2011-12-21: Exelixis Trading Higher After Licensing Agreement with Merck

Financial news for MRK dated on 2011-12-21: Merck and the ADAP Crisis Task Force Announce New Agreement to Improve Access and Care for People with HIV

Financial news for MRK dated on 2011-12-21: Exelixis Licenses PI3K-Delta Program to Merck

Financial news for MRK dated on 2011-12-19: Can a Picture of the CEO Predict Stock Performance?

Financial news for MRK dated on 2011-12-13: Benzinga's Top Pre-Market Losers

Financial news for MRK dated on 2011-12-09: Are You Guaranteed Profits if These Rumors are True?

Financial news for MRK dated on 2011-12-09: Five Biotech Stocks to Watch Going into Big Doctors' Meeting

Financial news for MRK dated on 2011-12-01: Are the Samsung M&A Rumors True?

Financial news for MRK dated on 2011-12-01: These Stocks May Be Better Than Their Dow Equivalents

Financial news for MRK dated on 2011-11-28: Is Arena Pharma Going to Cure Obesity?

Financial news for MRK dated on 2011-11-22: Merck KGAA Says Merck & Co Has Taken Over Its Facebook Page; Asks Court to Order Facebook to Give Information

Financial news for MRK dated on 2011-11-22: End-of-Day Market Summary for November 22, 2011

Financial news for MRK dated on 2011-11-22: UPDATE: Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S. Attorney's Office for the District of Massachusetts Related to Vioxx

Financial news for MRK dated on 2011-11-22: Merck Will Pay \$950M to Settle Government Vioxx Probe

Financial news for MRK dated on 2011-11-15: Merck Settles Vioxx Suits From NY,

Florida, S Carolina -Reuters

Financial news for MRK dated on 2011-11-14: Appaloosa Took Stakes in ETrade, BP, and Dana Holding in Q3; Exited Pfizer, Bank of America, Hewlett-Packard, Wells Fargo, Merck, Unitedhealth Group and MetLife in Q3

Financial news for MRK dated on 2011-11-11: Morgan Stanley Maintains Equal-Weight Rating and \$34 PT on Merck & Co

Financial news for MRK dated on 2011-11-10: Merck CEO Saying Will Not Make Disproportionate Changes to R&D Spending

Financial news for MRK dated on 2011-11-10: Merck Increase Quarterly Dividend by 11%

Financial news for MRK dated on 2011-11-10: Citi Maintains Neutral Rating and \$34 PT on Merck

Financial news for MRK dated on 2011-11-09: UPDATE: Merck To Pay \$49.5M To Settle Certain Vioxx-Related Lawsuits

Financial news for MRK dated on 2011-11-09: Merck Gets Justice Dept. Requests For Information On Drug Marketing Relate To Marketing Of Integrilin, Avelox And AzaSite

Financial news for MRK dated on 2011-11-09: Merck: FDA Declines To Approve Merck Eye-Disease Drug Tafluprost -DJ

Financial news for MRK dated on 2011-11-09: Merck Launches NEXPLANON 68 mg in the United States

Financial news for MRK dated on 2011-11-07: JP Morgan Maintains Overweight Rating and \$44 PT on Merck & Co

Financial news for MRK dated on 2011-11-05: Merck Announces Interim Data for Merck's VICTRELISM in Prior Null Responder Patients with Chronic Hepatitis C Genotype 1

Financial news for MRK dated on 2011-11-02: FDA Advisory Committee Unanimously Recommends Approval of Merck's VYTORIN for Use in Patients with Pre-Dialysis Chronic Kidney Disease

Financial news for MRK dated on 2011-11-02: FDA Advisers Vote 16-0 Efficacy, Safety data Support Approval of Merck's Vytorin

Financial news for MRK dated on 2011-11-02: Are Upcoming Study Results Spurring Insider Buying at Ligand Pharmaceuticals?

Financial news for MRK dated on 2011-11-01: Which Pharma Stock Should You Short?

Financial news for MRK dated on 2011-11-01: One Pill Makes You Stronger: Pfizer Earnings Are the "White Knight"

Financial news for MRK dated on 2011-10-31: A Look at The New DRGS ETN

Financial news for MRK dated on 2011-10-31: Merck Can Block Teva on Generic Temodar as Court Rejects Appeal -Bloomberg

Financial news for MRK dated on 2011-10-31: Citi Maintains Neutral Rating and \$34 PT on Merck

Financial news for MRK dated on 2011-10-28: Merck Announces Increased Earnings

Financial news for MRK dated on 2011-10-28: Financial Breakfast: Morning News Summary for October 28, 2011

Financial news for MRK dated on 2011-10-28: Merck & Co Reports Q3 EPS \$0.94 vs \$0.91 Est; Revenues \$12.02B vs \$11.61B Est

Financial news for MRK dated on 2011-10-28: US Stock Futures Signal Lower Start On Wall Street

Financial news for MRK dated on 2011-10-28: Earnings Scheduled For October 28

Financial news for MRK dated on 2011-10-26: Deutsche Bank Maintains Buy Rating on Merck & Co

Financial news for MRK dated on 2011-10-25: Merck Announces CDC Advisory Committee on Immunization Practices Votes for Expanded Use of GARDASIL(r) in Boys and Young Men

Financial news for MRK dated on 2011-10-25: What Does Novartis' Earnings Release Really Mean for the Company?

Financial news for MRK dated on 2011-10-25: Merck Earnings Preview: Analysts Expect Higher EPS, Revenue

Financial news for MRK dated on 2011-10-24: Merck Announces Presentation of Phase III Investigational Studies Evaluating DULERA Inhalation Aerosol in Chronic Obstructive Pulmonary Disease

Financial news for MRK dated on 2011-10-23: Earnings Expectations for the Week of October 24

Financial news for MRK dated on 2011-10-21: Mylan Laboratories Earnings Preview: Analysts Expect Higher EPS, Revenue

Financial news for MRK dated on 2011-10-14: Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield

Financial news for MRK dated on 2011-10-13: Under The Hood: Emerging Markets Health Care

Financial news for MRK dated on 2011-10-06: Merck Announces Retirement of Chairman and Former CEO Richard T. Clark

Financial news for MRK dated on 2011-10-06: Bristol-Myers and Quidel to Open Near 52-Week Highs

Financial news for MRK dated on 2011-10-05: FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor

Financial news for MRK dated on 2011-10-03: Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX

Financial news for MRK dated on 2011-09-30: Merck Announces New Data Analyses for VICTRELIS will be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting

Financial news for MRK dated on 2011-09-28: Merck Sells Its Interest in Johnson & Johnson-Merck Consumer Pharmaceuticals for \$175M

Financial news for MRK dated on 2011-09-27: Merck Names Cuong Viet Do as Chief Strategy Officer

Financial news for MRK dated on 2011-09-19: Merck's Iss=entress Combo Showed Efficacy, Tolerability

Financial news for MRK dated on 2011-09-14: S&P Likes Three Health Care ETFs

Financial news for MRK dated on 2011-09-14: Bounce-Back Kings: 9 Stocks Up More Than 30% in the Past Month

Financial news for MRK dated on 2011-09-13: Merck Issues Statement on HPV Vaccine

Financial news for MRK dated on 2011-09-13: A Peek Into The Market Before The Trading Starts

Financial news for MRK dated on 2011-09-13: Merck and BGI Establish Strategic Collaboration focused on Biomarkers and Genomic Technologies

Financial news for MRK dated on 2011-09-08: Bank of America Merrill Lynch Maintains Buy on Merck & Co.

Financial news for MRK dated on 2011-09-07: Stocks Going Ex Dividend the Third Week of September

Financial news for MRK dated on 2011-08-30: Merck Millipore Strengthens Bioscience Business by acquiring Amnis Corporation

Financial news for MRK dated on 2011-08-29: Zymeworks Announces Collaboration with Merck to Develop Bi-specific Antibody Therapeutics

Financial news for MRK dated on 2011-08-26: Texas Supreme Court Rules in Favor of Merck in Vioxx Case; Overturns Judgement in Favor of Garza Family

Financial news for MRK dated on 2011-08-25: 12 Most Popular Healthcare Stocks Among Hedge Funds

Financial news for MRK dated on 2011-08-25: 12 Most Popular Healthcare Stocks Among Hedge Funds

Financial news for MRK dated on 2011-08-18: Merck and ARIAD Announce European Medicines Agency Accepts Marketing Authorization Application for Ridaforolimus

Financial news for MRK dated on 2011-08-18: Merck and ARIAD Announce European Medicines Agency Accepts Marketing Authorization Application for Ridaforolimus

Financial news for MRK dated on 2011-08-11: Mad Money Lightning Round: Cramer Likes Cummins

Financial news for MRK dated on 2011-08-09: UPDATE: Jefferies Upgrades Merck & Co To Buy

Financial news for MRK dated on 2011-08-09: News Summary for August 9, 2011

Financial news for MRK dated on 2011-08-09: Benzinga's Top Upgrades

Financial news for MRK dated on 2011-08-09: Jefferies Upgrades Merck & Co. To Buy, Lowers PT To \$37

Financial news for MRK dated on 2011-08-03: Merck and Serum Institute Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine

Financial news for MRK dated on 2011-08-02: Aw Snap, Is Market Gonna Crackle or Pop?

Financial news for MRK dated on 2011-08-01: Weak Data in Focus 08-01-2011

Financial news for MRK dated on 2011-08-01: Merck To Close Mission Bay Research Center

Financial news for MRK dated on 2011-08-01: J.P. Morgan Maintains Overweight Rating On Merck & Co

Financial news for MRK dated on 2011-08-01: ARIAD Announces That Merck Has Submitted for Approval of Ridaforolimus, an Investigational mTOR Inhibitor, in the EU

Financial news for MRK dated on 2011-07-29: 6 Deeply Undervalued Biotech Stocks

Financial news for MRK dated on 2011-07-29: Looking at T. Boone Pickens' 6 Newest Energy Stock Buys

Financial news for MRK dated on 2011-07-29: 5 Dividend Stocks to Hold Forever

Financial news for MRK dated on 2011-07-29: 5 Stocks You Can Buy for Less Than Bill Gates Paid

Financial news for MRK dated on 2011-07-29: AUD/USD: Trading the Reserve Bank of Australia Interest Rate Decision

Financial news for MRK dated on 2011-07-29: 6 Safe Stocks for an Inflation Proof Portfolio

Financial news for MRK dated on 2011-07-29: US Debt Ceiling Negotiations At Risk as Boehner Plan Vote Looms

Financial news for MRK dated on 2011-07-29: 6 Companies That Could Be Acquired This Year

Financial news for MRK dated on 2011-07-29: 8 REITs at High Risk of Cutting Dividends and 3 Safer Options

Financial news for MRK dated on 2011-07-29: 10 Stocks Near \$30 That Could Trade for \$40

Financial news for MRK dated on 2011-07-29: 5 Core Dividend Stocks Underappreciated by Investors

Financial news for MRK dated on 2011-07-29: Invest Like a Billionaire: John Paulson's 6 New Stock Picks

Financial news for MRK dated on 2011-07-29: Merck Cites Brand and Emerging Market Investment for Higher Quarter Costs

Financial news for MRK dated on 2011-07-29: Merck Doubles Profits In Second Quarter

Financial news for MRK dated on 2011-07-29: News Summary for July 29, 2011

Financial news for MRK dated on 2011-07-29: Merck: FDA Accepts SNDAs For Vytorin, Zetia Indications For Review

Financial news for MRK dated on 2011-07-29: Merck to Cut Workforce by Added 12-13% From 2009 Levels

Financial news for MRK dated on 2011-07-29: Merck Guides FY 2011 EPS \$3.68-\$3.76 vs \$3.74 Est

Financial news for MRK dated on 2011-07-29: Merck Reports Q2 EPS \$0.95 vs \$0.95 Est; Revenues \$12.15B vs \$11.78B Est

Financial news for MRK dated on 2011-07-29: US Stock Futures Down On Debt Worries

Financial news for MRK dated on 2011-07-29: Earnings Scheduled For July 29

Financial news for MRK dated on 2011-07-29: Stocks To Watch For July 29

Financial news for MRK dated on 2011-07-28: High Yield Birth Control Stocks

Financial news for MRK dated on 2011-07-28: How to Profit from Exploding Government Healthcare Costs

Financial news for MRK dated on 2011-07-27: Hearing Supreme Court Asked to Overturn Obama's Health Care Reform

Financial news for MRK dated on 2011-07-26: Earnings Preview: Merck EPS, Revenue Expected to Rise from Previous Quarter

Financial news for MRK dated on 2011-07-26: Merck to Acquire Rights to Vernakalant i.v. in Canada, Mexico and the United States from Astellas

Financial news for MRK dated on 2011-07-25: Ratchet Back The Risk With These ETFs

Financial news for MRK dated on 2011-07-24: Earnings Expectations for the Week of July 25

Financial news for MRK dated on 2011-07-22: Earnings Preview: Mylan Laboratories EPS, Revenue Expected to Rise from Previous Quarter

Financial news for MRK dated on 2011-07-21: Fifteen Health Care ETFs Trading Near 52-Week Highs

Financial news for MRK dated on 2011-07-21: Earnings Preview: Gilead Sciences EPS, Revenue Expected to Rise from Previous Quarter

Financial news for MRK dated on 2011-07-20: Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C

Financial news for MRK dated on 2011-07-19: Dow Jones Industrial Average Companies Increase Expected Dividend Distribution by 12.66% From a Year Ago

Financial news for MRK dated on 2011-07-18: Merck Announces VICTRELIS First-in-Class Oral Hepatitis C Virus Protease Inhibitor, Approved in the EU for Treatment of Chronic Hepatitis C

Financial news for MRK dated on 2011-07-18: Merck's ISENTRESS in Combination Therapy Demonstrated Efficacy in a Phase II Study Extending to Nearly Five Years in Previously Untreated Adults with HIV-1

Financial news for MRK dated on 2011-07-14: 5 High Dividend Names For Sound Sleeping

Financial news for MRK dated on 2011-07-13: Twelve Health Care ETFs Trading Near 52-Week Highs

Financial news for MRK dated on 2011-07-12: Twelve ETFs Trading Near 52-Week Highs

Financial news for MRK dated on 2011-07-11: Merck to Participate in New Research Efforts to Eradicate HIV

Financial news for MRK dated on 2011-07-08: Hottest and Coldest Sectors for Friday 7/8/11

Financial news for MRK dated on 2011-07-08: Teva and Merck Settle Patent Dispute Over Generic Vytorin; Teva Will Not Sell Generic Until 2017

Financial news for MRK dated on 2011-07-07: Goldman Sachs Suggests Buying Calls on Merck & Co.

Financial news for MRK dated on 2011-07-01: Merck Receives Approval to Market GARDASIL, ZOLINZA and CUBICIN in Japan

Financial news for MRK dated on 2011-06-28: A Peek Into The Market Before The Trading Starts

Financial news for MRK dated on 2011-06-28: UPS and Merck Expand Their Distribution and Logistics Agreement

Financial news for MRK dated on 2011-06-27: Stocks Shrug Off Greece, Deficit Uncertainty

Financial news for MRK dated on 2011-06-24: Morgan Stanley Reiterates Equal-Weight on Merck

Financial news for MRK dated on 2011-06-24: High Yield Big Pharmaceutical Stocks

Financial news for MRK dated on 2011-06-20: Ligand Enters into Captisol Commercial Supply Agreement with Merck

Financial news for MRK dated on 2011-06-14: Build a Wealthy Portfolio with These Economic Moats

Financial news for MRK dated on 2011-06-09: 5-Alpha Reductase Inhibitors May Increase Risk of Prostate Cancer -FDA

Financial news for MRK dated on 2011-06-08: Merck Announces U.S. Prescribing Information for Simvastatin Revised to Include New Limits on the Use of the Highest Dose and Updated Drug Interaction Information

Financial news for MRK dated on 2011-06-08: UPDATE: Merck and Intercell AG Announce Termination of Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710

Financial news for MRK dated on 2011-06-07: Bank of America Merrill Lynch Maintains Buy on Merck & Co.

Financial news for MRK dated on 2011-06-07: Roche and Merck Collaborate to Develop Diagnostic Tests for Merck's Investigational Cancer Therapies

Financial news for MRK dated on 2011-06-06: Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting

Financial news for MRK dated on 2011-06-03: Hepatitis C Virus (HCV) Updates from Biotech/Pharma Stocks

Financial news for MRK dated on 2011-06-03: Pimco's Gross Likes P&G and Merck, Offer Better Yields and Conservative -Bloomberg

Financial news for MRK dated on 2011-06-03: Pimco's Gross Says Procter & Gamble and Merck are Relatively Attractive to Savers -Bloomberg

Financial news for MRK dated on 2011-06-02: My Top 20 Defensive Stock Plays

Financial news for MRK dated on 2011-06-02: FDA: Treatment With Angiotensin Receptor Blockers for High Blood Pressure Does Not Increase Risk of Cancer

Financial news for MRK dated on 2011-06-02: FDA Says that High Blood Pressure Drugs Do Not Increase Cancer Risk -Bloomberg

Financial news for MRK dated on 2011-06-01: Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer

Financial news for MRK dated on 2011-06-01: Hapoalim Cutting Ocverage On Multitude Of Names

Financial news for MRK dated on 2011-05-31: Health Canada Approves Gardasil to Prevent Anal Cancer

Financial news for MRK dated on 2011-05-27: Morgan Stanley Reports on Merck

Financial news for MRK dated on 2011-05-26: InSite Vision Announces Joint Patent Infringement Lawsuit with Merck Against Sandoz

Financial news for MRK dated on 2011-05-26: Joel Greenblatt: One Bubble After Another

Financial news for MRK dated on 2011-05-24: FTC Files Amicus Brief In K-dur Antitrust Litigation -Bloomberg

Financial news for MRK dated on 2011-05-23: Europe's sovereign-debt crisis Effects on Drug Stocks

Financial news for MRK dated on 2011-05-23: Vertex Hepatitis C Drug Approved by the FDA -Bloomberg

Financial news for MRK dated on 2011-05-22: Top Healthcare and Major Drugs stocks to watch- Sector Performance

Financial news for MRK dated on 2011-05-20: CHMP Issues Positive Opinion for Merck's VICTRELISM, Oral Hepatitis C Virus Protease Inhibitor

Financial news for MRK dated on 2011-05-19: Exclusive - Merck Talks To Benzinga About Collaboration With Roche (MRK)

Financial news for MRK dated on 2011-05-19: Deutsche Bank Comments On Merck And Roche Collaboration

Financial news for MRK dated on 2011-05-17: Biotech/Pharma Stocks News Alert; Hepatitis C Virus (HCV) FDA News from Aethlon Medical, Vertex Pharmaceuticals, Merck & Company

Financial news for MRK dated on 2011-05-17: Merck and Roche Establish Strategic Agreements in Fight Against Chronic Hepatitis C

Financial news for MRK dated on 2011-05-17: Biotech/Pharma Stocks Alert; Hepatitis C Virus (HCV) FDA News from (OTCBB: AEMD), (NYSE: MRK), (VRTX)

Financial news for MRK dated on 2011-05-17: Biotech/Pharma Stocks Alert; Hepatitis C Virus (HCV) FDA News from (OTCBB: AEMD), (NYSE: MRK), (VRTX)

Financial news for MRK dated on 2011-05-17: Piper Jaffray Discontinues Coverage On ISPH

Financial news for MRK dated on 2011-05-16: Goldman Sachs Reports on Merck & Co (MRK)

Financial news for MRK dated on 2011-05-16: Deutsche Bank Comments on Victrelis FDA Approval

Financial news for MRK dated on 2011-05-16: J.P. Morgan Calls Merck & Co's Hep C Treatment A "Modest Positive"

Financial news for MRK dated on 2011-05-16: Bank Of America Raises PT To \$29 On MRK

Financial news for MRK dated on 2011-05-13: Biotech/Pharma Stock News Alert: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV)

Financial news for MRK dated on 2011-05-13: Biotech/Pharma Stocks: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV)

Financial news for MRK dated on 2011-05-13: Biotech/Pharma Stocks: (OTCBB: AEMD), (NYSE: MRK), (VRTX) Progress on Potential New Treatments for Hepatitis C Virus (HCV)

Financial news for MRK dated on 2011-05-11: The Father of Growth Investing: T. Rowe Price Screen

Financial news for MRK dated on 2011-05-06: UPDATE: FDA Approves New Treatment for Rare Type of Pancreatic Cancer (PFE, MRK, GSK)

Financial news for MRK dated on 2011-05-04: May Catalysts for Biotech and Drug Stocks

Financial news for MRK dated on 2011-05-03: Morning News Summary for May 3, 2011

Financial news for MRK dated on 2011-05-03: Earnings Preview For Allergan (AGN, MRK, ISPH, VRX, CEPH)

Financial news for MRK dated on 2011-05-03: Top 4 Large-Cap Stocks In The Drug Manufacturers-Major Industry With The Lowest PEG Ratio (GSK, ABT, MRK, JNJ)

Financial news for MRK dated on 2011-05-02: UPDATE: J.P. Morgan Raises PT on Merck & Co. to \$44 (MRK)

Financial news for MRK dated on 2011-05-02: Citi Updates FY Estimates On Merck After Reporting Solid Earnings

Financial news for MRK dated on 2011-05-02: JP Morgan Raises PT On Merck & Company To \$44

Financial news for MRK dated on 2011-05-02: CEOWORLD Top 5 Analyst Calls of the Week-DNDN, INSP, MCP, SIRI, VICL

Financial news for MRK dated on 2011-04-29: Royal Put(z) Not to Be Confused with Married Put(z) 04-29-2011

Financial news for MRK dated on 2011-04-29: Married Put(z) 04-29-2011

Financial news for MRK dated on 2011-04-29: Merck Up On Strong Earnings Today (MRK)

Financial news for MRK dated on 2011-04-29: Citi Reports Strong 1Q11 Results For Merck

Financial news for MRK dated on 2011-04-29: Friday Morning Market Summary 4/29/2011

Financial news for MRK dated on 2011-04-29: A Peek Into The Market Before The Trading Starts

Financial news for MRK dated on 2011-04-29: UPDATE: Merck Reports Upbeat Q1 Earnings; Shares Rise In Pre-Market trading

Financial news for MRK dated on 2011-04-29: Merck Announces First Quarter 2011 Financial Results

Financial news for MRK dated on 2011-04-29: Merck Guides FY 2011 EPS \$3.66-3.76 vs. \$3.69 Est. (MRK)

Financial news for MRK dated on 2011-04-29: Merck Reports EPS of \$0.92 vs. \$0.84 Estimate; Revenues \$11.58B vs. \$11.37B Estimate

Financial news for MRK dated on 2011-04-29: US Stock Futures Mixed As Investors Await Economic Data, Earnings Reports; Research In Motion Shares Decline In Pre-Market trading

Financial news for MRK dated on 2011-04-29: Earnings Scheduled For April 29 (WY, AXL, NWL, ITT, MRK, PBI, MI, CPN, GT, CAT, AGP, NEE, CVX, PPC, DHI, ETR, VFC)

Financial news for MRK dated on 2011-04-29: Stocks To Watch For April 29 (CVX, RIMM, CAT, MSFT, MRK)

Financial news for MRK dated on 2011-04-28: Merck and Inspire Announce Expiration of Hart-Scott-Rodino Act Waiting Period Relating to Tender Offer for Shares of Inspire (ISPH, MRK)

Financial news for MRK dated on 2011-04-27: VICTRELIS(tm) Unanimously Recommended for Approval by FDA Advisory Committee (MRK)

Financial news for MRK dated on 2011-04-27: VICTRELIS Unanimously Recommended for Approval by FDA Advisory Committee for Treatment of Chronic HCV Genotype 1 Infection

Financial news for MRK dated on 2011-04-27: Hepatitis Treatment Wins Over the U.S. FDA Panel -Bloomberg (MRK)

Financial news for MRK dated on 2011-04-27: Deutsche Bank To Hold 36th Annual Healthcare Conference Next Week

Financial news for MRK dated on 2011-04-27: Merck Announces New \$5 Billion Share Repurchase Program (MRK)

Financial news for MRK dated on 2011-04-26: Vertex Stock Booms After FDA Reports New Drug is Effective (VRTX)

Financial news for MRK dated on 2011-04-25: Rwanda, Merck and QIAGEN Launch Africa's First Comprehensive Cervical Cancer Prevention Program Incorporating Both HPV Vaccination and HPV Testing

Financial news for MRK dated on 2011-04-25: Merck's Hepatitis C Drug Increases Anemia Risk, FDA Staff Says -Bloomberg (MRK)

Financial news for MRK dated on 2011-04-21: Merck and Sanofi Pasteur Initiate Phase III Study in the United States of Pediatric Combination Vaccine to Help Prevent Six Infectious Diseases

Financial news for MRK dated on 2011-04-18: Don't Fall For The 'Defensive Portfolio' Hype

Financial news for MRK dated on 2011-04-18: J.P. Morgan Adjusting Estimates On Merck & Co

Financial news for MRK dated on 2011-04-15: Weird Dynamic at Play 04-15-2011

Financial news for MRK dated on 2011-04-15: Merck Commences Tender Offer for Inspire Pharmaceuticals at \$5.00 per Share

Financial news for MRK dated on 2011-04-15: A Peek Into The Market Before The Trading Starts

Financial news for MRK dated on 2011-04-15: Merck Reaffirms 2011 Non-GAAP EPS Target of \$3.64 to \$3.76

Financial news for MRK dated on 2011-04-15: Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck (JNJ, MRK)

Financial news for MRK dated on 2011-04-15: Merck and Johnson & Johnson Reach Agreement on Distribution Rights for REMICADE(r) and SIMPONI(r) (MRK, JNJ)

Financial news for MRK dated on 2011-04-12: Inspire Pharmaceuticals Shareholder Sues Over Merck Deal (MRK, ISPH)

Financial news for MRK dated on 2011-04-11: FDA Approves Merck's SYLATRON for Injection, a New Adjuvant Treatment for Melanoma with Microscopic or Gross Nodal Involvement

Financial news for MRK dated on 2011-04-11: Merck & Co and Sun Pharma Establish Joint Venture (MRK)

Financial news for MRK dated on 2011-04-08: Merck Loses U.K. Appeal Against Teva to Reinstate Cosopt Patent (MRK)

Financial news for MRK dated on 2011-04-07: LifeTech Capital Comments On Merck Acquisition (MRK, ISPH)

Financial news for MRK dated on 2011-04-06: Experts Think Merck's Gardasil Could Be Widely Distributed (MRK)

Financial news for MRK dated on 2011-04-05: Mid Afternoon Top-5 and Bottom-5 Percentage Gainers (NSM, ISPH, MRK, QCOR, PK, AAU, DGW, LEDS, MERU, WMGI, ZSTN)

Financial news for MRK dated on 2011-04-05: Merck to Acquire Inspire Pharmaceuticals, Inc. for \$5.00 per Share Totaling \$430M

Financial news for MRK dated on 2011-04-05: Biotech/Pharma Stocks; Merck (NYSE:MRK) to Acquire Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH)

Financial news for MRK dated on 2011-04-05: Biotech/Pharma Stocks; Merck (NYSE:MRK) to Acquire Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH)

Financial news for MRK dated on 2011-04-01: April Catalysts For Biotech And Drug Stocks

Financial news for MRK dated on 2011-03-31: VICTRELIS, Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control

Financial news for MRK dated on 2011-03-28: Mad Money Lightning Round: Cramer Likes Alcoa, Health Care REIT (AA, SPPI, PANL, PFE, GILD, CELG, MRK, ABT, AGNC, NLY, HCN)

Financial news for MRK dated on 2011-03-25: March Market Madness: Merck (MRK)

Financial news for MRK dated on 2011-03-25: Citi Comments On MRK's Return Of Betrixaban, Maintains EPS Estimate

Financial news for MRK dated on 2011-03-24: Merck Announces FDA Approves Zostavax Vaccine to Prevent Shingles in Individuals 50 to 59 Years of Age

Financial news for MRK dated on 2011-03-24: Portola Pharmaceuticals to Regain Global Rights for Investigational Medicine Betrixaban from Merck

Financial news for MRK dated on 2011-03-22: Zings Of The Day (SNY, MRK, AAPL, AMZN)

Financial news for MRK dated on 2011-03-18: Committee for Medicinal Products for Human Use (CHMP) Issues Positive Opinion for New Contraception Offering

Financial news for MRK dated on 2011-03-17: ARIAD Announces Election to Co-Promote Ridaforolimus in Sarcoma Indication in U.S. upon Approval

Financial news for MRK dated on 2011-03-16: Some High Dividend Paying Stocks For A Weak Market (MO, MRK, JNJ, NLY)

Financial news for MRK dated on 2011-03-10: Health Insurers Triple S&P 500 Returns

Financial news for MRK dated on 2011-03-07: Merck Announces New Data Analyses for VICTRELIS Will Be Presented at The International Liver Congress

Financial news for MRK dated on 2011-02-14: Merck Wins First FOSAMAX State Court Trial

Financial news for MRK dated on 2011-02-14: Jefferies Raises PT On Merck & Company To \$34.50

Financial news for MRK dated on 2011-02-11: Two ETFs for the Recovery in Big Pharma

Financial news for MRK dated on 2011-02-04: Value In Valspar (VAL)

Financial news for MRK dated on 2011-02-04: UBS Price Target Research Summary

Financial news for MRK dated on 2011-02-03: Merck Beats but Guides Lower - Analyst Blog

Financial news for MRK dated on 2011-02-03: Merck Beats but Guides Lower - Analyst Blog

Financial news for MRK dated on 2011-02-03: A Peek Into The Market Before The Trading Starts

Financial news for MRK dated on 2011-02-03: Merck Reports Q4 EPS of \$0.88

Financial news for MRK dated on 2011-02-03: US Stock Futures Mixed As Investors Await Earnings Reports, Economic Data; Merck Earnings In Focus

Financial news for MRK dated on 2011-02-03: US Stock Futures Mixed As Investors Await Earnings Reports, Economic Data; Merck Earnings In Focus

Financial news for MRK dated on 2011-02-03: Earnings Scheduled For February 3 (K, MA, CI, ITT, SUN, CAH, MRK, NYT, DOW, BX, LVS, DO, CSTR, CME, IP, GR, MCO, HOT)

Financial news for MRK dated on 2011-01-28: Busy Earnings Week Ahead - Earnings Preview

Financial news for MRK dated on 2011-01-28: AstraZeneca Revenues Disappoint - Analyst Blog

Financial news for MRK dated on 2011-01-28: AstraZeneca Revenues Disappoint - Analyst Blog

Financial news for MRK dated on 2011-01-28: Busy Earnings Week Ahead - Earnings Preview

Financial news for MRK dated on 2011-01-25: Earnings Preview: Eli Lilly - Analyst Blog

Financial news for MRK dated on 2011-01-25: Earnings Preview: Eli Lilly - Analyst Blog

Financial news for MRK dated on 2011-01-21: Priority Review for Vertex HCV Drug - Analyst Blog

Financial news for MRK dated on 2011-01-21: Priority Review for Vertex HCV Drug - Analyst Blog

Financial news for MRK dated on 2011-01-21: Deutsche Bank Lowers MRK Target To \$43, Reiterates Buy Rating

Financial news for MRK dated on 2011-01-21: Deutsche Bank Lowers PT On Merck & Co.

Financial news for MRK dated on 2011-01-20: Bleeding Risk with MRK's Candidate - Analyst Blog

Financial news for MRK dated on 2011-01-20: Bleeding Risk with MRK's Candidate - Analyst Blog

Financial news for MRK dated on 2011-01-20: 4 Drug Stocks Poised to Stage Comeback

Financial news for MRK dated on 2011-01-19: Merck Says Additional Information Provided to Investigators in Clinical Study of Vorapaxar (MRK)

Financial news for MRK dated on 2011-01-19: Ariad Scores With SUCCEED - Analyst Blog

Financial news for MRK dated on 2011-01-19: Ariad Scores With SUCCEED - Analyst Blog

Financial news for MRK dated on 2011-01-18: Ariad Pharmaceuticals Skyrocketing (ARIA)

Financial news for MRK dated on 2011-01-18: Ariad Sarcoma Drug Delays Progression

Financial news for MRK dated on 2011-01-17: Company News for January 17, 2011 - Corporate Summary

Financial news for MRK dated on 2011-01-17: Company News for January 17, 2011 - Corporate Summary

Financial news for MRK dated on 2011-01-14: Merck's Blood Thinner in Trouble - Analyst Blog

Financial news for MRK dated on 2011-01-14: Merck's Blood Thinner in Trouble - Analyst Blog

Financial news for MRK dated on 2011-01-14: Stock Market News for Jan 14, 2011 - Market News

Financial news for MRK dated on 2011-01-14: Stock Market News for Jan 14, 2011 - Market News

Financial news for MRK dated on 2011-01-14: Merck: Analysts' Upgrades, Downgrades

Financial news for MRK dated on 2011-01-14: Jefferies Cuts Price Target On Merck (MRK)

Financial news for MRK dated on 2011-01-14: Jefferies Lowers PT On Merck & Co.

Financial news for MRK dated on 2011-01-13: The Fed Takes Credit: Dave's Daily

Financial news for MRK dated on 2011-01-13: Two Biggies Due to Report Earnings 01-13-2011

Financial news for MRK dated on 2011-01-13: Merck Pipeline Setback: Big Pharma Losers

Financial news for MRK dated on 2011-01-13: Merck & Parexel Enter Pact - Analyst Blog

Financial news for MRK dated on 2011-01-13: Merck & Parexel Enter Pact - Analyst Blog

Financial news for MRK dated on 2011-01-11: Merck Announces FDA Acceptance of New Drug Application for JANUMET(r)

Financial news for MRK dated on 2011-01-07: Priority Review for Merck's HCV Drug - Analyst Blog

Financial news for MRK dated on 2011-01-07: Priority Review for Merck's HCV Drug - Analyst Blog

Financial news for MRK dated on 2011-01-06: Enzon Pharm Upped to Neutral - Analyst Blog

Financial news for MRK dated on 2011-01-06: Enzon Pharm Upped to Neutral - Analyst Blog

Financial news for MRK dated on 2011-01-06: Goldman Sachs Healthcare CEO's Conference (BMJ, MRK, CELG)

Financial news for MRK dated on 2011-01-05: 'Mutts of the Dow' Have No Bite

Financial news for MRK dated on 2011-01-03: Cramer's 'Mad Money' Recap: Stellar Year for Stocks (Update 1)

Financial news for MRK dated on 2010-12-30: XOMA Shares Climb 8.6% (XOMA, NVG, MRK)

Financial news for MRK dated on 2010-12-23: 5 Best & Worst Performers In The Dow (AA, MRK, BAC, DIS, TRV)

Financial news for MRK dated on 2010-12-22: FDA's Approves Gardasil to Prevent Anal Cancer

Financial news for MRK dated on 2010-12-20: World stock markets daily report (December 20, 2010)

Financial news for MRK dated on 2010-12-15: CPI: Inflation Still Tame - Analyst Blog

Financial news for MRK dated on 2010-12-15: CPI: Inflation Still Tame - Analyst Blog

Financial news for MRK dated on 2010-12-13: 10 Best Dow Dividend Stocks for 2011

Financial news for MRK dated on 2010-12-10: Merck Closes on \$2 Billion Notes Sale

Financial news for MRK dated on 2010-12-10: Mad Money Lightning Round: Cramer Advises Investors To Buy BlackRock (LLY, DECK, CMI, OXPS, AXP, V, MRK, ABT, BLK)

Financial news for MRK dated on 2010-12-09: 'Mad Money Lightning Round': Go for BlackRock

Financial news for MRK dated on 2010-12-09: Best Stocks For Creating A Passive Income Stream

Financial news for MRK dated on 2010-12-07: Positive Data on Roche's Drug - Analyst Blog

Financial news for MRK dated on 2010-12-07: Positive Data on Roche's Drug - Analyst Blog

Financial news for MRK dated on 2010-12-06: ETFs For Biotech M&A Mania

Financial news for MRK dated on 2010-12-06: Change at Pfizer's Helm - Analyst Blog

Financial news for MRK dated on 2010-12-06: Change at Pfizer's Helm - Analyst Blog

Financial news for MRK dated on 2010-12-06: Goldman Recommends Stocks For 2011

Financial news for MRK dated on 2010-12-03: CBST's Fast-Injection Cubicin OK'd - Analyst Blog

Financial news for MRK dated on 2010-12-03: CBST's Fast-Injection Cubicin OK'd - Analyst Blog

Financial news for MRK dated on 2010-12-03: Merck Strikes Deal with SmartCells - Analyst Blog

Financial news for MRK dated on 2010-12-03: Merck Strikes Deal with SmartCells - Analyst Blog

Financial news for MRK dated on 2010-12-02: J&J, Merck Recall Mylanta, AlternaGel

Financial news for MRK dated on 2010-12-02: A Peek Into The Market Before The Trading Starts

Financial news for MRK dated on 2010-12-02: Merck to Acquire SmartCells, Inc; Transaction May Exceed \$500M

Financial news for MRK dated on 2010-12-02: Merck May Buy Biotech Firm SmartCells

Financial news for MRK dated on 2010-12-01: SurModics Cut to Underperform - Analyst Blog

Financial news for MRK dated on 2010-12-01: SurModics Cut to Underperform - Analyst Blog

Financial news for MRK dated on 2010-11-30: Merck Down Slightly On New CEO (MRK)

Financial news for MRK dated on 2010-11-30: Merck Halts Isentress Study - Analyst Blog

Financial news for MRK dated on 2010-11-30: News Summary

Financial news for MRK dated on 2010-11-30: Bootstrap Like Spanx to Start a Business

Financial news for MRK dated on 2010-11-30: Merck Names Kenneth Frazier as CEO

Financial news for MRK dated on 2010-11-30: Merck Board Elects Kenneth C. Frazier as Next CEO

Financial news for MRK dated on 2010-11-30: Merck Halts Isentress Study - Analyst Blog

Financial news for MRK dated on 2010-11-24: Vertex Eyes Telaprevir Approval - Analyst Blog

Financial news for MRK dated on 2010-11-24: Vertex Eyes Telaprevir Approval - Analyst Blog

Financial news for MRK dated on 2010-11-24: Stock Market News for November 24, 2010 - Market News

Financial news for MRK dated on 2010-11-24: Stock Market News for November 24, 2010 - Market News

Financial news for MRK dated on 2010-11-23: Top 5 Wellington Positions

Financial news for MRK dated on 2010-11-23: Vertex Files for Hep C Drug Approval

Financial news for MRK dated on 2010-11-22: Positive Data on Merck's Vytorin - Analyst Blog

Financial news for MRK dated on 2010-11-22: Positive Data on Merck's Vytorin - Analyst Blog

Financial news for MRK dated on 2010-11-22: Goldman Sachs Comments On Merck's SHARP Results

Financial news for MRK dated on 2010-11-22: Merck Stabilizes After SHARP Results (MRK)

Financial news for MRK dated on 2010-11-20: Study: Merck Drug Helps Kidney Patients

Financial news for MRK dated on 2010-11-18: Merck's Candidate Impresses - Analyst Blog

Financial news for MRK dated on 2010-11-18: Merck's Candidate Impresses - Analyst Blog

Financial news for MRK dated on 2010-11-17: Consumer Price Index Tame - Analyst Blog

Financial news for MRK dated on 2010-11-17: Merck Adding To Its List Of Late stage Revenue Generating Assets, Citigroup Reports

Financial news for MRK dated on 2010-11-17: Consumer Price Index Tame - Analyst Blog

Financial news for MRK dated on 2010-11-16: Goldman Sachs Adjusts MHS And ESRX Estimates

Financial news for MRK dated on 2010-11-15: Merck Plans New India Drug Launches

Financial news for MRK dated on 2010-11-15: Lowe's Earnings Rise, But Sales, Outlook Miss Estimates

Financial news for MRK dated on 2010-11-15: Week Ahead Market Report: 11/15/2010

Financial news for MRK dated on 2010-11-15: El Paso Pipeline Partners Acquires Assets from El Paso Corporation

Financial news for MRK dated on 2010-11-15: EMC to Buy Isilon Systems

Financial news for MRK dated on 2010-11-15: Caterpillar to Buy Bucyrus

Financial news for MRK dated on 2010-11-15: Retail Sales Surprise to the Upside

Financial news for MRK dated on 2010-11-15: Retail Sales Surprise to the Upside

Financial news for MRK dated on 2010-11-15: Jefferies & Company Adjusts Merck Estimates

Financial news for MRK dated on 2010-11-15: Stocks To Watch For November 15 (JWN, LOW, URBN, MRK, GYMB)

Financial news for MRK dated on 2010-11-10: Rolls for Breakfast 11-10-2010

Financial news for MRK dated on 2010-11-09: Pharma & Biotech Industry Outlook - Nov. 2010 - Zacks Analyst Interviews

Financial news for MRK dated on 2010-11-09: Pharma & Biotech Industry Outlook - Nov. 2010 - Industry Outlook

Financial news for MRK dated on 2010-11-09: Merck Wins TEMODAR Patent Infringement Lawsuit

Financial news for MRK dated on 2010-11-03: 3 High Paying Dividend Stocks To Consider

Financial news for MRK dated on 2010-11-02: Sectors To Benefit From Republican Victory: Oil Services, Healthcare (MRK, PFE, DO, RIG)

Financial news for MRK dated on 2010-11-02: Zacks Analyst Blog Highlights: Monster Worldwide, Yahoo, Merck & Co., Johnson & Johnson and VeriSign - Press Releases

Financial news for MRK dated on 2010-11-01: Citigroup Reiterates Buy Rating on Merck (MRK)

Financial news for MRK dated on 2010-10-29: Steve Grasso's Health Care Trades (UNH, CI, AET, AGP, HS, PFE, MRK, WLP)

Financial news for MRK dated on 2010-10-29: Markets Yawn at Data, Earnings Deluge

Financial news for MRK dated on 2010-10-29: Stock Market News for October 29, 2010 - Market News

Financial news for MRK dated on 2010-10-29: Company News for October 29, 2010 - Corporate Summary

Financial news for MRK dated on 2010-10-29: News Summary

Financial news for MRK dated on 2010-10-29: Merck Beats on EPS, Misses on Revs - Analyst Blog

Financial news for MRK dated on 2010-10-29: US Stock Futures Down As Investors Await Q3 GDP Data

Financial news for MRK dated on 2010-10-29: Earnings Scheduled For October 29 (CVX, POM, CEG, MRK, PGN, NEE, SNE, D, EL, ITT, CI, WY, EIX, LNT)

Financial news for MRK dated on 2010-10-29: Stocks To Watch For October 29 (MSFT, MRK, EXPE, CVX, MXIM)

Financial news for MRK dated on 2010-10-27: Merck In Talks To Acquire InterMune (MRK, ITMN)

Financial news for MRK dated on 2010-10-25: Stock Market News for October 25, 2010 - Market News

Financial news for MRK dated on 2010-10-25: Citi Says Merger Should Help Merck (MRK)

Financial news for MRK dated on 2010-10-20: Viagra Treatment for Muscular Dystrophy

Financial news for MRK dated on 2010-10-18: CPI Tame in September - Analyst Blog

Financial news for MRK dated on 2010-10-18: Zacks Analyst Blog Highlights: KR,TBT,PFE,MRK,GCI - Press Releases

Financial news for MRK dated on 2010-10-18: Citigroup Expects Big Things From Merck's New Osteoporosis Medication

Financial news for MRK dated on 2010-10-12: Highest Yielding Dow Jones Industrial Average Stocks

Financial news for MRK dated on 2010-10-06: Goldman Buying Hedges on Merck (MRK)

Financial news for MRK dated on 2010-10-05: 10 Dow Dividend Stocks for Weary Investors

Financial news for MRK dated on 2010-10-04: J&J-Galapagos in Anti-Cancer Deal - Analyst Blog

Financial news for MRK dated on 2010-10-04: Male Menopause: Another Treatment for Pharmaceutical Companies

Financial news for MRK dated on 2010-10-04: Merck to Appeal Reduced Jury Verdict in Federal FOSAMAX Case

Financial news for MRK dated on 2010-10-03: Structured Notes: The Retail Broker's Own Little Synthetic CDO

Financial news for MRK dated on 2010-10-01: Merck Announces Pivotal Phase III Data for Boceprevir will be Presented at Liver Diseases Meeting

Financial news for MRK dated on 2010-09-24: FDA Restricts Use of Glaxo Drug - Analyst Blog

Financial news for MRK dated on 2010-09-24: The Rapid Growth Of Layoffs In Pharma, As Industry Despairs Of Its Future (BMY, ABT, PFE, MRK)

Financial news for MRK dated on 2010-09-23: Travelers Mad As Hell

Financial news for MRK dated on 2010-09-21: BMY's Diabetes Candidate Encourages - Analyst Blog

Financial news for MRK dated on 2010-09-21: Zacks Analyst Blog Highlights: ProShares UltraShort 20+ Year ETF, Pfizer, Merck, Ford and CarMax - Press Releases

Financial news for MRK dated on 2010-09-21: Zacks Analyst Blog Highlights: Johnson & Johnson, Crucell NV, GlaxoSmithKline, Merck and Sanofi-Aventis - Press Releases

Financial news for MRK dated on 2010-09-21: Under The Hood: WisdomTree LargeCap Dividend Fund

Financial news for MRK dated on 2010-09-18: J&J Makes a Pitch for Crucell - Analyst Blog

Financial news for MRK dated on 2010-09-16: Unconfirmed Chatter that Merck & Co. Inc. (MRK) will buy Medicines Co. (MDCO) at \$23.00 a share

Financial news for MRK dated on 2010-09-16: Jefferies Initiates Hold Rating on Merck (MRK)

Financial news for MRK dated on 2010-09-13: SurModics Stays Neutral - Analyst Blog

Financial news for MRK dated on 2010-09-09: Top 10 'Buy'-Rated Stocks Under \$5

Financial news for MRK dated on 2010-09-08: Goldman Sachs: Buy MRK Puts As Hedge

Financial news for MRK dated on 2010-08-31: You'd Have To Be Sick To Touch This Drug Stock (PFE)

Financial news for MRK dated on 2010-08-30: Goldman Sachs Introduces And Adjusts Estimates For Major Pharmaceuticals

Financial news for MRK dated on 2010-08-29: Sunday Morning Coffee

Financial news for MRK dated on 2010-08-27: Birth Control Stocks: A Recession Play

Financial news for MRK dated on 2010-08-26: A New Round Of Corporate Layoffs?

Financial news for MRK dated on 2010-08-23: Generic Risk For Gilead's Hepsera - Analyst Blog

Financial news for MRK dated on 2010-08-18: 10 Highest-Rated Dow Dividend Stocks

Financial news for MRK dated on 2010-08-17: Oppenheimer Remains Buyer Of VRTX

Financial news for MRK dated on 2010-08-13: All Is Not Well In The Pharmaceutical Industry

Financial news for MRK dated on 2010-08-13: U.S. Probing Pharmaceutical Corruption (GSK, PFE, BMY, LLY)

Financial news for MRK dated on 2010-08-12: Merck Announces Mandatory Conversion of its 6.00% Mandatory Convertible Preferred Stock

Financial news for MRK dated on 2010-08-11: Dogs Of The Dow: 5 Highest Yielding Dow Stocks (MRK, PFE, PG, T, VZ)

Financial news for MRK dated on 2010-08-09: Cost Reduction Lowers ENZN Loss - Analyst Blog

Financial news for MRK dated on 2010-08-09: Finally There Is A Cure For Tobacco Addiction (CIGX)

Financial news for MRK dated on 2010-08-06: Best Stocks For A Deflationary Environment (NEM, ABX, GG, DLTR, FDO, MRK, JNJ)

Financial news for MRK dated on 2010-08-06: Oncothyreon Phase 3 Breast Cancer Trial Shut Down

Financial news for MRK dated on 2010-08-04: Vertex Loss Narrows, Reaffirms Guidance - Analyst Blog

Financial news for MRK dated on 2010-08-04: Santarus Beats on Higher Revs - Analyst Blog

Financial news for MRK dated on 2010-08-04: Zacks Analyst Blog Highlights: The

Clorox, AstraZeneca, Merck, Dean Foods and Coach - Press Releases

Financial news for MRK dated on 2010-08-03: AstraZeneca EPS Beats & Ups - Analyst Blog

Financial news for MRK dated on 2010-08-02: Top 4 NYSE Stocks In The Healthcare Sector With The Highest Free Cash Flow (PFE, JNJ, MRK, LLY)

Financial news for MRK dated on 2010-07-30: Hapoalim Securities Downgrades Merck to Hold from Buy (MRK)

Financial news for MRK dated on 2010-07-30: Company News for July 30, 2010 - Corporate Summary

Financial news for MRK dated on 2010-07-30: US Stock Futures Point To Weak Day Today

Financial news for MRK dated on 2010-07-30: Merck Posts Mixed Results (MRK)

Financial news for MRK dated on 2010-07-30: ETFs To Watch July 30, 2010 (HAO, PPH, YCS, PALL)

Financial news for MRK dated on 2010-07-30: Merck's Q2 Earnings Beat Targets, Revenue Misses

Financial news for MRK dated on 2010-07-30: Earnings Scheduled For July 30 (MRK, AON, CVX, CVH, WY, PPC)

Financial news for MRK dated on 2010-07-30: Stocks To Watch For July 30 (FSLR, MRK, CVX, AON, CSTR)

Financial news for MRK dated on 2010-07-28: Fast Money 360: Leerink Swann Is A Buyer Of Merck (MRK)

Financial news for MRK dated on 2010-07-27: Huge Call Purchase on Merck & Co. (MRK)

Financial news for MRK dated on 2010-07-27: A Peek Into The Market At The Start Of The Trading Day

Financial news for MRK dated on 2010-07-27: Sanofi-aventis and Merck Appoint CEO for Joint Venture

Financial news for MRK dated on 2010-07-27: Merck and Sinopharm Sign Statement of Mutual Intent

Financial news for MRK dated on 2010-07-26: Corporate Catalysts For The Week Starting July 26

Financial news for MRK dated on 2010-07-14: Ryan Recommends Bristol-Myers and Merck (BMY, MRK, PFE)

Financial news for MRK dated on 2010-07-14: 10 Firms Expecting Clinical Trial Results

Financial news for MRK dated on 2010-07-13: Miller Tabak Likes Bristol Myers Squibb (BMY), Novartis (NVS) And Merck (MRK)

Financial news for MRK dated on 2010-07-13: GlaxoSmithKline: Another Drug Company Runs Afoul Of The Truth

Financial news for MRK dated on 2010-07-08: Late Market Roundup

Financial news for MRK dated on 2010-07-08: News Summary (HRB, BP, MRK)

Financial news for MRK dated on 2010-07-08: Merck Details Global Restructuring Program

Financial news for MRK dated on 2010-07-08: Top Yielding Big Pharmaceutical Stocks

Financial news for MRK dated on 2010-07-07: Puts Purchased on Millipore Corp. (MIL)

Financial news for MRK dated on 2010-07-07: Stock Market News for July 7, 2010 - Market News

Financial news for MRK dated on 2010-07-02: Stock Market News for July 2, 2010 - Market News

Financial news for MRK dated on 2010-06-30: Pharmaceutical ETFs on the Rise

Financial news for MRK dated on 2010-06-29: Good News for NVO's Victoza - Analyst Blog

Financial news for MRK dated on 2010-06-29: Soleil Initiates MRK With Hold

Financial news for MRK dated on 2010-06-28: Citi (C) Has A Price Target Of \$30 For Bristol Myers Squibb (BMY)

Financial news for MRK dated on 2010-06-22: Late Market Roundup

Financial news for MRK dated on 2010-06-15: Dorfman Recommends Merck, Cal-Maine Foods, and Paycheck (MRK, CALM, PAYX)

Financial news for MRK dated on 2010-05-28: Fast Money Halftime Recommendations (OXY, CVX, ABT, PFE, MRK, AXP, C, BAC, JPM)

Financial news for MRK dated on 2010-05-27: Citigroup Outlook For U.S. Major Pharmaceuticals (MRK, PFE, BMY)

Financial news for MRK dated on 2010-05-27: Deutsche Bank Sees A Brighter Future for Drug Stocks (MRK, PFE)

Financial news for MRK dated on 2010-05-26: Bill Smead Likes Merck And Disney (MRK, DIS)

Financial news for MRK dated on 2010-05-24: Citi Says DMARDs "Not Immune to Tough Economy" (JNJ, MRK, BMY, AMGN, ABT)

Financial news for MRK dated on 2010-05-20: All 30 Dow Components In The Red (MRK, GE)

Financial news for MRK dated on 2010-05-12: US Stocks End Lower Yesterday After Soaring On Monday, Dow And S&P Down, Nasdaq Bucks Trend

Financial news for MRK dated on 2010-05-11: Five New Drugs On Cards for Merck (MRK)

Financial news for MRK dated on 2010-05-10: Citi Gives Thoughts On MRK's 2010 Annual Briefing And Its \$45.00 Price Target

Financial news for MRK dated on 2010-05-05: Merck And Ariad Re-Write Ridaforolimus Contract (MRK, ARIA)

Financial news for MRK dated on 2010-05-05: Stock Market News for May 5, 2010 - Market News

Financial news for MRK dated on 2010-05-05: Company News for May 5, 2010 - Corporate Summary

Financial news for MRK dated on 2010-05-05: Benzinga's Top Pre-Market Gainers (AMMD, HNSN, ACAS, ARIA, ERTS)

Financial news for MRK dated on 2010-05-05: Goldman Downgrades MRK To Neutral

Financial news for MRK dated on 2010-05-05: FOREX, COMMODITIES, STOCKS OUTLOOK May 5th: SPECIAL EU CRISIS MARKET CORRECTION 10:30 GMT

Financial news for MRK dated on 2010-05-05: US Stocks Dive, Hit By Europe Crisis, Investors Take Refuge In Dollar & Bonds

Financial news for MRK dated on 2010-05-04: Jim Cramer's Short Term Plays

Financial news for MRK dated on 2010-05-04: Pfizer (PFE) Breaches Above its 50 Day MA

Financial news for MRK dated on 2010-05-04: US Stock Futures Fall On Greece Worries

Financial news for MRK dated on 2010-05-04: MRK Shares Rise As Q1 Profits, Sales Exceeds Expectations

Financial news for MRK dated on 2010-05-04: Stock Market News for May 4, 2010 - Market News

Financial news for MRK dated on 2010-05-04: Company News for May 4, 2010 - Corporate Summary

Financial news for MRK dated on 2010-05-04: Merck & Co.'s (MRK) First-Quarter Profit Down By 77%

Financial news for MRK dated on 2010-05-03: Jim's Game Plan For This Week (SMG, CLNE, CPNO, JDSU, APA, DVN, RIG, MRK, PFE, SHOO, SBA, AMT, VMC, SYI)

Financial news for MRK dated on 2010-05-03: Stock Market News for May 3, 2010 -

Market News

Financial news for MRK dated on 2010-04-30: DOW Gains The Highest Since March 5, Led By Q1 Gains

Financial news for MRK dated on 2010-04-29: Fast Money Picks For April 30th (MRK, RIG, GLW, XOM)

Financial news for MRK dated on 2010-04-28: Afternoon Market Update - Goldman Sachs (NYSE: GS), Merck (NYSE: MRK), AstraZeneca (NYSE: AZN)

Financial news for MRK dated on 2010-04-28: Investors Allowed To Sue Merck Over Vioxx (MRK)

Financial news for MRK dated on 2010-04-23: Merck To Lose \$170 Million In Revenue (MRK)

Financial news for MRK dated on 2010-04-23: Merck & Co. (MRK) Says U.S. Health-Care Legislation To Reduce 2010 Revenue By \$170 Million

Financial news for MRK dated on 2010-04-23: Market Roundup (MS, C, HLS, UBS, HBC, USB, MRK)

Financial news for MRK dated on 2010-04-23: US Stock Ended In Positive Territory After Losing 100 Points

Financial news for MRK dated on 2010-04-22: Stock Market News for April 22, 2010 - Market News

Financial news for MRK dated on 2010-04-21: Top Stocks of New Jersey

Financial news for MRK dated on 2010-04-15: Mad Money Lightning Round: Jim Likes AMD, APC, ARMH, IMAX, YHOO, EXC, MUR

Financial news for MRK dated on 2010-04-08: Stock Market News for April 8, 2010 - Market News

Financial news for MRK dated on 2010-04-05: U.S. Equity Market Preview (AAPL, EXC, HSP, ITMN, MRK)

Financial news for MRK dated on 2010-03-25: Top Five Dow Stocks With High Yields (DD, MRK, PFE, T, VZ)

Financial news for MRK dated on 2010-03-25: The High Yielders of the Dow

Financial news for MRK dated on 2010-03-23: Before Jumping Into A Single Health Care Stock Consider This ETF

Financial news for MRK dated on 2010-03-23: Fast Money Picks For March 24th (MPXL, APA, PLL, BAC)

Financial news for MRK dated on 2010-03-22: Investors Flock To Healthcare ETFs On Historic Reform

Financial news for MRK dated on 2010-03-22: US Stocks Jump Up; Rally Driven By Health, Pharma Stocks (AXP, DD, MRK, PFE, MRK, THC, HMA)

Financial news for MRK dated on 2010-03-22: FDA Asks Doctors To Suspend Use Of GlaxoSmithKline (GSK) Rotavirus Vaccine

Financial news for MRK dated on 2010-03-22: Pfizer (PFE) and Merck (MRK) Advance Following Approval of Healthcare Legislation

Financial news for MRK dated on 2010-03-17: This Healthcare ETF (XLV) Is Seeing Above Average Call Buying

Financial news for MRK dated on 2010-03-15: Benzinga's News Roundup (PEP, ALKS, MRK)

Financial news for MRK dated on 2010-03-12: Merck To Continue Its M&A Spree (MRK, MIL)

Financial news for MRK dated on 2010-03-12: Overhang On Merck & Company (MRK) Lifted By IMPROVE-IT Update

Financial news for MRK dated on 2010-03-12: Stock Market News for March 12, 2010 - Market News

Financial news for MRK dated on 2010-03-09: Sonofi-Merck (MRK) Deal Positive

Financial news for MRK dated on 2010-03-08: ThinkEquity Reiterates Buy on OraSure Technologies (OSUR, MRK, PFE)

Financial news for MRK dated on 2010-03-08: Simple Quantitative View of Goldman's VIP List Generates Some Other Long Ideas

Financial news for MRK dated on 2010-03-05: Goldman Sachs (GS) VIP List of Top Hedge Fund Holdings

Financial news for MRK dated on 2010-03-01: Karen Finerman Thinks There Might Be Other Bidders For MIL

Financial news for MRK dated on 2010-02-25: Eli Lilly Banks On Its Restructured Development Process To Offset Sales Loss (LLY)

Financial news for MRK dated on 2010-02-18: Large Hacking Instance Detected (MRK, CAH)

Financial news for MRK dated on 2010-02-16: John Paulson Sells Merck (MRK), Buys Bank Of America (BAC)

Financial news for MRK dated on 2010-02-16: Movement Expected In The Shares Of These Companies Amid Significant Events (BRK.B, BX, JPM, ORCL, YHOO)

Financial news for MRK dated on 2010-02-16: Merck & Co. (MRK) Reports Bigger Profit, Helped By Schering-Plough Deal

Financial news for MRK dated on 2010-02-16: Merck Posts Bigger Profit (MRK)

Financial news for MRK dated on 2010-02-16: Company News for February 16, 2010 - Corporate Summary

Financial news for MRK dated on 2010-02-16: MRK Shares Up As 4Q Earnings Match Expectations

Financial news for MRK dated on 2010-02-16: Stock Market News for February 16, 2010 - Market News

Financial news for MRK dated on 2010-02-16: Merck & Co. (MRK) Reports Schering Fueled Profit Jump

Financial news for MRK dated on 2010-02-16: Merck Reports Inline, Stock Off To Good Start In Premarket (MRK)

Financial news for MRK dated on 2010-02-16: Top 5 Large Cap Growth Stocks (ESRX, MRK, VALE, AAPL, BHP)

Financial news for MRK dated on 2010-02-11: Credit Suisse Lowers Estimates, Price Targets On Merck, Pfizer

Financial news for MRK dated on 2010-02-10: Merck & Co. To Change Safety Procedures (MRK)

Financial news for MRK dated on 2010-02-10: Merck & Co. (MRK) Agrees To Changes In Vioxx Settlement

Financial news for MRK dated on 2010-02-10: Market Roundup (AAPL, MRK, FITB, PNC, TTWO, GOOG)

Financial news for MRK dated on 2010-02-05: Market Round-up (UBS, GOOG, AAPL, MOT, PG, PFE, MRK, LLY, CVS, WAG)

Financial news for MRK dated on 2010-02-04: Merck (MRK) Is A Frontrunner Among Pharma Stocks

Financial news for MRK dated on 2010-02-03: Mad Money Lightning Round: Jim Prefers MRK, SYK, INTC, AAPL To COMS, ZMH, EBIX, MSFT, MOT

Financial news for MRK dated on 2010-01-29: Invest In High Quality Stocks Like Merck (MRK) : Analyst Says On CNBC

Financial news for MRK dated on 2010-01-25: Merck (MRK) Doing Well, But Becoming More Transparent

Financial news for MRK dated on 2010-01-22: Big Pharma Will Trade On the Following Fundamentals: Morningstar Says Big Pharma Well Positioned

Financial news for MRK dated on 2010-01-20: Stock Market News for January 20, 2010 - Market News

Financial news for MRK dated on 2010-01-18: Merck Has The Best Pharma Bet (MRK)

Financial news for MRK dated on 2010-01-14: Pete Najarian Sees An Opportunity In Pharma (XLV, WLP, AET, UNH, HUM, MRK, PFE, JNJ)

Financial news for MRK dated on 2010-01-14: Merck & Co (MRK) Submits New Data To FDA To Widen Gardasil Use

Financial news for MRK dated on 2010-01-14: Stock Market News for January 14, 2010 - Market News

Financial news for MRK dated on 2010-01-14: Top 5 Large-Cap Stocks In The Healthcare Sector With The Highest ROE (GSK, GILD, AZN, ACL, MRK)

Financial news for MRK dated on 2010-01-13: Merck leads drug stocks up

Financial news for MRK dated on 2010-01-13: Merck & Co. (MRK) Soars On Upgrade By Credit Suisse

Financial news for MRK dated on 2010-01-13: Merck Upgraded At Credit Suisse (MRK)

Financial news for MRK dated on 2010-01-13: Benzinga's Top Upgrades (BIDU, MRK, NTAP, UPS, AAWW)

Financial news for MRK dated on 2010-01-13: Company News for January 13, 2010 - Corporate Summary

Financial news for MRK dated on 2010-01-08: Investment Mantra 2010: Be Bullish On Mega Caps In 'The Dogs Of The Dow'. (XOM, WFC, BA, CVX, DU, MCD, MRK, PFE)

Financial news for MRK dated on 2010-01-05: Drug Pipeline Targeting High Growth Markets May Boost Merck Prospects (MRK, C)

Financial news for MRK dated on 2010-01-04: Biotech Listings To Form A Major Chunk Of IPO Market (JNJ, PFE, MRK, CDXS, TNGN, MBGI)

Financial news for MRK dated on 2009-12-28: The World's Largest M&A Deals in 2009 (PFE, WLA, GM, SGP, MRK)

Financial news for MRK dated on 2009-12-24: Merck Decides To Discontinue Its Collaboration With ARNA For Dyslipidemia

Financial news for MRK dated on 2009-12-23: Above Average EPS Growth Projected For MRK

Financial news for MRK dated on 2009-12-23: FDA Indicates Role Of Vytorin and Zetia In Increased Cancer Risk Unlikely

Financial news for MRK dated on 2009-12-23: Merck & Co. Inc (MRK) Gets A Hold Rating

Financial news for MRK dated on 2009-12-22: Walmart (WMT) And Comcast (CMCSA) For 2010

Financial news for MRK dated on 2009-12-22: Buying Value for 2010

Financial news for MRK dated on 2009-12-21: Health Brings Wealth To The Street (PFE, MRK, AET, UNH, SNY, CHTT)

Financial news for MRK dated on 2009-12-21: New PBM President Good For Caremark (CVS)

Financial news for MRK dated on 2009-12-21: 2010 Dogs Of The Dow

Financial news for MRK dated on 2009-12-18: Peak Sales Of MRK's Isentress May Touch \$2 Billion

Financial news for MRK dated on 2009-12-16: Top 5 Large-Cap Stocks with Highest Sales Growth Estimate for Next Year (TM, SU, MRK, ESRX, POT)

Financial news for MRK dated on 2009-12-14: Large Caps Breaking Out - Johnson & Johnson (JNJ), Coke (KO), IBM (IBM), Merck (MRK), Verizon (VZ), Disney (DIS), 3M (MMM)

Financial news for MRK dated on 2009-12-10: SEC On Trail Of Insider Trading Transactions

Financial news for MRK dated on 2009-12-08: Stock Market News for December 08, 2009 - Market News

Financial news for MRK dated on 2009-12-02: Cowen stays Neutral On Santarus (SNTS), Cites Litigation Concerns , PRX, MRK, AZN, NVS

Financial news for MRK dated on 2009-12-02: Google's Most Popular Stock Searches Today, SNTS, MRK, ITVI, DYAX, SNDA

Financial news for MRK dated on 2009-11-28: Taking A Look At Two Pharma ETFs (IHE, PPH)

Financial news for MRK dated on 2009-11-20: Stocks That Will Continue to Achieve New Highs (BBY, SJM, AGU, KO, TRA, MRK, CTL)

Financial news for MRK dated on 2009-11-16: JPMorgan Likes Abbott (ABT) Because of Niaspan

Financial news for MRK dated on 2009-11-14: Merck Sends Letter To NYT Editor About Arbiter Story

Financial news for MRK dated on 2009-11-13: Merck (MRK) Drugs Under Scanner Of Cholesterol Study

Financial news for MRK dated on 2009-11-09: Leerink Swann Upgrades Merck To Outperform

Financial news for MRK dated on 2009-11-06: The ETF Professor Told You To Watch This Healthcare ETF (XLV)

Financial news for MRK dated on 2009-11-04: Merck Says It Won't Seek Another Larger Merger

Financial news for MRK dated on 2009-11-04: Fitch Downgrades Merck, Outlook Stable

Financial news for MRK dated on 2009-09-18: Sanofi-aventis (SNY) Completes Acquisition of Merial

Financial news for MRK dated on 2009-08-17: BenchmarkJournal.com Free Analyst Review for ABK, EQR, KMB, BBD, FIG and MRK

Financial news for MRK dated on 2009-08-17: Trends in the U.K. and Irish Pharmaceutical and Biotechnology Industry, an Industrial Info News Alert

Financial news for MRK dated on 2009-08-10: ParagonReport.com Complimentary Market Update on Freddie Mac (NYSE: FRE), Best Buy Co. Inc. (NYSE: BBY), American Express Company (NYSE: AXP), and Merck & Co. Inc. (NYSE: MRK)

Financial news for MRK dated on 2009-08-07: ParagonReport.com Complimentary Market Update on Alumina Ltd. (NYSE: AWC), CSB Corporation (NYSE: CBS), Merck & Co. Inc. (NYSE: MRK) and NVIDIA Corporation (NASDAQ: NVDA)

Financial news for MRK dated on 2009-07-27: Wall Street News Alert: Stocks This Morning: Green Star Alternative Energy -- July 27, 2009